<SEC-DOCUMENT>0001062822-22-000035.txt : 20220803
<SEC-HEADER>0001062822-22-000035.hdr.sgml : 20220803
<ACCEPTANCE-DATETIME>20220803160727
ACCESSION NUMBER:		0001062822-22-000035
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		46
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220803
DATE AS OF CHANGE:		20220803

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXICON PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001062822
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				760474169
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30111
		FILM NUMBER:		221132589

	BUSINESS ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381
		BUSINESS PHONE:		2818633000

	MAIL ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON PHARMACEUTICALS, INC./DE
		DATE OF NAME CHANGE:	20070426

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON GENETICS INC/TX
		DATE OF NAME CHANGE:	20000126
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>lxrx-20220630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:b429ed1f-e365-4ee0-b706-413f731644e3,g:a8252b48-0582-489a-8246-eed3b4e2cfac,d:bf95eabc4cf34ac1b0383c1ba8d7debc--><html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:lxrx="http://www.lexpharma.com/20220630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lxrx-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180L2ZyYWc6NGRiMDJhZjdhOTc4NDdkOWIyNTQzNjI2MTA1MTcyNmEvdGFibGU6N2ZkOWVhYzAyN2JkNDBjM2E3YmY5Mjg2MDUxODYxZDEvdGFibGVyYW5nZTo3ZmQ5ZWFjMDI3YmQ0MGMzYTdiZjkyODYwNTE4NjFkMV81LTQtMS0xLTI4NTMy_bc5a2254-012d-4c3d-9b54-55793c249b9c">Q2</ix:nonNumeric><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180L2ZyYWc6NGRiMDJhZjdhOTc4NDdkOWIyNTQzNjI2MTA1MTcyNmEvdGFibGU6N2ZkOWVhYzAyN2JkNDBjM2E3YmY5Mjg2MDUxODYxZDEvdGFibGVyYW5nZTo3ZmQ5ZWFjMDI3YmQ0MGMzYTdiZjkyODYwNTE4NjFkMV85LTQtMS0xLTI4NTMy_a2ebeaaa-45eb-47a9-a8e9-4ffb33cf4c10">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180L2ZyYWc6NGRiMDJhZjdhOTc4NDdkOWIyNTQzNjI2MTA1MTcyNmEvdGFibGU6N2ZkOWVhYzAyN2JkNDBjM2E3YmY5Mjg2MDUxODYxZDEvdGFibGVyYW5nZTo3ZmQ5ZWFjMDI3YmQ0MGMzYTdiZjkyODYwNTE4NjFkMV8xMC00LTEtMS0yODUzMg_3af84fd7-7115-447e-9f8f-332dce878ea1">2022</ix:nonNumeric><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180L2ZyYWc6NGRiMDJhZjdhOTc4NDdkOWIyNTQzNjI2MTA1MTcyNmEvdGFibGU6N2ZkOWVhYzAyN2JkNDBjM2E3YmY5Mjg2MDUxODYxZDEvdGFibGVyYW5nZTo3ZmQ5ZWFjMDI3YmQ0MGMzYTdiZjkyODYwNTE4NjFkMV8xMS00LTEtMS0yODUzMg_7b8ebde5-2eec-4d55-af98-ee58e5314b9d">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180L2ZyYWc6NGRiMDJhZjdhOTc4NDdkOWIyNTQzNjI2MTA1MTcyNmEvdGFibGU6N2ZkOWVhYzAyN2JkNDBjM2E3YmY5Mjg2MDUxODYxZDEvdGFibGVyYW5nZTo3ZmQ5ZWFjMDI3YmQ0MGMzYTdiZjkyODYwNTE4NjFkMV8xNC00LTEtMS0yODUzMg_32bce68b-185a-47ba-ab96-cf2223ed8e78">0001062822</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lxrx-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7a0858cf5024c25bf4b6aaa1fb4a8ca_I20220803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="if0442bec3f404e9aa34207eb1d897a99_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i219835b855164c3eb8447d1975735bec_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8a7ca19bc1a4556a6e59951312a250b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebb39511180847c6b73ea2044b1bbc86_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bfe69c4a75a471ab0ff5ee12bde76cc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45657a0096954cda95b6dd011117c958_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i159bdd976c5a411daa2d75f84b7d64a6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3ab6ec7ca184c0b98f71ea5fbc23b66_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6294895f68fb461d8a0149ff1352660b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64b8f1ab07f04390b4b79e6f8c6eb68e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f6fc7cd72c34badba8bff35c5c227ac_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ea8108d1eb5464fb0ec1f1c33b681cd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab6948c85b864af88b2035a19dd666a2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6cf877d5e034cbe9a21bc4654ebb5f6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i067eeafe353e47bc8c8d21624e5bafe8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaabab49ebc5c4a4a9b6b4ef4966aefcd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d665691473c45ecb646640a37531cf4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafe0378736e444aab2cfabe4f48ecbb9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4de99efa8fac4a1e9b601bcb9a760fad_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id997a83da5644f6987121d06d68d06ae_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70f53509a43b46f7918ad0068ee464f4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6a00923dd164c3185de2bb3200711b3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaf692e06bd247aebe797f2c2d1665d7_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id974764582f944f191de99110577719e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i436bb19a139f4e90a3435d0ce8396f1d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84c6845ef1af474d99b31053aaec57d8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic04a7ab6695e4594b37dbd4ef6202519_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1997cf5cac44c6eb336f27c85ee57c4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fc68f10369542aaafc82c10cdef36a8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4921c0cb0fbb40faa165f5a6e62d660d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdf3d3ccc7584900aada54e1568caba4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a7c2141afe24e7f83e4d67a5ccdfff8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4163eee5a3740f5846f34cdd0ae242b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i191fd4fe2f08479884c4e65d4e9cfdff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42fe192fe5ca436e9ed23d15187dbe84_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75b83c9dc24f45598d1213d5e8d33a7e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4de86438d8b40de8534780d8f45dbf0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa991937faa74a41905808343286e8d9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ede75339061443d9b99e442e4e84e69_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i781fc25c166b4fe180c4b24a19f09109_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1fe783955bb4f568c7b32b3eb3734e4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i225dda2db10c426f89723c6eb6264105_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff773ff7f7f9457f9791bde81fb05630_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47c159cf741e4073a1ff14f684d085d7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d8b5096b7ac4e1fa83572cd7c51c76b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0a99ce76ff74360997f9515e9e301b9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaeb348ef20a2445c8833795108ee3835_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b20225add3d49819abcc6c8ffa1f6c2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i172ba7c5c11849e1b3e8f93623452a80_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ab63a6a7f16414f93ebff593d6bd562_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbe2a09570334122960c7e63bb722f5c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bd35a0adb644d578ef0843d8d92e8f2_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25a8adb9e6404469bce5c119cc2f7260_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic77941f6de784e4bb794c54a3abaf069_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22f4f9fb2c4b49c99b790d66a23b28ae_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46ba5caa20034a00b88a7290fc681f9a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d2be377b37d4ddb9010f544cecc5772_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3de097a4f4c24c0083c05150f6b098a0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i152ac39e5811437cb0ee3de3ef7041ea_I20210301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="if8c71021eb1240e190c19cb072abf3f6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8144b5bc25dd4902831fa92228fd7f51_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7be8ac7d31ef4e4f9fdbd039f264c959_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff0b3ea9ca3c45e1b81425040542255e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32d0edfce10547eaa9f6a4a37c3c0e9e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id14ea6e6ad9241c2a3f636b30639bd35_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6ff6b135bf9430bb09afc4a228eb9cd_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0e56591afc54f4ebeb3c8aa3ab4fbe1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a2a8f5d314144a884fb86491fc334b7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i310d9b9a89454544b9e9d7c6399db39a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2834e4b26174a4a8a9f1d26de96cce2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bf59d25162d4274b7c672eb48a47901_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib76a1e00d0be407f9aad476b9558aa02_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i537aa7da0127497a9ab35f8f1601120c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a1de474406c4d5ca2bd60c12dcee520_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5d0942946ce4b92a48bd388374cd857_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab52133a24a345c2b5b462deff22d656_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2d670c1a5724338a60501f42187b7e0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i082b646328b744be992ad3f152baee86_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb00505b86b4445ea664e50b7f30071c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a860a8253cc468dab9782964e9008d2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafe66fc19ba44522a7249f23c4348b8c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d359c13687c4b70afe72962c41749e1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i308c9eedd5de4813af1e34bfdc45b87d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dd8b9f384214850b5f4fd852ba9f217_D20260101-20260331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fc078bde80e4f5eaa692435aa8a2da3_D20270101-20270331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2027-01-01</xbrli:startDate><xbrli:endDate>2027-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20828fea2889439ba7af1b8a7dcb42eb_D20280101-20280331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2028-01-01</xbrli:startDate><xbrli:endDate>2028-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="rate"><xbrli:measure>utr:Rate</xbrli:measure></xbrli:unit><xbrli:context id="i71a46b4fd0da412cbd90061ff289cf49_D20141101-20141130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2014-11-01</xbrli:startDate><xbrli:endDate>2014-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cc6e78d37b6446ba787713f65cd8666_I20141120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2014-11-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fa52b6205c847e4888033f43b0077d3_I20200928"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idedefb7f68d74e2aa8370ccd51445b1d_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie65c2031672c436c9ffb9020a455b7c6_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ibf95eabc4cf34ac1b0383c1ba8d7debc_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGV4dHJlZ2lvbjpmYTUwOWRmNjYyN2U0MTI2YTA5Y2EzOWQ4MjJlNDVkN184Mg_f491a7b6-1ac3-4952-bada-24dbca72e6cd">10-Q</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:1.972%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.828%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGFibGU6NjM3OGVhOTI1ZDNhNGViZTgzY2M0OTFkOWFlYWM1MzgvdGFibGVyYW5nZTo2Mzc4ZWE5MjVkM2E0ZWJlODNjYzQ5MWQ5YWVhYzUzOF8wLTAtMS0xLTI4NTMy_7d984397-6965-4185-b016-28af5341de9c">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Quarterly Period Ended <ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGV4dHJlZ2lvbjpmYTUwOWRmNjYyN2U0MTI2YTA5Y2EzOWQ4MjJlNDVkN18xMjk_84c53058-412b-4f91-ae50-faf6b6eff04d">June 30, 2022</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:1.972%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.828%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGFibGU6NzQ1MTZmZjEzZDQyNDcwNzg4YjRhMDhhYmFlMTUyNWIvdGFibGVyYW5nZTo3NDUxNmZmMTNkNDI0NzA3ODhiNGEwOGFiYWUxNTI1Yl8wLTAtMS0xLTI4NTMy_8c49ebbe-caac-4f33-9c07-10c57c67d439">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Transition Period from _____________ to _____________</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number:&#160;&#160;<ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGV4dHJlZ2lvbjpmYTUwOWRmNjYyN2U0MTI2YTA5Y2EzOWQ4MjJlNDVkN18yMjU_b5e2a817-8223-498f-9bed-22e3776b50dc">000-30111</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGV4dHJlZ2lvbjpmYTUwOWRmNjYyN2U0MTI2YTA5Y2EzOWQ4MjJlNDVkN18yMjg_6d355f25-ac72-4f9b-8f3a-5bd32e350b3e">Lexicon Pharmaceuticals, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGFibGU6YjdmMWVjYzJjZDNhNGJlZDk3MjQzZTUzOGVmOWJiZDYvdGFibGVyYW5nZTpiN2YxZWNjMmNkM2E0YmVkOTcyNDNlNTM4ZWY5YmJkNl8wLTAtMS0xLTI4NTMy_667cf7de-153c-4f38-b854-c4631fc780b7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGFibGU6YjdmMWVjYzJjZDNhNGJlZDk3MjQzZTUzOGVmOWJiZDYvdGFibGVyYW5nZTpiN2YxZWNjMmNkM2E0YmVkOTcyNDNlNTM4ZWY5YmJkNl8wLTEtMS0xLTI4NTMy_6d849c4c-d0a1-4813-8703-fad182c62350">76-0474169</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of<br/>Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGV4dHJlZ2lvbjpmYTUwOWRmNjYyN2U0MTI2YTA5Y2EzOWQ4MjJlNDVkN18yODc_c094ecb2-b09a-423e-9f12-5c226a1a9811">2445 Technology Forest Blvd.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGV4dHJlZ2lvbjpmYTUwOWRmNjYyN2U0MTI2YTA5Y2EzOWQ4MjJlNDVkN18yOTA_4cf07eb7-0022-46bc-b588-1b14f2611d84">11th Floor</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGV4dHJlZ2lvbjpmYTUwOWRmNjYyN2U0MTI2YTA5Y2EzOWQ4MjJlNDVkN18yOTM_2244889a-b48d-4d17-9d39-8b0a9045a9f7">The Woodlands</ix:nonNumeric>, <ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGV4dHJlZ2lvbjpmYTUwOWRmNjYyN2U0MTI2YTA5Y2EzOWQ4MjJlNDVkN18yOTc_871652e2-61a1-454b-a6a3-77acb48d7579">Texas</ix:nonNumeric> <ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGV4dHJlZ2lvbjpmYTUwOWRmNjYyN2U0MTI2YTA5Y2EzOWQ4MjJlNDVkN18zMDA_516e246f-3639-4125-a6a0-f8ec4ef69cd8">77381</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of Principal Executive Offices and Zip Code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGV4dHJlZ2lvbjpmYTUwOWRmNjYyN2U0MTI2YTA5Y2EzOWQ4MjJlNDVkN18zNTg_99c8711c-8b87-4f3f-82ef-d0a6f60a4a22">281</ix:nonNumeric>) <ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGV4dHJlZ2lvbjpmYTUwOWRmNjYyN2U0MTI2YTA5Y2EzOWQ4MjJlNDVkN18zNjI_4f1e07bf-860d-4665-85b7-05a84cbd98cd">863-3000</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGFibGU6NDA1ZjEzYzk5M2EyNDdmYTk5OWMyZWI1ZWE3Y2JjNTcvdGFibGVyYW5nZTo0MDVmMTNjOTkzYTI0N2ZhOTk5YzJlYjVlYTdjYmM1N18xLTAtMS0xLTI4NTMy_d0df40d8-88c5-4e97-af74-54bbe94ba7d7">Common Stock, par value $0.001</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGFibGU6NDA1ZjEzYzk5M2EyNDdmYTk5OWMyZWI1ZWE3Y2JjNTcvdGFibGVyYW5nZTo0MDVmMTNjOTkzYTI0N2ZhOTk5YzJlYjVlYTdjYmM1N18xLTEtMS0xLTI4NTMy_fdc4ab1f-78ba-443e-bab6-e4355b741b91">LXRX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGFibGU6NDA1ZjEzYzk5M2EyNDdmYTk5OWMyZWI1ZWE3Y2JjNTcvdGFibGVyYW5nZTo0MDVmMTNjOTkzYTI0N2ZhOTk5YzJlYjVlYTdjYmM1N18xLTItMS0xLTI4NTMy_ab4ef2f6-6d56-4615-8dd9-8d61188bc542">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160; </span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                     </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:30.263%"><tr><td style="width:1.0%"></td><td style="width:21.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGFibGU6YWRiZDI3NjBmZWEyNDk0Yjk0N2YwNThjZjNhNmNhYWYvdGFibGVyYW5nZTphZGJkMjc2MGZlYTI0OTRiOTQ3ZjA1OGNmM2E2Y2FhZl8wLTAtMS0xLTI4NTMy_3516d004-f823-4a44-a083-23b32c7211d7">Yes</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                     </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:30.263%"><tr><td style="width:1.0%"></td><td style="width:21.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGFibGU6MjY0Nzc3OTBhZmQxNDRlMmExZjljMmIxZTUwOWUzMzYvdGFibGVyYW5nZToyNjQ3Nzc5MGFmZDE0NGUyYTFmOWMyYjFlNTA5ZTMzNl8wLTAtMS0xLTI4NTMy_7a0a74cf-8835-41fd-a181-8246a93c37b9">Yes</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.&#160;&#160;See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large accelerated filer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;     Accelerated filer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">          <ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGV4dHJlZ2lvbjpmYTUwOWRmNjYyN2U0MTI2YTA5Y2EzOWQ4MjJlNDVkN18yMzAz_9f246df0-125c-4f1a-bb9b-b949746cfc93">Non-accelerated filer</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#9745;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;<ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGV4dHJlZ2lvbjpmYTUwOWRmNjYyN2U0MTI2YTA5Y2EzOWQ4MjJlNDVkN18yMzA0_fd7d26e7-cb47-4733-a293-eb187d0f6bd4">&#9745;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     Emerging growth company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;<ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGV4dHJlZ2lvbjpmYTUwOWRmNjYyN2U0MTI2YTA5Y2EzOWQ4MjJlNDVkN18yMzA1_22939e8a-8ecc-40ec-91ee-8ea4dc47aaa8">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registration has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:30.263%"><tr><td style="width:1.0%"></td><td style="width:21.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGFibGU6NmI1YTYzYjcxMzA3NGUyYWFiOGVmYWM2ODcxZmRjMTkvdGFibGVyYW5nZTo2YjVhNjNiNzEzMDc0ZTJhYWI4ZWZhYzY4NzFmZGMxOV8wLTEtMS0xLTI4NTMy_823643cb-f878-42e9-aeb9-bdd3f9df7715">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of August&#160;3, 2022, <ix:nonFraction unitRef="shares" contextRef="if7a0858cf5024c25bf4b6aaa1fb4a8ca_I20220803" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGV4dHJlZ2lvbjpmYTUwOWRmNjYyN2U0MTI2YTA5Y2EzOWQ4MjJlNDVkN18xMDk5NTExNjMwMTQ1_84aa1295-2a71-4c49-9664-34764ecd74d4">183,625,743</ix:nonFraction> shares of the registrant&#8217;s common stock, par value $0.001 per share, were outstanding.  </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ibf95eabc4cf34ac1b0383c1ba8d7debc_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.783%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibf95eabc4cf34ac1b0383c1ba8d7debc_10">Factors Affecting Forward-Looking Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibf95eabc4cf34ac1b0383c1ba8d7debc_10">2</a></span></div></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibf95eabc4cf34ac1b0383c1ba8d7debc_13">Part I &#8211; Financial Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibf95eabc4cf34ac1b0383c1ba8d7debc_13">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibf95eabc4cf34ac1b0383c1ba8d7debc_16">Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibf95eabc4cf34ac1b0383c1ba8d7debc_16">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Balance Sheets - June 30, 2022 (unaudited) and December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibf95eabc4cf34ac1b0383c1ba8d7debc_19">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Comprehensive Loss (unaudited) - Three and Six Months Ended June 30, 2022 and 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibf95eabc4cf34ac1b0383c1ba8d7debc_22">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Stockholders&#8217; Equity (unaudited) - Three and Six Months Ended June 30, 2022 and 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibf95eabc4cf34ac1b0383c1ba8d7debc_25">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Cash Flows (unaudited) - Six Months Ended June 30, 2022 and 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibf95eabc4cf34ac1b0383c1ba8d7debc_28">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Condensed Consolidated Financial Statements (unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibf95eabc4cf34ac1b0383c1ba8d7debc_31">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibf95eabc4cf34ac1b0383c1ba8d7debc_58">Management&#8217;s Discussion and Analysis of Financial Condition and Results&#160;of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibf95eabc4cf34ac1b0383c1ba8d7debc_58">15</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibf95eabc4cf34ac1b0383c1ba8d7debc_67">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibf95eabc4cf34ac1b0383c1ba8d7debc_67">20</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibf95eabc4cf34ac1b0383c1ba8d7debc_70">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibf95eabc4cf34ac1b0383c1ba8d7debc_67">20</a></span></div></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibf95eabc4cf34ac1b0383c1ba8d7debc_73">Part II &#8211; Other Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibf95eabc4cf34ac1b0383c1ba8d7debc_73">21</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibf95eabc4cf34ac1b0383c1ba8d7debc_76">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibf95eabc4cf34ac1b0383c1ba8d7debc_76">21</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibf95eabc4cf34ac1b0383c1ba8d7debc_79">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibf95eabc4cf34ac1b0383c1ba8d7debc_79">21</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibf95eabc4cf34ac1b0383c1ba8d7debc_85">Exhibits</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibf95eabc4cf34ac1b0383c1ba8d7debc_85">24</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibf95eabc4cf34ac1b0383c1ba8d7debc_88">Signatures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibf95eabc4cf34ac1b0383c1ba8d7debc_88">25</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lexicon name and logo are registered trademarks of Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div><span><br/></span></div><div id="ibf95eabc4cf34ac1b0383c1ba8d7debc_10"></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Factors Affecting Forward Looking Statements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This quarterly report on Form 10-Q contains forward-looking statements.  These statements relate to future events or our future financial performance. We have attempted to identify forward-looking statements by terminology including &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;should&#8221; or &#8220;will&#8221; or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks outlined under &#8220;Part&#160;II, Item 1A. - Risk Factors&#8221; and in our annual report on Form 10-K for the year ended December&#160;31, 2021, that may cause our or our industry&#8217;s actual results, levels of activity, performance or achievements to be materially different from any future results, levels or activity, performance or achievements expressed or implied by these forward-looking statements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that the expectations reflected in the forward-looking statements are reasonable, future results, levels of activity, performance or achievements may vary materially from our expectations. We are not undertaking any duty to update any of the forward-looking statements after the date of this quarterly report on Form 10-Q to conform these statements to actual results, unless required by law.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ibf95eabc4cf34ac1b0383c1ba8d7debc_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Part I &#8211; Financial Information</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ibf95eabc4cf34ac1b0383c1ba8d7debc_16"></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;Financial Statements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ibf95eabc4cf34ac1b0383c1ba8d7debc_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except par value)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:60.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfNC0yLTEtMS0yODUzMg_77d5b4e0-6851-46ae-a26d-0a64683033e7">21,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfNC00LTEtMS0yODUzMg_2234961d-57fc-4436-b890-92f848bb53a7">64,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfNS0yLTEtMS0yODUzMg_0a0f1740-9d8e-4905-842a-d14317b2c9e5">40,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfNS00LTEtMS0yODUzMg_5b364e5a-4856-4779-b165-649bfb753723">22,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfNi0yLTEtMS0yODUzMg_4653b1ea-7080-4fcd-aaeb-462cc715d56c">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfNi00LTEtMS0yODUzMg_e9f64683-31c4-4b3f-9014-509908eecc8c">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfNy0yLTEtMS0yODUzMg_711c11f5-9e8e-40c5-abbc-b2c049999117">2,896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfNy00LTEtMS0yODUzMg_36532764-2d6d-4915-b258-7949b4133d1c">2,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfOC0yLTEtMS0yODUzMg_15e55abd-dd07-4bfb-b0eb-dbb2faae88af">64,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfOC00LTEtMS0yODUzMg_eca4886f-6cf7-4fd6-acb5-b8ea860c0f2d">88,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation and amortization of $<ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfOS0wLTEtMS0yODUzMi90ZXh0cmVnaW9uOmNkMzk3NGVjZTE4OTRlYzg4NDg4OWYzY2U1NmY5MGIxXzgw_30472e2d-1829-4ace-a6e6-a999991974bf">5,070</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfOS0wLTEtMS0yODUzMi90ZXh0cmVnaW9uOmNkMzk3NGVjZTE4OTRlYzg4NDg4OWYzY2U1NmY5MGIxXzg3_9ac2f7bc-183a-48a0-8947-0677c745b7e6">4,853</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfOS0yLTEtMS0yODUzMg_de0c67d0-828b-4ac0-bf24-33e330af0760">1,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfOS00LTEtMS0yODUzMg_f9d40d11-678b-44e3-b113-4706bc4313f2">1,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTAtMi0xLTEtMjg1MzI_d6442466-eac0-47f7-af25-fb6a7434eef2">44,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTAtNC0xLTEtMjg1MzI_773767d5-9452-4e50-a327-49ee7994c16d">44,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTEtMi0xLTEtMjg1MzI_062dc6e9-0798-442c-82fa-2bfe8abccb18">1,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTEtNC0xLTEtMjg1MzI_169d9e8e-0e32-4122-b5e3-b4a1f97bcdc3">2,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTItMi0xLTEtMjg1MzI_11487860-e01a-4b06-80d9-6ce1fe988d2d">112,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTItNC0xLTEtMjg1MzI_ff588c79-9013-4af5-93a0-88df1d8fb037">136,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTUtMi0xLTEtMjg1MzI_d97671ae-b43d-42ea-ba5d-14dfae7faab1">7,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTUtNC0xLTEtMjg1MzI_c8b94bae-2ca1-43c1-9a6e-5fa26b5fa983">9,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTYtMi0xLTEtMjg1MzI_71a7c63c-d37d-4c35-baf1-b955b60657fb">9,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTYtNC0xLTEtMjg1MzI_125667a8-210d-4ec8-bc82-91b6837d7729">12,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTctMi0xLTEtMjg1MzI_7213e881-c35c-4054-995f-b9b5c12044f2">16,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTctNC0xLTEtMjg1MzI_f1ce8a98-be6c-4cff-8c24-1af7d9c0fb84">22,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTgtMi0xLTEtMjg1MzI_20ab8795-83ef-4a86-9c8e-6b5c8a924f3f">23,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTgtNC0xLTEtMjg1MzI_0033569a-77f0-481d-8951-0a689242accd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTktMi0xLTEtMjg1MzI_22e8e8ee-7a19-4056-a2e1-493c1873976d">1,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTktNC0xLTEtMjg1MzI_28a969f5-9b82-4211-84ea-32a9c862477e">1,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjAtMi0xLTEtMjg1MzI_f752ac1b-5ce1-4c3d-abe5-ae658f4ced86">41,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjAtNC0xLTEtMjg1MzI_3362a604-9cbb-4c74-a4ac-1307e6604f99">23,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjEtMi0xLTEtMjg1MzI_c1253264-a35b-4c98-bd15-4c38ade131ad"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjEtNC0xLTEtMjg1MzI_2d734a23-d78c-4d75-9123-6c5b86b2e88e"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; Equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="2" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjMtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjpjZjdhMWUwODFiNWI0ZjkwYjZhODE1OGJkZDFkYTkwM18yMQ_32e64d52-db2f-4351-9e85-71af08aa2191"><ix:nonFraction unitRef="usdPerShare" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="2" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjMtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjpjZjdhMWUwODFiNWI0ZjkwYjZhODE1OGJkZDFkYTkwM18yMQ_c6ebf5df-9fbe-48a5-af6d-3831b4d3b6e2">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjMtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjpjZjdhMWUwODFiNWI0ZjkwYjZhODE1OGJkZDFkYTkwM18zNQ_738abc9b-4d0b-424a-a5c9-4d5315687d16"><ix:nonFraction unitRef="shares" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjMtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjpjZjdhMWUwODFiNWI0ZjkwYjZhODE1OGJkZDFkYTkwM18zNQ_84c6f3c5-c804-4d63-a156-6861e658738b">5,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjMtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjpjZjdhMWUwODFiNWI0ZjkwYjZhODE1OGJkZDFkYTkwM181Nw_126951d5-1f6f-41e1-9115-71afeacfb86f"><ix:nonFraction unitRef="shares" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjMtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjpjZjdhMWUwODFiNWI0ZjkwYjZhODE1OGJkZDFkYTkwM181Nw_4df0f957-d925-4be8-a85d-8cc64fff7e3f"><ix:nonFraction unitRef="shares" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjMtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjpjZjdhMWUwODFiNWI0ZjkwYjZhODE1OGJkZDFkYTkwM181Nw_5db56796-3ae6-4aeb-bb34-4e1dc9fb68b0"><ix:nonFraction unitRef="shares" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjMtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjpjZjdhMWUwODFiNWI0ZjkwYjZhODE1OGJkZDFkYTkwM181Nw_856455aa-56d7-4419-9d17-3fde7e9a635a">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjMtMi0xLTEtMjg1MzI_79b3f591-ff8d-4fa3-9035-82e55228042d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjMtNC0xLTEtMjg1MzI_6a3335b8-aadc-4a8b-96e5-0c64e5295078">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjQtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjo0YzNiNTFhYWUwM2Q0M2Y3OGE3Yzc0MWMxMWRlMWUwYV8xOA_0bd9cf32-873b-480d-b16d-9f78acdf6a9a"><ix:nonFraction unitRef="usdPerShare" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjQtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjo0YzNiNTFhYWUwM2Q0M2Y3OGE3Yzc0MWMxMWRlMWUwYV8xOA_c47dc128-9097-4e11-8398-acf5d6958721">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjQtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjo0YzNiNTFhYWUwM2Q0M2Y3OGE3Yzc0MWMxMWRlMWUwYV8zMg_4d6efa4e-14d1-4076-b6d4-991682e0ac37"><ix:nonFraction unitRef="shares" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjQtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjo0YzNiNTFhYWUwM2Q0M2Y3OGE3Yzc0MWMxMWRlMWUwYV8zMg_77347186-5cf2-453b-a716-c8fe7ba95bba">300,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjQtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjo0YzNiNTFhYWUwM2Q0M2Y3OGE3Yzc0MWMxMWRlMWUwYV81NA_02a7fd6b-f211-4591-9e8e-d9c5bd155e9c">150,114</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjQtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjo0YzNiNTFhYWUwM2Q0M2Y3OGE3Yzc0MWMxMWRlMWUwYV82MQ_216e637d-bcf7-4c9d-b0fb-0bd6e985be21">150,082</ix:nonFraction> shares issued, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjQtMi0xLTEtMjg1MzI_811afe06-5d4a-4a89-9242-24e277edba3f">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjQtNC0xLTEtMjg1MzI_5eeeff97-5eee-4fd8-8314-31bab60bff0b">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjUtMi0xLTEtMjg1MzI_4e4e1206-29d0-40e1-92fc-c3ee12e2b3de">1,608,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjUtNC0xLTEtMjg1MzI_13947c8a-d4c8-4d1e-ac81-4bd76ce934d5">1,608,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjYtMi0xLTEtMjg1MzI_80779c10-45e8-4c27-8ebe-e6889bb20249">1,535,839</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjYtNC0xLTEtMjg1MzI_33e6a2ee-6463-4b56-9bb1-929a139230c5">1,487,776</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjctMi0xLTEtMjg1MzI_039e7fb7-e273-4655-8e40-ba3ce2848b53">150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjctNC0xLTEtMjg1MzI_57ba7a6e-06e1-45f8-91dd-97f8c1294dfa">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost, <ix:nonFraction unitRef="shares" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:TreasuryStockShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjgtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjo4NDRkMzA1NWUwMzQ0MzY4YjU1NjJkNDdmMDU5NjA1ZF8yOQ_c6e50378-d43b-4599-9bbb-2331f2ed01f0">488</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjgtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjo4NDRkMzA1NWUwMzQ0MzY4YjU1NjJkNDdmMDU5NjA1ZF8zNg_1f32c62b-9344-4d8e-a0ab-b06831c114c5">1,165</ix:nonFraction> shares, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjgtMi0xLTEtMjg1MzI_0e9f4779-945d-4919-8661-6cb366654fc8">2,061</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjgtNC0xLTEtMjg1MzI_6845a6a0-06c0-4e65-a08d-90295f1d2d3b">7,518</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjktMi0xLTEtMjg1MzI_4a22a3df-4339-4808-b1be-78d1614be526">70,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjktNC0xLTEtMjg1MzI_c0b13884-dccc-4eda-a9d0-c55ef4caf106">113,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMzAtMi0xLTEtMjg1MzI_6fb72bd8-73a1-489c-8658-b8e36349954f">112,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMzAtNC0xLTEtMjg1MzI_03c72681-04e7-4236-b8da-cd84b8c26fb3">136,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ibf95eabc4cf34ac1b0383c1ba8d7debc_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.261%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties and other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630" decimals="-3" name="us-gaap:RoyaltyIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMy0xLTEtMS0yODg5OQ_59a6f2b0-1070-473a-9a3b-4d229b8a22ef">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630" decimals="-3" name="us-gaap:RoyaltyIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMy0zLTEtMS0yODg5OQ_cc378f0e-10d6-45ac-b965-af8ca7744582">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" name="us-gaap:RoyaltyIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMy0yLTEtMS0yODUzMg_874ff920-285c-4ab0-ae86-5997d5dfa04b">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" name="us-gaap:RoyaltyIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMy00LTEtMS0yODUzMg_7aacfedb-c619-4606-b4ef-89db0e80b1e4">261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development, including stock-based compensation of $<ix:nonFraction unitRef="usd" contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630" decimals="-3" name="lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNi0wLTEtMS0yODUzMi90ZXh0cmVnaW9uOjIyMzQ5MjY4MTc1MjQ1ZThhNjY3MTQ2Yjc5MzA5MTNhXzY4_ff941083-fd5f-4d2a-a905-843c1784c1fe">1,098</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630" decimals="-3" name="lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNi0wLTEtMS0yODUzMi90ZXh0cmVnaW9uOjIyMzQ5MjY4MTc1MjQ1ZThhNjY3MTQ2Yjc5MzA5MTNhXzc2_cf0dacaf-794f-4ab8-abe7-82d52449842b">1,184</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" name="lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNi0wLTEtMS0yODUzMi90ZXh0cmVnaW9uOjIyMzQ5MjY4MTc1MjQ1ZThhNjY3MTQ2Yjc5MzA5MTNhXzEwOTk1MTE2Mjc4Njk_2ce8c3b3-f8fe-4a9e-be38-246852f9957c">2,130</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" name="lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNi0wLTEtMS0yODUzMi90ZXh0cmVnaW9uOjIyMzQ5MjY4MTc1MjQ1ZThhNjY3MTQ2Yjc5MzA5MTNhXzEwOTk1MTE2Mjc4OTE_485d5a35-0576-40b7-88f6-c83b0ccf6c9b">2,470</ix:nonFraction> respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNi0xLTEtMS0yODg3MA_2aacb8a4-024f-4649-9586-7e189e759302">13,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNi0zLTEtMS0yODg5OQ_c844052f-4739-4eae-a766-44aeee18e9f1">10,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNi0yLTEtMS0yODUzMg_f39de704-3d74-487d-90d0-bd13bb45b0ec">28,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNi00LTEtMS0yODUzMg_070ff337-b9a1-40fd-93c4-927e4b19692a">22,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative, including stock-based compensation of $<ix:nonFraction unitRef="usd" contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630" decimals="-3" name="lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNy0wLTEtMS0yODUzMi90ZXh0cmVnaW9uOmU2ZTYyOTBjMDkzMzQ0NjlhZTA4NDhmNWQ2NGM5NzA4Xzc5_167152e8-e3f3-4308-a877-1b9a75ac1fef">1,734</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630" decimals="-3" name="lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNy0wLTEtMS0yODUzMi90ZXh0cmVnaW9uOmU2ZTYyOTBjMDkzMzQ0NjlhZTA4NDhmNWQ2NGM5NzA4Xzg3_df9fc65c-f4f4-43b9-9972-b558c8690251">1,602</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" name="lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNy0wLTEtMS0yODUzMi90ZXh0cmVnaW9uOmU2ZTYyOTBjMDkzMzQ0NjlhZTA4NDhmNWQ2NGM5NzA4XzEwOTk1MTE2Mjc4ODI_b6b0d29f-b024-457e-9acf-ae82a793d8a8">3,474</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" name="lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNy0wLTEtMS0yODUzMi90ZXh0cmVnaW9uOmU2ZTYyOTBjMDkzMzQ0NjlhZTA4NDhmNWQ2NGM5NzA4XzEwOTk1MTE2Mjc5MDA_d3491de5-6918-4933-9de8-dedc1a1fd3a7">3,167</ix:nonFraction> respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630" decimals="-3" name="lxrx:Sellinggeneralandadministrativeexpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNy0xLTEtMS0yODg5OQ_c1cbf0b7-efab-4ffa-bc3f-1ce30b349c90">10,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630" decimals="-3" name="lxrx:Sellinggeneralandadministrativeexpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNy0zLTEtMS0yODg5OQ_3f106904-f6e0-440c-a15b-cd44aaf3ccfa">7,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" name="lxrx:Sellinggeneralandadministrativeexpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNy0yLTEtMS0yODUzMg_17fd5f2f-c943-4f57-b725-4ea928808d78">19,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" name="lxrx:Sellinggeneralandadministrativeexpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNy00LTEtMS0yODUzMg_f35e45ed-973b-41f5-82e4-0d4a406fd17c">16,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfOC0xLTEtMS0yODg5OQ_95732398-d8c1-45c0-8c15-a01d02305f53">24,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfOC0zLTEtMS0yODg5OQ_efed90a6-724e-4fc4-865e-5edbcee633a2">18,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfOC0yLTEtMS0yODUzMg_06544e8f-1c9d-41b5-b05a-5d956407006e">47,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfOC00LTEtMS0yODUzMg_0d8d55b4-aad4-469b-a140-e2580d0c6e6a">39,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfOS0xLTEtMS0yODg5OQ_e4623195-5e97-4927-b953-3d884d8b70c7">24,007</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfOS0zLTEtMS0yODg5OQ_effefc49-9be8-4e7e-acb0-57f0237991c7">17,959</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfOS0yLTEtMS0yODUzMg_3ca20b5b-6eb8-48f0-ace1-3b7163bc078a">47,387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfOS00LTEtMS0yODUzMg_48ec2880-e87b-4865-a232-6b85b594225a">38,798</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTAtMS0xLTEtMjg4OTk_5f13e14a-1142-41d1-b84c-4f5ef1035868">703</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTAtMy0xLTEtMjg4OTk_ce7fa173-ea43-446c-a138-64168d9d07e8">169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTAtMi0xLTEtMjg1MzI_25029430-9c4a-400c-a3bf-ad0b42f6ebbd">813</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTAtNC0xLTEtMjg1MzI_5d4901a4-5739-4435-b5c1-c19760b2001f">336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTEtMS0xLTEtMjg4OTk_ab50d8e5-f36f-4355-b1f3-2c08448336b3">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTEtMy0xLTEtMjg4OTk_6b97abec-4732-4fb9-b25a-3da297266b9b">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTEtMi0xLTEtMjg1MzI_d176085b-0d03-45c2-aed4-e8177131ec6a">137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTEtNC0xLTEtMjg1MzI_15a62279-8aac-4137-b998-4c7da522066f">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTItMS0xLTEtMjg4OTk_2be46468-a990-4a1b-abfc-9e857b5f8e6d">24,587</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTItMy0xLTEtMjg4OTk_17c0e601-ec6d-4284-9546-7a07e389475b">18,067</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTItMi0xLTEtMjg1MzI_a6fb63e1-276b-4f88-be61-48059bdb9d5e">48,063</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTItNC0xLTEtMjg1MzI_a0b96d8c-18fa-4255-a493-e016ea62694d">39,025</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share, basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTMtMS0xLTEtMjg4OTk_9a2e54ab-c4db-4d04-9fce-797a077afbfc">0.16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTMtMy0xLTEtMjg4OTk_e04df881-3276-4962-a57f-10597852941f">0.13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTMtMi0xLTEtMjg1MzI_8f6832fd-792a-42f7-bd0d-99b579da90a9">0.32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTMtNC0xLTEtMjg1MzI_301f29c7-9cc4-46f3-b18b-7c8c7acb651d">0.27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net loss per common share, basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTUtMS0xLTEtMjg4OTk_21162575-f134-4b69-8ef1-081945df33da">149,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTUtMy0xLTEtMjg4OTk_b4061548-ec90-42c8-90f4-f9340b6c198a">144,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTUtMi0xLTEtMjg1MzI_512f4fff-9d32-47f9-a0de-b5e6fa351d03">149,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTUtNC0xLTEtMjg1MzI_f3def612-7a5b-4463-bf5c-092889ed1910">143,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (loss) gain on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTgtMS0xLTEtMjg4OTk_10fece99-96c4-4ce1-babc-5f429fffddcc">113</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTgtMy0xLTEtMjg4OTk_ba8e7898-b48c-4b78-a16c-9573515ac8f5">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTgtMi0xLTEtMjg1MzI_3d6713b2-0320-469d-9c36-ce3bca32350d">140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTgtNC0xLTEtMjg1MzI_de5c4deb-8f1c-4964-aaa6-d9b091b739f8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTktMS0xLTEtMjg4OTk_26912a5a-6e5f-4a02-91a6-57aa0c184fac">24,700</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTktMy0xLTEtMjg4OTk_ca0c0161-f77b-4571-81e1-e618880c6974">18,077</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTktMi0xLTEtMjg1MzI_8c022fd4-da90-42b7-90bf-917eb4d2bd98">48,203</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTktNC0xLTEtMjg1MzI_ed883fd0-25e3-4f7c-abf0-81991800df9b">39,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ibf95eabc4cf34ac1b0383c1ba8d7debc_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.779%"><tr><td style="width:1.0%"></td><td style="width:36.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.481%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Gain (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie8a7ca19bc1a4556a6e59951312a250b_I20201231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMi0yLTEtMS0yODUzMg_2220c302-ac81-40c5-b005-d82d3a7c5b3a">142,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8a7ca19bc1a4556a6e59951312a250b_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMi00LTEtMS0yODUzMg_d6b9432a-0641-4651-851b-aabd3860f852">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebb39511180847c6b73ea2044b1bbc86_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMi02LTEtMS0yODUzMg_19588b21-2cb0-4d03-a719-066e8caaf228">1,561,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1bfe69c4a75a471ab0ff5ee12bde76cc_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMi04LTEtMS0yODUzMg_6f198aeb-52b7-4964-b500-a17ab70d3293">1,400,018</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45657a0096954cda95b6dd011117c958_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMi0xMC0xLTEtMjg1MzI_2d03a709-1c38-4252-8522-00db234d6082">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i159bdd976c5a411daa2d75f84b7d64a6_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMi0xMi0xLTEtMjg1MzI_da7ff6e8-91e9-4f08-9fef-078ad3e78cbf">4,843</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ab6ec7ca184c0b98f71ea5fbc23b66_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMi0xNC0xLTEtMjg1MzI_c8461bd1-75ce-493f-8dfc-416613e05f47">156,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6294895f68fb461d8a0149ff1352660b_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMy00LTEtMS0yODUzMg_c2b21f48-3337-4749-9ca3-1da34da150e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64b8f1ab07f04390b4b79e6f8c6eb68e_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMy02LTEtMS0yODUzMg_37adeeaa-b62d-49b5-9a49-024e867b74e0">2,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f6fc7cd72c34badba8bff35c5c227ac_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMy04LTEtMS0yODUzMg_9a72dcbd-0a58-4136-8666-44e321c61f35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ea8108d1eb5464fb0ec1f1c33b681cd_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMy0xMC0xLTEtMjg1MzI_88e9ede7-5e26-47cb-b8c8-c752e6f0b8d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab6948c85b864af88b2035a19dd666a2_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMy0xMi0xLTEtMjg1MzI_01eb8e36-f6c4-4d05-9a40-3141a58effe0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cf877d5e034cbe9a21bc4654ebb5f6_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMy0xNC0xLTEtMjg1MzI_fa25b0f8-92b2-448a-85a4-5456b8f0ffc5">2,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under Equity Incentive Plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6294895f68fb461d8a0149ff1352660b_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNC0yLTEtMS0yODUzMg_7d841876-2c37-4cfb-9130-3610025ab472">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6294895f68fb461d8a0149ff1352660b_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNC00LTEtMS0yODUzMg_0e522a01-2d49-470c-9f27-bc5e23d47b74">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64b8f1ab07f04390b4b79e6f8c6eb68e_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNC02LTEtMS0yODUzMg_3c0cbb00-51f4-47fc-bed3-17de6497b633">547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f6fc7cd72c34badba8bff35c5c227ac_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNC04LTEtMS0yODUzMg_a0055175-0804-453a-9843-0c0aa51cd903">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ea8108d1eb5464fb0ec1f1c33b681cd_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNC0xMC0xLTEtMjg1MzI_960a8bd7-5982-42f4-b1b3-1659e7250b88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab6948c85b864af88b2035a19dd666a2_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNC0xMi0xLTEtMjg1MzI_9cfbf7a9-953f-480c-b3e2-21c7709a31f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cf877d5e034cbe9a21bc4654ebb5f6_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNC0xNC0xLTEtMjg1MzI_2139c497-3dc0-4ac5-b899-849ffd33d1aa">548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under an Open Market Sale Agreement, net of issuance fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6294895f68fb461d8a0149ff1352660b_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNS0yLTEtMS0yODUzMg_048e134e-7e40-4090-b08e-174666fc18e5">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6294895f68fb461d8a0149ff1352660b_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNS00LTEtMS0yODUzMg_0c4223d9-c105-4f9d-bcfc-5be29317135a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64b8f1ab07f04390b4b79e6f8c6eb68e_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNS02LTEtMS0yODUzMg_d77f5d97-3ef1-4b29-bd24-2852ddb49ac8">16,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f6fc7cd72c34badba8bff35c5c227ac_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNS04LTEtMS0yODUzMg_c706d5c5-105d-4384-bcb1-b19f8167159f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ea8108d1eb5464fb0ec1f1c33b681cd_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNS0xMC0xLTEtMjg1MzI_3af66d28-1b88-43d8-ad6c-9cf4915d35b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab6948c85b864af88b2035a19dd666a2_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNS0xMi0xLTEtMjg1MzI_34a29b38-95ab-401b-b616-48d05114fc10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cf877d5e034cbe9a21bc4654ebb5f6_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNS0xNC0xLTEtMjg1MzI_57efcd5b-f276-439f-a4ac-9fa4919f13ba">16,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6294895f68fb461d8a0149ff1352660b_D20210101-20210331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNi00LTEtMS0yODUzMg_cebfff6c-c8bf-48b0-9080-221a0aa74f57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64b8f1ab07f04390b4b79e6f8c6eb68e_D20210101-20210331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNi02LTEtMS0yODUzMg_3625b257-15c5-45fc-bd05-d2e90b112974">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f6fc7cd72c34badba8bff35c5c227ac_D20210101-20210331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNi04LTEtMS0yODUzMg_fb2384db-8195-4b90-9067-2dcbc1bbbe10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ea8108d1eb5464fb0ec1f1c33b681cd_D20210101-20210331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNi0xMC0xLTEtMjg1MzI_35d48530-f7dd-411a-a5d2-ed96129a454f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab6948c85b864af88b2035a19dd666a2_D20210101-20210331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNi0xMi0xLTEtMjg1MzI_c22b8dc7-795c-42a5-8be6-d1d4c089b0ff">2,675</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6cf877d5e034cbe9a21bc4654ebb5f6_D20210101-20210331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNi0xNC0xLTEtMjg1MzI_779f620a-b8cb-463e-ae58-bacd973cf619">2,675</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6294895f68fb461d8a0149ff1352660b_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNy00LTEtMS0yODUzMg_04ba4053-2d8b-45e9-a9b1-75199c03f310">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64b8f1ab07f04390b4b79e6f8c6eb68e_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNy02LTEtMS0yODUzMg_1e2f59fa-681a-47b1-bc21-f2824ad47717">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f6fc7cd72c34badba8bff35c5c227ac_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNy04LTEtMS0yODUzMg_f6548439-fa01-4389-99f7-f5ef8850ff3f">20,958</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ea8108d1eb5464fb0ec1f1c33b681cd_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNy0xMC0xLTEtMjg1MzI_c0f4f23a-e3fa-4152-85fc-cb7833a04778">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab6948c85b864af88b2035a19dd666a2_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNy0xMi0xLTEtMjg1MzI_9221848f-7379-456e-9c1b-10b3924e48fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f6fc7cd72c34badba8bff35c5c227ac_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNy0xNC0xLTEtMjg1MzI_8d4fee09-aebd-4c8f-b634-322f3687e596">20,958</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6294895f68fb461d8a0149ff1352660b_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfOC00LTEtMS0yODUzMg_504e2022-df03-4c64-a36d-a545bd96f7ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64b8f1ab07f04390b4b79e6f8c6eb68e_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfOC02LTEtMS0yODUzMg_92066640-cacc-4605-ba8a-7f8d145d5893">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f6fc7cd72c34badba8bff35c5c227ac_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfOC04LTEtMS0yODUzMg_025d68ac-a566-490c-abc2-02332615afdc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ea8108d1eb5464fb0ec1f1c33b681cd_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfOC0xMC0xLTEtMjg1MzI_9c600128-64ec-4edd-aca8-12f054065253">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab6948c85b864af88b2035a19dd666a2_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfOC0xMi0xLTEtMjg1MzI_47d25843-6623-4fce-a6bf-d1916f02548b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cf877d5e034cbe9a21bc4654ebb5f6_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfOC0xNC0xLTEtMjg1MzI_1e01d3e4-fb53-4a53-9aa1-630f3365393d">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i067eeafe353e47bc8c8d21624e5bafe8_I20210331" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfOS0yLTEtMS0yODUzMg_bc8d06ad-288e-4768-85de-407265c86f49">145,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i067eeafe353e47bc8c8d21624e5bafe8_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfOS00LTEtMS0yODUzMg_824d23d3-1246-48cd-8a87-54f4c1925128">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabab49ebc5c4a4a9b6b4ef4966aefcd_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfOS02LTEtMS0yODUzMg_bf15cbe6-6df1-43e7-83e0-33aaac70498c">1,580,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d665691473c45ecb646640a37531cf4_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfOS04LTEtMS0yODUzMg_e83896a9-c0a6-4695-a818-d96c1a398182">1,420,976</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe0378736e444aab2cfabe4f48ecbb9_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfOS0xMC0xLTEtMjg1MzI_08621d85-883b-4778-9e7b-d69e6f35dfe3">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de99efa8fac4a1e9b601bcb9a760fad_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfOS0xMi0xLTEtMjg1MzI_d2f94e04-e441-48d9-aacc-c50a036d883d">7,518</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id997a83da5644f6987121d06d68d06ae_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfOS0xNC0xLTEtMjg1MzI_384473c3-4fca-466d-9146-eaddca1c95ad">152,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70f53509a43b46f7918ad0068ee464f4_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTAtNC0xLTEtMjkzNzA_d88371c5-b1db-4f16-a963-2d0c684ade56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6a00923dd164c3185de2bb3200711b3_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTAtNi0xLTEtMjkzNzA_c6d947fe-28d5-4011-b584-e32a2943a4ae">2,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaf692e06bd247aebe797f2c2d1665d7_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTAtOC0xLTEtMjkzNzA_992ebafd-dae3-4d77-8e8d-93e14b09ce01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id974764582f944f191de99110577719e_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTAtMTAtMS0xLTI5Mzcw_237c264c-c9c2-45f7-b3d2-be0a1986c04d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i436bb19a139f4e90a3435d0ce8396f1d_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTAtMTItMS0xLTI5Mzcw_3425f010-b7b9-49fe-963d-f26029d8304d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTAtMTQtMS0xLTI5Mzcw_dad2908a-a0fd-4732-8793-71bf260b7d27">2,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under Equity Incentive Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i70f53509a43b46f7918ad0068ee464f4_D20210401-20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTEtMi0xLTEtMjkzNzc_7cd6e608-233d-4541-94e9-47a9c4d4fe18">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70f53509a43b46f7918ad0068ee464f4_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTEtNC0xLTEtMjkzNzc_c1ee76c2-0d9d-4514-8ae7-ef7f80328166">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6a00923dd164c3185de2bb3200711b3_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTEtNi0xLTEtMjkzNzc_15eae2a2-079f-4060-9990-0e22e6610e1e">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaf692e06bd247aebe797f2c2d1665d7_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTEtOC0xLTEtMjkzNzc_437e26ab-70b3-46a4-a05f-337ee4c5c1a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id974764582f944f191de99110577719e_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTEtMTAtMS0xLTI5Mzc3_d543b3cb-5548-4060-8462-ac66f82f3a12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i436bb19a139f4e90a3435d0ce8396f1d_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTEtMTItMS0xLTI5Mzc3_fa0af13d-66c4-4a2c-b596-148327581357">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTEtMTQtMS0xLTI5Mzc3_8d4c68e7-c009-4b7a-99be-b4446761697f">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance fees related to Open Market Sale Agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70f53509a43b46f7918ad0068ee464f4_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTItNC0xLTEtMjkzNzc_e5d09575-02c3-424b-b311-0a5f24657bf6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6a00923dd164c3185de2bb3200711b3_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTItNi0xLTEtMjkzNzc_9ed165f6-f650-4968-be37-7664730b6b5a">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaf692e06bd247aebe797f2c2d1665d7_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTItOC0xLTEtMjkzNzc_26094e47-da9f-465d-a6dd-cb7713a46cdb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id974764582f944f191de99110577719e_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTItMTAtMS0xLTI5Mzc3_57fe6e07-3f65-4769-abd1-abb5cd0dca64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i436bb19a139f4e90a3435d0ce8396f1d_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTItMTItMS0xLTI5Mzc3_cced0343-6bbf-4bf9-8394-a234564508b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTItMTQtMS0xLTI5Mzc3_0c2a887b-45e5-41a6-b56a-b89d94411678">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70f53509a43b46f7918ad0068ee464f4_D20210401-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTMtNC0xLTEtMjkzNzc_10d924b9-8bf7-40e7-bc0a-1b8a6554c9ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6a00923dd164c3185de2bb3200711b3_D20210401-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTMtNi0xLTEtMjkzNzc_ad79ea33-d268-4ac2-8764-78a0e3503172">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaf692e06bd247aebe797f2c2d1665d7_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTMtOC0xLTEtMjkzNzc_9360782d-fcd0-4288-a0a7-ab9977854f7f">18,067</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id974764582f944f191de99110577719e_D20210401-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTMtMTAtMS0xLTI5Mzc3_82a3c27c-d4bb-4793-9352-bde79c3eecbd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i436bb19a139f4e90a3435d0ce8396f1d_D20210401-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTMtMTItMS0xLTI5Mzc3_b699e879-6045-402b-aa49-c0089b7b8ce6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaf692e06bd247aebe797f2c2d1665d7_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTMtMTQtMS0xLTI5Mzc3_95a223d6-73d0-46a7-90e1-2724499f6d18">18,067</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70f53509a43b46f7918ad0068ee464f4_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTQtNC0xLTEtMjkzNzc_c4997f2c-3935-4d4d-bd14-7d760a068108">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6a00923dd164c3185de2bb3200711b3_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTQtNi0xLTEtMjkzNzc_20a46528-dac8-422a-8d1f-292d72efebf2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaf692e06bd247aebe797f2c2d1665d7_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTQtOC0xLTEtMjkzNzc_8222a6e5-cb06-4b73-9358-deb3cc2c5eb0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id974764582f944f191de99110577719e_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTQtMTAtMS0xLTI5Mzc3_a28285e3-f83e-471e-8cb0-1112aae0b338">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i436bb19a139f4e90a3435d0ce8396f1d_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTQtMTItMS0xLTI5Mzc3_fac551ff-01fa-4325-8114-fd04bf11f79d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTQtMTQtMS0xLTI5Mzc3_c921b9d9-8552-41ac-8dda-7dac179a5da6">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i84c6845ef1af474d99b31053aaec57d8_I20210630" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTUtMi0xLTEtMjkzODQ_67bfc03b-2a2e-4305-9909-cde83541c07a">145,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84c6845ef1af474d99b31053aaec57d8_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTUtNC0xLTEtMjkzODQ_7c9129b0-5762-4308-a513-df21a4493b98">146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic04a7ab6695e4594b37dbd4ef6202519_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTUtNi0xLTEtMjkzODQ_b3c112ea-128f-45fa-83fa-ea6d877ff9dc">1,583,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1997cf5cac44c6eb336f27c85ee57c4_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTUtOC0xLTEtMjkzODQ_b834c816-5c15-4a77-a77c-56aea03819b9">1,439,043</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fc68f10369542aaafc82c10cdef36a8_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTUtMTAtMS0xLTI5Mzg0_f16ace37-f218-4353-887e-0ad499506d42">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4921c0cb0fbb40faa165f5a6e62d660d_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTUtMTItMS0xLTI5Mzg0_6ada1a4d-3080-46c4-92e4-60a07cd9d7d1">7,518</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdf3d3ccc7584900aada54e1568caba4_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTUtMTQtMS0xLTI5Mzg0_86554c8a-0a80-429b-8eb1-489e63f16c8b">137,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.779%"><tr><td style="width:1.0%"></td><td style="width:36.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.481%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a7c2141afe24e7f83e4d67a5ccdfff8_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMi0yLTEtMS0yODUzMg_4266d56a-e8b7-4f8a-be9c-5160d0082757">150,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a7c2141afe24e7f83e4d67a5ccdfff8_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMi00LTEtMS0yODUzMg_49dcd07a-becd-4a8e-8415-a3028d13b735">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4163eee5a3740f5846f34cdd0ae242b_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMi02LTEtMS0yODUzMg_5dc3641f-1690-498d-9d6f-a1758c21f7ab">1,608,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i191fd4fe2f08479884c4e65d4e9cfdff_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMi04LTEtMS0yODUzMg_7a779c89-3acb-408e-972e-f8d0f286fef2">1,487,776</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42fe192fe5ca436e9ed23d15187dbe84_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMi0xMC0xLTEtMjg1MzI_b5f8ae45-bc33-4b3a-a3b7-f169e871cb47">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75b83c9dc24f45598d1213d5e8d33a7e_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMi0xMi0xLTEtMjg1MzI_1df94bb1-7333-459d-92ab-0972dd32c799">7,518</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMi0xNC0xLTEtMjg1MzI_a734c274-ae55-4493-9189-2d43bc383ef8">113,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4de86438d8b40de8534780d8f45dbf0_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMy00LTEtMS0yODUzMg_81c39e55-3990-4539-b06d-0a3d687ee56d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa991937faa74a41905808343286e8d9_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMy02LTEtMS0yODUzMg_b35a7a18-1482-4597-aad3-7e5cf888d5b7">2,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ede75339061443d9b99e442e4e84e69_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMy04LTEtMS0yODUzMg_24940dbe-0a44-407f-9621-71e471bc73bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i781fc25c166b4fe180c4b24a19f09109_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMy0xMC0xLTEtMjg1MzI_e0b4228a-b2fa-4999-a145-a2ff2a9e3e29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1fe783955bb4f568c7b32b3eb3734e4_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMy0xMi0xLTEtMjg1MzI_278eb36b-2628-4d25-9abf-fe8bb6bec04c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i225dda2db10c426f89723c6eb6264105_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMy0xNC0xLTEtMjg1MzI_c3e97b02-35f6-4254-bd4c-9ed0dd7a21fa">2,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of equity classified warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib4de86438d8b40de8534780d8f45dbf0_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNC0yLTEtMS0yODUzMg_4221708c-a0bb-409c-b4f5-5b2e2eb31e8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4de86438d8b40de8534780d8f45dbf0_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNC00LTEtMS0yODUzMg_b5629663-add1-45a6-bf21-771be27f8b6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa991937faa74a41905808343286e8d9_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNC02LTEtMS0yODUzMg_d43a8a9e-5fee-4ee7-813f-7a2204baec2c">698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ede75339061443d9b99e442e4e84e69_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNC04LTEtMS0yODUzMg_6a3fad34-0425-427f-9187-32e716c3c915">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i781fc25c166b4fe180c4b24a19f09109_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNC0xMC0xLTEtMjg1MzI_0f8286a8-1373-4832-8bfb-d75e3099b78f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1fe783955bb4f568c7b32b3eb3734e4_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNC0xMi0xLTEtMjg1MzI_e0f05e4e-2368-4d58-9e41-a57b92e2167f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i225dda2db10c426f89723c6eb6264105_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNC0xNC0xLTEtMjg1MzI_87ec316a-d14b-4cb0-874a-77484fa6fa38">698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of treasury stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib4de86438d8b40de8534780d8f45dbf0_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNS0yLTEtMS0yOTQ4NQ_ad7ef893-ef46-4582-bad5-e281abf0238a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4de86438d8b40de8534780d8f45dbf0_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNS00LTEtMS0yOTQ4NQ_d8f30651-f786-4b46-a862-fce81eca8372">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa991937faa74a41905808343286e8d9_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNS02LTEtMS0yOTQ4NQ_a15e3f8a-9125-4048-bafb-29d60ce3a1d3">6,321</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ede75339061443d9b99e442e4e84e69_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNS04LTEtMS0yOTQ4NQ_07c93eaa-df88-48cf-9633-db0a2714a625">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i781fc25c166b4fe180c4b24a19f09109_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNS0xMC0xLTEtMjk0ODU_9e7e8cde-953c-4a64-b150-659304bfa0ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1fe783955bb4f568c7b32b3eb3734e4_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNS0xMi0xLTEtMjk0ODU_e888a37a-817b-4634-98b1-440f536c5357">6,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i225dda2db10c426f89723c6eb6264105_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNS0xNC0xLTEtMjk0ODU_6a463359-9f11-4250-924e-be71ae95d36a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib4de86438d8b40de8534780d8f45dbf0_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNi0yLTEtMS0yODUzMg_e64bc8c0-e008-418e-ac78-cb56bd53823e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4de86438d8b40de8534780d8f45dbf0_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNi00LTEtMS0yODUzMg_67e3da9b-07e8-408c-9724-438b79f3a13e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa991937faa74a41905808343286e8d9_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNi02LTEtMS0yODUzMg_26d5602c-9b3d-4e46-9ba7-e5e3243a03ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ede75339061443d9b99e442e4e84e69_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNi04LTEtMS0yODUzMg_5f53d8d2-9d6f-4273-89be-65207f83bd15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i781fc25c166b4fe180c4b24a19f09109_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNi0xMC0xLTEtMjg1MzI_f4158780-ac97-47f2-994a-18145653271e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1fe783955bb4f568c7b32b3eb3734e4_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNi0xMi0xLTEtMjg1MzI_3b77eda0-814f-44bd-968c-3e9507789878">864</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i225dda2db10c426f89723c6eb6264105_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNi0xNC0xLTEtMjg1MzI_f3876ff4-7435-4e81-9e34-56d8024b5851">864</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4de86438d8b40de8534780d8f45dbf0_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNy00LTEtMS0yODUzMg_d0e2e91b-9e25-43a5-906e-68decbe3a89a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa991937faa74a41905808343286e8d9_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNy02LTEtMS0yODUzMg_5757fd09-4750-4aa4-b8fd-102ba2e5adf9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ede75339061443d9b99e442e4e84e69_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNy04LTEtMS0yODUzMg_50585fb1-ccd7-43af-a5ca-85e264d22a3d">23,476</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i781fc25c166b4fe180c4b24a19f09109_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNy0xMC0xLTEtMjg1MzI_91256753-9b57-4c1a-ae1e-666cf9da4ae6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1fe783955bb4f568c7b32b3eb3734e4_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNy0xMi0xLTEtMjg1MzI_de2cad58-6135-4138-97c4-ba1f8923465f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i225dda2db10c426f89723c6eb6264105_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNy0xNC0xLTEtMjg1MzI_16f6330c-1c22-4154-9acf-47146f4c26b7">23,476</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4de86438d8b40de8534780d8f45dbf0_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfOC00LTEtMS0yODUzMg_1a63c666-92de-4864-846a-426eb2baa8ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa991937faa74a41905808343286e8d9_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfOC02LTEtMS0yODUzMg_cece9910-7b49-4259-8dfd-bde6dab09d23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ede75339061443d9b99e442e4e84e69_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfOC04LTEtMS0yODUzMg_e7e6259d-921e-4df6-bf04-5f775abfd593">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i781fc25c166b4fe180c4b24a19f09109_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfOC0xMC0xLTEtMjg1MzI_d42b78a1-5c83-4bca-9164-74980dee4e79">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1fe783955bb4f568c7b32b3eb3734e4_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfOC0xMi0xLTEtMjg1MzI_99bed58d-53db-4089-b8cc-b2952509f56a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i225dda2db10c426f89723c6eb6264105_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfOC0xNC0xLTEtMjg1MzI_567a387a-44a0-4ef4-9534-0a423d9937ec">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff773ff7f7f9457f9791bde81fb05630_I20220331" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfOS0yLTEtMS0yODUzMg_7adb9f93-fd6f-4af1-9391-8ad54a3b803f">150,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff773ff7f7f9457f9791bde81fb05630_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfOS00LTEtMS0yODUzMg_f9d1b8e8-3a62-40d2-a463-ff514e920597">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c159cf741e4073a1ff14f684d085d7_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfOS02LTEtMS0yODUzMg_91a23ac8-bf55-480b-be70-74e984598579">1,605,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d8b5096b7ac4e1fa83572cd7c51c76b_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfOS04LTEtMS0yODUzMg_c8b39a32-8f53-4bda-9931-5c12459bbdab">1,511,252</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0a99ce76ff74360997f9515e9e301b9_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfOS0xMC0xLTEtMjg1MzI_bb8a0ebb-0bc3-4dcd-afcd-24ba959965d7">37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeb348ef20a2445c8833795108ee3835_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfOS0xMi0xLTEtMjg1MzI_1228e653-b4df-47b9-a399-6dc08a5ed5b1">2,061</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b20225add3d49819abcc6c8ffa1f6c2_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfOS0xNC0xLTEtMjg1MzI_87d9bddc-f436-49fb-b908-94e7fa39ca84">92,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under Equity Incentive Plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i172ba7c5c11849e1b3e8f93623452a80_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTAtMi0xLTEtMzA1MDk_e18ca65e-9f93-4fad-a328-ac96a47e518b">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i172ba7c5c11849e1b3e8f93623452a80_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTAtNC0xLTEtMzA1MDk_16d067a4-83cd-4c24-a015-9e5f4525461d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ab63a6a7f16414f93ebff593d6bd562_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTAtNi0xLTEtMzA1MDk_37c195fb-6b36-485e-a0b0-cf9368861a2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbe2a09570334122960c7e63bb722f5c_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTAtOC0xLTEtMzA1MDk_1b8d271b-7214-4e11-9d68-87159915b3d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd35a0adb644d578ef0843d8d92e8f2_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTAtMTAtMS0xLTMwNTA5_dba52ca0-6003-4721-b03f-f1c409f79079">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a8adb9e6404469bce5c119cc2f7260_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTAtMTItMS0xLTMwNTA5_80467fcd-eb03-448e-acb8-944a4fc1d6df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTAtMTQtMS0xLTMwNTA5_f6243b1e-0ade-4e6e-97a9-242525dc8469">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i172ba7c5c11849e1b3e8f93623452a80_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTAtNC0xLTEtMjk0NTg_859e4a02-79a4-44d2-9b52-ea8750c18f57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ab63a6a7f16414f93ebff593d6bd562_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTAtNi0xLTEtMjk0NTg_9f65d428-9e35-4e9e-a388-650b0f5182f8">2,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbe2a09570334122960c7e63bb722f5c_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTAtOC0xLTEtMjk0NTg_500e589b-23bd-4ddf-80b1-f3814c55ffaa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd35a0adb644d578ef0843d8d92e8f2_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTAtMTAtMS0xLTI5NDU4_5a099ed3-8416-467d-ada2-34ab31c2297a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a8adb9e6404469bce5c119cc2f7260_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTAtMTItMS0xLTI5NDU4_0fbf14ed-7db0-42cc-a416-c5b5c02bdf2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTAtMTQtMS0xLTI5NDU4_d0be37a8-3c50-4270-9b24-dba5295ee208">2,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i172ba7c5c11849e1b3e8f93623452a80_D20220401-20220630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTEtNC0xLTEtMjk0ODE_5fa0e94c-cd2c-4223-8843-7a8b78f6c4fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ab63a6a7f16414f93ebff593d6bd562_D20220401-20220630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTEtNi0xLTEtMjk0ODE_a5bcd319-6074-4ff2-866a-4da04055a851">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbe2a09570334122960c7e63bb722f5c_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTEtOC0xLTEtMjk0ODE_5d430b02-7f65-43a5-835d-62b29b72b883">24,587</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd35a0adb644d578ef0843d8d92e8f2_D20220401-20220630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTEtMTAtMS0xLTI5NDgx_b41e0717-8258-4a62-9a6d-13bb2d6a17e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a8adb9e6404469bce5c119cc2f7260_D20220401-20220630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTEtMTItMS0xLTI5NDgx_4af3d408-08ea-4835-8cd2-b54e4b3bb521">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTEtMTQtMS0xLTI5NDgx_874cfbc3-e3cc-4bda-b363-f84d17936a7a">24,587</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i172ba7c5c11849e1b3e8f93623452a80_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTItNC0xLTEtMjk0ODE_8c8e5fe0-cc73-48a1-81e6-4f622c7ea8f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ab63a6a7f16414f93ebff593d6bd562_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTItNi0xLTEtMjk0ODE_b50b76a1-e7bc-4a48-b361-692f8391bd22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbe2a09570334122960c7e63bb722f5c_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTItOC0xLTEtMjk0ODE_80d66bec-df94-4dda-9330-b74c26009614">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bd35a0adb644d578ef0843d8d92e8f2_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTItMTAtMS0xLTI5NDgx_ff7cafde-d305-4942-be2a-d75f9784c3f7">113</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a8adb9e6404469bce5c119cc2f7260_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTItMTItMS0xLTI5NDgx_17c33181-3481-4e3e-980f-7ae7882b9649">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTItMTQtMS0xLTI5NDgx_f4de9313-7abf-4e0d-98e4-5251e66fcd22">113</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic77941f6de784e4bb794c54a3abaf069_I20220630" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTMtMi0xLTEtMjk0ODE_4d453c17-46c0-4a50-bc92-cae4aebbc70b">150,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic77941f6de784e4bb794c54a3abaf069_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTMtNC0xLTEtMjk0ODE_dd8caf93-e168-4310-8c12-f9db3af1f5b3">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22f4f9fb2c4b49c99b790d66a23b28ae_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTMtNi0xLTEtMjk0ODE_353d0956-30dc-4032-9162-d8bfb008fe83">1,608,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ba5caa20034a00b88a7290fc681f9a_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTMtOC0xLTEtMjk0ODE_944cf5c2-1c92-4325-a02e-00be5da64f26">1,535,839</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d2be377b37d4ddb9010f544cecc5772_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTMtMTAtMS0xLTI5NDgx_fb95185d-9ef2-43ae-852c-b4fa13cc31e2">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3de097a4f4c24c0083c05150f6b098a0_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTMtMTItMS0xLTI5NDgx_bb79d0e3-652b-4418-9cb1-05472f4316ba">2,061</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTMtMTQtMS0xLTI5NDgx_cb948a79-c4e0-4a28-ac54-8f2ec802ff38">70,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ibf95eabc4cf34ac1b0383c1ba8d7debc_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:73.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMy0yLTEtMS0yODUzMg_b6484a55-cf49-4f3a-8952-cca795c0b345">48,063</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMy00LTEtMS0yODUzMg_f60f4ad7-b5cf-4844-8e87-61473dca93ac">39,025</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfNS0yLTEtMS0yODUzMg_fe050e6e-5498-45c7-b590-a3ff2d7f172e">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfNS00LTEtMS0yODUzMg_8e80c5c6-ec73-4f5e-9caa-768de35bd7ef">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfNi0yLTEtMS0yODUzMg_697ba210-08a6-4a53-89b3-d5a10343666c">5,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfNi00LTEtMS0yODUzMg_8f345aa4-4c29-448e-a8f9-f7842a57c0af">5,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfNy0yLTEtMS0yODUzMg_d40977fb-7c4a-4504-bb87-c7bc56d41675">179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfNy00LTEtMS0yODUzMg_1a6bc7db-3826-4cd8-a484-387a0c732e54">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Increase) decrease in accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfOS0yLTEtMS0yODUzMg_f3df7bbd-fb74-44d8-96d6-a0ec7bb66b01">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfOS00LTEtMS0yODUzMg_d143fbd3-aa6a-4441-91ab-1ad721e65ee0">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Increase) decrease in prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTAtMi0xLTEtMjg1MzI_64dd435e-7739-4864-880a-ad689987023c">732</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTAtNC0xLTEtMjg1MzI_fea4eb0a-b094-45d1-83f6-2a10bf7396f0">451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTEtMi0xLTEtMjg1MzI_1e6c024d-3bb4-4a70-92aa-487782ae2169">420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTEtNC0xLTEtMjg1MzI_8277e05d-dc5b-4da1-81fe-2ea3449df11b">261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in accounts payable and other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTItMi0xLTEtMjg1MzI_684400a8-9de3-4ef1-bb52-598d73dfba52">5,447</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTItNC0xLTEtMjg1MzI_38df5188-0f0e-4fd1-9349-ca4f3764080b">14,707</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTMtMi0xLTEtMjg1MzI_4b4014cb-3fcc-482c-8549-f5c722e9b906">47,843</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTMtNC0xLTEtMjg1MzI_52f96633-c053-4336-bd9a-8b1442e76f35">47,039</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTUtMi0xLTEtMjg1MzI_45636158-79a4-4488-9132-07d4b69d225f">76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTUtNC0xLTEtMjg1MzI_3477eae0-bc90-4dd9-b756-24fa68aa1d12">985</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTYtMi0xLTEtMjg1MzI_c22a097a-17ef-4225-8c58-2782777a3286">40,171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTYtNC0xLTEtMjg1MzI_f12fd463-c0fb-43a4-91e4-319f4b56b3d0">24,373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTctMi0xLTEtMjg1MzI_8cd4d404-cabd-415e-80ed-0ec72e00746a">22,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTctNC0xLTEtMjg1MzI_62a4de1c-5fe7-43af-9eb2-39a5b2a71dda">21,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTgtMi0xLTEtMjg1MzI_2d60321c-6831-482d-af39-0041563ba5cc">18,056</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTgtNC0xLTEtMjg1MzI_285b3683-8033-4d46-b4a9-bcbe118aa318">3,586</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjAtMi0xLTEtMjg1MzI_9cbf141d-898b-434f-a2b0-ab70920a5e0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjAtNC0xLTEtMjg1MzI_470deb30-20e7-45a8-b6c0-e134006a3650">16,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjEtMi0xLTEtMjg1MzI_76cb7201-cb99-411f-aa00-e7f805fffa75">864</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjEtNC0xLTEtMjg1MzI_2a5a1a2e-afb5-4822-9d39-940c7b383c57">2,675</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from debt borrowings, net of fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjItMi0xLTEtMjg1MzI_288551d0-3601-4342-80e3-ad964321eb3f">24,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjItNC0xLTEtMjg1MzI_2d71bfe3-75a1-4aee-9286-4ce5d607336c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjMtMi0xLTEtMjg1MzI_433468d7-2cfc-4775-8caa-56dec77c5d60">23,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjMtNC0xLTEtMjg1MzI_f0231fa7-5815-4e7f-bf23-5018d0507839">14,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjQtMi0xLTEtMjg1MzI_37ef0615-680a-4c09-a879-f92a3aa6b4f3">42,615</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjQtNC0xLTEtMjg1MzI_802afd89-7831-4c32-bed7-c4e0d1893934">36,376</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjUtMi0xLTEtMjg1MzI_f392f832-1d7d-4908-8fe9-76d02e30e44a">64,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ab6ec7ca184c0b98f71ea5fbc23b66_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjUtNC0xLTEtMjg1MzI_bddc0c6d-7b2f-4df3-bd98-e990c3f556a8">126,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjYtMi0xLTEtMjg1MzI_a0ff7b43-9ece-4818-9eeb-8bbf9bc86775">21,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdf3d3ccc7584900aada54e1568caba4_I20210630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjYtNC0xLTEtMjg1MzI_cb265799-ddc1-498e-b6c7-945aa2acce77">89,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjktMi0xLTEtMjg1MzI_2026f0cf-7324-482f-ade1-e60a676959c4">634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjktNC0xLTEtMjg1MzI_2289a7c1-d968-4f42-b94d-3a3f34cf570d">307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Right-of-use asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="lxrx:InitialRecognitionOfRightOfUseAsset" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMzItMi0xLTEtMjg1MzI_99c72670-3e31-457e-8220-757c2f561243">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdf3d3ccc7584900aada54e1568caba4_I20210630" decimals="-3" name="lxrx:InitialRecognitionOfRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMzItNC0xLTEtMjg1MzI_ce363d35-5f1d-41cb-bf49-3f272c359f5c">1,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Issuance of equity classified warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="0" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMzMtMi0xLTEtMjg1MzI_f60874b6-5448-478d-a3ae-11abb4b4217e">698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMzMtNC0xLTEtMjg1MzI_a0accbc6-bdc1-48eb-9398-b167bdb7a386">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Issuance of treasury stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMzQtMi0xLTEtMjg1MzI_56bdd94e-2e74-4671-993e-8c0bd45fafa7">6,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMzQtNC0xLTEtMjg1MzI_4bee89a1-9956-4140-8a96-cfd669708a6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Recognition of exit fee liability related to debt borrowings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="0" name="us-gaap:BusinessExitCosts1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMzUtMi0xLTEtMjg1MzI_a18a288c-8588-444c-be87-65f319c81310">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" name="us-gaap:BusinessExitCosts1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMzUtNC0xLTEtMjg1MzI_30c0d94d-8b6f-4ce6-aa75-441ca16dd789">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ibf95eabc4cf34ac1b0383c1ba8d7debc_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ibf95eabc4cf34ac1b0383c1ba8d7debc_34"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RleHRyZWdpb246MDU2MjlmZWEyNDI1NDkyODhjYTNlYTM4MzM5MTI0MGRfMTAxOTE_89ad0ae4-7e02-4ccb-aa88-3ca60e06a5bf" continuedAt="i0973d86a04074a76bb7c029642a1b549" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i0973d86a04074a76bb7c029642a1b549" continuedAt="i331cbf698932421d9509bc83af880af4"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accompanying unaudited condensed consolidated financial statements of Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221; or the &#8220;Company&#8221;) have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the six-month period ended June&#160;30, 2022 are not necessarily indicative of the results that may be expected for the year ended December&#160;31, 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RleHRyZWdpb246MDU2MjlmZWEyNDI1NDkyODhjYTNlYTM4MzM5MTI0MGRfMTAxNjA_8b1f30f8-3072-44ea-987b-062a3fef9892" escape="true">The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.</ix:nonNumeric></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further information, refer to the financial statements and footnotes thereto included in Lexicon&#8217;s annual report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC.&#160;</span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RleHRyZWdpb246MDU2MjlmZWEyNDI1NDkyODhjYTNlYTM4MzM5MTI0MGRfMTAxOTM_2746736f-dc72-4ab5-95a4-8a993c933a29" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span></ix:nonNumeric></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RleHRyZWdpb246MDU2MjlmZWEyNDI1NDkyODhjYTNlYTM4MzM5MTI0MGRfMTAxODA_9b0343d8-97f6-4e74-87bd-8f2b367519c0" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents and Short-Term Investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of June&#160;30, 2022 and December&#160;31, 2021, short-term investments consisted of U.S. treasury bills and corporate debt securities. The Company&#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations as they all contain maturities of less than one year.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</span></ix:nonNumeric></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RleHRyZWdpb246MDU2MjlmZWEyNDI1NDkyODhjYTNlYTM4MzM5MTI0MGRfMTAxNjI_5aaa2198-5786-485b-b322-a1de5a46274f" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued liabilities: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accrued liabilities consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:60.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.961%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.963%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="lxrx:AccruedResearchAndDevelopmentServicesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmYxYjZhNjEwYjJlNzRiYjNiZTY5NDI5MmJjZmY4MjVhL3RhYmxlcmFuZ2U6ZjFiNmE2MTBiMmU3NGJiM2JlNjk0MjkyYmNmZjgyNWFfMy0yLTEtMS0yODUzMg_40926279-2c2d-44c7-86ab-ebff8ba5b9f1">3,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="lxrx:AccruedResearchAndDevelopmentServicesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmYxYjZhNjEwYjJlNzRiYjNiZTY5NDI5MmJjZmY4MjVhL3RhYmxlcmFuZ2U6ZjFiNmE2MTBiMmU3NGJiM2JlNjk0MjkyYmNmZjgyNWFfMy00LTEtMS0yODUzMg_f7658add-daed-4e6f-b6a7-22d107d0db94">3,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="lxrx:AccruedCompensationAndBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmYxYjZhNjEwYjJlNzRiYjNiZTY5NDI5MmJjZmY4MjVhL3RhYmxlcmFuZ2U6ZjFiNmE2MTBiMmU3NGJiM2JlNjk0MjkyYmNmZjgyNWFfNC0yLTEtMS0yODUzMg_b3417b73-d68b-4445-944c-39f9e1506754">4,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="lxrx:AccruedCompensationAndBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmYxYjZhNjEwYjJlNzRiYjNiZTY5NDI5MmJjZmY4MjVhL3RhYmxlcmFuZ2U6ZjFiNmE2MTBiMmU3NGJiM2JlNjk0MjkyYmNmZjgyNWFfNC00LTEtMS0yODUzMg_ace6c056-2b26-4d3c-a483-30d840aeb463">5,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmYxYjZhNjEwYjJlNzRiYjNiZTY5NDI5MmJjZmY4MjVhL3RhYmxlcmFuZ2U6ZjFiNmE2MTBiMmU3NGJiM2JlNjk0MjkyYmNmZjgyNWFfNS0yLTEtMS0yODUzMg_72c8a61c-9243-4121-84c2-ce0e6e7beda0">789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmYxYjZhNjEwYjJlNzRiYjNiZTY5NDI5MmJjZmY4MjVhL3RhYmxlcmFuZ2U6ZjFiNmE2MTBiMmU3NGJiM2JlNjk0MjkyYmNmZjgyNWFfNS00LTEtMS0yODUzMg_8448a7f3-41af-48c3-b8a0-3dcb6bf0fbee">1,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmYxYjZhNjEwYjJlNzRiYjNiZTY5NDI5MmJjZmY4MjVhL3RhYmxlcmFuZ2U6ZjFiNmE2MTBiMmU3NGJiM2JlNjk0MjkyYmNmZjgyNWFfNi0yLTEtMS0yODUzMg_4ecba26f-61ed-4642-ba63-f46e8948a3ef">477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmYxYjZhNjEwYjJlNzRiYjNiZTY5NDI5MmJjZmY4MjVhL3RhYmxlcmFuZ2U6ZjFiNmE2MTBiMmU3NGJiM2JlNjk0MjkyYmNmZjgyNWFfNi00LTEtMS0yODUzMg_69a57b98-f8ff-4906-bbe6-8161880aef85">2,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmYxYjZhNjEwYjJlNzRiYjNiZTY5NDI5MmJjZmY4MjVhL3RhYmxlcmFuZ2U6ZjFiNmE2MTBiMmU3NGJiM2JlNjk0MjkyYmNmZjgyNWFfNy0yLTEtMS0yODUzMg_a3ce92c1-452e-4458-be7e-13f6fa4eef6a">9,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmYxYjZhNjEwYjJlNzRiYjNiZTY5NDI5MmJjZmY4MjVhL3RhYmxlcmFuZ2U6ZjFiNmE2MTBiMmU3NGJiM2JlNjk0MjkyYmNmZjgyNWFfNy00LTEtMS0yODUzMg_76af3003-6c29-4d9e-ab52-96439b8ffa36">12,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="us-gaap:RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RleHRyZWdpb246MDU2MjlmZWEyNDI1NDkyODhjYTNlYTM4MzM5MTI0MGRfMTAxNzg_6dec981b-b965-4806-821d-e5fe150bf6fc" continuedAt="i548659dda2e04f2b929c408d71dacb06" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon determines if a contract is or contains a lease at inception or upon modification of the contract. A contract is or contains a lease if it conveys the right to control the use of an identified asset for a period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset. Lexicon does not apply this accounting to those leases with terms of twelve (12) months or less.</span></ix:nonNumeric></div></ix:continuation><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i331cbf698932421d9509bc83af880af4" continuedAt="i66e926074684442882fdb04cdc83a253"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i548659dda2e04f2b929c408d71dacb06">Operating lease right-of-use assets and associated lease liabilities are recorded in the balance sheet at the lease commencement date based on the present value of future lease payments to be made over the expected lease term. As the implicit rate is not determinable in its leases, Lexicon used a borrowing rate of <ix:nonFraction unitRef="number" contextRef="i152ac39e5811437cb0ee3de3ef7041ea_I20210301" decimals="INF" name="lxrx:LexiconIncrementalBorrowingRate" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RleHRyZWdpb246MDU2MjlmZWEyNDI1NDkyODhjYTNlYTM4MzM5MTI0MGRfMTAxODI_2d18eb22-a010-46c6-9903-eb0f0e5e402a">9</ix:nonFraction>% at the commencement date in determining the present value of future payments.</ix:continuation> </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RleHRyZWdpb246MDU2MjlmZWEyNDI1NDkyODhjYTNlYTM4MzM5MTI0MGRfMTAxNzU_7d83284e-1ab6-43ff-9102-841bbf58826b" continuedAt="i68aa598f4c074acf85fb1e27b190f09b" escape="true"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performs the following five steps in determining the amount of revenue to recognize as its performance obligations under each of its contracts with customers: (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) we satisfy the performance obligation. At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those milestones are achieved.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In agreements in which a license to the Company&#8217;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  </span></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i68aa598f4c074acf85fb1e27b190f09b">The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under the relevant agreement.  Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.</ix:continuation> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RleHRyZWdpb246MDU2MjlmZWEyNDI1NDkyODhjYTNlYTM4MzM5MTI0MGRfMTAxOTQ_78677fde-5995-41b1-a5a1-f66bdae6921c" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</span></ix:nonNumeric></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RleHRyZWdpb246MDU2MjlmZWEyNDI1NDkyODhjYTNlYTM4MzM5MTI0MGRfMTAxNDk_5a9c5da5-2e9e-47e6-9fa2-7b7ad7db32eb" continuedAt="i3224792a9226421d9b8eb8e35ae5c634" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units granted to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i66e926074684442882fdb04cdc83a253" continuedAt="ifbc79bbcd0ca4479b7aadf0075d0f54d"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3224792a9226421d9b8eb8e35ae5c634">behaviors, resulting in a change in the assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#8217;s stock price.</ix:continuation>&#160;&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilized the Black-Scholes valuation model for estimating the fair value of the stock option compensation granted, with the following weighted-average assumptions for stock options granted in the six months ended June&#160;30, 2022 and 2021:</span><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RleHRyZWdpb246MDU2MjlmZWEyNDI1NDkyODhjYTNlYTM4MzM5MTI0MGRfMTAxODc_f53baedb-5481-4efd-bd40-779ed6836f3a" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:51.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.916%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Volatility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Risk-free Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dividend<br/>Rate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2022:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if8c71021eb1240e190c19cb072abf3f6_D20220101-20220630" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfMi0yLTEtMS0yODUzMg_01b31b23-576d-4468-ac98-9369228d777d">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if8c71021eb1240e190c19cb072abf3f6_D20220101-20220630" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfMi00LTEtMS0yODUzMg_097751ff-d949-4dd6-be03-970156e0d6ae">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if8c71021eb1240e190c19cb072abf3f6_D20220101-20220630" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfMi02LTEtMS0yODUzMg_d6ee7195-caf3-46f3-a3ec-65853e37b9ee">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if8c71021eb1240e190c19cb072abf3f6_D20220101-20220630" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfMi04LTEtMS0yODUzMg_58266e39-2191-4976-8837-6975d1ccbd39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if8c71021eb1240e190c19cb072abf3f6_D20220101-20220630" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfMy0yLTEtMS0yODUzMg_192571af-24e3-4953-8eca-1bb3def8ee64">91</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if8c71021eb1240e190c19cb072abf3f6_D20220101-20220630" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfMy00LTEtMS0yODUzMg_55461a53-2b29-4f16-9855-906bf578f3e0">1.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if8c71021eb1240e190c19cb072abf3f6_D20220101-20220630" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfMy02LTEtMS0yODUzMg_8a01a6ad-e0e2-4feb-85c2-27704cbf3387">7</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if8c71021eb1240e190c19cb072abf3f6_D20220101-20220630" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfMy04LTEtMS0yODUzMg_ecc5f6f1-27de-4075-b647-69534cdf3b7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8144b5bc25dd4902831fa92228fd7f51_D20210101-20210630" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfNS0yLTEtMS0yODUzMg_197bc3b6-5a93-4216-93e2-12b36014b237">101</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8144b5bc25dd4902831fa92228fd7f51_D20210101-20210630" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfNS00LTEtMS0yODUzMg_59357a61-de9c-4737-9792-89dad05a67a7">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8144b5bc25dd4902831fa92228fd7f51_D20210101-20210630" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfNS02LTEtMS0yODUzMg_36778f28-877f-4709-8309-80e54668971a">4</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8144b5bc25dd4902831fa92228fd7f51_D20210101-20210630" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfNS04LTEtMS0yODUzMg_766d9f31-1710-4daf-9713-5a0fafd24d95">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8144b5bc25dd4902831fa92228fd7f51_D20210101-20210630" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfNi0yLTEtMS0yODUzMg_0eaaa8b3-400f-40e5-ab17-12f1ea3c6ed3">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8144b5bc25dd4902831fa92228fd7f51_D20210101-20210630" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfNi00LTEtMS0yODUzMg_e70ea4e2-87db-4b0e-b72c-7ac0489f8e75">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8144b5bc25dd4902831fa92228fd7f51_D20210101-20210630" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfNi02LTEtMS0yODUzMg_465e39bd-7385-4db7-aabc-b76aca4c9566">7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8144b5bc25dd4902831fa92228fd7f51_D20210101-20210630" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfNi04LTEtMS0yODUzMg_fb2a88cd-e27c-4f2c-9198-8a22fb931238">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock option activity under Lexicon&#8217;s stock-based compensation plans for the six months ended June&#160;30, 2022:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RleHRyZWdpb246MDU2MjlmZWEyNDI1NDkyODhjYTNlYTM4MzM5MTI0MGRfMTAxNjU_32da5f2b-e043-49af-a176-9fa7e8f9ec64" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:66.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7be8ac7d31ef4e4f9fdbd039f264c959_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOjhmM2Y1MWRkZWVkYjQxYTg4ZGU5OWExNmQ5ZTM5MjI4L3RhYmxlcmFuZ2U6OGYzZjUxZGRlZWRiNDFhODhkZTk5YTE2ZDllMzkyMjhfMi0yLTEtMS0yODUzMg_c40c72c6-73b6-4efd-b25b-67f5c990684b">8,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7be8ac7d31ef4e4f9fdbd039f264c959_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOjhmM2Y1MWRkZWVkYjQxYTg4ZGU5OWExNmQ5ZTM5MjI4L3RhYmxlcmFuZ2U6OGYzZjUxZGRlZWRiNDFhODhkZTk5YTE2ZDllMzkyMjhfMi00LTEtMS0yODUzMg_d020b281-a9f0-4b51-b0bb-c08185bb9e6f">6.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff0b3ea9ca3c45e1b81425040542255e_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOjhmM2Y1MWRkZWVkYjQxYTg4ZGU5OWExNmQ5ZTM5MjI4L3RhYmxlcmFuZ2U6OGYzZjUxZGRlZWRiNDFhODhkZTk5YTE2ZDllMzkyMjhfMy0yLTEtMS0yODUzMg_079d3ae6-0fc9-4126-a48a-e40ca85e4a27">4,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff0b3ea9ca3c45e1b81425040542255e_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOjhmM2Y1MWRkZWVkYjQxYTg4ZGU5OWExNmQ5ZTM5MjI4L3RhYmxlcmFuZ2U6OGYzZjUxZGRlZWRiNDFhODhkZTk5YTE2ZDllMzkyMjhfMy00LTEtMS0yODUzMg_76cf5a5f-c093-4a29-abc9-9fa4370a675c">3.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iff0b3ea9ca3c45e1b81425040542255e_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOjhmM2Y1MWRkZWVkYjQxYTg4ZGU5OWExNmQ5ZTM5MjI4L3RhYmxlcmFuZ2U6OGYzZjUxZGRlZWRiNDFhODhkZTk5YTE2ZDllMzkyMjhfNS0yLTEtMS0yODUzMg_5867cae8-1d68-4cc2-84d4-877ca70f5654">163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff0b3ea9ca3c45e1b81425040542255e_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOjhmM2Y1MWRkZWVkYjQxYTg4ZGU5OWExNmQ5ZTM5MjI4L3RhYmxlcmFuZ2U6OGYzZjUxZGRlZWRiNDFhODhkZTk5YTE2ZDllMzkyMjhfNS00LTEtMS0yODUzMg_27295cec-bb54-480c-9979-c463f39c6ade">12.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iff0b3ea9ca3c45e1b81425040542255e_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOjhmM2Y1MWRkZWVkYjQxYTg4ZGU5OWExNmQ5ZTM5MjI4L3RhYmxlcmFuZ2U6OGYzZjUxZGRlZWRiNDFhODhkZTk5YTE2ZDllMzkyMjhfNi0yLTEtMS0yODUzMg_ef7f78b1-dc1d-47fc-bc13-d8f56f964e34">353</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff0b3ea9ca3c45e1b81425040542255e_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOjhmM2Y1MWRkZWVkYjQxYTg4ZGU5OWExNmQ5ZTM5MjI4L3RhYmxlcmFuZ2U6OGYzZjUxZGRlZWRiNDFhODhkZTk5YTE2ZDllMzkyMjhfNi00LTEtMS0yODUzMg_6a500511-a903-48d8-b844-64aadf9292f3">9.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i32d0edfce10547eaa9f6a4a37c3c0e9e_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOjhmM2Y1MWRkZWVkYjQxYTg4ZGU5OWExNmQ5ZTM5MjI4L3RhYmxlcmFuZ2U6OGYzZjUxZGRlZWRiNDFhODhkZTk5YTE2ZDllMzkyMjhfNy0yLTEtMS0yODUzMg_1af71e72-cb0b-4d84-a219-7780131a2800">12,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i32d0edfce10547eaa9f6a4a37c3c0e9e_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOjhmM2Y1MWRkZWVkYjQxYTg4ZGU5OWExNmQ5ZTM5MjI4L3RhYmxlcmFuZ2U6OGYzZjUxZGRlZWRiNDFhODhkZTk5YTE2ZDllMzkyMjhfNy00LTEtMS0yODUzMg_6b50e21d-099b-43c3-8116-f1ab8bcc71f9">5.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i32d0edfce10547eaa9f6a4a37c3c0e9e_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOjhmM2Y1MWRkZWVkYjQxYTg4ZGU5OWExNmQ5ZTM5MjI4L3RhYmxlcmFuZ2U6OGYzZjUxZGRlZWRiNDFhODhkZTk5YTE2ZDllMzkyMjhfOC0yLTEtMS0yODUzMg_eca58980-7fa9-457a-9d92-0a92bb7cea32">5,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i32d0edfce10547eaa9f6a4a37c3c0e9e_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOjhmM2Y1MWRkZWVkYjQxYTg4ZGU5OWExNmQ5ZTM5MjI4L3RhYmxlcmFuZ2U6OGYzZjUxZGRlZWRiNDFhODhkZTk5YTE2ZDllMzkyMjhfOC00LTEtMS0yODUzMg_a8fc159f-51f3-45cc-972f-8f471382ba60">7.35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022, Lexicon granted its employees and non-employee directors annual restricted stock units. Outstanding employee restricted stock units vest in three annual installments.  Outstanding non-employee director restricted stock units vest fully on the first anniversary of the grant.  The following is a summary of restricted stock units activity under Lexicon&#8217;s stock-based compensation plans for the six months ended June&#160;30, 2022:</span><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RleHRyZWdpb246MDU2MjlmZWEyNDI1NDkyODhjYTNlYTM4MzM5MTI0MGRfMTAxODg_1fa38e76-7797-4b81-bad4-dbfc909910d7" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id14ea6e6ad9241c2a3f636b30639bd35_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmMzYTYzOTI1NjUxYzQzYzNhY2UzZjc3MjBjOWE4ZjdmL3RhYmxlcmFuZ2U6YzNhNjM5MjU2NTFjNDNjM2FjZTNmNzcyMGM5YThmN2ZfMi0yLTEtMS0yODUzMg_cd2f1860-a6f5-40a3-ac9c-0b992d485aac">1,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id14ea6e6ad9241c2a3f636b30639bd35_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmMzYTYzOTI1NjUxYzQzYzNhY2UzZjc3MjBjOWE4ZjdmL3RhYmxlcmFuZ2U6YzNhNjM5MjU2NTFjNDNjM2FjZTNmNzcyMGM5YThmN2ZfMi00LTEtMS0yODUzMg_3443e28c-5a11-422d-b931-523244976a40">5.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib6ff6b135bf9430bb09afc4a228eb9cd_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmMzYTYzOTI1NjUxYzQzYzNhY2UzZjc3MjBjOWE4ZjdmL3RhYmxlcmFuZ2U6YzNhNjM5MjU2NTFjNDNjM2FjZTNmNzcyMGM5YThmN2ZfMy0yLTEtMS0yODUzMg_7eb31d19-27d1-4595-a5e6-96180b8bdda6">2,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib6ff6b135bf9430bb09afc4a228eb9cd_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmMzYTYzOTI1NjUxYzQzYzNhY2UzZjc3MjBjOWE4ZjdmL3RhYmxlcmFuZ2U6YzNhNjM5MjU2NTFjNDNjM2FjZTNmNzcyMGM5YThmN2ZfMy00LTEtMS0yODUzMg_0f2d2aed-52de-4cac-ac92-ddbfc92fa066">2.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib6ff6b135bf9430bb09afc4a228eb9cd_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmMzYTYzOTI1NjUxYzQzYzNhY2UzZjc3MjBjOWE4ZjdmL3RhYmxlcmFuZ2U6YzNhNjM5MjU2NTFjNDNjM2FjZTNmNzcyMGM5YThmN2ZfNC0yLTEtMS0yODUzMg_95b434a6-a0d6-4b30-b9d1-b9ea132f3c76">1,012</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib6ff6b135bf9430bb09afc4a228eb9cd_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmMzYTYzOTI1NjUxYzQzYzNhY2UzZjc3MjBjOWE4ZjdmL3RhYmxlcmFuZ2U6YzNhNjM5MjU2NTFjNDNjM2FjZTNmNzcyMGM5YThmN2ZfNC00LTEtMS0yODUzMg_fb383c11-9190-456e-85b6-ffd9586e293d">4.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib6ff6b135bf9430bb09afc4a228eb9cd_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmMzYTYzOTI1NjUxYzQzYzNhY2UzZjc3MjBjOWE4ZjdmL3RhYmxlcmFuZ2U6YzNhNjM5MjU2NTFjNDNjM2FjZTNmNzcyMGM5YThmN2ZfNS0yLTEtMS0yODUzMg_f85aaedf-2880-4519-aed1-fd39e7709452">108</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib6ff6b135bf9430bb09afc4a228eb9cd_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmMzYTYzOTI1NjUxYzQzYzNhY2UzZjc3MjBjOWE4ZjdmL3RhYmxlcmFuZ2U6YzNhNjM5MjU2NTFjNDNjM2FjZTNmNzcyMGM5YThmN2ZfNS00LTEtMS0yODUzMg_0c631cb6-52a0-4902-9a5f-3c5207a58682">3.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if0e56591afc54f4ebeb3c8aa3ab4fbe1_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmMzYTYzOTI1NjUxYzQzYzNhY2UzZjc3MjBjOWE4ZjdmL3RhYmxlcmFuZ2U6YzNhNjM5MjU2NTFjNDNjM2FjZTNmNzcyMGM5YThmN2ZfNi0yLTEtMS0yODUzMg_ebfbfd13-01cc-46cb-bd6c-8416306d9ebf">2,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if0e56591afc54f4ebeb3c8aa3ab4fbe1_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmMzYTYzOTI1NjUxYzQzYzNhY2UzZjc3MjBjOWE4ZjdmL3RhYmxlcmFuZ2U6YzNhNjM5MjU2NTFjNDNjM2FjZTNmNzcyMGM5YThmN2ZfNi00LTEtMS0yODUzMg_d8fa5a7b-2039-456b-a702-1b0de2d347de">3.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="ifbc79bbcd0ca4479b7aadf0075d0f54d" continuedAt="iffa4e8fddc8b41c89e5b91d966f92476"><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RleHRyZWdpb246MDU2MjlmZWEyNDI1NDkyODhjYTNlYTM4MzM5MTI0MGRfMTAxOTA_a38c26da-1f15-4a20-b92f-63402adbf204" continuedAt="i7de1b6dbd1c54f619825e463943f337b" escape="true">Net Loss per Common Share:</ix:nonNumeric></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iffa4e8fddc8b41c89e5b91d966f92476"><ix:continuation id="i7de1b6dbd1c54f619825e463943f337b"> Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.</ix:continuation></ix:continuation> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ibf95eabc4cf34ac1b0383c1ba8d7debc_37"></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNy9mcmFnOjY0NDI4ZWZmOTU5ZjQzNDFiMjg3MjM0OTdhMzhjY2IwL3RleHRyZWdpb246NjQ0MjhlZmY5NTlmNDM0MWIyODcyMzQ5N2EzOGNjYjBfMTQ1OA_5240a1b7-9ff3-4194-89ea-bf199dbcc386" continuedAt="i705c91ce95ce4011ae56bce4cd06ba96" escape="true">Recent Accounting Pronouncements</ix:nonNumeric></span></div><ix:continuation id="i705c91ce95ce4011ae56bce4cd06ba96"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2019-12, Income Taxes (Topic 740) Simplifying Accounting for Income Taxes, as part of its initiative to reduce complexity in the accounting standards. The guidance amended certain disclosure requirements that had become redundant, outdated or superseded. Additionally, this guidance amends accounting for the interim period effects of changes in tax laws or rates, and simplifies aspects of the accounting for franchise taxes. The guidance is effective for annual periods beginning after December 15, 2020, including interim periods therein. The adoption of ASU 2019-12 in the first quarter of 2021 did not have a material impact on the condensed consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40), which removes the separation models for convertible debt with cash conversion or beneficial conversion features. ASU 2020-06 also requires the application of the if-converted method for calculating earnings per diluted share, as the treasury stock method will no longer be permitted for convertible instruments. The adoption of ASU 2020-06 during the first quarter of 2022 did not have a material impact on the condensed consolidated financial statements.</span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="ibf95eabc4cf34ac1b0383c1ba8d7debc_40"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RleHRyZWdpb246NDkyMWQyNGY1NjM3NDE3NDliNDIyMDY2YmI4ZjA3MTlfMzM5_d8f8faf3-24e8-45d6-9a13-d75dd813459b" continuedAt="ib2719f0edf6e4aadaf9f2aeb4129f878" escape="true">Cash and Cash Equivalents and Investments</ix:nonNumeric></span></div><ix:continuation id="ib2719f0edf6e4aadaf9f2aeb4129f878"><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of cash and cash equivalents and investments held at June&#160;30, 2022 and December&#160;31, 2021 are as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RleHRyZWdpb246NDkyMWQyNGY1NjM3NDE3NDliNDIyMDY2YmI4ZjA3MTlfMzM1_b7a300f4-0650-4d37-b7ea-534287c1a3bc" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:52.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.885%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a2a8f5d314144a884fb86491fc334b7_I20220630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMy0yLTEtMS0yODUzMg_2cd73880-ed6f-4479-8e16-8126d1cd2e07">21,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a2a8f5d314144a884fb86491fc334b7_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMy00LTEtMS0yODUzMg_d1d8011f-bb84-4b89-86ba-f423144a03fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a2a8f5d314144a884fb86491fc334b7_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMy02LTEtMS0yODUzMg_8762c165-00ba-44a0-bfac-d5a4171267a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a2a8f5d314144a884fb86491fc334b7_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMy04LTEtMS0yODUzMg_4c23bfa3-d085-4ab8-8724-a92782c9b43c">21,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i310d9b9a89454544b9e9d7c6399db39a_I20220630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfNS0yLTEtMS0yODUzMg_e2300cc3-79d7-4655-86dc-35ef3b7620fe">30,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i310d9b9a89454544b9e9d7c6399db39a_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfNS00LTEtMS0yODUzMg_0af30178-219a-4efc-88c6-48cd4c8e1f30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i310d9b9a89454544b9e9d7c6399db39a_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfNS02LTEtMS0yODUzMg_4bc08765-45fb-42f8-abed-fe8233d1ad21">89</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i310d9b9a89454544b9e9d7c6399db39a_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfNS04LTEtMS0yODUzMg_5df22a9c-7ec3-4b99-8bdd-b5522cb20150">30,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2834e4b26174a4a8a9f1d26de96cce2_I20220630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfNi0yLTEtMS0yODUzMg_c5a5feac-fc85-4cf1-9803-5c2a08ef342f">10,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2834e4b26174a4a8a9f1d26de96cce2_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfNi00LTEtMS0yODUzMg_9241a012-d0cc-4c51-a98a-d79d7d27b0d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2834e4b26174a4a8a9f1d26de96cce2_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfNi02LTEtMS0yODUzMg_ad48d469-823e-437d-8810-0f4fc2965681">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2834e4b26174a4a8a9f1d26de96cce2_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfNi04LTEtMS0yODUzMg_c40ec321-e216-4e7d-bee1-23b0dd393f37">10,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bf59d25162d4274b7c672eb48a47901_I20220630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfNy0yLTEtMS0yODUzMg_55c2b97d-7e39-40f5-9db7-eee0cf6a619a">40,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bf59d25162d4274b7c672eb48a47901_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfNy00LTEtMS0yODUzMg_1e248aa4-6855-4706-a7fd-fe2f2a76518a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bf59d25162d4274b7c672eb48a47901_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfNy02LTEtMS0yODUzMg_37f286ab-5812-40d6-9227-e94c4f85625f">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bf59d25162d4274b7c672eb48a47901_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfNy04LTEtMS0yODUzMg_2226c6e5-b914-4690-981b-16d3238e078b">40,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib76a1e00d0be407f9aad476b9558aa02_I20220630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfOC0yLTEtMS0yODUzMg_7a72ee2b-f993-4d1c-9fd9-286031f8dbc6">62,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib76a1e00d0be407f9aad476b9558aa02_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfOC00LTEtMS0yODUzMg_87197e92-ddc5-445a-a402-6c1dc623979b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib76a1e00d0be407f9aad476b9558aa02_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfOC02LTEtMS0yODUzMg_bc54aca8-f299-4d3b-b2c6-43a823f73031">150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib76a1e00d0be407f9aad476b9558aa02_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfOC04LTEtMS0yODUzMg_e8c47230-5258-4bb6-85d4-8a60fa4db7ed">61,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i537aa7da0127497a9ab35f8f1601120c_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTMtMi0xLTEtMjg1MzI_a5aa0102-2f64-463c-9d6e-0885d3a067d4">64,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i537aa7da0127497a9ab35f8f1601120c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTMtNC0xLTEtMjg1MzI_6b803c69-5d10-49a6-9f10-ecfdc0702a9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i537aa7da0127497a9ab35f8f1601120c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTMtNi0xLTEtMjg1MzI_d4917b33-cca3-46a2-89c1-5db3628a9d64">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i537aa7da0127497a9ab35f8f1601120c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTMtOC0xLTEtMjg1MzI_ab22538c-0eee-43d3-b170-c8cdc5a54d91">64,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a1de474406c4d5ca2bd60c12dcee520_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTUtMi0xLTEtMjg1MzI_b29b9bd0-1612-48de-b978-1e3aa8e0f2d6">7,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a1de474406c4d5ca2bd60c12dcee520_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTUtNC0xLTEtMjg1MzI_26462da1-50af-444a-8a59-22ac9d0b7f4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a1de474406c4d5ca2bd60c12dcee520_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTUtNi0xLTEtMjg1MzI_c667c6df-8022-4b12-860a-d632eaff7614">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a1de474406c4d5ca2bd60c12dcee520_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTUtOC0xLTEtMjg1MzI_f23fc81d-ef27-4743-ba6f-002eacdcbeeb">7,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5d0942946ce4b92a48bd388374cd857_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTYtMi0xLTEtMjg1MzI_492e245d-c84c-47cc-9f6e-6ad8e9b6a2fa">15,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5d0942946ce4b92a48bd388374cd857_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTYtNC0xLTEtMjg1MzI_859aada4-4057-4d57-a5fb-7dd61d597205">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5d0942946ce4b92a48bd388374cd857_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTYtNi0xLTEtMjg1MzI_93cba72b-9ab7-4849-874f-42d44349561a">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5d0942946ce4b92a48bd388374cd857_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTYtOC0xLTEtMjg1MzI_2f09cdfa-90f1-412f-9e82-b7846c1fcf82">15,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab52133a24a345c2b5b462deff22d656_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTctMi0xLTEtMjg1MzI_fbb3f3e0-1d48-40f2-8171-d57fd3aa0c9a">22,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab52133a24a345c2b5b462deff22d656_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTctNC0xLTEtMjg1MzI_84f0e150-d6b4-4e83-bfed-4094fbb65652">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab52133a24a345c2b5b462deff22d656_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTctNi0xLTEtMjg1MzI_bd7378d2-d9e8-4b49-ba1e-4fc886138e3e">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab52133a24a345c2b5b462deff22d656_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTctOC0xLTEtMjg1MzI_4ae4f56a-efa1-485f-b7f2-2c4d9bf92b87">22,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d670c1a5724338a60501f42187b7e0_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTgtMi0xLTEtMjg1MzI_972f849b-cbf2-4841-8846-66e75131b2ae">86,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d670c1a5724338a60501f42187b7e0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTgtNC0xLTEtMjg1MzI_9064268f-45fe-4f33-a63d-5d0c9aa52261">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2d670c1a5724338a60501f42187b7e0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTgtNi0xLTEtMjg1MzI_10dc8565-3d9b-45b3-be40-25a9f6d70069">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d670c1a5724338a60501f42187b7e0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTgtOC0xLTEtMjg1MzI_2bc50af0-a90b-475e-afa0-f15ac14d8eb6">86,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630" decimals="-3" name="us-gaap:RealizedInvestmentGainsLosses" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RleHRyZWdpb246NDkyMWQyNGY1NjM3NDE3NDliNDIyMDY2YmI4ZjA3MTlfMTcw_9b27b9d9-56e3-4e8c-a13e-39f03daa436f"><ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="0" name="us-gaap:RealizedInvestmentGainsLosses" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RleHRyZWdpb246NDkyMWQyNGY1NjM3NDE3NDliNDIyMDY2YmI4ZjA3MTlfMTcw_cfbec8e5-077c-4b1f-af75-227354fb2faa">no</ix:nonFraction></ix:nonFraction> realized losses during either of the six months ended June&#160;30, 2022 and 2021, respectively.  The cost of securities sold is based on the specific identification method.</span></div></ix:continuation><div id="ibf95eabc4cf34ac1b0383c1ba8d7debc_43"></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RleHRyZWdpb246M2ZjOGM2YzBhZjExNGFiYTkzNmM1ZWY5OTAyZDQ2ZmZfMTU3Ng_f89cd076-436f-45d7-8194-088489f18d40" continuedAt="ib43f2186a7174477ac952cf35c97906e" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="ib43f2186a7174477ac952cf35c97906e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.  Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.  The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - quoted prices in active markets for identical investments, which include U.S. treasury securities </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which includes corporate debt securities</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - significant unobservable inputs </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.  The following table provides the fair value measurements of applicable Company assets that are measured at fair value on a recurring basis according to the fair value levels defined above as of June&#160;30, 2022 and December&#160;31, 2021.</span></div><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RleHRyZWdpb246M2ZjOGM2YzBhZjExNGFiYTkzNmM1ZWY5OTAyZDQ2ZmZfMTU2NQ_c81d5415-c898-4490-ab4e-0bd5b969f9bf" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:46.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i082b646328b744be992ad3f152baee86_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjRjZjQ3YTQ3ZmM0NTQwY2JiMzVmZGU3ZTM1YjhiMTExL3RhYmxlcmFuZ2U6NGNmNDdhNDdmYzQ1NDBjYmIzNWZkZTdlMzViOGIxMTFfNC0yLTEtMS0yODUzMg_9aa323cb-f858-43c5-8dfb-709cbfb9c08b">21,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb00505b86b4445ea664e50b7f30071c_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjRjZjQ3YTQ3ZmM0NTQwY2JiMzVmZGU3ZTM1YjhiMTExL3RhYmxlcmFuZ2U6NGNmNDdhNDdmYzQ1NDBjYmIzNWZkZTdlMzViOGIxMTFfNC00LTEtMS0yODUzMg_441005ff-0ed1-4c95-be6a-1e3aa17b24c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a860a8253cc468dab9782964e9008d2_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjRjZjQ3YTQ3ZmM0NTQwY2JiMzVmZGU3ZTM1YjhiMTExL3RhYmxlcmFuZ2U6NGNmNDdhNDdmYzQ1NDBjYmIzNWZkZTdlMzViOGIxMTFfNC02LTEtMS0yODUzMg_47e69394-890b-4fd8-a4a1-e5f99ea1deb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjRjZjQ3YTQ3ZmM0NTQwY2JiMzVmZGU3ZTM1YjhiMTExL3RhYmxlcmFuZ2U6NGNmNDdhNDdmYzQ1NDBjYmIzNWZkZTdlMzViOGIxMTFfNC04LTEtMS0yODUzMg_39a1896c-20b5-4c6b-9770-1f6eb9570354">21,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i082b646328b744be992ad3f152baee86_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjRjZjQ3YTQ3ZmM0NTQwY2JiMzVmZGU3ZTM1YjhiMTExL3RhYmxlcmFuZ2U6NGNmNDdhNDdmYzQ1NDBjYmIzNWZkZTdlMzViOGIxMTFfNS0yLTEtMS0yODUzMg_cef3d6bf-95f1-40a0-8c02-b378fdbadc75">30,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb00505b86b4445ea664e50b7f30071c_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjRjZjQ3YTQ3ZmM0NTQwY2JiMzVmZGU3ZTM1YjhiMTExL3RhYmxlcmFuZ2U6NGNmNDdhNDdmYzQ1NDBjYmIzNWZkZTdlMzViOGIxMTFfNS00LTEtMS0yODUzMg_402f076b-f93c-4691-94d1-2ed09429b55f">10,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a860a8253cc468dab9782964e9008d2_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjRjZjQ3YTQ3ZmM0NTQwY2JiMzVmZGU3ZTM1YjhiMTExL3RhYmxlcmFuZ2U6NGNmNDdhNDdmYzQ1NDBjYmIzNWZkZTdlMzViOGIxMTFfNS02LTEtMS0yODUzMg_b5f62a3f-a47d-49f9-b9d5-9006ae3cca98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjRjZjQ3YTQ3ZmM0NTQwY2JiMzVmZGU3ZTM1YjhiMTExL3RhYmxlcmFuZ2U6NGNmNDdhNDdmYzQ1NDBjYmIzNWZkZTdlMzViOGIxMTFfNS04LTEtMS0yODUzMg_8fa9cce8-a6dd-4d97-9451-74763d1231a8">40,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i082b646328b744be992ad3f152baee86_I20220630" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjRjZjQ3YTQ3ZmM0NTQwY2JiMzVmZGU3ZTM1YjhiMTExL3RhYmxlcmFuZ2U6NGNmNDdhNDdmYzQ1NDBjYmIzNWZkZTdlMzViOGIxMTFfNi0yLTEtMS0yODUzMg_6127bd4c-98cd-473b-99bd-9421226e4fd0">51,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb00505b86b4445ea664e50b7f30071c_I20220630" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjRjZjQ3YTQ3ZmM0NTQwY2JiMzVmZGU3ZTM1YjhiMTExL3RhYmxlcmFuZ2U6NGNmNDdhNDdmYzQ1NDBjYmIzNWZkZTdlMzViOGIxMTFfNi00LTEtMS0yODUzMg_82aa39fa-adec-46e5-98cd-e249cc0653ed">10,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a860a8253cc468dab9782964e9008d2_I20220630" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjRjZjQ3YTQ3ZmM0NTQwY2JiMzVmZGU3ZTM1YjhiMTExL3RhYmxlcmFuZ2U6NGNmNDdhNDdmYzQ1NDBjYmIzNWZkZTdlMzViOGIxMTFfNi02LTEtMS0yODUzMg_9cc58301-5b9a-43ac-a493-54464922da73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjRjZjQ3YTQ3ZmM0NTQwY2JiMzVmZGU3ZTM1YjhiMTExL3RhYmxlcmFuZ2U6NGNmNDdhNDdmYzQ1NDBjYmIzNWZkZTdlMzViOGIxMTFfNi04LTEtMS0yODUzMg_de0ba131-de32-4115-b9fc-49a326096791">61,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:46.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe66fc19ba44522a7249f23c4348b8c_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjc4OWUwOWVkZTBhZTRlMmE5YjNjZDk0ZjFiN2Y4MGMzL3RhYmxlcmFuZ2U6Nzg5ZTA5ZWRlMGFlNGUyYTliM2NkOTRmMWI3ZjgwYzNfNC0yLTEtMS0yODUzMg_b450bc73-0850-4dd5-b2ab-c2edeb148b2e">64,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d359c13687c4b70afe72962c41749e1_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjc4OWUwOWVkZTBhZTRlMmE5YjNjZDk0ZjFiN2Y4MGMzL3RhYmxlcmFuZ2U6Nzg5ZTA5ZWRlMGFlNGUyYTliM2NkOTRmMWI3ZjgwYzNfNC00LTEtMS0yODUzMg_9f679044-4260-4bfa-8dd2-86fd5c4141f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i308c9eedd5de4813af1e34bfdc45b87d_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjc4OWUwOWVkZTBhZTRlMmE5YjNjZDk0ZjFiN2Y4MGMzL3RhYmxlcmFuZ2U6Nzg5ZTA5ZWRlMGFlNGUyYTliM2NkOTRmMWI3ZjgwYzNfNC02LTEtMS0yODUzMg_4feb449b-9d6e-46d1-81ed-a166141c6334">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjc4OWUwOWVkZTBhZTRlMmE5YjNjZDk0ZjFiN2Y4MGMzL3RhYmxlcmFuZ2U6Nzg5ZTA5ZWRlMGFlNGUyYTliM2NkOTRmMWI3ZjgwYzNfNC04LTEtMS0yODUzMg_f21e623f-89c2-4a8d-8708-5803186fb7f8">64,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe66fc19ba44522a7249f23c4348b8c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjc4OWUwOWVkZTBhZTRlMmE5YjNjZDk0ZjFiN2Y4MGMzL3RhYmxlcmFuZ2U6Nzg5ZTA5ZWRlMGFlNGUyYTliM2NkOTRmMWI3ZjgwYzNfNS0yLTEtMS0yODUzMg_a72ea26e-ba80-46a3-ae70-9e276c7c47f1">7,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d359c13687c4b70afe72962c41749e1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjc4OWUwOWVkZTBhZTRlMmE5YjNjZDk0ZjFiN2Y4MGMzL3RhYmxlcmFuZ2U6Nzg5ZTA5ZWRlMGFlNGUyYTliM2NkOTRmMWI3ZjgwYzNfNS00LTEtMS0yODUzMg_71752661-ecdd-4fce-a3a6-0b40182687e0">15,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i308c9eedd5de4813af1e34bfdc45b87d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjc4OWUwOWVkZTBhZTRlMmE5YjNjZDk0ZjFiN2Y4MGMzL3RhYmxlcmFuZ2U6Nzg5ZTA5ZWRlMGFlNGUyYTliM2NkOTRmMWI3ZjgwYzNfNS02LTEtMS0yODUzMg_561532e8-ccde-4ce8-ae85-f512bcdf9d94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjc4OWUwOWVkZTBhZTRlMmE5YjNjZDk0ZjFiN2Y4MGMzL3RhYmxlcmFuZ2U6Nzg5ZTA5ZWRlMGFlNGUyYTliM2NkOTRmMWI3ZjgwYzNfNS04LTEtMS0yODUzMg_dab90c24-da80-4d9a-a79c-63f5ee005d56">22,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe66fc19ba44522a7249f23c4348b8c_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjc4OWUwOWVkZTBhZTRlMmE5YjNjZDk0ZjFiN2Y4MGMzL3RhYmxlcmFuZ2U6Nzg5ZTA5ZWRlMGFlNGUyYTliM2NkOTRmMWI3ZjgwYzNfNi0yLTEtMS0yODUzMg_5af9d284-f6a1-4910-b84f-4c15bc94b586">71,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d359c13687c4b70afe72962c41749e1_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjc4OWUwOWVkZTBhZTRlMmE5YjNjZDk0ZjFiN2Y4MGMzL3RhYmxlcmFuZ2U6Nzg5ZTA5ZWRlMGFlNGUyYTliM2NkOTRmMWI3ZjgwYzNfNi00LTEtMS0yODUzMg_505424db-2555-4f8b-8e3e-362ec227058e">15,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i308c9eedd5de4813af1e34bfdc45b87d_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjc4OWUwOWVkZTBhZTRlMmE5YjNjZDk0ZjFiN2Y4MGMzL3RhYmxlcmFuZ2U6Nzg5ZTA5ZWRlMGFlNGUyYTliM2NkOTRmMWI3ZjgwYzNfNi02LTEtMS0yODUzMg_2e018a4a-7d79-4ecd-80b9-0abadb232ed8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjc4OWUwOWVkZTBhZTRlMmE5YjNjZDk0ZjFiN2Y4MGMzL3RhYmxlcmFuZ2U6Nzg5ZTA5ZWRlMGFlNGUyYTliM2NkOTRmMWI3ZjgwYzNfNi04LTEtMS0yODUzMg_81bae742-ea0a-47b3-9bc2-5d3f1adc40b6">86,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any Level 3 assets or liabilities as of June&#160;30, 2022 or December&#160;31, 2021. Transfers between levels are recognized at the actual date of the circumstance that caused the transfer.  There were no transfers between Level 1 and Level 2 during the periods presented.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 5, Debt Obligations, for fair value measurements of debt obligations.</span></div></ix:continuation><div id="ibf95eabc4cf34ac1b0383c1ba8d7debc_46"></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfNTkzMA_d86e95bf-b830-4a4d-9c18-2fd7dd6fbedd" continuedAt="i1232fcabd9c54b17a87859ada8ef1f3b" escape="true">Debt Obligations</ix:nonNumeric></span></div><ix:continuation id="i1232fcabd9c54b17a87859ada8ef1f3b" continuedAt="i587094520f3d4839b361744403dd86aa"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2022, Lexicon and one of its subsidiaries entered into a loan and security agreement with Oxford Finance LLC (&#8220;Oxford&#8221;) that provides up to $<ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="lxrx:OxfordLoanFacility" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMTg4_cf7a68b0-f837-4201-95f4-c2ba733472bd">150</ix:nonFraction>&#160;million in borrowing capacity (the &#8220;Oxford Term Loans&#8221;) available in four tranches, each maturing in March 2027. Monthly interest-only payments are due during an initial 36-month period, which may be extended at Lexicon&#8217;s option to 48 months if Lexicon maintains compliance with a financial covenant relating to net sales of sotagliflozin following regulatory approval. The interest-only period will be followed by principal payments of $<ix:nonFraction unitRef="usd" contextRef="i2dd8b9f384214850b5f4fd852ba9f217_D20260101-20260331" decimals="-3" name="lxrx:A2027OxfordPrincipalPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfNjIw_192f41fe-63bd-4bc6-991a-a916cdd09cb2">8.7</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i7fc078bde80e4f5eaa692435aa8a2da3_D20270101-20270331" decimals="-3" name="lxrx:A2026OxfordPrincipalPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfNjI0_638f1723-6c2f-4bd0-85d6-969ea1f6b1a2">13.0</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="i20828fea2889439ba7af1b8a7dcb42eb_D20280101-20280331" decimals="-3" name="lxrx:A2027OxfordPrincipalPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfNjMy_4915804b-cf27-4766-a0aa-005281b82e78">4.8</ix:nonFraction>&#160;million during the fiscal years ended December 31, 2025, December 31, 2026 and December 31, 2027, respectively. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first $<ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="lxrx:TermLoanA" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfNzA1_b029b1b9-0c64-4af5-8949-5258e8ac6d8e">25</ix:nonFraction>&#160;million tranche was funded at closing. The second $<ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="lxrx:TermLoanB" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfNzUw_38c6cb91-8b01-45f8-a2c0-d40fc6a638e3">25</ix:nonFraction>&#160;million tranche is available for draw at Lexicon&#8217;s option prior to August 25, 2022. The third $<ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="lxrx:TermLoanC" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMTAzMw_f62e8304-db79-489b-94af-eae6ba447aa6">50</ix:nonFraction>&#160;million tranche is available for draw at Lexicon&#8217;s option prior to June 30, 2023, but within 60 days of U.S. regulatory approval of sotagliflozin for heart failure. The fourth $<ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="lxrx:TermLoanD" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMTIwNA_49c1560b-33ac-41e2-9120-e4abac0be2ed">50</ix:nonFraction>&#160;million tranche is available for draw at Lexicon&#8217;s option, subject to Oxford&#8217;s consent, at any time prior to the expiration of the interest-only payment period.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i587094520f3d4839b361744403dd86aa" continuedAt="i0575575433934162b863fc9bf8f9e978"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loan and security agreement provides that, upon funding of the first three tranches, Lexicon will grant Oxford a warrant to purchase shares of its common stock having a value equal to <ix:nonFraction unitRef="number" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="INF" name="lxrx:TermLoanABWarrant" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMTU0OQ_d6302572-e799-4097-b424-1f04ecf22692">3.50</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="INF" name="lxrx:TermLoanCWarrant" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMTU1Mw_968120e0-b008-4183-b9bb-86d006723f83">1.75</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="INF" name="lxrx:TermLoanDWarrant" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMTU2MA_e42704dd-9613-4b87-a4b2-06e74cfbf7de">0.875</ix:nonFraction>%, respectively, of each such tranche, as determined by reference to a 10-day average closing price of the shares. Each warrant will have an exercise price equal to such average closing price, be exercisable for a five-year period from the date of issuance and feature a net cashless exercise provision. Concurrent with the funding of the first tranche, Lexicon granted Oxford a warrant to purchase <ix:nonFraction unitRef="shares" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="0" name="lxrx:TermLoanAWarrantsNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMTk2MA_18fe741e-233b-4c91-a0a1-256b62ba7d48">420,673</ix:nonFraction> shares of Lexicon&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="2" name="lxrx:TermLoanAWarrantExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMjAyMA_d6d0e76d-2dcc-4e1c-bbaa-ca12e8cd773c">2.08</ix:nonFraction> per share. The warrant is exercisable through March 1, 2027 and is classified as an equity instrument.  The Company allocated the proceeds from the first tranche to the warrant using the relative fair value method and used the Black-Scholes model to calculate the fair value of the warrants.  The fair value of the warrant of $<ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMjM0OQ_5e6f5fd1-9968-4a12-b66b-87375cdc51ea">0.7</ix:nonFraction>&#160;million was recognized as equity with a corresponding debt discount of $<ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMjQxNQ_5e6f5fd1-9968-4a12-b66b-87375cdc51ea">0.7</ix:nonFraction>&#160;million.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Oxford Term Loans bear interest at a floating rate equal to the 30-day U.S. Dollar LIBOR plus <ix:nonFraction unitRef="number" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMjUxOA_c1902510-a7b6-4c0c-a49f-e639d1798631">7.90</ix:nonFraction>%, but not less than <ix:nonFraction unitRef="number" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="INF" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMjU0MA_6e11940c-3a98-4b70-9d1f-a167fc7b3ed3">8.01</ix:nonFraction>%, subject to additional interest if an event of default occurs and is continuing.  As of June&#160;30, 2022, the interest rate was <ix:nonFraction unitRef="number" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="INF" name="us-gaap:SubordinatedBorrowingInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMjY1Nw_28640bae-60e4-4b58-a486-7a6151171df2">9.02</ix:nonFraction>%. If an event of default occurs and is continuing, Oxford may declare all amounts outstanding under the loan and security agreement to be immediately due and payable. Lexicon may prepay the Oxford Term Loans in whole at its option at any time. Any prepayment of the Oxford Term Loans is subject to prepayment fees for up to three years after the funding of each tranche of the loans.  A final payment exit fee equal to <ix:nonFraction unitRef="rate" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="INF" name="lxrx:FinalPaymentWithNoExtention" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMzA3OA_c87519e4-2cfb-4a86-8505-ab747084de03">6</ix:nonFraction>% of the amount funded under the Oxford Term Loans is due upon prepayment or maturity, which final payment will be adjusted to <ix:nonFraction unitRef="rate" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="INF" name="lxrx:FinalPaymentWithExtention" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMzIwNg_c55f3ea7-4e2a-4dbf-86d3-ffc9743e1014">7</ix:nonFraction>% of the amount funded upon extension of the interest-only payment period.  The final payment exit fee of $<ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="lxrx:TermLoanAFinalPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMzMxMw_78de98f0-55cb-46e9-a97a-0d4cf62192df">1.5</ix:nonFraction>&#160;million was recorded as a debt discount on the closing date of the first tranche.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During March 2022, in connection with the first tranche of the loan and security agreement, the Company received cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="lxrx:TermLoanANetCashReceipt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMzUyMQ_20787ff4-0538-47a3-b6a6-79f496ce5c36">24.2</ix:nonFraction>&#160;million, net of debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="lxrx:TermLoanADebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMzU1NQ_1d5b0a8b-af77-4c5c-a944-3869096c51c3">0.4</ix:nonFraction>&#160;million and a facility fee of $<ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="lxrx:OxfordFacilityFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMzU4MA_e34b337a-fc15-4a54-ac56-6247af2f920e">0.5</ix:nonFraction>&#160;million. The debt issuance costs and facility fee have been recorded as a debt discount on the Company&#8217;s condensed consolidated balance sheet, which together with the final payment exit fee of $<ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="lxrx:TermLoanAFinalPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMzc2OA_78de98f0-55cb-46e9-a97a-0d4cf62192df">1.5</ix:nonFraction>&#160;million and warrant fair value of $<ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMzc5Nw_5e6f5fd1-9968-4a12-b66b-87375cdc51ea">0.7</ix:nonFraction>&#160;million are being amortized to interest expense throughout the life of the term loan using the effective interest rate method.  As of June&#160;30, 2022, the balance of the debt discount was $<ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="lxrx:TermLoanADebtDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMzk2Nw_e5c7c50d-c995-4ff6-80e5-8009dd88c36f">2.9</ix:nonFraction>&#160;million. During the six months ended June&#160;30, 2022, the Company recognized interest expense of $<ix:nonFraction unitRef="usd" contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" decimals="0" name="lxrx:TermLoanAInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfNDA0NQ_450f26b1-1340-4725-a7ec-e591284d116e">0.8</ix:nonFraction>&#160;million.  As of  June&#160;30, 2022, the carrying value of the Oxford Term Loans was $<ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfNDEwOQ_271f79bc-b6f3-4ff0-b759-0ccfcf129aaf">23.6</ix:nonFraction>&#160;million.  The fair value of the Oxford Term Loans approximates its carrying value and was determined using Level 2 inputs using discounted cash flow analysis, based on the Company&#8217;s estimated current incremental borrowing rate.       </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon&#8217;s obligations under the Oxford Term Loans are secured by a first lien security interest in all of the assets of the Company and its subsidiaries. The loan and security agreement contains certain customary representations and warranties, affirmative and negative covenants and events of default applicable to Lexicon and its subsidiaries. In addition to the financial covenant, additional covenants include those restricting dispositions, fundamental changes to its business, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt. The Company was in compliance with its debt covenants as of June&#160;30, 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Debt.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In November 2014, Lexicon completed an offering of $<ix:nonFraction unitRef="usd" contextRef="i71a46b4fd0da412cbd90061ff289cf49_D20141101-20141130" decimals="-5" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfNTA5MA_5ae74f49-1487-45f4-a313-e85400fc35d9">87.5</ix:nonFraction> million in aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="i0cc6e78d37b6446ba787713f65cd8666_I20141120" decimals="4" name="lxrx:ConvDebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfNTEzMA_fb1b0668-6ffd-4320-9391-b600ae7a2158">5.25</ix:nonFraction>% Convertible Senior Notes due 2021 (the &#8220;Convertible Notes&#8221;).  The conversion feature did not meet the criteria for bifurcation as required by generally accepted accounting principles and the entire principal amount was recorded as long-term debt on the Company&#8217;s condensed consolidated balance sheets.  </span></div></ix:continuation><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0575575433934162b863fc9bf8f9e978">In 2020, the Company entered into separate, privately negotiated exchange agreements to exchange $<ix:nonFraction unitRef="usd" contextRef="i1fa52b6205c847e4888033f43b0077d3_I20200928" decimals="-3" name="lxrx:ConvertibleDebtExchangeTotalPrincipalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfNTUzNA_28b617f9-08aa-42d7-8354-3fa6fc22112b">75.8</ix:nonFraction> million aggregate principal amount of the Convertible Notes for consideration valued at 85% of the principal amount of the Convertible Notes. In 2020, the Company issued 10,368,956 shares of the Company&#8217;s common stock and paid $50.0 million in cash, which included $1.3 million of accrued interest, to exchange such Convertible Notes. In December 2021, the remaining balance of $<ix:nonFraction unitRef="usd" contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231" decimals="-3" name="lxrx:ConvertibleDebtExchangeRemainingNotes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfNTkwNw_8cb1b6eb-45b8-4c03-8162-fac3033fda74">11.6</ix:nonFraction> million was repaid in cash.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div id="ibf95eabc4cf34ac1b0383c1ba8d7debc_49"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180OS9mcmFnOmIyNGYwMWRiMTZlMzQyZDJhODBiYTBkMWNhZmMyNTMzL3RleHRyZWdpb246YjI0ZjAxZGIxNmUzNDJkMmE4MGJhMGQxY2FmYzI1MzNfMTE3Mw_3a173c94-c3cf-4efc-a9e3-218937670652" continuedAt="i1870fafaf74943f2905a711696bd85ab" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i1870fafaf74943f2905a711696bd85ab"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Lease Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;Lexicon&#8217;s operating leases include office space in The Woodlands, Texas and Basking Ridge, New Jersey and will expire in August 2025 and December 2022, respectively. Under its lease agreements, Lexicon is obligated to pay property taxes, insurance, and maintenance costs. In July 2022, the Company entered into a lease agreement for a 22,000 square-foot office space in Bridgewater, New Jersey to which it plans to relocate the New Jersey offices.  The term of the lease is expected to commence in December 2022, will extend for ten years and 11 months from such commencement date and provides for escalating yearly base rent payments starting at $820,000 and increasing to $986,000 in the final year of the lease.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the right-of-use assets for the office space leases had a balance of $<ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180OS9mcmFnOmIyNGYwMWRiMTZlMzQyZDJhODBiYTBkMWNhZmMyNTMzL3RleHRyZWdpb246YjI0ZjAxZGIxNmUzNDJkMmE4MGJhMGQxY2FmYzI1MzNfNDMz_1662c838-f5d4-4f47-8a3f-aa43141eeb7c">1.8</ix:nonFraction> million, which is included in other assets in the condensed consolidated balance sheet. Current and non-current liabilities relating to the leases were $<ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-5" name="us-gaap:ShortTermLeaseCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180OS9mcmFnOmIyNGYwMWRiMTZlMzQyZDJhODBiYTBkMWNhZmMyNTMzL3RleHRyZWdpb246YjI0ZjAxZGIxNmUzNDJkMmE4MGJhMGQxY2FmYzI1MzNfNTgw_6b7c25b6-f948-4df1-8db7-55ed244aafea">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180OS9mcmFnOmIyNGYwMWRiMTZlMzQyZDJhODBiYTBkMWNhZmMyNTMzL3RleHRyZWdpb246YjI0ZjAxZGIxNmUzNDJkMmE4MGJhMGQxY2FmYzI1MzNfNTg3_daf5453e-4729-4664-9c99-d1511d16fb6d">1.0</ix:nonFraction> million, respectively, which are included in accrued liabilities and other long-term liabilities in the condensed consolidated balance sheet, respectively.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the undiscounted cash flows of the operating lease liability to the recorded lease liability at June&#160;30, 2022:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:80.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.168%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="INF" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180OS9mcmFnOmIyNGYwMWRiMTZlMzQyZDJhODBiYTBkMWNhZmMyNTMzL3RhYmxlOmQyMWYzODBlM2M2ZDQ0OWNiNmZiMjYxNDhiNGVhZmYzL3RhYmxlcmFuZ2U6ZDIxZjM4MGUzYzZkNDQ5Y2I2ZmIyNjE0OGI0ZWFmZjNfMi0xLTEtMS0yODUzMg_84c81fe5-4329-4814-a67d-88debda3c4ac">583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="INF" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180OS9mcmFnOmIyNGYwMWRiMTZlMzQyZDJhODBiYTBkMWNhZmMyNTMzL3RhYmxlOmQyMWYzODBlM2M2ZDQ0OWNiNmZiMjYxNDhiNGVhZmYzL3RhYmxlcmFuZ2U6ZDIxZjM4MGUzYzZkNDQ5Y2I2ZmIyNjE0OGI0ZWFmZjNfMy0xLTEtMS0yODUzMg_73c7708d-d6ee-431d-a3ef-4d16a4b20918">531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="INF" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180OS9mcmFnOmIyNGYwMWRiMTZlMzQyZDJhODBiYTBkMWNhZmMyNTMzL3RhYmxlOmQyMWYzODBlM2M2ZDQ0OWNiNmZiMjYxNDhiNGVhZmYzL3RhYmxlcmFuZ2U6ZDIxZjM4MGUzYzZkNDQ5Y2I2ZmIyNjE0OGI0ZWFmZjNfNC0xLTEtMS0yODUzMg_ed0ddac3-2df4-418a-a134-4178e78c7ce4">544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="INF" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180OS9mcmFnOmIyNGYwMWRiMTZlMzQyZDJhODBiYTBkMWNhZmMyNTMzL3RhYmxlOmQyMWYzODBlM2M2ZDQ0OWNiNmZiMjYxNDhiNGVhZmYzL3RhYmxlcmFuZ2U6ZDIxZjM4MGUzYzZkNDQ5Y2I2ZmIyNjE0OGI0ZWFmZjNfNS0xLTEtMS0yODUzMg_097478a7-fb98-4f46-803d-7d4bb2ce02c3">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="INF" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180OS9mcmFnOmIyNGYwMWRiMTZlMzQyZDJhODBiYTBkMWNhZmMyNTMzL3RhYmxlOmQyMWYzODBlM2M2ZDQ0OWNiNmZiMjYxNDhiNGVhZmYzL3RhYmxlcmFuZ2U6ZDIxZjM4MGUzYzZkNDQ5Y2I2ZmIyNjE0OGI0ZWFmZjNfNi0xLTEtMS0yODUzMg_8ab1adaa-2fe8-45bb-9e0e-7b89f144a5f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="INF" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180OS9mcmFnOmIyNGYwMWRiMTZlMzQyZDJhODBiYTBkMWNhZmMyNTMzL3RhYmxlOmQyMWYzODBlM2M2ZDQ0OWNiNmZiMjYxNDhiNGVhZmYzL3RhYmxlcmFuZ2U6ZDIxZjM4MGUzYzZkNDQ5Y2I2ZmIyNjE0OGI0ZWFmZjNfOC0xLTEtMS0yODUzMg_d82b02aa-1099-4cd3-ba21-fbe6fdad9972">2,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="INF" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180OS9mcmFnOmIyNGYwMWRiMTZlMzQyZDJhODBiYTBkMWNhZmMyNTMzL3RhYmxlOmQyMWYzODBlM2M2ZDQ0OWNiNmZiMjYxNDhiNGVhZmYzL3RhYmxlcmFuZ2U6ZDIxZjM4MGUzYzZkNDQ5Y2I2ZmIyNjE0OGI0ZWFmZjNfOS0xLTEtMS0yODUzMg_988d950b-127f-4698-957b-f0b69515be28">237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="INF" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180OS9mcmFnOmIyNGYwMWRiMTZlMzQyZDJhODBiYTBkMWNhZmMyNTMzL3RhYmxlOmQyMWYzODBlM2M2ZDQ0OWNiNmZiMjYxNDhiNGVhZmYzL3RhYmxlcmFuZ2U6ZDIxZjM4MGUzYzZkNDQ5Y2I2ZmIyNjE0OGI0ZWFmZjNfMTAtMS0xLTEtMjg1MzI_e29e3701-00ae-4f5c-99aa-b2281cbaa721">1,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: short-term operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="INF" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180OS9mcmFnOmIyNGYwMWRiMTZlMzQyZDJhODBiYTBkMWNhZmMyNTMzL3RhYmxlOmQyMWYzODBlM2M2ZDQ0OWNiNmZiMjYxNDhiNGVhZmYzL3RhYmxlcmFuZ2U6ZDIxZjM4MGUzYzZkNDQ5Y2I2ZmIyNjE0OGI0ZWFmZjNfMTEtMS0xLTEtMjg1MzI_841f9368-49d9-4ed8-8174-5c587d565c1b">789</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630" decimals="INF" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180OS9mcmFnOmIyNGYwMWRiMTZlMzQyZDJhODBiYTBkMWNhZmMyNTMzL3RhYmxlOmQyMWYzODBlM2M2ZDQ0OWNiNmZiMjYxNDhiNGVhZmYzL3RhYmxlcmFuZ2U6ZDIxZjM4MGUzYzZkNDQ5Y2I2ZmIyNjE0OGI0ZWFmZjNfMTItMS0xLTEtMjg1MzI_0f6ecd3c-0c76-49f7-925e-3a0b5387c7a5">1,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="ibf95eabc4cf34ac1b0383c1ba8d7debc_52"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY181Mi9mcmFnOjRlNDEyMjcxYmQ0OTRjZjViMGRiZjNhYTdkMzY3MjZiL3RleHRyZWdpb246NGU0MTIyNzFiZDQ5NGNmNWIwZGJmM2FhN2QzNjcyNmJfNjM5_720bfd23-d594-4a8c-b59f-cc7f785b3f92" continuedAt="i32feb26a2ec9485cae54d51995acf0d0" escape="true">Collaboration and License Agreements</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i32feb26a2ec9485cae54d51995acf0d0" continuedAt="i6e8d6c8913924948a0d314adeb2f6707">&#160;</ix:continuation></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6e8d6c8913924948a0d314adeb2f6707">Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, product sales, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales, as well as from commercial sales of its XERMELO product following its commercial launch in February 2017 until its sale of XERMELO and related assets to TerSera Therapeutics, LLC in September 2020.</ix:continuation> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="ibf95eabc4cf34ac1b0383c1ba8d7debc_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630" name="lxrx:OtherCapitalAgreementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY181NS9mcmFnOjYzMGM4NGIzZTQ2MTQ5NWNiMjUyMGYxNDVmNWI2ZWZhL3RleHRyZWdpb246NjMwYzg0YjNlNDYxNDk1Y2IyNTIwZjE0NWY1YjZlZmFfNjg1_85fa4c6e-324f-444d-b209-b9718f1ddabc" continuedAt="i4cc50ab8e26640bf97ffd455e02a5719" escape="true">Other Capital Agreements</ix:nonNumeric></span></div><ix:continuation id="i4cc50ab8e26640bf97ffd455e02a5719"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  In 2020, Lexicon entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Sales Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;) relating to the shares of its common stock. In January 2021, Lexicon sold <ix:nonFraction unitRef="shares" contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630" decimals="0" name="lxrx:SharesSoldInJanuary2021ATMOffering" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY181NS9mcmFnOjYzMGM4NGIzZTQ2MTQ5NWNiMjUyMGYxNDVmNWI2ZWZhL3RleHRyZWdpb246NjMwYzg0YjNlNDYxNDk1Y2IyNTIwZjE0NWY1YjZlZmFfMjQ0_4b1f8f70-fcab-4062-a205-01d18240c3cd">2,000,000</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="shares" contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630" decimals="3" name="lxrx:SharePriceInJanuary2021ATMOffering" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY181NS9mcmFnOjYzMGM4NGIzZTQ2MTQ5NWNiMjUyMGYxNDVmNWI2ZWZhL3RleHRyZWdpb246NjMwYzg0YjNlNDYxNDk1Y2IyNTIwZjE0NWY1YjZlZmFfMjg4_579ed04a-e4d0-4fc2-80ac-7114c3a8cb16">8.463</ix:nonFraction> per share pursuant to the Sales Agreement, resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630" decimals="-5" name="lxrx:ProceedsFromJanuary2021ATMOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY181NS9mcmFnOjYzMGM4NGIzZTQ2MTQ5NWNiMjUyMGYxNDVmNWI2ZWZhL3RleHRyZWdpb246NjMwYzg0YjNlNDYxNDk1Y2IyNTIwZjE0NWY1YjZlZmFfMzYz_72e40c72-d4d6-4e7c-94ce-0ab8acf97d5c">16.4</ix:nonFraction>&#160;million. In August and September 2021, Lexicon sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="idedefb7f68d74e2aa8370ccd51445b1d_D20211001-20211231" decimals="0" name="lxrx:SharesSoldInSeptember2021ATMOfferring" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY181NS9mcmFnOjYzMGM4NGIzZTQ2MTQ5NWNiMjUyMGYxNDVmNWI2ZWZhL3RleHRyZWdpb246NjMwYzg0YjNlNDYxNDk1Y2IyNTIwZjE0NWY1YjZlZmFfNTUz_899e8c0c-7782-437b-9fc2-45967f2885de">4,176,953</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="usd" contextRef="idedefb7f68d74e2aa8370ccd51445b1d_D20211001-20211231" decimals="3" name="lxrx:SharePriceInSeptember2021ATMOfferring" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY181NS9mcmFnOjYzMGM4NGIzZTQ2MTQ5NWNiMjUyMGYxNDVmNWI2ZWZhL3RleHRyZWdpb246NjMwYzg0YjNlNDYxNDk1Y2IyNTIwZjE0NWY1YjZlZmFfNTk3_a06b075d-4a3e-461c-a312-8f18369eac2f">4.732</ix:nonFraction> per share pursuant to the Sales Agreement, resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="idedefb7f68d74e2aa8370ccd51445b1d_D20211001-20211231" decimals="6" name="lxrx:ProceedsFromSeptember2021ATMOffering" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY181NS9mcmFnOjYzMGM4NGIzZTQ2MTQ5NWNiMjUyMGYxNDVmNWI2ZWZhL3RleHRyZWdpb246NjMwYzg0YjNlNDYxNDk1Y2IyNTIwZjE0NWY1YjZlZmFfNjcz_42beddf3-faa1-4613-bc28-9090184a6203">19.1</ix:nonFraction> million. The net proceeds are reflected as issuances of common stock in the accompanying condensed consolidated financial statements.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div id="ibf95eabc4cf34ac1b0383c1ba8d7debc_879"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie65c2031672c436c9ffb9020a455b7c6_D20220701-20220930" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY184NzkvZnJhZzphZmY1ZDM2MjAwZWQ0ODRkOTM4YmZlM2ZlMTkwYzc3OC90ZXh0cmVnaW9uOmFmZjVkMzYyMDBlZDQ4NGQ5MzhiZmUzZmUxOTBjNzc4XzM2OA_e699efce-2048-49a1-a93c-923bc64e2713" continuedAt="i6c847199d8ae4f2b854942483fe80204" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="i6c847199d8ae4f2b854942483fe80204"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  In August 2022, Lexicon sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="ie65c2031672c436c9ffb9020a455b7c6_D20220701-20220930" decimals="-3" name="lxrx:SharesSoldInJuly2022Offering" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY184NzkvZnJhZzphZmY1ZDM2MjAwZWQ0ODRkOTM4YmZlM2ZlMTkwYzc3OC90ZXh0cmVnaW9uOmFmZjVkMzYyMDBlZDQ4NGQ5MzhiZmUzZmUxOTBjNzc4Xzg5_876e8c17-9a14-41a6-8487-a0c5426479c8">34,000,000</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="usd" contextRef="ie65c2031672c436c9ffb9020a455b7c6_D20220701-20220930" decimals="2" name="lxrx:SharePriceInJuly2022Offering" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY184NzkvZnJhZzphZmY1ZDM2MjAwZWQ0ODRkOTM4YmZlM2ZlMTkwYzc3OC90ZXh0cmVnaW9uOmFmZjVkMzYyMDBlZDQ4NGQ5MzhiZmUzZmUxOTBjNzc4XzEzMw_25b7f01e-c3a9-4759-b23a-31fd76989f41">2.50</ix:nonFraction> per share in a public offering and concurrent private placement to two affiliates of Invus, L.P., resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="ie65c2031672c436c9ffb9020a455b7c6_D20220701-20220930" decimals="-3" name="lxrx:ProceedsFromJuly2022Offering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY184NzkvZnJhZzphZmY1ZDM2MjAwZWQ0ODRkOTM4YmZlM2ZlMTkwYzc3OC90ZXh0cmVnaW9uOmFmZjVkMzYyMDBlZDQ4NGQ5MzhiZmUzZmUxOTBjNzc4XzI3Nw_7e766574-ee14-4915-a87a-9eead9319f16">82.2</ix:nonFraction>&#160;million, after deducting underwriting discounts and commissions and estimated offering expenses.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="ibf95eabc4cf34ac1b0383c1ba8d7debc_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company with a mission of pioneering medicines that transform patients&#8217; lives.  We are devoting most of our resources to the research, development and preparation for commercialization of our most advanced drug candidates:</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes. We have reported positive results from two Phase 3 clinical trials evaluating the effect of sotagliflozin on long-term outcomes related to cardiovascular death and heart failure in approximately 10,500 and 1,200 patients, respectively. The U.S. Food and Drug Administration, or FDA, has accepted for filing our submission of an application for regulatory approval to market sotagliflozin for the reduction of the risk of cardiovascular death, hospitalization for heart failure and urgent heart failure visits in adults with heart failure, including those with worsening heart failure, and reduction in the risk of cardiovascular death, hospitalization for heart failure, urgent heart failure visits, nonfatal myocardial infarction and nonfatal stroke in adults with type 2 diabetes, chronic kidney disease and other cardiovascular risk factors, including a history of heart failure.  We are now preparing for the commercial launch of sotagliflozin in the United States, if approved.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have reported positive results from three Phase 3 clinical trials evaluating the effect of sotagliflozin on type 1 diabetes in approximately 800, 800 and 1,400 patients, respectively. The FDA issued a complete response letter regarding our application for regulatory approval to market sotagliflozin for type 1 diabetes in the United States. At our request, the FDA has issued a public Notice of Opportunity for Hearing on whether there are grounds for denying approval of our application and the hearing process is ongoing.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are developing LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain. We have reported positive top-line results from a Phase 2 clinical trial of LX9211 in painful diabetic neuropathic pain and are conducting a second Phase 2 clinical trial of LX9211 in post-herpetic neuralgia, from which we expect top-line results in the fourth quarter of 2022. LX9211 has received Fast Track designation from the FDA for development in diabetic peripheral neuropathic pain.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are conducting preclinical research and development and preparing to conduct clinical development of compounds from a number of additional drug programs originating from our internal drug discovery efforts.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> LX9211 originated from our collaborative neuroscience drug discovery efforts with Bristol-Myers Squibb, and sotagliflozin and compounds from a number of additional drug programs originated from our own internal drug discovery efforts. Those efforts were driven by a systematic, target biology-driven approach in which we used gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. We have identified and validated in living animals, or in vivo, more than 100 targets with promising profiles for drug discovery.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We are working both independently and through collaborations and strategic alliances with third parties to capitalize on our drug target discoveries and drug discovery and development programs. We seek to retain exclusive or co-exclusive rights to the benefits of certain drug discovery and development programs by developing and commercializing drug candidates from those programs internally, particularly in the United States for indications treated by specialist physicians. We seek to collaborate with other pharmaceutical and biotechnology companies with respect to drug discovery or the development and commercialization of certain of our drug candidates, particularly with respect to commercialization in territories outside the United States or commercialization in the United States for indications treated by primary care physicians, or when the collaboration may otherwise provide us with access to expertise and resources that we do not possess internally or are complementary to our own.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have derived substantially all of our revenues from strategic collaborations and other research and development collaborations and technology licenses, as well as from commercial sales of our XERMELO product following its commercial launch in February 2017 until our sale of XERMELO and related assets to TerSera Therapeutics, LLC in September 2020. To date, we have generated a substantial portion of our revenues from a limited number of sources.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results and, in particular, our ability to generate additional revenues are dependent on many factors, including the success of our ongoing nonclinical and clinical development efforts and the ability to obtain necessary regulatory approvals of the drug candidates which are the subject of such efforts; our success in establishing new collaborations and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">licenses and our receipt of milestones, royalties and other payments under such arrangements; and general and industry-specific economic conditions which may affect research, development and commercialization expenditures.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to secure future revenue-generating agreements will depend upon our ability to address the needs of our potential future collaborators and licensees, and to negotiate agreements that we believe are in our long-term best interests.  We may determine, as we have with certain of our drug candidates, that our interests are better served by retaining rights to our discoveries and advancing our therapeutic programs to a later stage, which could limit our near-term revenues and increase expenses.  Because of these and other factors, our operating results have fluctuated in the past and are likely to do so in the future, and we do not believe that period-to-period comparisons of our operating results are a good indication of our future performance. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant losses and, as of June&#160;30, 2022, we had an accumulated deficit of $1.5&#160;billion. Our losses have resulted principally from costs incurred in research and development, selling, general and administrative costs associated with our operations, and non-cash stock-based compensation expenses associated with stock options and restricted stock units granted to employees and consultants.  Research and development expenses consist primarily of salaries and related personnel costs, external research costs related to our nonclinical and clinical efforts, material costs, facility costs, depreciation on property and equipment, and other expenses related to our drug discovery and development programs. Selling, general and administrative expenses consist primarily of salaries and related expenses for executive, sales and marketing, and administrative personnel, professional fees and other corporate expenses, including information technology, facilities costs and general legal activities.  We expect to continue to incur significant research and development costs in connection with the continuing research and development of our drug candidates. As a result, we will need to generate significantly higher revenues to achieve profitability.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with generally accepted accounting principles requires us to make judgments, estimates and assumptions in the preparation of our condensed consolidated financial statements and accompanying notes.&#160;&#160;Actual results could differ from those estimates.&#160;&#160;We believe there have been no significant changes in our critical accounting policies as discussed in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) Simplifying Accounting for Income Taxes, as part of its initiative to reduce complexity in the accounting standards. The guidance amended certain disclosure requirements that had become redundant, outdated or superseded. Additionally, this guidance amends accounting for the interim period effects of changes in tax laws or rates, and simplifies aspects of the accounting for franchise taxes. The guidance is effective for annual periods beginning after December 15, 2020, including interim periods therein. The adoption of ASU 2019-12 in the first quarter of 2021 did not have a material impact on the condensed consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40), which removes the separation models for convertible debt with cash conversion or beneficial conversion features. ASU 2020-06 also requires the application of the if-converted method for calculating earnings per diluted share, as the treasury stock method will no longer be permitted for convertible instruments. The adoption of ASU 2020-06 during the first quarter of 2022 did not have a material impact on the condensed consolidated financial statements.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="ibf95eabc4cf34ac1b0383c1ba8d7debc_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses and dollar and percentage changes as compared to the corresponding periods in the prior year are as follows (dollar amounts are presented in millions):</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:42.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.401%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.808%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.922%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dollar increase</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage increase</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of third-party and other services principally related to nonclinical and clinical development activities, salaries and other personnel-related expenses, stock-based compensation expense, and facility and equipment costs.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Third-party and other services &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Third-party and other services for the three months ended June&#160;30, 2022 increased 37% to $7.6 million, and for the six months ended June&#160;30, 2022 increased 34% to $17.0 million, as compared to the corresponding periods in 2021 primarily due to increases in both clinical trial and related development and professional and consulting fees relating to preparations for the submission of our application for regulatory approval to market sotagliflozin in the United States for heart failure. Third-party and other services relate principally to our clinical trial and related development activities, such as nonclinical and clinical studies and contract manufacturing.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Personnel &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Personnel costs for the three months ended June&#160;30, 2022 increased 61% to $3.5 million, and for the six months ended June&#160;30, 2022 increased 32% to $6.7 million, as compared to the corresponding periods in 2021, primarily due to higher employee salaries and benefit costs as a result of increasing headcount during 2022 in preparation for commercialization of sotagliflozin.  Salaries, bonuses, employee benefits, payroll taxes, recruiting and relocation costs are included in personnel costs.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Stock-based compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Stock-based compensation expenses for the three months ended June&#160;30, 2022 decreased 7% to $1.1 million, and for the six months ended June&#160;30, 2022 decreased 14% to $2.1 million, as compared to the corresponding periods in 2021, primarily due to cancellation of unvested share-based awards during 2021.  </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Facilities and equipment &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities and equipment costs for the three months ended June&#160;30, 2022 and 2021 were $0.3 million and $0.4 million, respectively.   Facilities and equipment costs for the six months ended June&#160;30, 2022 and 2021 were $0.6 million and $0.7 million, respectively.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Other &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other costs for the three months ended June&#160;30, 2022 and 2021 were $0.9 million and $1.0 million, respectively.  Other costs for the six months ended June&#160;30, 2022 and 2021 were $1.8 million and $1.9 million, respectively.</span></div><div style="padding-left:36pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses and dollar and percentage changes as compared to the corresponding periods in the prior year are as follows (dollar amounts are presented in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:40.022%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.405%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.862%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.410%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total selling, general and administrative expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dollar increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage increase</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of personnel costs to support our research and development activities, professional and consulting fees, stock-based compensation expense, and facility and equipment costs.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Personnel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Personnel costs for the three months ended June&#160;30, 2022 increased 79% to $4.2 million, and for the six months ended June&#160;30, 2022 increased 36% to $7.6 million, as compared to the corresponding periods in 2021, primarily due to higher employee salaries and benefit costs as a result of increasing headcount during 2022 in preparation for commercialization of sotagliflozin.  Salaries, bonuses, employee benefits, payroll taxes, recruiting and relocation costs are included in personnel costs.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Professional and consulting fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Professional and consulting fees for the three months ended June&#160;30, 2022 increased 24% to $3.5 million, and for the six months ended June&#160;30, 2022 increased 11% to $5.7 million, as compared to the corresponding periods in 2021, primarily due to higher marketing and professional fees, partially offset by lower legal fees. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Stock-based compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Stock-based compensation expenses for the three months ended June&#160;30, 2022 increased 8% to $1.7 million, and for the six months ended June&#160;30, 2022 increased 10% to $3.5 million as compared to the corresponding periods in 2021.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Facilities and equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Facilities and equipment costs for the three months ended June&#160;30, 2022 and 2021 were $0.3 million and $0.4 million, respectively. Facilities and equipment costs for the six months ended June&#160;30, 2022 and 2021 were $0.6 million and $0.7 million, respectively.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Other &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other costs for the three months ended June&#160;30, 2022 and 2021 were $1.0 million and $0.8 million, respectively.  Other costs for the six months ended June&#160;30, 2022 and 2021 were $1.8 million and $1.6 million, respectively.</span></div><div style="padding-left:36pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss and Net Loss per Common Share</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net loss and Net loss per Common Share.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss was $24.6 million, or $0.16 per share, in the three months ended June&#160;30, 2022 as compared to a net loss of $18.1 million, or $0.13 per share, in the corresponding period in 2021.   Net loss was $48.1 million, or $0.32 per share, in the six months ended June&#160;30, 2022 as compared to a net loss of $39.0 million, or $0.27 per share, in the corresponding period in 2021.   </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly operating results have fluctuated in the past and are likely to do so in the future, and we believe that quarter-to-quarter comparisons of our operating results are not a good indication of our future performance.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="ibf95eabc4cf34ac1b0383c1ba8d7debc_64"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have financed our operations from inception primarily through sales of common and preferred stock, contract and milestone payments we received under our collaborations and strategic licenses, target validation, database subscription and technology license agreements, product sales, government grants and contracts, and financing under debt and lease arrangements, as well as from commercial sales of our XERMELO product following its commercial launch in February 2017 until our sale of XERMELO and related assets to TerSera Therapeutics, LLC in September 2020.  We have also financed certain of our research and development activities under financing arrangements with Symphony Icon, Inc. In March 2022, we entered into a loan and security agreement with Oxford Finance LLC that provides up to $150 million in borrowing capacity, available in four tranches, under which $25 million has been funded.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we had $62.0&#160;million in cash, cash equivalents and short-term investments.  As of December&#160;31, 2021, we had $86.7&#160;million in cash, cash equivalents and short-term investments.  We used cash of $47.8&#160;million from operations in the six months ended June&#160;30, 2022.  This consisted primarily of the net loss for the period of $48.1&#160;million and a net decrease in operating liabilities net of assets of $5.8 million, partially offset by non-cash charges of $5.6&#160;million related to stock-based compensation expense. Investing activities used cash of $18.1&#160;million in the six&#160;months ended June&#160;30, 2022, primarily due to net purchases of investments.  Financing activities provided cash of $23.3&#160;million primarily from $24.2 million of net proceeds from the Oxford debt financing during March 2022, which was partially offset by $0.9 million used to repurchase common stock by retaining shares in substitution of the tax withholding obligations of recipients of restricted stock units granted under our 2017 Equity Incentive Plan with respect to the vesting of such restricted stock units.  </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other commitments.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, sotagliflozin was approved in the European Union for use as an adjunct to insulin therapy to improve glycemic control in adults with type 1 diabetes and a body mass index &#8805; </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27 kg/m</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, who could not achieve adequate glycemic control despite optimal insulin therapy. In March 2022, we filed an application for withdrawal of such approval for business reasons, which request was granted by the European Commission. Upon the achievement of certain European regulatory pricing approvals, we would have been required to make certain royalty payments, totaling $4.5 million, in three equal annual installments of $1.5 million. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In February 2021, we leased a 25,000 square-foot office space in The Woodlands, Texas. The term of the sublease extends from March 1, 2021 through August&#160;31, 2025, and provides for escalating yearly base rent payments starting at $506,000 and increasing to $557,000 in the final year of the lease. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2015, our subsidiary Lexicon Pharmaceuticals (New Jersey), Inc. leased a 25,000 square-foot office space in Basking Ridge, New Jersey.  The term of the lease extends from June&#160;1, 2015 through December&#160;31, 2022, and provides for escalating yearly base rent payments starting at $482,000 and increasing to $646,000 in the final year of the lease. In July 2022, Lexicon Pharmaceuticals (New Jersey), Inc. entered into an agreement to lease a 22,000 square-foot office space in Bridgewater, New Jersey to which we plan to relocate our New Jersey offices.  The term of the lease is expected to commence in December 2022, will extend for ten years and 11 months from such commencement date and provides for escalating yearly base rent payments starting at $820,000 and increasing to $986,000 in the final year of the lease.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will be substantial and will depend on many factors, including the success of our ongoing nonclinical and clinical development efforts and the ability to obtain necessary regulatory approvals of the drug candidates which are the subject of such efforts; our success in establishing new collaborations and licenses and our receipt of milestones, royalties and other payments under such arrangements; the amount and timing of our research, development and commercialization expenditures; the resources we devote to developing and supporting our products and other factors.&#160;&#160;Our capital requirements will also be affected by any expenditures we make in connection with license agreements and acquisitions of and investments in complementary technologies and businesses.&#160;&#160;We expect to continue to devote substantial capital resources to prepare for the commercialization of sotagliflozin, if approved; successfully complete our nonclinical and clinical development efforts with respect to sotagliflozin, LX9211 and our other drug candidates; and for other general corporate activities.&#160;&#160;We believe that our current unrestricted cash and investment balances and cash and revenues we expect to derive from strategic and other collaborations and other sources will be sufficient to fund our operations for at least the next 12 months.&#160;&#160;During or after this period, if cash generated by operations is insufficient to satisfy our liquidity requirements, we will need to sell additional equity or debt securities or obtain additional credit arrangements.&#160;&#160;Additional financing may not be available on terms acceptable to us or at all. The sale of additional equity or convertible debt securities may result in additional dilution to our stockholders.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, our board of directors may authorize us to repurchase shares of our common stock.  If and when our board of directors should determine to authorize any such action, it would be on terms and under market conditions that our board of directors determines are in the best interest of us and our stockholders.  Any such actions could deplete significant amounts of our cash resources and/or result in additional dilution to our stockholders.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure about Market Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to limited market and credit risk on our cash equivalents which have maturities of three months or less at the time of purchase. We maintain a short-term investment portfolio which consists of U.S. Treasury bills and corporate debt securities that mature three to 12 months from the time of purchase, which we believe are subject to limited market and credit risk. We currently do not hedge interest rate exposure or hold any derivative financial instruments in our investment portfolio.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had approximately $62.0&#160;million in cash and cash equivalents and short-term investments as of June&#160;30, 2022.  We believe that the working capital available to us will be sufficient to meet our cash requirements for at least the next 12&#160;months. We are subject to interest rate sensitivity on our outstanding Oxford Term Loans as they contain a floating rate tied to the 30-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">day LIBOR rate.  The Oxford Term Loans interest is payable in cash monthly and matures in March 2027, unless earlier repaid in accordance with their terms.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operated primarily in the United States and substantially all sales to date have been made in U.S. dollars. Accordingly, we have not had any material exposure to foreign currency rate fluctuations.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="ibf95eabc4cf34ac1b0383c1ba8d7debc_67"></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Disclosure about Market Risk&#8221; under &#8220;Item 2. Management&#8217;s Discussion and Analysis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of Financial Condition and Results of Operations&#8221; for quantitative and qualitative disclosures about market risk.</span></div><div><span><br/></span></div><div id="ibf95eabc4cf34ac1b0383c1ba8d7debc_70"></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;Controls and Procedures</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures (as defined in rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) are effective to ensure that the information required to be disclosed by us in the reports we file under the Securities Exchange Act is gathered, analyzed and disclosed with adequate timeliness, accuracy and completeness, based on an evaluation of such controls and procedures as of the end of the period covered by this report. There were no changes in our internal control over financial reporting during the three months ended June&#160;30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="ibf95eabc4cf34ac1b0383c1ba8d7debc_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Part II -- Other Information&#160;</span></div><div style="text-align:center"><span><br/></span></div><div id="ibf95eabc4cf34ac1b0383c1ba8d7debc_76"></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;Legal Proceedings</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are from time to time party to claims and legal proceedings that arise in the normal course of our business and that we believe will not have, individually or in the aggregate, a material adverse effect on our results of operations, financial condition or liquidity.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="ibf95eabc4cf34ac1b0383c1ba8d7debc_79"></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.&#160;&#160;Risk Factors</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following risks and uncertainties are important factors that could cause actual results or events to differ materially from those indicated by forward-looking statements.  The factors described below are not the only ones we face and additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Business and Industry</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;&#160;&#160;&#160;&#160;We depend heavily on our ability to obtain regulatory approval in the United States for sotagliflozin in heart failure. If we fail to obtain such regulatory approval, our business will suffer and our stock price will likely decline.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">If approved, we will depend heavily on the commercial success of sotagliflozin in heart failure. If we do not achieve commercial success with sotagliflozin, our business will suffer and our stock price will likely decline.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;We depend on our ability to obtain positive results from our ongoing Phase 2 clinical trial of LX9211 in post-herpetic neuralgia. If we fail to successfully complete and obtain positive results from such clinical trial, our business will suffer and our stock price will likely decline.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;Clinical testing of our drug candidates in humans is an inherently risky and time-consuming process that may fail to demonstrate safety and efficacy, which could result in the delay, limitation or prevention of regulatory approval.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;Our drug candidates are subject to a lengthy and uncertain regulatory process that may not result in the necessary regulatory approvals, which could adversely affect our and our collaborators&#8217; ability to commercialize products.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The commercial success of any products that we or our collaborators may develop will depend upon the degree of market acceptance among physicians, patients, health care payers and the medical communit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">y.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">If we are unable to reestablish an effective sales force, marketing infrastructure and distribution capabilities, we will not be able to successfully commercialize any products that we or our collaborators may develop.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">If we are unable to maintain adequate coverage and reimbursement from third-party payers for any products that we or our collaborators may develop, our revenues and prospects for profitability will suffer.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We may not be able to manufacture products that we or our collaborators may develop in commercial quantities, which would impair our ability to commercialize such products.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We and our collaborators are subject to extensive and rigorous ongoing regulation relating to any products that we or our collaborators may develop.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We are subject to certain healthcare laws, regulation and enforcement; our failure to comply with those laws could have a material adverse effect on our results of operations and financial condition.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Current healthcare laws and regulations and future legislative or regulatory reforms to the healthcare system may negatively affect our revenues and prospects for profitability.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;Our competitors may develop products that impair the value of any products that we or our collaborators may develop.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;We face business disruption and related risks resulting from the outbreak of the novel coronavirus, or COVID-19, including delays in the enrollment of ongoing clinical trials and other operational impacts, each of which could have a material adverse effect on our business.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Risks Related to Our Capital Requirements and Financial Results</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;We will need additional capital in the future and, if it is unavailable, we will be forced to delay, reduce or eliminate our research and development programs. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;If additional capital is not available on reasonable terms, we will be forced to obtain funds, if at all, by entering into financing agreements on unattractive terms.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have a history of net losses, and we expect to continue to incur net losses and may not achieve or maintain profitability.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Our operating results have fluctuated and likely will continue to fluctuate, and we believe that period-to-period comparisons of our operating results are not a good indication of our future performance.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;&#160;&#160;&#160;&#160;We have substantial indebtedness that may limit cash flow available to invest in the ongoing needs of our business. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">If we do not effectively manage our affirmative and restrictive covenants under the Oxford Term Loans, our financial condition and results of operations could be adversely affected.</span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Relationships with Third Parties</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We depend on our ability to establish collaborations with pharmaceutical and biotechnology companies for the development and commercialization of our drug candidates, particularly for the development and commercialization of LX9211 for neuropathic pain. If we are unable to establish such collaborations, or if pharmaceutical products are not successfully and timely developed and commercialized under such collaborations, our opportunities to generate revenues from our drug candidates will be greatly reduced.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Conflicts with our collaborators could jeopardize the success of our collaborative agreements and harm our product development efforts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We rely on third parties to carry out our nonclinical studies and clinical trials, which may harm or delay our research and development efforts.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We lack the capability to manufacture materials for nonclinical studies and clinical trials and commercial supplies for any products which gain regulatory approval. Our reliance on third parties to manufacture our drug candidates may harm or delay our research, development and commercialization efforts.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Intellectual Property</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we are unable to adequately protect our intellectual property, third parties may be able to use our products and technologies, which could adversely affect our ability to compete in the market.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We may be involved in patent litigation and other disputes regarding intellectual property rights and may require licenses from third parties for our planned nonclinical and clinical development and commercialization activities.&#160;&#160;We may not prevail in any such litigation or other dispute or be able to obtain required licenses.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Data breaches and cyber-attacks could compromise our intellectual property or other sensitive information and cause significant damage to our business, reputational harm and financial loss.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We may be subject to damages resulting from claims that we, our employees or independent contractors have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Employees and Facilities</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we are unable to manage our growth, our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The loss of key personnel or the inability to attract and retain additional personnel could impair our ability to operate and expand our operations.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Our facilities are located near coastal zones, and the occurrence of a hurricane or other disaster could damage our facilities and equipment, which could harm our operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Environmental and Product Liability</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;We have used hazardous chemicals and radioactive and biological substances in our business. Any claims relating to improper handling, storage or disposal of these substances could be time consuming and costly.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business has a substantial risk of product liability and we face potential product liability exposure far in excess of our limited insurance coverage.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Common Stock</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Invus, L.P. and its affiliates own a controlling interest in our outstanding common stock and may have interests which conflict with those of our other stockholders.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;&#160;&#160;&#160;&#160;Invus has additional rights under its stockholders&#8217; agreement relating to the membership of our board of directors and under our certificate of incorporation relating to preemptive and consent rights, which provide Invus with substantial influence over significant corporate matters.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">Our stock price may be extremely volatile.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">Future issuances or sales of our common stock, or the perception that such issuances or sales may occur, may depress our stock price.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional discussion of the risks and uncertainties that affect our business, see &#8220;Item&#160;1A. Risk Factors&#8221; included in our annual report on Form 10-K for the year ended December&#160;31, 2021 as filed with the Securities and Exchange Commission. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="ibf95eabc4cf34ac1b0383c1ba8d7debc_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;Exhibits</span></div><div style="padding-left:72pt;text-indent:-72pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:10.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;text-indent:4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282222000024/exh31-fifthamendedandresta.htm">Fifth Amended and Restated Certificate of Incorporation (filed as Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K dated May 20, 2022 and incorporated by reference herein).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*31.1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh311certificationofprinc.htm">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*31.2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh312certificationofprinc.htm">Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*32.1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh321certificationofprinc.htm">Certification of Principal Executive and Principal Financial Officers Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension  Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:1.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="ibf95eabc4cf34ac1b0383c1ba8d7debc_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:5.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lexicon Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 3, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Lonnel Coats</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonnel Coats</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:5.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 3, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jeffrey L. Wade</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey L. Wade</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>exh31-fifthamendedandresta.htm
<DESCRIPTION>EX-3.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iedd7ec1767264509a40e6de1755c4cc0_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 3.1</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEXICON PHARMACEUTICALS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> INC.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LEXICON PHARMACEUTICALS, INC. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">DGCL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), hereby certifies as follows pursuant to Sections 242 and 245 of the DGCL&#58;</font></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-58.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FIRST&#58; &#160;&#160;&#160;&#160;The name of the Corporation is &#8220;Lexicon Pharmaceuticals, Inc.&#8221; The Corporation was previously incorporated as &#8220;Lexicon Genetics Incorporated.&#8221;</font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-58.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECOND&#58; &#160;&#160;&#160;&#160;The current Certificate of Incorporation of the Corporation was filed in the Office of the Secretary of State of the State of Delaware (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Secretary of State</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) on April 30, 2021.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-58.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">THIRD&#58; &#160;&#160;&#160;&#160;The Board of Directors of the Corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Board of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), in accordance with Sections 242 and 245 of the DGCL, (i) adopted and approved this Fifth Amended and Restated Certificate of Incorporation (including the amendments to the Corporation&#8217;s Certificate of Incorporation effected hereby) and (ii) proposed that the Corporation&#8217;s stockholders adopt and approve this Fifth Amended and Restated Certificate of Incorporation (including the amendments to the Corporation&#8217;s Certificate of Incorporation effected hereby).</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-58.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOURTH&#58; &#160;&#160;&#160;&#160;The holders of not less than a majority of the outstanding shares of the Corporation&#8217;s common stock, par value $.001 per share, and preferred stock, par value $0.01 per share, in accordance with Sections 242 and 245 of the DGCL, approved and adopted on behalf of the stockholders this Fifth Amended and Restated Certificate of Incorporation (including the amendments to the Corporation&#8217;s Certificate of Incorporation effected hereby).</font></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-58.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FIFTH&#58;&#160;&#160;&#160;&#160;This Fifth Amended and Restated Certificate of Incorporation shall become effective on its filing with the Secretary of State.</font></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-58.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIXTH&#58;&#160;&#160;&#160;&#160;The current Certificate of Incorporation of the Corporation is hereby amended and restated to read in its entirety as follows&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE I</font></div><div style="margin-bottom:9pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Name</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The name of the Corporation is &#8220;Lexicon Pharmaceuticals, Inc.&#8221;</font></div><div style="margin-bottom:0.03pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE II</font></div><div style="margin-bottom:9pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Registered Office and Registered Agent</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registered office of the Corporation in the State of Delaware is located at 251 Little Falls Drive in the City of Wilmington, County of New Castle, Zip Code 19808. The name of the registered agent of the Corporation at such address is Corporation Service Company.</font></div><div style="margin-bottom:0.03pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE III</font></div><div style="margin-bottom:9pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Purpose</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose for which the Corporation is organized is to engage in any lawful acts and activities for which corporations may be organized under the General Corporation Law of the State of Delaware (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">DGCL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:0.03pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE IV</font></div><div style="margin-bottom:9pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Capitalization</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.04pt;text-decoration:underline">Authorized Capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. (a) The total number of shares of stock that the Corporation shall have the authority to issue is 305,000,000 shares of capital stock, consisting of (i) 5,000,000 shares of preferred stock, par value $0.01 </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and (ii) 300,000,000 shares of common stock, par value $0.001 per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Subject to the provisions of this Certificate of Incorporation and the Preferred Stock Designation (as defined below) creating any series of Preferred Stock, the Corporation may issue shares of its capital stock from time to time for such consideration (not less than the par value thereof) as may be fixed by the Board of Directors of the Corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Board of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), which is expressly authorized to fix the same in its absolute discretion subject to the foregoing conditions. Shares so issued for which the consideration shall have been paid or delivered to the Corporation shall be deemed fully paid stock and shall not be liable to any further call or assessment thereon, and the holders of such shares shall not be liable for any further payments in respect of such shares.</font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The right to cumulate votes for the election of directors as provided in Section 214 of the DGCL shall not be granted and is hereby expressly denied.</font></div><div><font><br></font></div><div style="margin-bottom:0.03pt;margin-top:0.12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Subject to Article XII, no stockholder of the Corporation shall by reason of his or her holding shares of any class of capital stock of the Corporation have any preemptive or preferential right to acquire or subscribe for any additional, unissued or treasury shares (whether now or hereafter acquired) of any class of capital stock of the Corporation now or hereafter to be authorized, or any notes, debentures, bonds or other securities convertible into or carrying any right, option or warrant to subscribe for or acquire shares of any class of capital stock of the Corporation now or hereafter to be authorized, whether or not the issuance of any such shares or such notes, debentures, bonds or other securities would adversely affect the dividends or voting or other rights of that stockholder.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.02&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. (a) The Preferred Stock may be issued from time to time in one or more series. Authority is hereby expressly granted to and vested in the Board of Directors to authorize from time to time the issuance of Preferred Stock in one or more series. With respect to each series of Preferred Stock authorized by it, the Board of Directors shall be authorized to establish by resolution or resolutions, and by filing a certificate pursuant to applicable law of the State of Delaware (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Preferred Stock Designation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the following to the fullest extent now or hereafter permitted by the DGCL&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">the designation of such series&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">the number of shares to constitute such series&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">whether such series is to have voting rights (full, special or limited) or is to be without voting rights&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">if such series is to have voting rights, whether or not such series is to be entitled to vote as a separate class either alone or together with the holders of the Common Stock or one or more other series of Preferred Stock&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">the preferences and relative, participating, optional, conversion or other special rights (if any) of such series and the qualifications, limitations or restrictions (if any) with respect to such series&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">the redemption rights and price(s), if any, of such series, and whether or not the shares of such series shall be subject to the operation of retirement or sinking funds to be applied to the purchase or redemption of such shares for retirement and, if such retirement or sinking funds or funds are to be established, the periodic amount thereof and the terms and provisions relative to the operation thereof&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">the dividend rights and preferences (if any) of such series, including, without limitation, (i) the rates of dividends payable thereon, (ii) the conditions upon which and the time when such dividends are payable, (iii) whether or not such dividends shall be cumulative or noncumulative and, if cumulative, the date or dates from which such dividends shall accumulate and (iv) whether or not the payment of such dividends shall be preferred to the payment of dividends payable on the Common Stock or any other series of Preferred Stock&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">the preferences (if any), and the amounts thereof, which the holders of such series shall be entitled to receive upon the voluntary or involuntary liquidation, dissolution or winding-up of, or upon any distribution of the assets of, the Corporation&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">whether or not the shares of such series, at the option of the Corporation or the holders thereof or upon the happening of any specified event, shall be convertible into or exchangeable for (i) shares of Common Stock, (ii) shares of any other series of Preferred Stock or (iii) any other stock or securities of the Corporation&#59;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.34pt">if such series is to be convertible or exchangeable, the price or prices or ratio or ratios or rate or rates at which such conversion or exchange may be made and the terms and conditions (if any) upon which such price or prices or ratio or ratios or rate or rates may be adjusted&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.34pt">such other rights, powers and preferences with respect to such series as may to the Board of Directors seem advisable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any series of Preferred Stock may vary from any other series of Preferred Stock in any or all of the foregoing respects and in any other manner.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Board of Directors may, with respect to any existing series of Preferred Stock but subject to the Preferred Stock Designation creating such series, (i) increase the number of shares of Preferred Stock designated for such series by a resolution adding to such series authorized and unissued shares of Preferred Stock not designated for any other series and (ii) decrease the number of shares of Preferred Stock designated for such series by a resolution subtracting from such series shares of Preferred Stock designated for such series (but not below the number of shares of such series then outstanding), and the shares so subtracted shall become authorized, unissued and undesignated shares of Preferred Stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;No vote of the holders of the Common Stock or the Preferred Stock shall, unless otherwise expressly provided in a Preferred Stock Designation creating any series of Preferred Stock, be a prerequisite to the issuance of any shares of any series of the Preferred Stock authorized by and complying with the conditions of this Certificate of Incorporation. Shares of any series of Preferred Stock that have been authorized for issuance pursuant to this Certificate of Incorporation and that have been issued and reacquired in any manner by the Corporation (including upon conversion or exchange thereof) shall be restored to the status of authorized and unissued shares of Preferred Stock and may be reissued as part of a new series of Preferred Stock to be created by resolution or resolutions of the Board of Directors and a Preferred Stock Designation as set forth above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.03.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. (a) The holders of shares of the Common Stock shall be entitled to vote upon all matters submitted to a vote of the common stockholders of the Corporation and shall be entitled to one vote for each share of the Common Stock held.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Subject to the prior rights and preferences (if any) applicable to shares of Preferred Stock of any series, the holders of shares of the Common Stock shall be entitled to receive such dividends (payable in cash, stock or otherwise) as may be declared thereon by the Board of Directors at any time and from time to time out of any funds of the Corporation legally available therefor.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;In the event of any voluntary or involuntary liquidation, dissolution or winding-up of the Corporation, after payment or provision for payment of the debts and other liabilities of the Corporation and subject to the preferential or other rights (if any) of the holders of shares of the Preferred Stock in respect thereof, the holders of shares of the Common Stock shall be entitled to receive all the remaining assets of the Corporation available for distribution to its stockholders, ratably in proportion to the number of shares of the Common Stock held by them. For purposes of this paragraph (c), a liquidation, dissolution or winding-up of the Corporation shall not be deemed to be occasioned by or to include (i) any consolidation or merger of the Corporation with or into another corporation or other entity or (ii) a sale, lease, exchange or conveyance of all or a part of the assets of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.04.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stock Options, Warrants, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Unless otherwise expressly prohibited in the Preferred Stock Designation creating any series of Preferred Stock, the Corporation shall have authority to create and issue warrants, rights and options entitling the holders thereof to purchase from the Corporation shares of the Corporation&#8217;s capital stock of any class or series or other securities of the Corporation for such consideration and to such persons, firms or corporations as the Board of Directors, in its sole discretion, may determine, setting aside from the authorized but unissued capital stock of the Corporation the requisite number of shares for issuance upon the exercise of such warrants, rights or options. Such warrants, rights and options shall be evidenced by one or more instruments approved by the Board of Directors. The Board of Directors shall be empowered to set the exercise price, duration, time for exercise and other terms of such warrants, rights or options&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that the consideration to be received for any shares of capital stock subject thereto shall not be less than the par value thereof.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE V</font></div><div style="margin-bottom:9pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Directors</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.01.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Number and Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The number of directors of the Corporation shall from time to time be fixed exclusively by the Board of Directors in accordance with, and subject to the limitations set forth in, the bylaws of the Corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Bylaws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that the Board of Directors shall at all times consist of a minimum of three and a maximum of 13 directors, subject, however, to increases above 13 directors as may be required in order to permit the holders of any series of Preferred Stock to exercise their right (if any) to elect additional directors under specified circumstances or to permit the election or appointment to the Board of Directors of the Required Director Number of Investor Designated Directors (each as defined in the Stockholders&#8217; Agreement, dated as of June 17, 2007, between Invus, L.P. and the Corporation (as amended, supplemented or otherwise modified, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stockholders&#8217; Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)) pursuant to the Stockholders&#8217; Agreement. No decrease in the number of directors shall have the effect of shortening the term of any incumbent director. Anything in this Certificate of Incorporation or the Bylaws to the contrary notwithstanding, each director shall hold office until his successor is elected and qualified or until his earlier death, resignation or removal.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.02.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Limitation of Personal Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. (a) No person who is or was a director of the Corporation shall be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i) for any breach of the director&#8217;s duty of loyalty to the Corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the DGCL or (iv) for any transaction from which the director derived an improper personal benefit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;If the DGCL is hereafter amended to authorize corporate action further limiting or eliminating the personal liability of directors, then the personal liability of the directors to the Corporation or its stockholders shall be limited or eliminated to the fullest extent permitted by the DGCL, as so amended from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.03.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Classification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Board of Directors shall be divided into three classes designated as Class I, Class II and Class III, respectively, all as nearly equal in number as possible, with each director then in office receiving the classification to be determined with respect to such director by the Board of Directors. The initial term of office of Class I directors shall expire at the annual meeting of the Corporation&#8217;s stockholders in 2001. The initial term of office of Class II directors shall expire at the annual meeting of stockholders in 2002. The initial term of office of Class III directors shall expire at the annual meeting of stockholders in 2003. Each director elected at an annual meeting of stockholders to succeed a director whose term is then expiring shall hold office until the third annual meeting of stockholders after his election or until his successor is elected and qualified or until his earlier death, resignation or removal. Increases and decreases in the number of directors shall be apportioned among the classes of directors so that all classes will be as nearly equal in number as possible. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.04.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Nomination and Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. (a) Nominations of persons for election or reelection to the Board of Directors may be made by or at the direction of the Board of Directors. The Bylaws may set forth procedures for the nomination of persons for election or reelection to the Board of Directors and only persons who are nominated in accordance with such procedures (if any) shall be eligible for election or reelection as directors of the Corporation&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that such procedures shall not infringe upon (i) the right of the Board of Directors to nominate persons for election or reelection to the Board of Directors or (ii) the rights of the holders of any class or series of Preferred Stock, voting separately by class or series, to elect additional directors under specified circumstances.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Each director shall be elected in accordance with this Certificate of Incorporation, the Bylaws and applicable law. Election of directors by the Corporation&#8217;s stockholders need not be by written ballot unless the Bylaws so provide.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.05.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Removal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. No director of any class may be removed before the expiration of his term of office except for cause and then only by the affirmative vote of the holders of not less than a majority in voting power of all the outstanding shares of capital stock of the Corporation entitled to vote generally in an election of directors, voting together as a single class. The Board of Directors may not remove any director, and no recommendation by the Board of Directors that a director be removed may be made to the Corporation&#8217;s stockholders unless such recommendation is set forth in a resolution adopted by the affirmative vote of not less than 66-2&#47;3% of the whole Board of Directors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.06.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Vacancies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. (a) In case any vacancy shall occur on the Board of Directors because of death, resignation or removal, such vacancy may be filled only by a majority (or such higher percentage as may be specified in the Bylaws) of the directors remaining in office (though less than a quorum), or by the sole remaining director. The director so appointed shall serve for the unexpired term of his predecessor or until his successor is elected and qualified or until his earlier </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">death, resignation or removal. If there are no directors then in office, an election of directors may be held in the manner provided by applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any newly-created directorship resulting from any increase in the number of directors may be filled only by a majority (or such higher percentage as may be specified in the Bylaws) of the directors then in office (though less than a quorum), or by the sole remaining director. The director so appointed shall be assigned to such class of directors as such majority of directors or the sole remaining director, as the case may be, shall determine&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that newly-created directorships shall be apportioned among the classes of directors so that all classes will be as nearly equal in number as possible. Each director so appointed shall hold office for the remaining term of the class to which he is assigned or until his successor is elected and qualified or until his earlier death, resignation or removal.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Except as expressly provided in this Certificate of Incorporation or as otherwise provided by applicable law, stockholders of the Corporation shall not have the right to fill vacancies on the Board of Directors, including newly-created directorships.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.07.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Subject to Rights of Holders of Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding the foregoing provisions of this Article&#160;V, if the Preferred Stock Designation creating any series of Preferred Stock entitles the holders of such Preferred Stock, voting separately by class or series, to elect additional directors under specified circumstances, then all provisions of such Preferred Stock Designation relating to the nomination, election, term of office, removal, filling of vacancies and other features of such directorships shall, as to such directorships, govern and control over any conflicting provisions of this Article&#160;V, and such directors so elected need not be divided into classes pursuant to this Article&#160;V unless expressly provided by the provisions of such Preferred Stock Designation.</font></div><div style="margin-bottom:0.03pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE VI</font></div><div style="margin-bottom:9pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment of Bylaws</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors is expressly authorized and empowered to adopt, alter, amend or repeal the Bylaws. Stockholders of the Corporation shall have the power to alter, amend, expand or repeal the Bylaws but only by the affirmative vote of the holders of not less than 66-2&#47;3% in voting power of all outstanding shares of capital stock of the Corporation entitled to vote generally at an election of directors, voting together as a single class.</font></div><div style="margin-bottom:0.03pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE VII</font></div><div style="margin-bottom:9pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Actions and Meetings of Stockholders</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.01.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">No Action by Written Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. No action shall be taken by the stockholders of the Corporation except at an annual or special meeting of stockholders. Stockholders of the Corporation may not act by written consent in lieu of a meeting.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.02.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. (a) Meetings of the stockholders of the Corporation (whether annual or special) may only be called by the Board of Directors or by such officer or officers of the Corporation as the Board of Directors may from time to time authorize to call meetings of the stockholders of the Corporation. Stockholders of the Corporation shall not be entitled to call any meeting of stockholders or to require the Board of Directors or any officer or officers of the Corporation to call a meeting of stockholders except as otherwise expressly provided in the Bylaws or in the Preferred Stock Designation creating any series of Preferred Stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Stockholders of the Corporation shall not be entitled to propose business for consideration at any meeting of stockholders except as otherwise expressly provided in the Bylaws or in the Preferred Stock Designation creating any series of Preferred Stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Business transacted at any special meeting of stockholders shall be limited to the purposes stated in the notice or waivers of notice of such meeting. The person presiding at a meeting of stockholders may determine whether business has been properly brought before the meeting and, if the facts so warrant, such person may refuse to transact any business at such meeting which has not been properly brought before such meeting.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.03.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Appoint and Remove Officers, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The stockholders of the Corporation shall have no right or power to appoint or remove officers of the Corporation nor to abrogate the power of the Board of Directors to elect and remove officers of the Corporation. The stockholders of the Corporation shall have no power to appoint or remove directors as members of committees of the Board of Directors nor to abrogate the power of the Board of Directors to establish one or more such committees or the power of any such committee to exercise the powers and authority of the Board of Directors.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.04.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Compromises and Arrangements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Whenever a compromise or arrangement is proposed between this corporation and its creditors or any class of them and&#47;or between this corporation and its stockholders or any class of them, any court of equitable jurisdiction within the State of Delaware may, on the application in a summary way of this corporation or of any creditor or stockholder thereof or on the application of any receiver or receivers appointed for this corporation under &#167; 291 of Title 8 of the Delaware Code or on the application of trustees in dissolution or of any receiver or receivers appointed for this corporation under &#167; 279 of Title 8 of the Delaware code order a meeting of the creditors or class of creditors, and&#47;or of the stockholders or class of stockholders of this corporation, as the case may be, to be summoned in such manner as the said court directs. If a majority in number representing three fourths in value of the creditors or class of creditors, and&#47;or of the stockholders or class of stockholders of this corporation, as the case may be, agree to any compromise or arrangement and to any reorganization of this corporation as a consequence of such compromise or arrangement, the said compromise or arrangement and the said reorganization shall, if sanctioned by the court to which the said application has been made, be binding on all the creditors or class of creditors, and&#47;or on all the stockholders or class of stockholders, of this corporation, as the case may be, and also on this corporation.</font></div><div style="margin-bottom:0.03pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE VIII</font></div><div style="margin-bottom:9pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification of Directors and Officers</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporation shall indemnify, to the fullest extent permitted by applicable law and pursuant to the Bylaws, each person who is or was a director or officer of the Corporation, and may indemnify each employee and agent of the Corporation and all other persons whom the Corporation is authorized to indemnify under the provisions of the DGCL.</font></div><div style="margin-bottom:0.03pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE IX</font></div><div style="margin-bottom:9pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Election to be Governed by Section 203 of the DGCL</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporation hereby elects to be governed by Section 203 of the DGCL&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that the provisions of this Article&#160;IX shall not apply to restrict a business combination between the Corporation and an interested stockholder (as defined in Section 203 of the DGCL) of the Corporation if either (i) such business combination was approved by the Board of Directors prior to the time that such stockholder became an interested stockholder or (ii) such stockholder became an interested stockholder as a result of, and at or prior to the effective time of, a transaction which was approved by the Board of Directors prior to the time that such stockholder became an interested stockholder.</font></div><div style="margin-bottom:0.03pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE X</font></div><div style="margin-bottom:9pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment of Certificate of Incorporation</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporation reserves the right to amend, alter, change or repeal any provisions contained in this Certificate of Incorporation, in the manner now or hereafter prescribed by applicable law, and all rights conferred upon stockholders, directors or any other persons by or pursuant to this Certificate of Incorporation are granted subject to this reservation. Notwithstanding the foregoing or any other provision of this Certificate of Incorporation or any provision of law that might otherwise permit a lesser or no vote, the provisions of this Article&#160;X and of Articles V, VI, VII and VIII may not be repealed or amended in any respect, and no provision inconsistent with any such provision or imposing cumulative voting in the election of directors may be added to this Certificate of Incorporation, unless such action is approved by the affirmative vote of the holders of not less than 66-2&#47;3% in voting power of all outstanding shares of capital stock of the Corporation entitled to vote generally at an election of directors, voting together as a single class&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that any amendment or repeal of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or Article&#160;VIII of this Certificate of Incorporation shall not adversely affect any right or protection existing thereunder in respect of any act or omission occurring prior to such amendment or repeal and, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that no Preferred Stock Designation shall be amended after the issuance of any shares of the Series of Preferred Stock created thereby, except in accordance with the terms of such Preferred Stock Designation and the requirements of applicable law.</font></div><div style="margin-bottom:0.03pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE XI</font></div><div style="margin-bottom:9pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Voting Requirements Not Exclusive</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The voting requirements contained in this Certificate of Incorporation shall be in addition to the voting requirements imposed by law or by the Preferred Stock Designation creating any series of Preferred Stock.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE XII</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Certain Rights of Covered Stockholders</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 12.01.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Rights to Purchase New Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. (a)&#160;Notwithstanding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.01(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the event that the Corporation proposes to issue New Securities, a Covered Stockholder shall have the right to purchase, in lieu of the person to whom the Corporation proposed to issue such New Securities, in accordance with paragraph (b)&#160;below, a number of New Securities equal to the product of (i)&#160;the total number or amount of New Securities which the Corporation proposes to issue at such time and (ii)&#160;a fraction, the numerator of which shall be the total number of shares of Common Stock which the Covered Stockholder beneficially owns at the relevant measurement point, and the denominator of which shall be the aggregate number of shares of Common Stock then outstanding (the number referred to in clause (ii), the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pro Rata Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;12.01(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the event that the Corporation proposes to undertake an issuance of New Securities, it shall give written notice (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notice of Issuance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of its intention to the Covered Stockholder indicating the price per New Security (or, to the extent not reasonably known to the Corporation at such time, the methodology for determining such price) and the number of New Securities to be issued by the Corporation, and describing the material terms of the New Securities and the material terms upon which the Corporation proposes to issue such New Securities. The Covered Stockholder shall have two business days from the date of receipt of the Notice of Issuance to agree to purchase all or a portion of the Covered Stockholder&#8217;s Pro Rata Share of such New Securities (as determined pursuant to paragraph (a)&#160;above) for the same consideration and otherwise upon the terms specified in the Notice of Issuance (unless better terms are provided to any other purchaser) by giving written notice to the Corporation and stating therein the quantity of New Securities to be purchased by the Covered Stockholder. If the Covered Stockholder exercises its right to purchase New Securities pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;12.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the purchase and sale of such New Securities shall close at the same time as the issuance of New Securities to the other purchaser or purchasers and, subject to the preceding sentence, shall be issued on the same terms and subject to the same conditions as applicable to the other purchaser or purchasers&#59;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that (i)&#160;such terms and conditions applicable to the Covered Stockholder shall not include any restrictions on the transferability of such New Securities (except pursuant to applicable laws and regulations) or any standstill, voting or other restrictions, (ii)&#160;the Covered Stockholder shall not be required to make any representations and warranties except those that relate solely to the Covered Stockholder and (iii)&#160;the Covered Stockholder will not be required to undertake any indemnification obligation.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rights given by the Corporation under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;12.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall terminate if unexercised within two business days after receipt of the Notice of Issuance referred to in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;12.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding anything to the contrary contained herein, if (i)&#160;the price or any other material terms upon which the Corporation proposes to issue such New Securities are amended by the Corporation following the delivery to the Covered Stockholder of the Notice of Issuance or (ii)&#160;the offering of New Securities to which a Notice of Issuance relates is not completed within five&#160;business days from the delivery of such notice to the Covered Stockholder, the Covered Stockholder&#8217;s election with respect to the purchase of New Securities covered by such Notice of Issuance shall be void and the Corporation shall be obligated to deliver a new Notice of Issuance to the Covered Stockholder, and the Covered Stockholder shall be entitled to make a new election with respect to the purchase by it of New Securities covered by such notice within the two-business day period from the date of delivery of the new Notice of Issuance and otherwise in accordance with the procedure specified in the second sentence of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;12.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;12.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if  the Corporation proposes to issue New Securities in an aggregate amount of at least $25,000,000 in a Public Offering, the Notice of Issuance may, in lieu of specifying the price at which the Corporation proposes to issue New Securities  and the number of New Securities to be issued by the Corporation in such offering, provide an estimated aggregate public offering size (in dollar amount) of the New Securities (exclusive of any Overallotment Securities, as contemplated by the following paragraph) that the Corporation estimates will ultimately be issued in such offering (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Estimated Offering Size</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and, to the extent different from the closing price per share of the Common Stock on the Nasdaq Stock Market or the principal securities exchange on which the Common Stock is then listed on the date immediately prior to the date on which the Notice of Issuance is delivered to the Covered Stockholder pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.01(c),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> an estimated public offering price per New Security (such closing price of the Common Stock or, if specified in such Issuance Notice, the estimated price per New Security so specified, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Estimated Offering Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). If the Covered Stockholder desires to exercise its rights under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;12.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with respect to such Public Offering, the Covered Stockholder shall be required to make an election with respect to the purchase, at the public offering price in such Public Offering, of a dollar amount of New Securities up to its Pro Rata Share of the Estimated Offering Size no later than two business days from the date of receipt of the Notice of Issuance (which period shall be reduced to one business day if, prior to delivery of such Notice of Issuance, such Covered Stockholder, to the extent requested by the Corporation, had not entered into a customary agreement reasonably satisfactory to the Corporation requiring that the Covered Stockholder maintain the confidentiality of the proposed Public Offering unless and until publicly announced by the Corporation)&#59;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that the Covered Stockholder&#8217;s obligation to purchase the dollar amount of New Securities subject to its election shall be conditioned upon (i)&#160;the issuance by the Corporation of New Securities in such Public Offering at an aggregate public offering </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">price of at least 85% and no more than 115% of the Estimated Offering Size and (ii)&#160;the New Securities so issued being priced not higher than 15% above the Estimated Offering Price. For clarity, in the event the Covered Stockholder does not purchase the dollar amount of New Securities subject to its election in reliance upon the foregoing proviso, the Covered Stockholder shall be deemed to have chosen not to exercise its rights under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with respect to such Public Offering.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any Notice of Issuance provided by the Corporation to the Covered Stockholder in connection with a Public Offering may specify that the underwriters or agents in such offering shall be entitled to purchase upon exercise of an overallotment option, if any, additional New Securities in an amount up to 15% of the New Securities issued in such Public Offering (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Overallotment Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). If the Covered Stockholder desires to exercise its rights under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;12.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with respect to Overallotment Securities, the Covered Stockholder shall be required to make an election with respect to the purchase of up to its Pro Rata Share of the Overallotment Securities at the same time the Covered Stockholder makes an election pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.01(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that the Covered Stockholder&#8217;s obligation to purchase Overallotment Securities in accordance with its election shall be subject to the same conditions to which its obligations to purchase New Securities in the Public Offering, before giving effect to such Overallotment Securities, are subject.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a Public Offering contemplated by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;12.01(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is not completed within five&#160;business days following the Notice of Issuance with respect thereto, then the Corporation will be required to comply again with the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">12.01(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in order to avail itself of the benefits of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;12.01(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In case a Public Offering contemplated by this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;12.01(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is consummated, the Covered Stockholder shall be obligated to purchase the New Securities which it has elected to purchase hereunder at the closing of such Public Offering if and to the extent the conditions to the Covered Stockholder&#8217;s obligations hereunder are met, on the same terms and subject to the same conditions that would be applicable to the underwriters in such offering&#59;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">however,&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that (i)&#160;such terms and conditions applicable to the Covered Stockholder shall not include any restrictions on the transferability of such New Securities (except pursuant to applicable laws and regulations) or any standstill, voting or other restrictions,, (ii)&#160;the Covered Stockholder shall not be required to make any representations and warranties except those that relate solely to the Covered Stockholder and (iii)&#160;the Covered Stockholder shall not be required to undertake any indemnity obligations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding any other provision of this section, the Corporation may, in lieu of allowing the Covered Stockholder to participate in a Public Offering in fulfillment of its rights under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.01(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, offer instead to issue and sell to the Covered Stockholder up to a number of New Securities equal to the Covered Stockholder&#8217;s Pro Rata Share of the New Securities issued in such Public Offering in a concurrent private placement on terms reasonably acceptable to both parties and at a price equal to the price at which the New Securities are sold to the public in the Public Offering.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 12.02.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Approval of the Covered Stockholder Required for Certain Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition to any approval by the Board of Directors required by this Certificate of Incorporation, the Bylaws, applicable laws and regulations or Nasdaq Stock Market, the prior written approval of the Covered Stockholder shall be required in order for the Corporation to take, or the Board of Directors to approve, authorize or effect, any of the following (including by merger, consolidation or otherwise)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;the creation (by reclassification or otherwise) or issuance of any new class or series of shares of capital stock of the Corporation (or securities convertible into or exercisable for shares of capital stock of the Corporation) having rights, preferences or privileges senior to or on parity with the Common Stock&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;any action to repurchase, retire, redeem or otherwise acquire any equity securities (or securities convertible into or exchangeable for equity securities) of the Corporation or any subsidiary of the Corporation, pursuant to self-tender offers, stock repurchase programs, open market transactions, privately-negotiated purchases or similar transactions&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that no consent of the Covered Stockholder pursuant to this section shall be required in connection with the repurchase, retirement, redemption or other acquisition by the Corporation of securities issued or issuable upon any exercise of options or vesting or exercise of any other equity-based award, in each case under the Corporation&#8217;s equity incentive plans or any other plan or agreement approved by the Board of Directors, to pay the applicable exercise price or taxes associated with such awards&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;take any action to adopt, or propose to adopt, or maintain any shareholders&#8217; rights plan, &#8220;poison pill&#8221; or other similar plan or agreement, unless the Covered Stockholder is exempt from the provisions of such shareholders&#8217; rights plan, &#8220;poison pill&#8221; or other similar plan or agreement&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;any authorization of, or entering into an agreement for, or the commitment to agree to take, any of the foregoing actions.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 12.03&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For purposes of this Article XII&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Covered Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a person that is the beneficial owner of 20% or more of the Corporation&#8217;s outstanding Common Stock as reflected in the person&#8217;s most recent filings under section 13 of the Securities Exchange Act of 1934, as amended, and that continues to be the beneficial owner of more than 20% of the Corporation&#8217;s Common Stock immediately prior to the time of the transaction or event to which the Covered Stockholder is entitled to rights under this Article XII&#59; provided that for a person to be considered a &#8220;Covered Stockholder,&#8221; such person must send a written notice to the Corporation at its corporate offices, which notice must contain the number of shares of Common Stock beneficially owned by such person and the notice information, which must include a valid email address, at which such person may be reached for purposes of this Article XII. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">New Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any capital stock of the Corporation, whether now authorized or not, and rights, options or warrants to purchase such capital stock, and securities of any type whatsoever (including convertible debt securities) that are, or may become, convertible into or exchangeable or exercisable for capital stock of the Corporation&#59;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that the term &#8220;New Securities&#8221; does not include (a)&#160;Common Stock or rights, options or warrants to acquire Common Stock of the Corporation issued to employees, consultants, officers or directors of the Corporation or any Subsidiary, or which have been reserved for issuance, pursuant to an employee stock option, stock purchase, stock bonus plan, or other similar compensation plan or arrangement approved by the Board of Directors, (b)&#160;securities of the Corporation issued to all then-existing stockholders in connection with any stock split, stock dividend, reclassification or recapitalization of the Corporation, (c) securities of the Corporation issued upon the conversion or exercise of exchangeable or convertible securities of the Corporation, including warrants and convertible notes, that are (i) outstanding as of the date of this Certificate of Incorporation of the Corporation or (ii) issued subsequently after receipt of the consent of the Covered Stockholder pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (d) securities of the Corporation issued as consideration in the acquisition of business or assets of another person, (e) Common Stock not otherwise contemplated by the foregoing clauses (a) through (d) issued in a given fiscal year pursuant to an &#8220;at the market&#8221; offering in an amount that does not exceed, in the aggregate, 2% of the outstanding Common Stock of the Corporation calculated as of the end of the preceding fiscal year, and (g)&#160;securities of the Corporation issued in connection with a transaction of the type described in Rule&#160;145 under the Securities Act of 1933, as amended. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Public Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an underwritten public offering of New Securities that is registered under the Securities Act of 1933, as amended.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, this Fifth Amended and Restated Certificate of Incorporation has been executed for and on behalf and in the name of the Corporation by its officers thereunto duly authorized on May 20, 2022.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LEXICON PHARMACEUTICALS, INC.</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:256.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lonnel Coats</font></div><div style="margin-bottom:30pt;padding-left:256.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chief Executive Officer</font></div><div style="margin-bottom:24pt;padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attest&#58;</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:256.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brian T. Crum</font></div><div style="padding-left:256.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Secretary</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exh311certificationofprinc.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ifdfc7826d0cd438f833677ad68a32ad8_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Lonnel Coats, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Lexicon Pharmaceuticals, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;  </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;3, 2022 </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:46.599%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.201%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Lonnel Coats</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonnel Coats</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>exh312certificationofprinc.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6a2a42c2ec7748d98c86b674ff2a9a5a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jeffrey L. Wade, certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Lexicon Pharmaceuticals, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;  </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;3, 2022 </font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.023%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey L. Wade</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey L. Wade</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Financial Officer</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>exh321certificationofprinc.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3244ea0cc2b84ca4864290ee3dcec256_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350, as adopted), Lonnel Coats, Principal Executive Officer of Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221;), and Jeffrey L. Wade, Principal Financial Officer of Lexicon, each hereby certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Lexicon's Quarterly Report on Form 10-Q for the period ended June&#160;30, 2022, and to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of section 13(a) or section 15(d) of the Securities Exchange Act of 1934, and </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of Lexicon. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 3rd day of August, 2022.</font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.432%"><tr><td style="width:1.0%"></td><td style="width:7.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.833%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Lonnel Coats</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonnel Coats</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.286%"><tr><td style="width:1.0%"></td><td style="width:8.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.550%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey L. Wade</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey L. Wade</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Financial Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>lxrx-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b429ed1f-e365-4ee0-b706-413f731644e3,g:a8252b48-0582-489a-8246-eed3b4e2cfac-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lxrx="http://www.lexpharma.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lexpharma.com/20220630">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.lexpharma.com/role/DocumentandEntityInformation">
        <link:definition>0001001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsUnaudited" roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets-Unaudited</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParentheticals" roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets Parentheticals</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLossUnaudited" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited">
        <link:definition>1003004 - Statement - Consolidated Statements of Comprehensive Loss-Unaudited</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLossParentheticals" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals">
        <link:definition>1004005 - Statement - Consolidated Statements of Comprehensive Loss Parentheticals</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1005006 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited">
        <link:definition>1006007 - Statement - Consolidated Statements of Stockholders' Equity/Deficit-Unaudited</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNotes" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes">
        <link:definition>2101101 - Disclosure - Summary of Significant Accounting Policies (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables">
        <link:definition>2303301 - Disclosure - Summary of Significant Accounting Policies Equity Incentive Awards (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails">
        <link:definition>2404401 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1">
        <link:definition>2405402 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2">
        <link:definition>2406403 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails">
        <link:definition>2407404 - Disclosure - Summary of Significant Accounting Policies Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails">
        <link:definition>2408405 - Disclosure - Summary of Significant Accounting Policies Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAccountingPronouncementsLevel1Notes" roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes">
        <link:definition>2109102 - Disclosure - Recent Accounting Pronouncements Level 1 (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestments" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments">
        <link:definition>2110103 - Disclosure - Cash and Cash Equivalents and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestmentsTables" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables">
        <link:definition>2311302 - Disclosure - Cash and Cash Equivalents and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestmentsDetails1" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1">
        <link:definition>2412406 - Disclosure - Cash and Cash Equivalents and Investments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestmentsDetails2" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2">
        <link:definition>2413407 - Disclosure - Cash and Cash Equivalents and Investments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.lexpharma.com/role/FairValueMeasurements">
        <link:definition>2114104 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables">
        <link:definition>2315303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1">
        <link:definition>2416408 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligations" roleURI="http://www.lexpharma.com/role/DebtObligations">
        <link:definition>2117105 - Disclosure - Debt Obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligationsTables" roleURI="http://www.lexpharma.com/role/DebtObligationsTables">
        <link:definition>2318304 - Disclosure - Debt Obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligationsDetails" roleURI="http://www.lexpharma.com/role/DebtObligationsDetails">
        <link:definition>2419409 - Disclosure - Debt Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.lexpharma.com/role/CommitmentsandContingencies">
        <link:definition>2120106 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails">
        <link:definition>2421410 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreements" roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreements">
        <link:definition>2122107 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsTables" roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsTables">
        <link:definition>2323305 - Disclosure - Collaboration and License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsDetails" roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails">
        <link:definition>2424411 - Disclosure - Collaboration and License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCapitalAgreements" roleURI="http://www.lexpharma.com/role/OtherCapitalAgreements">
        <link:definition>2125108 - Disclosure - Other Capital Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCapitalAgreementsDetails" roleURI="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails">
        <link:definition>2426412 - Disclosure - Other Capital Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCapitalAgreementsDetails_1" roleURI="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails_1">
        <link:definition>2427413 - Disclosure - Other Capital Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_SharesSoldInSeptember2021ATMOfferring" abstract="false" name="SharesSoldInSeptember2021ATMOfferring" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_FutureConvertibleDebtExchange" abstract="false" name="FutureConvertibleDebtExchange" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_AccruedInterestOnConvertible" abstract="false" name="AccruedInterestOnConvertible" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharePriceInNovember20ATMOffering" abstract="false" name="SharePriceInNovember20ATMOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharePriceInJuly2022Offering" abstract="false" name="SharePriceInJuly2022Offering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_FinalPaymentWithNoExtention" abstract="false" name="FinalPaymentWithNoExtention" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_IpsenMilestonePaymentReceived" abstract="false" name="IpsenMilestonePaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_LiabilitiesAssumedByTerSera" abstract="false" name="LiabilitiesAssumedByTerSera" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" abstract="false" name="ConvertibleDebtExchangeTotalPrincipalAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConvertibleDebtExchangeSeptemberSharePayment" abstract="false" name="ConvertibleDebtExchangeSeptemberSharePayment" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_A2027OxfordPrincipalPayments" abstract="false" name="A2027OxfordPrincipalPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConsolidatedStatementsOfOperationsAbstract" abstract="true" name="ConsolidatedStatementsOfOperationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_TermLoanC" abstract="false" name="TermLoanC" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConvertibleDebtExchangeRemainingNotes" abstract="false" name="ConvertibleDebtExchangeRemainingNotes" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanADebtIssuanceCosts" abstract="false" name="TermLoanADebtIssuanceCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_FinalPaymentWithExtention" abstract="false" name="FinalPaymentWithExtention" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_TermLoanDWarrant" abstract="false" name="TermLoanDWarrant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_ConvertibleDebtExchangeSeptemberCashPortion" abstract="false" name="ConvertibleDebtExchangeSeptemberCashPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanAWarrantExercisePrice" abstract="false" name="TermLoanAWarrantExercisePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="lxrx_CollaborationAndLicenseAgreementsAbstract" abstract="true" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_IpsenRevenueRecognized" abstract="false" name="IpsenRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SanofiDisputedCosts" abstract="false" name="SanofiDisputedCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ProceedsFromJuly2022Offering" abstract="false" name="ProceedsFromJuly2022Offering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanAFinalPayment" abstract="false" name="TermLoanAFinalPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" abstract="true" name="ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_Netproductrevenue" abstract="false" name="Netproductrevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" abstract="false" name="StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" abstract="true" name="CashAndCashEquivalentsAndInvestmentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_LexiconIncrementalBorrowingRate" abstract="false" name="LexiconIncrementalBorrowingRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_ConvertibleDebtExchange" abstract="false" name="ConvertibleDebtExchange" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_IpsenTotalPayments" abstract="false" name="IpsenTotalPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_RecentAccountingPronouncementsAbstract" abstract="true" name="RecentAccountingPronouncementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_OtherCapitalAgreementsTextBlock" abstract="false" name="OtherCapitalAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lxrx_FutureConvertibleDebtExchangeShares" abstract="false" name="FutureConvertibleDebtExchangeShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_AccruedLiabilitiesDomain" abstract="true" name="AccruedLiabilitiesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lxrx_SanofiRevenueRecognized" abstract="false" name="SanofiRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_GainOnSaleOfNonFinancialAssets" abstract="false" name="GainOnSaleOfNonFinancialAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_AccruedCompensationAndBenefitsCurrent" abstract="false" name="AccruedCompensationAndBenefitsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConsolidatedBalanceSheetsAbstract" abstract="true" name="ConsolidatedBalanceSheetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_A2026OxfordPrincipalPayments" abstract="false" name="A2026OxfordPrincipalPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SummaryOfSignificantAccountingPoliciesAbstract" abstract="true" name="SummaryOfSignificantAccountingPoliciesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_Lxrx_sanofiInitialCashPayment" abstract="false" name="Lxrx_sanofiInitialCashPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_IpsenMilestonePayment" abstract="false" name="IpsenMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" abstract="false" name="Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_AccruedLiabilitiesTable" abstract="true" name="AccruedLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_DebtObligationsAbstract" abstract="true" name="DebtObligationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_Lxrx_Sanofiterminationcashpayment" abstract="false" name="Lxrx_Sanofiterminationcashpayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharesSoldInJanuary2021ATMOffering" abstract="false" name="SharesSoldInJanuary2021ATMOffering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_InitialRecognitionOfRightOfUseAsset" abstract="false" name="InitialRecognitionOfRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" abstract="false" name="IpsenRevenueAllocatedtoDevelopmentDeliverable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConvDebtInstrumentInterestRateStatedPercentage" abstract="false" name="ConvDebtInstrumentInterestRateStatedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_IpsenMaximumSalesMilestones" abstract="false" name="IpsenMaximumSalesMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lxrx_OxfordFacilityFee" abstract="false" name="OxfordFacilityFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SettlementPaymentFromTermination" abstract="false" name="SettlementPaymentFromTermination" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanCWarrant" abstract="false" name="TermLoanCWarrant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_SharesSoldInJuly2022Offering" abstract="false" name="SharesSoldInJuly2022Offering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_TermLoanADebtDiscount" abstract="false" name="TermLoanADebtDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanAInterestExpense" abstract="false" name="TermLoanAInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanABWarrant" abstract="false" name="TermLoanABWarrant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_TermLoanANetCashReceipt" abstract="false" name="TermLoanANetCashReceipt" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_ProceedsFromJanuary2021ATMOffering" abstract="false" name="ProceedsFromJanuary2021ATMOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_PrincipalAmountOfConvertibleNotes" abstract="false" name="PrincipalAmountOfConvertibleNotes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ATMOfferingTotal" abstract="false" name="ATMOfferingTotal" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_FairValueMeasurementsAbstract" abstract="true" name="FairValueMeasurementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_AccruedLiabilitiesAxis" abstract="true" name="AccruedLiabilitiesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lxrx_TermLoanD" abstract="false" name="TermLoanD" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharePriceInJanuary2021ATMOffering" abstract="false" name="SharePriceInJanuary2021ATMOffering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" abstract="true" name="ConsolidatedStatementsOfStockholdersEquityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_AccruedLiabilitiesLineItems" abstract="true" name="AccruedLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ProceedsFromSeptember2021ATMOffering" abstract="false" name="ProceedsFromSeptember2021ATMOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_A2025OxfordPrincipalPayments" abstract="false" name="A2025OxfordPrincipalPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanA" abstract="false" name="TermLoanA" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ProceedsFromNov2020ATMOffering" abstract="false" name="ProceedsFromNov2020ATMOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanB" abstract="false" name="TermLoanB" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_AccruedResearchAndDevelopmentServicesCurrent" abstract="false" name="AccruedResearchAndDevelopmentServicesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_OxfordLoanFacility" abstract="false" name="OxfordLoanFacility" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharesSoldInNov2020ATMOffering" abstract="false" name="SharesSoldInNov2020ATMOffering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_SharePriceInSeptember2021ATMOfferring" abstract="false" name="SharePriceInSeptember2021ATMOfferring" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_Sellinggeneralandadministrativeexpenses" abstract="false" name="Sellinggeneralandadministrativeexpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanAWarrantsNumber" abstract="false" name="TermLoanAWarrantsNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>lxrx-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b429ed1f-e365-4ee0-b706-413f731644e3,g:a8252b48-0582-489a-8246-eed3b4e2cfac-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="lxrx-20220630.xsd#ConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7bb0d4fd-7563-47c9-b7ed-5c7ce789d460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0209a2db-1a4f-49b9-b0f8-edb5680c0529" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7bb0d4fd-7563-47c9-b7ed-5c7ce789d460" xlink:to="loc_us-gaap_AssetsCurrent_0209a2db-1a4f-49b9-b0f8-edb5680c0529" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fc0e7242-1085-497e-a0f8-8fb091008ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7bb0d4fd-7563-47c9-b7ed-5c7ce789d460" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fc0e7242-1085-497e-a0f8-8fb091008ab4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f7d50894-40ec-460d-b8d8-0cf9c75e015a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7bb0d4fd-7563-47c9-b7ed-5c7ce789d460" xlink:to="loc_us-gaap_Goodwill_f7d50894-40ec-460d-b8d8-0cf9c75e015a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1385bda2-ed55-4f30-bd62-621787583da0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7bb0d4fd-7563-47c9-b7ed-5c7ce789d460" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1385bda2-ed55-4f30-bd62-621787583da0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6f0d0562-437f-4c6b-bf92-d81bd6f47d45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e29ee4f4-c815-4c83-90e1-c55bb9388033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6f0d0562-437f-4c6b-bf92-d81bd6f47d45" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e29ee4f4-c815-4c83-90e1-c55bb9388033" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_fa5ac5a9-5fa8-4faa-b437-c7da529579b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6f0d0562-437f-4c6b-bf92-d81bd6f47d45" xlink:to="loc_us-gaap_ShortTermInvestments_fa5ac5a9-5fa8-4faa-b437-c7da529579b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a1ceffe8-8ec7-4079-9682-484fd03ef5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6f0d0562-437f-4c6b-bf92-d81bd6f47d45" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a1ceffe8-8ec7-4079-9682-484fd03ef5a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_a6cae131-f43b-45ac-a28e-a11d7ba841cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6f0d0562-437f-4c6b-bf92-d81bd6f47d45" xlink:to="loc_us-gaap_OtherAssetsCurrent_a6cae131-f43b-45ac-a28e-a11d7ba841cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_fc97d238-3062-4847-8829-ed1af56ed272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6bf4f2b7-00f1-46db-98d4-de5dcafce013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fc97d238-3062-4847-8829-ed1af56ed272" xlink:to="loc_us-gaap_Liabilities_6bf4f2b7-00f1-46db-98d4-de5dcafce013" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dc56d0b5-d674-445b-a97e-9edccb2459fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fc97d238-3062-4847-8829-ed1af56ed272" xlink:to="loc_us-gaap_StockholdersEquity_dc56d0b5-d674-445b-a97e-9edccb2459fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_eccc6b72-126f-4a8f-be82-d2108537a32a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_aeefbf3c-732c-48d6-a75e-02b555162e24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_eccc6b72-126f-4a8f-be82-d2108537a32a" xlink:to="loc_us-gaap_PreferredStockValue_aeefbf3c-732c-48d6-a75e-02b555162e24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_24e4bd9e-3224-4d4f-8a5b-d199c868c795" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_eccc6b72-126f-4a8f-be82-d2108537a32a" xlink:to="loc_us-gaap_CommonStockValue_24e4bd9e-3224-4d4f-8a5b-d199c868c795" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_0a390c39-cdfe-4c90-a5a5-56f2f8c0ddf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_eccc6b72-126f-4a8f-be82-d2108537a32a" xlink:to="loc_us-gaap_AdditionalPaidInCapital_0a390c39-cdfe-4c90-a5a5-56f2f8c0ddf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_52cd5d92-b010-4f28-8077-b51e06a83c31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_eccc6b72-126f-4a8f-be82-d2108537a32a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_52cd5d92-b010-4f28-8077-b51e06a83c31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3f54e1eb-2c64-41e1-ae1c-ad93e7536694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_eccc6b72-126f-4a8f-be82-d2108537a32a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3f54e1eb-2c64-41e1-ae1c-ad93e7536694" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_50d8e266-ee4f-4887-ac38-20c576c9aa3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_eccc6b72-126f-4a8f-be82-d2108537a32a" xlink:to="loc_us-gaap_TreasuryStockValue_50d8e266-ee4f-4887-ac38-20c576c9aa3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_eab3507f-e7e1-4840-8daa-21aefef0fdef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_60b0353f-40eb-42bc-a1ac-696fb4e43f91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_eab3507f-e7e1-4840-8daa-21aefef0fdef" xlink:to="loc_us-gaap_AccountsPayableCurrent_60b0353f-40eb-42bc-a1ac-696fb4e43f91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_cba76332-0f12-4a0f-987f-6b0a8c8728b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_eab3507f-e7e1-4840-8daa-21aefef0fdef" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_cba76332-0f12-4a0f-987f-6b0a8c8728b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_92974f44-ba4d-4d9a-9c01-7404585864b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_eab3507f-e7e1-4840-8daa-21aefef0fdef" xlink:to="loc_us-gaap_LongTermDebtCurrent_92974f44-ba4d-4d9a-9c01-7404585864b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5e7302fe-46bc-4661-9789-7a43d61d8b26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_02c4e7be-8c8c-4689-9480-dfcd004c169c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5e7302fe-46bc-4661-9789-7a43d61d8b26" xlink:to="loc_us-gaap_LiabilitiesCurrent_02c4e7be-8c8c-4689-9480-dfcd004c169c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ac67c9fc-ea65-4642-b710-f79335e1b740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5e7302fe-46bc-4661-9789-7a43d61d8b26" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ac67c9fc-ea65-4642-b710-f79335e1b740" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_59fd8a83-e8e0-47fd-bae9-a60ce007e571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5e7302fe-46bc-4661-9789-7a43d61d8b26" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_59fd8a83-e8e0-47fd-bae9-a60ce007e571" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="lxrx-20220630.xsd#ConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_876ec03a-df7b-4df2-a455-b6ce7714396f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_99abc3b2-4552-4366-9fcd-0d6bcacf6efa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_876ec03a-df7b-4df2-a455-b6ce7714396f" xlink:to="loc_us-gaap_Revenues_99abc3b2-4552-4366-9fcd-0d6bcacf6efa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_aa49a3ac-3b3d-47e0-b8a5-ae7d604062ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_876ec03a-df7b-4df2-a455-b6ce7714396f" xlink:to="loc_us-gaap_OperatingExpenses_aa49a3ac-3b3d-47e0-b8a5-ae7d604062ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_30a5471f-7ab1-46ca-96c7-cd945bbb3b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c2a02e75-d479-46a9-831e-dd8d9768e2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_30a5471f-7ab1-46ca-96c7-cd945bbb3b0f" xlink:to="loc_us-gaap_NetIncomeLoss_c2a02e75-d479-46a9-831e-dd8d9768e2bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b294d230-b879-45dc-badc-6ac3dd52e9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_30a5471f-7ab1-46ca-96c7-cd945bbb3b0f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b294d230-b879-45dc-badc-6ac3dd52e9c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_044cc381-cb31-4c76-91c6-e5e3c9f16920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d30bf7a1-afe2-44d7-8c14-443c3d549889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_044cc381-cb31-4c76-91c6-e5e3c9f16920" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d30bf7a1-afe2-44d7-8c14-443c3d549889" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Sellinggeneralandadministrativeexpenses_4f790668-a08a-4f27-80cf-f475500af9fa" xlink:href="lxrx-20220630.xsd#lxrx_Sellinggeneralandadministrativeexpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_044cc381-cb31-4c76-91c6-e5e3c9f16920" xlink:to="loc_lxrx_Sellinggeneralandadministrativeexpenses_4f790668-a08a-4f27-80cf-f475500af9fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c5a85864-d55d-4cdb-b6bf-b7688f7c1dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Netproductrevenue_38145737-9487-4acd-aa64-5ba1806fef57" xlink:href="lxrx-20220630.xsd#lxrx_Netproductrevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_c5a85864-d55d-4cdb-b6bf-b7688f7c1dbd" xlink:to="loc_lxrx_Netproductrevenue_38145737-9487-4acd-aa64-5ba1806fef57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f66f42c2-6e97-4791-9c40-f9b2199a9e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_c5a85864-d55d-4cdb-b6bf-b7688f7c1dbd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f66f42c2-6e97-4791-9c40-f9b2199a9e19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_5f8b064a-d8c4-4bb2-8660-d74b23582e02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_c5a85864-d55d-4cdb-b6bf-b7688f7c1dbd" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_5f8b064a-d8c4-4bb2-8660-d74b23582e02" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="lxrx-20220630.xsd#ConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_df59d330-d076-46e9-b64c-f0bbb027247c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfabb645-7a8c-46b8-a791-c7abc94330e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_df59d330-d076-46e9-b64c-f0bbb027247c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfabb645-7a8c-46b8-a791-c7abc94330e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7db95467-f22b-4d2a-9e75-392f34aa1c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_df59d330-d076-46e9-b64c-f0bbb027247c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7db95467-f22b-4d2a-9e75-392f34aa1c1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e98bebee-bcdc-4bfc-a29f-2ce1b8abba7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_df59d330-d076-46e9-b64c-f0bbb027247c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e98bebee-bcdc-4bfc-a29f-2ce1b8abba7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9bd002d1-dbae-480d-b0b1-622930f90cad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_015d5a8e-74ef-4df4-a159-1d2b64b10b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9bd002d1-dbae-480d-b0b1-622930f90cad" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_015d5a8e-74ef-4df4-a159-1d2b64b10b2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_6ec902b1-935f-4879-aed9-cede407a9b43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9bd002d1-dbae-480d-b0b1-622930f90cad" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_6ec902b1-935f-4879-aed9-cede407a9b43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_5a72538d-0282-4280-bf29-53c6a89b9488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9bd002d1-dbae-480d-b0b1-622930f90cad" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_5a72538d-0282-4280-bf29-53c6a89b9488" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_8f655001-0401-44d6-9b34-3ebc856c3f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9bd002d1-dbae-480d-b0b1-622930f90cad" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_8f655001-0401-44d6-9b34-3ebc856c3f7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_708abae6-ad43-461f-a3b8-c6e4f96826c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c33fd51e-afe4-4c99-af62-da7ed93fc1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_708abae6-ad43-461f-a3b8-c6e4f96826c7" xlink:to="loc_us-gaap_ShareBasedCompensation_c33fd51e-afe4-4c99-af62-da7ed93fc1b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_87fdf720-8084-4adf-8d51-7d3082ea0901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_708abae6-ad43-461f-a3b8-c6e4f96826c7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_87fdf720-8084-4adf-8d51-7d3082ea0901" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_397e66bc-d584-446b-8f05-0e37cc0421f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_708abae6-ad43-461f-a3b8-c6e4f96826c7" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_397e66bc-d584-446b-8f05-0e37cc0421f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_20e25a16-64a8-42f2-9911-07cfa7dad19d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_708abae6-ad43-461f-a3b8-c6e4f96826c7" xlink:to="loc_us-gaap_AssetImpairmentCharges_20e25a16-64a8-42f2-9911-07cfa7dad19d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_4497852d-8d69-4071-b90d-71b6128350a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_708abae6-ad43-461f-a3b8-c6e4f96826c7" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_4497852d-8d69-4071-b90d-71b6128350a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1e0cb1b4-abc1-4929-b6be-897e171902fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_708abae6-ad43-461f-a3b8-c6e4f96826c7" xlink:to="loc_us-gaap_NetIncomeLoss_1e0cb1b4-abc1-4929-b6be-897e171902fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_cc22d51d-e9b7-45d4-bebc-11432640ca2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_708abae6-ad43-461f-a3b8-c6e4f96826c7" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_cc22d51d-e9b7-45d4-bebc-11432640ca2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_461ab921-8958-45d3-8146-71722743d171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_708abae6-ad43-461f-a3b8-c6e4f96826c7" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_461ab921-8958-45d3-8146-71722743d171" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_eca7cb5e-cafe-42a0-951a-f022b85e30de" xlink:href="lxrx-20220630.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_708abae6-ad43-461f-a3b8-c6e4f96826c7" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_eca7cb5e-cafe-42a0-951a-f022b85e30de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_af1e0a22-e26d-4c95-9fbc-c5b8240a95f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_708abae6-ad43-461f-a3b8-c6e4f96826c7" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_af1e0a22-e26d-4c95-9fbc-c5b8240a95f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_128edd76-2293-42da-800a-92196abd2820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_708abae6-ad43-461f-a3b8-c6e4f96826c7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_128edd76-2293-42da-800a-92196abd2820" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4c527492-ddf5-4116-8c6a-0c018c6a7dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_708abae6-ad43-461f-a3b8-c6e4f96826c7" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4c527492-ddf5-4116-8c6a-0c018c6a7dbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0f4330f-ad9a-4d1b-b4b6-a097a58fa9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b162bd0a-9618-4a16-a4ee-eb008befff02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0f4330f-ad9a-4d1b-b4b6-a097a58fa9ae" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b162bd0a-9618-4a16-a4ee-eb008befff02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_77af38db-bfcd-4a8b-8c12-32bd7627d730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0f4330f-ad9a-4d1b-b4b6-a097a58fa9ae" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_77af38db-bfcd-4a8b-8c12-32bd7627d730" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_94c47a79-89e5-425c-bf75-b743f5c9860a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0f4330f-ad9a-4d1b-b4b6-a097a58fa9ae" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_94c47a79-89e5-425c-bf75-b743f5c9860a" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>lxrx-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b429ed1f-e365-4ee0-b706-413f731644e3,g:a8252b48-0582-489a-8246-eed3b4e2cfac-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="lxrx-20220630.xsd#ConsolidatedBalanceSheetsUnaudited"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="extended" id="i8f1c7761bba246eebdb1716a3236e65d_ConsolidatedBalanceSheetsUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0c86062b-b016-4722-bd32-51719ecf25c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_e4a6d208-3136-45fe-a1b4-4694ef0f1c64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c86062b-b016-4722-bd32-51719ecf25c9" xlink:to="loc_us-gaap_AssetsCurrentAbstract_e4a6d208-3136-45fe-a1b4-4694ef0f1c64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f46aae83-4b22-46ed-8dd3-dd7864865cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e4a6d208-3136-45fe-a1b4-4694ef0f1c64" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f46aae83-4b22-46ed-8dd3-dd7864865cbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_c70a5494-cc70-4346-a5f2-d143e6afd7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e4a6d208-3136-45fe-a1b4-4694ef0f1c64" xlink:to="loc_us-gaap_ShortTermInvestments_c70a5494-cc70-4346-a5f2-d143e6afd7b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5dfa00db-c448-4ae1-94df-1718f49f1da0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e4a6d208-3136-45fe-a1b4-4694ef0f1c64" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5dfa00db-c448-4ae1-94df-1718f49f1da0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_8d40c42d-07c6-40ba-bd8d-843a549c1976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e4a6d208-3136-45fe-a1b4-4694ef0f1c64" xlink:to="loc_us-gaap_OtherAssetsCurrent_8d40c42d-07c6-40ba-bd8d-843a549c1976" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2a216622-7b57-48ed-b182-0ed92a017328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e4a6d208-3136-45fe-a1b4-4694ef0f1c64" xlink:to="loc_us-gaap_AssetsCurrent_2a216622-7b57-48ed-b182-0ed92a017328" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d3b0cb88-a87b-4455-bc9e-32369683ed63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c86062b-b016-4722-bd32-51719ecf25c9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d3b0cb88-a87b-4455-bc9e-32369683ed63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_493dc247-1061-41c5-ab21-2e80dc7afc53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c86062b-b016-4722-bd32-51719ecf25c9" xlink:to="loc_us-gaap_Goodwill_493dc247-1061-41c5-ab21-2e80dc7afc53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1a4f9eb7-797d-48d0-9836-8f2d8a8340d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c86062b-b016-4722-bd32-51719ecf25c9" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1a4f9eb7-797d-48d0-9836-8f2d8a8340d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_bd8cda3f-62e8-4a71-939d-fae1d0eb3ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c86062b-b016-4722-bd32-51719ecf25c9" xlink:to="loc_us-gaap_Assets_bd8cda3f-62e8-4a71-939d-fae1d0eb3ad0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_073b2a7c-3e99-4c25-88b3-8d610f2dd3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c86062b-b016-4722-bd32-51719ecf25c9" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_073b2a7c-3e99-4c25-88b3-8d610f2dd3ba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8d2097b6-6568-429e-a33a-681fe68008f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_073b2a7c-3e99-4c25-88b3-8d610f2dd3ba" xlink:to="loc_us-gaap_AccountsPayableCurrent_8d2097b6-6568-429e-a33a-681fe68008f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1e0a3129-c162-4051-8279-19d6f103fe8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_073b2a7c-3e99-4c25-88b3-8d610f2dd3ba" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1e0a3129-c162-4051-8279-19d6f103fe8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_62aca060-ec7e-4f74-b931-d8eb0aa55893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_073b2a7c-3e99-4c25-88b3-8d610f2dd3ba" xlink:to="loc_us-gaap_LongTermDebtCurrent_62aca060-ec7e-4f74-b931-d8eb0aa55893" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_cd7cf309-4153-4562-b757-ab3862a67b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_073b2a7c-3e99-4c25-88b3-8d610f2dd3ba" xlink:to="loc_us-gaap_LiabilitiesCurrent_cd7cf309-4153-4562-b757-ab3862a67b52" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt_7eff40b5-e3c0-4f5f-b6ef-eea3b58c0c86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_073b2a7c-3e99-4c25-88b3-8d610f2dd3ba" xlink:to="loc_us-gaap_SecuredLongTermDebt_7eff40b5-e3c0-4f5f-b6ef-eea3b58c0c86" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7a9048c1-0fcf-4ca4-8164-15389e75018c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c86062b-b016-4722-bd32-51719ecf25c9" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7a9048c1-0fcf-4ca4-8164-15389e75018c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0de9bf6c-f02f-45ba-8114-c9e44d8748c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c86062b-b016-4722-bd32-51719ecf25c9" xlink:to="loc_us-gaap_Liabilities_0de9bf6c-f02f-45ba-8114-c9e44d8748c9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_d089dd92-dc3c-4275-8114-45cc822b0883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c86062b-b016-4722-bd32-51719ecf25c9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_d089dd92-dc3c-4275-8114-45cc822b0883" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_78e9dcf6-3537-41f8-a61c-aa3f6b35c990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c86062b-b016-4722-bd32-51719ecf25c9" xlink:to="loc_us-gaap_EquityAbstract_78e9dcf6-3537-41f8-a61c-aa3f6b35c990" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_6b118a98-1ab4-4a03-85b5-5d7652d95b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_78e9dcf6-3537-41f8-a61c-aa3f6b35c990" xlink:to="loc_us-gaap_PreferredStockValue_6b118a98-1ab4-4a03-85b5-5d7652d95b04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d6bccdeb-0d31-4f32-9ca1-7e821f4d936a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_78e9dcf6-3537-41f8-a61c-aa3f6b35c990" xlink:to="loc_us-gaap_CommonStockValue_d6bccdeb-0d31-4f32-9ca1-7e821f4d936a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_cd6f7a2b-bdd1-4ef7-8cfb-97c720bf9b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_78e9dcf6-3537-41f8-a61c-aa3f6b35c990" xlink:to="loc_us-gaap_AdditionalPaidInCapital_cd6f7a2b-bdd1-4ef7-8cfb-97c720bf9b34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d41b32b0-b39b-496d-8a0d-025aeab24a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_78e9dcf6-3537-41f8-a61c-aa3f6b35c990" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d41b32b0-b39b-496d-8a0d-025aeab24a2c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_228c8647-c919-4360-bdc0-e9de7db3b8eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_78e9dcf6-3537-41f8-a61c-aa3f6b35c990" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_228c8647-c919-4360-bdc0-e9de7db3b8eb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_807c1586-7ac8-42a0-8f61-bddf9d14fb40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_78e9dcf6-3537-41f8-a61c-aa3f6b35c990" xlink:to="loc_us-gaap_TreasuryStockValue_807c1586-7ac8-42a0-8f61-bddf9d14fb40" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_23005fcc-abcc-4c8d-b258-ac39a5ee2c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_78e9dcf6-3537-41f8-a61c-aa3f6b35c990" xlink:to="loc_us-gaap_StockholdersEquity_23005fcc-abcc-4c8d-b258-ac39a5ee2c5d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_97936db4-c2ea-465a-962a-10b90b73e629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c86062b-b016-4722-bd32-51719ecf25c9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_97936db4-c2ea-465a-962a-10b90b73e629" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_bfa6b837-1f66-4701-aa7e-e2a0791d2b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c86062b-b016-4722-bd32-51719ecf25c9" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_bfa6b837-1f66-4701-aa7e-e2a0791d2b8c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1b991bd3-5363-4651-af27-db2bb07bc958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0c86062b-b016-4722-bd32-51719ecf25c9" xlink:to="loc_us-gaap_StatementTable_1b991bd3-5363-4651-af27-db2bb07bc958" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_1124981f-d9c6-4b21-8792-4c6e82f11636" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1b991bd3-5363-4651-af27-db2bb07bc958" xlink:to="loc_srt_StatementScenarioAxis_1124981f-d9c6-4b21-8792-4c6e82f11636" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1124981f-d9c6-4b21-8792-4c6e82f11636_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_1124981f-d9c6-4b21-8792-4c6e82f11636" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1124981f-d9c6-4b21-8792-4c6e82f11636_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_571a8d8a-5b26-4d2d-93a1-4bebaa829474" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_1124981f-d9c6-4b21-8792-4c6e82f11636" xlink:to="loc_srt_ScenarioUnspecifiedDomain_571a8d8a-5b26-4d2d-93a1-4bebaa829474" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_af0dcc4c-1518-475c-9639-5dc5992fe8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1b991bd3-5363-4651-af27-db2bb07bc958" xlink:to="loc_us-gaap_StatementClassOfStockAxis_af0dcc4c-1518-475c-9639-5dc5992fe8a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_af0dcc4c-1518-475c-9639-5dc5992fe8a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_af0dcc4c-1518-475c-9639-5dc5992fe8a5" xlink:to="loc_us-gaap_ClassOfStockDomain_af0dcc4c-1518-475c-9639-5dc5992fe8a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5ca6f65a-ebfe-44c6-9ae1-ed7f2d7eac48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_af0dcc4c-1518-475c-9639-5dc5992fe8a5" xlink:to="loc_us-gaap_ClassOfStockDomain_5ca6f65a-ebfe-44c6-9ae1-ed7f2d7eac48" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="lxrx-20220630.xsd#ConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended" id="ic7c074e9cac343f58d2a165db2e9f968_ConsolidatedStatementsofComprehensiveLossUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_49784fb1-b0bb-4714-b5e4-ff9d2d9534f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_us-gaap_RevenuesAbstract_49784fb1-b0bb-4714-b5e4-ff9d2d9534f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Netproductrevenue_55655bbd-e731-4200-9093-23104d1c8035" xlink:href="lxrx-20220630.xsd#lxrx_Netproductrevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_49784fb1-b0bb-4714-b5e4-ff9d2d9534f3" xlink:to="loc_lxrx_Netproductrevenue_55655bbd-e731-4200-9093-23104d1c8035" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_07148494-57b8-4683-9f92-16b3f66209ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_49784fb1-b0bb-4714-b5e4-ff9d2d9534f3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_07148494-57b8-4683-9f92-16b3f66209ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_cbb48fa7-3327-432c-8d62-831d2dfa5652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_49784fb1-b0bb-4714-b5e4-ff9d2d9534f3" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_cbb48fa7-3327-432c-8d62-831d2dfa5652" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_443076d9-6dc1-461e-9107-ad467701bc2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_49784fb1-b0bb-4714-b5e4-ff9d2d9534f3" xlink:to="loc_us-gaap_Revenues_443076d9-6dc1-461e-9107-ad467701bc2d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_650e3138-aedf-4129-986b-bbc6a81a77f1" xlink:href="lxrx-20220630.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_49784fb1-b0bb-4714-b5e4-ff9d2d9534f3" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_650e3138-aedf-4129-986b-bbc6a81a77f1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_e642cc79-bf48-4564-974a-9b106ee0acd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_us-gaap_OperatingExpensesAbstract_e642cc79-bf48-4564-974a-9b106ee0acd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_cba7a722-077a-479e-9355-6e498bad5322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e642cc79-bf48-4564-974a-9b106ee0acd0" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_cba7a722-077a-479e-9355-6e498bad5322" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3757934c-3626-484e-9530-a37d5319bfb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e642cc79-bf48-4564-974a-9b106ee0acd0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3757934c-3626-484e-9530-a37d5319bfb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Sellinggeneralandadministrativeexpenses_d0ad27da-f736-4acb-8742-0407fa3a9424" xlink:href="lxrx-20220630.xsd#lxrx_Sellinggeneralandadministrativeexpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e642cc79-bf48-4564-974a-9b106ee0acd0" xlink:to="loc_lxrx_Sellinggeneralandadministrativeexpenses_d0ad27da-f736-4acb-8742-0407fa3a9424" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_e38a94b6-e646-4dfd-af75-0e89aa5d1df4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e642cc79-bf48-4564-974a-9b106ee0acd0" xlink:to="loc_us-gaap_AssetImpairmentCharges_e38a94b6-e646-4dfd-af75-0e89aa5d1df4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_70a72080-a4e6-43c8-9594-7f1c88414469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e642cc79-bf48-4564-974a-9b106ee0acd0" xlink:to="loc_us-gaap_OperatingExpenses_70a72080-a4e6-43c8-9594-7f1c88414469" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_7dad1cf0-d90c-4b40-bcac-e9591585b441" xlink:href="lxrx-20220630.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_7dad1cf0-d90c-4b40-bcac-e9591585b441" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e3bd9c76-34a9-442a-bfd2-3fd64546246d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_us-gaap_OperatingIncomeLoss_e3bd9c76-34a9-442a-bfd2-3fd64546246d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_53fc0625-82aa-4fcc-93fa-f785bf346cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_53fc0625-82aa-4fcc-93fa-f785bf346cc8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_5566a152-a335-400c-8278-1f60cf0066f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_us-gaap_InterestExpense_5566a152-a335-400c-8278-1f60cf0066f3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_086c543a-eac8-495d-9762-cde01c8afd83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_086c543a-eac8-495d-9762-cde01c8afd83" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_baff95e6-3b9a-4477-b2cf-a6822d53cd7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_us-gaap_NetIncomeLoss_baff95e6-3b9a-4477-b2cf-a6822d53cd7f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a083a79c-11c8-4916-bf3d-bba789a6f84a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_us-gaap_EarningsPerShareBasic_a083a79c-11c8-4916-bf3d-bba789a6f84a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f36b5887-37f7-4035-8f30-57b81bae6177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f36b5887-37f7-4035-8f30-57b81bae6177" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d6d18d28-07df-42ad-a312-2e6c32f2507b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d6d18d28-07df-42ad-a312-2e6c32f2507b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b6136d49-b408-4f7d-91d2-58904651495f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b6136d49-b408-4f7d-91d2-58904651495f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3fada8ed-97a9-4ef7-86e6-2a136686970d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3fada8ed-97a9-4ef7-86e6-2a136686970d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6d3bbb0a-df06-42e3-8cdc-48673457d918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_6d3bbb0a-df06-42e3-8cdc-48673457d918" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalIncomeStatementElementsAbstract_357ed768-f27f-437e-972d-da9fc0bc9b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalIncomeStatementElementsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_us-gaap_SupplementalIncomeStatementElementsAbstract_357ed768-f27f-437e-972d-da9fc0bc9b6e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_139ae493-fbed-4ded-bbd9-8d0c9f2a37f4" xlink:href="lxrx-20220630.xsd#lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalIncomeStatementElementsAbstract_357ed768-f27f-437e-972d-da9fc0bc9b6e" xlink:to="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_139ae493-fbed-4ded-bbd9-8d0c9f2a37f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_cc2eea7b-b2c2-468e-97bf-7e7b64d60631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_us-gaap_BusinessExitCosts1_cc2eea7b-b2c2-468e-97bf-7e7b64d60631" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b57dd605-964b-4824-b0b5-dc6e2dc5a9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_us-gaap_StatementTable_b57dd605-964b-4824-b0b5-dc6e2dc5a9f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_9e2c8054-7de3-45aa-8b85-a110873e6ad6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b57dd605-964b-4824-b0b5-dc6e2dc5a9f5" xlink:to="loc_srt_StatementScenarioAxis_9e2c8054-7de3-45aa-8b85-a110873e6ad6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_9e2c8054-7de3-45aa-8b85-a110873e6ad6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_9e2c8054-7de3-45aa-8b85-a110873e6ad6" xlink:to="loc_srt_ScenarioUnspecifiedDomain_9e2c8054-7de3-45aa-8b85-a110873e6ad6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_c28583f6-2d01-47ca-b91b-49d151e6554d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_9e2c8054-7de3-45aa-8b85-a110873e6ad6" xlink:to="loc_srt_ScenarioUnspecifiedDomain_c28583f6-2d01-47ca-b91b-49d151e6554d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="simple" xlink:href="lxrx-20220630.xsd#ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="extended" id="ife1be668c77e49b0b80fd0fbb6a33814_ConsolidatedStatementsofStockholdersEquityDeficitUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_43713b90-ed38-43ac-b5b3-6dbd32f27054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:to="loc_us-gaap_CommonStockSharesIssued_43713b90-ed38-43ac-b5b3-6dbd32f27054" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6222d627-b093-489b-9a24-9c5a955567b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6222d627-b093-489b-9a24-9c5a955567b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_cb71eb52-1415-4e55-a098-d6807cd90a82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_cb71eb52-1415-4e55-a098-d6807cd90a82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1bda53b3-3500-4523-95a3-480f0c049451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1bda53b3-3500-4523-95a3-480f0c049451" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_77968a00-660d-4ad9-9105-b8de82dc6f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_77968a00-660d-4ad9-9105-b8de82dc6f97" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_5e669e8c-1f30-4815-b662-c65f5358af75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_5e669e8c-1f30-4815-b662-c65f5358af75" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_1c22a1c2-f0d8-4412-b231-3d3e8dcaa9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_1c22a1c2-f0d8-4412-b231-3d3e8dcaa9c1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9a6e477a-0386-4fb6-90a2-a624295fba9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:to="loc_us-gaap_NetIncomeLoss_9a6e477a-0386-4fb6-90a2-a624295fba9a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_cedbc5d9-5ebd-434e-9419-90e84fbe67a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_cedbc5d9-5ebd-434e-9419-90e84fbe67a7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_fe311055-be8e-465f-ae08-dc01233c9bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_fe311055-be8e-465f-ae08-dc01233c9bb5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_9c0bcf58-17b8-4ac1-890c-438598712033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bbf5aac6-26ce-4f74-86bc-045730cd1b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_6cc6a73c-a166-4544-8cea-91a5b89cc71e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_6cc6a73c-a166-4544-8cea-91a5b89cc71e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_568509d9-8112-4290-9846-7638346a3702" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_568509d9-8112-4290-9846-7638346a3702" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_98749da0-6e11-4015-a014-74c23bc2c8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_98749da0-6e11-4015-a014-74c23bc2c8ba" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_08324122-75b9-4eee-b7af-f94323d95afd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_08324122-75b9-4eee-b7af-f94323d95afd" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e46f24d5-7d6d-4c63-bdbe-e8dd00ebb9b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:to="loc_us-gaap_StatementTable_e46f24d5-7d6d-4c63-bdbe-e8dd00ebb9b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_a2e799c9-4d11-4a4e-9072-d91289ee4122" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e46f24d5-7d6d-4c63-bdbe-e8dd00ebb9b0" xlink:to="loc_srt_StatementScenarioAxis_a2e799c9-4d11-4a4e-9072-d91289ee4122" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a2e799c9-4d11-4a4e-9072-d91289ee4122_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_a2e799c9-4d11-4a4e-9072-d91289ee4122" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a2e799c9-4d11-4a4e-9072-d91289ee4122_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_cce16fd7-3b6c-45fb-999e-a0313211f317" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_a2e799c9-4d11-4a4e-9072-d91289ee4122" xlink:to="loc_srt_ScenarioUnspecifiedDomain_cce16fd7-3b6c-45fb-999e-a0313211f317" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6291fa1c-7952-472e-9316-b3243130e164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e46f24d5-7d6d-4c63-bdbe-e8dd00ebb9b0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6291fa1c-7952-472e-9316-b3243130e164" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6291fa1c-7952-472e-9316-b3243130e164_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6291fa1c-7952-472e-9316-b3243130e164" xlink:to="loc_us-gaap_EquityComponentDomain_6291fa1c-7952-472e-9316-b3243130e164_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2d377a89-9c13-47f4-9839-3680529e7a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6291fa1c-7952-472e-9316-b3243130e164" xlink:to="loc_us-gaap_EquityComponentDomain_2d377a89-9c13-47f4-9839-3680529e7a7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_fe02f790-10b0-437a-9789-3a6aea2d1e14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2d377a89-9c13-47f4-9839-3680529e7a7a" xlink:to="loc_us-gaap_CommonStockMember_fe02f790-10b0-437a-9789-3a6aea2d1e14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_cfc6d2c3-d11b-4b5d-a736-9121a27a6562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2d377a89-9c13-47f4-9839-3680529e7a7a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_cfc6d2c3-d11b-4b5d-a736-9121a27a6562" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2843b2da-c732-4eb9-b94f-230667211c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2d377a89-9c13-47f4-9839-3680529e7a7a" xlink:to="loc_us-gaap_RetainedEarningsMember_2843b2da-c732-4eb9-b94f-230667211c5b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_45e071d4-f85e-4420-bb23-6f9547451ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2d377a89-9c13-47f4-9839-3680529e7a7a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_45e071d4-f85e-4420-bb23-6f9547451ee7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_9edfdc74-2112-4804-948d-e6d18ad8dd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2d377a89-9c13-47f4-9839-3680529e7a7a" xlink:to="loc_us-gaap_TreasuryStockMember_9edfdc74-2112-4804-948d-e6d18ad8dd4d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6786a67d-47de-4382-8ef1-5a75d155aa83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e46f24d5-7d6d-4c63-bdbe-e8dd00ebb9b0" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6786a67d-47de-4382-8ef1-5a75d155aa83" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6786a67d-47de-4382-8ef1-5a75d155aa83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6786a67d-47de-4382-8ef1-5a75d155aa83" xlink:to="loc_us-gaap_ClassOfStockDomain_6786a67d-47de-4382-8ef1-5a75d155aa83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6dcb2e36-84df-47a6-98a4-ebea59e32200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6786a67d-47de-4382-8ef1-5a75d155aa83" xlink:to="loc_us-gaap_ClassOfStockDomain_6dcb2e36-84df-47a6-98a4-ebea59e32200" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" xlink:type="simple" xlink:href="lxrx-20220630.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" xlink:type="extended" id="iacb12f8e8cf24e80a80ce012e254800e_SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59b889b7-9f56-4e25-bedc-d95c48c57178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_e9692fbb-5e9f-4232-97bc-e1cb7e5a0595" xlink:href="lxrx-20220630.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59b889b7-9f56-4e25-bedc-d95c48c57178" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_e9692fbb-5e9f-4232-97bc-e1cb7e5a0595" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_978f087f-bc4a-47dc-bc03-0ef3c62f1d06" xlink:href="lxrx-20220630.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59b889b7-9f56-4e25-bedc-d95c48c57178" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_978f087f-bc4a-47dc-bc03-0ef3c62f1d06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_fb6290cf-bdf1-4632-8308-3b4e704429b6" xlink:href="lxrx-20220630.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59b889b7-9f56-4e25-bedc-d95c48c57178" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_fb6290cf-bdf1-4632-8308-3b4e704429b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_9cf68706-2cdb-4408-9107-c32739b5d9d8" xlink:href="lxrx-20220630.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59b889b7-9f56-4e25-bedc-d95c48c57178" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_9cf68706-2cdb-4408-9107-c32739b5d9d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_3ad3a028-d99b-414d-a88a-50bd92004d80" xlink:href="lxrx-20220630.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59b889b7-9f56-4e25-bedc-d95c48c57178" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_3ad3a028-d99b-414d-a88a-50bd92004d80" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_867f778b-4239-4668-95da-dba012bad13b" xlink:href="lxrx-20220630.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59b889b7-9f56-4e25-bedc-d95c48c57178" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_867f778b-4239-4668-95da-dba012bad13b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_69f2049f-4ff7-4d4a-a3d8-33b26efab683" xlink:href="lxrx-20220630.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59b889b7-9f56-4e25-bedc-d95c48c57178" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_69f2049f-4ff7-4d4a-a3d8-33b26efab683" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_63daa51b-270b-4d57-b38e-171eb8f88950" xlink:href="lxrx-20220630.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59b889b7-9f56-4e25-bedc-d95c48c57178" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_63daa51b-270b-4d57-b38e-171eb8f88950" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11df94fb-c900-447f-98ca-2e664e004c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59b889b7-9f56-4e25-bedc-d95c48c57178" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11df94fb-c900-447f-98ca-2e664e004c5f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9488df0f-d121-441f-a7fb-248ea87d5dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11df94fb-c900-447f-98ca-2e664e004c5f" xlink:to="loc_us-gaap_PlanNameAxis_9488df0f-d121-441f-a7fb-248ea87d5dc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9488df0f-d121-441f-a7fb-248ea87d5dc4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_9488df0f-d121-441f-a7fb-248ea87d5dc4" xlink:to="loc_us-gaap_PlanNameDomain_9488df0f-d121-441f-a7fb-248ea87d5dc4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8102b90a-dc5a-4673-bca9-5c9310295427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_9488df0f-d121-441f-a7fb-248ea87d5dc4" xlink:to="loc_us-gaap_PlanNameDomain_8102b90a-dc5a-4673-bca9-5c9310295427" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_e4b9dff4-9151-4091-a859-426b20d8d6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11df94fb-c900-447f-98ca-2e664e004c5f" xlink:to="loc_us-gaap_AwardDateAxis_e4b9dff4-9151-4091-a859-426b20d8d6c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_e4b9dff4-9151-4091-a859-426b20d8d6c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_e4b9dff4-9151-4091-a859-426b20d8d6c6" xlink:to="loc_us-gaap_AwardDateDomain_e4b9dff4-9151-4091-a859-426b20d8d6c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_f58a71f4-2977-4e01-9650-41800f1423a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_e4b9dff4-9151-4091-a859-426b20d8d6c6" xlink:to="loc_us-gaap_AwardDateDomain_f58a71f4-2977-4e01-9650-41800f1423a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_65dc3fd5-4b9b-4f73-9b99-9c3c95118d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11df94fb-c900-447f-98ca-2e664e004c5f" xlink:to="loc_us-gaap_AwardTypeAxis_65dc3fd5-4b9b-4f73-9b99-9c3c95118d4e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65dc3fd5-4b9b-4f73-9b99-9c3c95118d4e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_65dc3fd5-4b9b-4f73-9b99-9c3c95118d4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65dc3fd5-4b9b-4f73-9b99-9c3c95118d4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be7a9fb1-9a87-43e8-8448-b8a276623689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_65dc3fd5-4b9b-4f73-9b99-9c3c95118d4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be7a9fb1-9a87-43e8-8448-b8a276623689" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_6a27d246-5557-4ae1-9ebd-29bb780820d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be7a9fb1-9a87-43e8-8448-b8a276623689" xlink:to="loc_us-gaap_StockOptionMember_6a27d246-5557-4ae1-9ebd-29bb780820d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f3367119-1571-45c1-b441-4357f3586a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11df94fb-c900-447f-98ca-2e664e004c5f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f3367119-1571-45c1-b441-4357f3586a5e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f3367119-1571-45c1-b441-4357f3586a5e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f3367119-1571-45c1-b441-4357f3586a5e" xlink:to="loc_us-gaap_ClassOfStockDomain_f3367119-1571-45c1-b441-4357f3586a5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_487bec15-3407-47d0-931b-1c6cb0ed8bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f3367119-1571-45c1-b441-4357f3586a5e" xlink:to="loc_us-gaap_ClassOfStockDomain_487bec15-3407-47d0-931b-1c6cb0ed8bc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7981b66c-6827-425f-bab4-41aaa564b05d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11df94fb-c900-447f-98ca-2e664e004c5f" xlink:to="loc_srt_RangeAxis_7981b66c-6827-425f-bab4-41aaa564b05d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7981b66c-6827-425f-bab4-41aaa564b05d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7981b66c-6827-425f-bab4-41aaa564b05d" xlink:to="loc_srt_RangeMember_7981b66c-6827-425f-bab4-41aaa564b05d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_51b5fe3e-aa7f-4454-9061-d9e5180dd3d9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7981b66c-6827-425f-bab4-41aaa564b05d" xlink:to="loc_srt_RangeMember_51b5fe3e-aa7f-4454-9061-d9e5180dd3d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_ed212d83-ebf3-4f5c-b133-d0cbf4980e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11df94fb-c900-447f-98ca-2e664e004c5f" xlink:to="loc_us-gaap_VestingAxis_ed212d83-ebf3-4f5c-b133-d0cbf4980e5f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_ed212d83-ebf3-4f5c-b133-d0cbf4980e5f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_ed212d83-ebf3-4f5c-b133-d0cbf4980e5f" xlink:to="loc_us-gaap_VestingDomain_ed212d83-ebf3-4f5c-b133-d0cbf4980e5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_5b46ebc9-d21f-4ea9-8211-110938ea7845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_ed212d83-ebf3-4f5c-b133-d0cbf4980e5f" xlink:to="loc_us-gaap_VestingDomain_5b46ebc9-d21f-4ea9-8211-110938ea7845" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" xlink:type="simple" xlink:href="lxrx-20220630.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" xlink:type="extended" id="ic53944abd9fa428b85996238868ba984_SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4516ef08-fbf1-4947-a3e3-116476a195d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4516ef08-fbf1-4947-a3e3-116476a195d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_266a464f-f9b4-4dbe-8011-a66d6e7b5d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_266a464f-f9b4-4dbe-8011-a66d6e7b5d9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_f5b079b7-66d9-492e-8111-38e406915572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_f5b079b7-66d9-492e-8111-38e406915572" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f691addb-d136-468a-a8b4-85187800b145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f691addb-d136-468a-a8b4-85187800b145" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a41a2d8f-1ba2-45ce-b4b4-cfbd6cadaf8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a41a2d8f-1ba2-45ce-b4b4-cfbd6cadaf8d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_21d58633-9bdd-4c4f-a216-d0c04a7c0f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_21d58633-9bdd-4c4f-a216-d0c04a7c0f45" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_57a3c849-9f95-4de2-8a3e-647a6413cdbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_57a3c849-9f95-4de2-8a3e-647a6413cdbf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_8846c010-d7a9-4171-9e5e-215cc6f5ae90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_8846c010-d7a9-4171-9e5e-215cc6f5ae90" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3383f907-ff37-480f-91df-abe1d3374fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3383f907-ff37-480f-91df-abe1d3374fc6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_cb6ec240-77ed-4535-aacc-4b379ba0fffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_cb6ec240-77ed-4535-aacc-4b379ba0fffd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_51347d04-4440-456a-9c5c-d4fd6f79fd31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_51347d04-4440-456a-9c5c-d4fd6f79fd31" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c016828e-cc39-4566-a282-d273294f7157" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c016828e-cc39-4566-a282-d273294f7157" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_affa8079-16ec-4f59-84f6-a5ec3a2da2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_affa8079-16ec-4f59-84f6-a5ec3a2da2fe" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cfa8e225-6202-4cdb-be82-1cb66d8f7507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cfa8e225-6202-4cdb-be82-1cb66d8f7507" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4d9b5161-1a42-4d37-99f1-0bf65e24b61a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4d9b5161-1a42-4d37-99f1-0bf65e24b61a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0a1f7f76-7f34-4583-a25b-e4bf705fb6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0a1f7f76-7f34-4583-a25b-e4bf705fb6b9" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f1fe0475-81f9-4d3b-baae-b3501edc16ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f1fe0475-81f9-4d3b-baae-b3501edc16ac" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1d3b6085-ecd3-4f17-8dd9-b03b290b2165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1d3b6085-ecd3-4f17-8dd9-b03b290b2165" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7e9ea4b3-46ab-42d5-80e3-4167b1c53d20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7e9ea4b3-46ab-42d5-80e3-4167b1c53d20" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_953ce2d2-c329-4f84-81c0-66e77a5718d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_953ce2d2-c329-4f84-81c0-66e77a5718d7" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18f39341-e74f-4def-8b3a-41cb32404b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18f39341-e74f-4def-8b3a-41cb32404b0f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e823fd89-436c-4b2c-b665-90a7c795db0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18f39341-e74f-4def-8b3a-41cb32404b0f" xlink:to="loc_us-gaap_PlanNameAxis_e823fd89-436c-4b2c-b665-90a7c795db0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e823fd89-436c-4b2c-b665-90a7c795db0e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_e823fd89-436c-4b2c-b665-90a7c795db0e" xlink:to="loc_us-gaap_PlanNameDomain_e823fd89-436c-4b2c-b665-90a7c795db0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9d6d44f7-e5a5-4c05-b8c8-73fab638d732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_e823fd89-436c-4b2c-b665-90a7c795db0e" xlink:to="loc_us-gaap_PlanNameDomain_9d6d44f7-e5a5-4c05-b8c8-73fab638d732" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_9b782563-a72b-4816-b012-5a87303545b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18f39341-e74f-4def-8b3a-41cb32404b0f" xlink:to="loc_us-gaap_AwardDateAxis_9b782563-a72b-4816-b012-5a87303545b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_9b782563-a72b-4816-b012-5a87303545b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_9b782563-a72b-4816-b012-5a87303545b2" xlink:to="loc_us-gaap_AwardDateDomain_9b782563-a72b-4816-b012-5a87303545b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_8aef8362-12e3-4890-9f64-d2b737c9af28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_9b782563-a72b-4816-b012-5a87303545b2" xlink:to="loc_us-gaap_AwardDateDomain_8aef8362-12e3-4890-9f64-d2b737c9af28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b6e9c90c-04a2-4fba-8337-73393f6c8f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18f39341-e74f-4def-8b3a-41cb32404b0f" xlink:to="loc_us-gaap_AwardTypeAxis_b6e9c90c-04a2-4fba-8337-73393f6c8f20" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6e9c90c-04a2-4fba-8337-73393f6c8f20_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b6e9c90c-04a2-4fba-8337-73393f6c8f20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6e9c90c-04a2-4fba-8337-73393f6c8f20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb247acc-70d6-4627-a7b9-270c79b29da0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b6e9c90c-04a2-4fba-8337-73393f6c8f20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb247acc-70d6-4627-a7b9-270c79b29da0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_24b423fd-72ff-4ca7-ac80-c402ace3a84c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb247acc-70d6-4627-a7b9-270c79b29da0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_24b423fd-72ff-4ca7-ac80-c402ace3a84c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f201813c-6659-4450-be43-062b01f6bd76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb247acc-70d6-4627-a7b9-270c79b29da0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f201813c-6659-4450-be43-062b01f6bd76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7260f618-cc9a-447d-9696-92fd0995ac22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18f39341-e74f-4def-8b3a-41cb32404b0f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7260f618-cc9a-447d-9696-92fd0995ac22" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7260f618-cc9a-447d-9696-92fd0995ac22_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7260f618-cc9a-447d-9696-92fd0995ac22" xlink:to="loc_us-gaap_ClassOfStockDomain_7260f618-cc9a-447d-9696-92fd0995ac22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e3f17c49-49ec-4963-af52-3f9ac7e49eed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7260f618-cc9a-447d-9696-92fd0995ac22" xlink:to="loc_us-gaap_ClassOfStockDomain_e3f17c49-49ec-4963-af52-3f9ac7e49eed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0fd8b85b-729d-44de-ba01-25b0c5c2eb15" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18f39341-e74f-4def-8b3a-41cb32404b0f" xlink:to="loc_srt_RangeAxis_0fd8b85b-729d-44de-ba01-25b0c5c2eb15" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0fd8b85b-729d-44de-ba01-25b0c5c2eb15_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0fd8b85b-729d-44de-ba01-25b0c5c2eb15" xlink:to="loc_srt_RangeMember_0fd8b85b-729d-44de-ba01-25b0c5c2eb15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_248f57ef-aca4-476e-8281-23b0c00395d1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0fd8b85b-729d-44de-ba01-25b0c5c2eb15" xlink:to="loc_srt_RangeMember_248f57ef-aca4-476e-8281-23b0c00395d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_9edfc4e8-4fdb-40d3-bf94-2536b967bc56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18f39341-e74f-4def-8b3a-41cb32404b0f" xlink:to="loc_us-gaap_VestingAxis_9edfc4e8-4fdb-40d3-bf94-2536b967bc56" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_9edfc4e8-4fdb-40d3-bf94-2536b967bc56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_9edfc4e8-4fdb-40d3-bf94-2536b967bc56" xlink:to="loc_us-gaap_VestingDomain_9edfc4e8-4fdb-40d3-bf94-2536b967bc56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_a5e273df-307c-4119-a874-03244eb1e99c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_9edfc4e8-4fdb-40d3-bf94-2536b967bc56" xlink:to="loc_us-gaap_VestingDomain_a5e273df-307c-4119-a874-03244eb1e99c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" xlink:type="simple" xlink:href="lxrx-20220630.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" xlink:type="extended" id="i08d5d594125d4e77b08253bc739be342_SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a5668b0-bd6a-4d69-9a0f-1140789687c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b925c0cb-507d-44fd-9bcd-56d1da991707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a5668b0-bd6a-4d69-9a0f-1140789687c8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b925c0cb-507d-44fd-9bcd-56d1da991707" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_8f7dd62a-3e1f-4619-8ae8-f2b5cc2dc935" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b925c0cb-507d-44fd-9bcd-56d1da991707" xlink:to="loc_us-gaap_PlanNameAxis_8f7dd62a-3e1f-4619-8ae8-f2b5cc2dc935" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8f7dd62a-3e1f-4619-8ae8-f2b5cc2dc935_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_8f7dd62a-3e1f-4619-8ae8-f2b5cc2dc935" xlink:to="loc_us-gaap_PlanNameDomain_8f7dd62a-3e1f-4619-8ae8-f2b5cc2dc935_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6e5dd3a4-f103-4381-b767-e3c08d86d017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_8f7dd62a-3e1f-4619-8ae8-f2b5cc2dc935" xlink:to="loc_us-gaap_PlanNameDomain_6e5dd3a4-f103-4381-b767-e3c08d86d017" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_26362f1b-21fb-458b-9485-1d812a27e1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b925c0cb-507d-44fd-9bcd-56d1da991707" xlink:to="loc_us-gaap_AwardTypeAxis_26362f1b-21fb-458b-9485-1d812a27e1cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26362f1b-21fb-458b-9485-1d812a27e1cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_26362f1b-21fb-458b-9485-1d812a27e1cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26362f1b-21fb-458b-9485-1d812a27e1cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c4de23a-1b5e-42f3-9910-1a632e4650cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_26362f1b-21fb-458b-9485-1d812a27e1cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c4de23a-1b5e-42f3-9910-1a632e4650cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_514d1647-4faf-4265-ac2c-475f0f382f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b925c0cb-507d-44fd-9bcd-56d1da991707" xlink:to="loc_us-gaap_StatementClassOfStockAxis_514d1647-4faf-4265-ac2c-475f0f382f0f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_514d1647-4faf-4265-ac2c-475f0f382f0f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_514d1647-4faf-4265-ac2c-475f0f382f0f" xlink:to="loc_us-gaap_ClassOfStockDomain_514d1647-4faf-4265-ac2c-475f0f382f0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3687b1b5-3329-4126-852e-f985411e3fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_514d1647-4faf-4265-ac2c-475f0f382f0f" xlink:to="loc_us-gaap_ClassOfStockDomain_3687b1b5-3329-4126-852e-f985411e3fcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7f24899f-5853-4323-bf4c-4633a21bfeba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b925c0cb-507d-44fd-9bcd-56d1da991707" xlink:to="loc_srt_RangeAxis_7f24899f-5853-4323-bf4c-4633a21bfeba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7f24899f-5853-4323-bf4c-4633a21bfeba_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7f24899f-5853-4323-bf4c-4633a21bfeba" xlink:to="loc_srt_RangeMember_7f24899f-5853-4323-bf4c-4633a21bfeba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_12560469-8c2b-444e-8fcf-b473c1ae3c7a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7f24899f-5853-4323-bf4c-4633a21bfeba" xlink:to="loc_srt_RangeMember_12560469-8c2b-444e-8fcf-b473c1ae3c7a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lxrx-20220630.xsd#SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" xlink:type="extended" id="i0c5521f6d34b46f2922fc5ae8c5a56cf_SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesLineItems_292cc32b-01db-477f-8359-62c7b71fade1" xlink:href="lxrx-20220630.xsd#lxrx_AccruedLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent_7462c153-2bc1-4671-91c6-e015a63555a5" xlink:href="lxrx-20220630.xsd#lxrx_AccruedResearchAndDevelopmentServicesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_292cc32b-01db-477f-8359-62c7b71fade1" xlink:to="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent_7462c153-2bc1-4671-91c6-e015a63555a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedCompensationAndBenefitsCurrent_113c5b0c-e370-45d4-a691-34b6d1085f9c" xlink:href="lxrx-20220630.xsd#lxrx_AccruedCompensationAndBenefitsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_292cc32b-01db-477f-8359-62c7b71fade1" xlink:to="loc_lxrx_AccruedCompensationAndBenefitsCurrent_113c5b0c-e370-45d4-a691-34b6d1085f9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_bbb749d8-f07a-4b00-b12e-304fb6856043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_292cc32b-01db-477f-8359-62c7b71fade1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_bbb749d8-f07a-4b00-b12e-304fb6856043" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_968e5fa9-c31c-4c8f-810a-469706ff5db0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_292cc32b-01db-477f-8359-62c7b71fade1" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_968e5fa9-c31c-4c8f-810a-469706ff5db0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_41cada58-5c45-4662-8222-12a9e27a6c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_292cc32b-01db-477f-8359-62c7b71fade1" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_41cada58-5c45-4662-8222-12a9e27a6c5e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LexiconIncrementalBorrowingRate_a5c560e8-e29c-4eeb-86b5-bacb368b4ecc" xlink:href="lxrx-20220630.xsd#lxrx_LexiconIncrementalBorrowingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_292cc32b-01db-477f-8359-62c7b71fade1" xlink:to="loc_lxrx_LexiconIncrementalBorrowingRate_a5c560e8-e29c-4eeb-86b5-bacb368b4ecc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesTable_1be11f5e-ec80-4009-837c-20847810cf17" xlink:href="lxrx-20220630.xsd#lxrx_AccruedLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_292cc32b-01db-477f-8359-62c7b71fade1" xlink:to="loc_lxrx_AccruedLiabilitiesTable_1be11f5e-ec80-4009-837c-20847810cf17" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesAxis_5cb4ede5-d356-4512-864d-d459cb55ffbb" xlink:href="lxrx-20220630.xsd#lxrx_AccruedLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lxrx_AccruedLiabilitiesTable_1be11f5e-ec80-4009-837c-20847810cf17" xlink:to="loc_lxrx_AccruedLiabilitiesAxis_5cb4ede5-d356-4512-864d-d459cb55ffbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesDomain_5cb4ede5-d356-4512-864d-d459cb55ffbb_default" xlink:href="lxrx-20220630.xsd#lxrx_AccruedLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_lxrx_AccruedLiabilitiesAxis_5cb4ede5-d356-4512-864d-d459cb55ffbb" xlink:to="loc_lxrx_AccruedLiabilitiesDomain_5cb4ede5-d356-4512-864d-d459cb55ffbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesDomain_3626e788-7ecb-4a63-8bd6-106aeecad34f" xlink:href="lxrx-20220630.xsd#lxrx_AccruedLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_lxrx_AccruedLiabilitiesAxis_5cb4ede5-d356-4512-864d-d459cb55ffbb" xlink:to="loc_lxrx_AccruedLiabilitiesDomain_3626e788-7ecb-4a63-8bd6-106aeecad34f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" xlink:type="simple" xlink:href="lxrx-20220630.xsd#CashandCashEquivalentsandInvestmentsDetails1"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" xlink:type="extended" id="i299e4545b7b64e80a67437fd7f2edcd1_CashandCashEquivalentsandInvestmentsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2df58ceb-afa5-461d-8e71-5197bb07a2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bc4aa511-7d66-4ec3-ba5a-99ebf2a35f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2df58ceb-afa5-461d-8e71-5197bb07a2ba" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bc4aa511-7d66-4ec3-ba5a-99ebf2a35f5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ed2583c9-505b-4936-8589-3476d1ec6b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2df58ceb-afa5-461d-8e71-5197bb07a2ba" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ed2583c9-505b-4936-8589-3476d1ec6b63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_964d7c1d-6ca6-4f83-8425-b118704a9e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2df58ceb-afa5-461d-8e71-5197bb07a2ba" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_964d7c1d-6ca6-4f83-8425-b118704a9e3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_611a5523-1dbc-42d5-a638-1407f0f0f997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2df58ceb-afa5-461d-8e71-5197bb07a2ba" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_611a5523-1dbc-42d5-a638-1407f0f0f997" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9c6ce87a-a5f4-4094-8750-1a80808d1ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2df58ceb-afa5-461d-8e71-5197bb07a2ba" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9c6ce87a-a5f4-4094-8750-1a80808d1ee4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_7acfb4b6-abac-45c6-ab43-43a7a30a3873" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2df58ceb-afa5-461d-8e71-5197bb07a2ba" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_7acfb4b6-abac-45c6-ab43-43a7a30a3873" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_707bce71-46d0-4c4b-90e9-e939751d239c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2df58ceb-afa5-461d-8e71-5197bb07a2ba" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_707bce71-46d0-4c4b-90e9-e939751d239c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_71a7b952-0556-46d1-8710-f11a12d9c184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2df58ceb-afa5-461d-8e71-5197bb07a2ba" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_71a7b952-0556-46d1-8710-f11a12d9c184" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_cf96fd23-9714-4172-90c4-d80a4b92cef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_71a7b952-0556-46d1-8710-f11a12d9c184" xlink:to="loc_us-gaap_InvestmentTypeAxis_cf96fd23-9714-4172-90c4-d80a4b92cef4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_cf96fd23-9714-4172-90c4-d80a4b92cef4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_cf96fd23-9714-4172-90c4-d80a4b92cef4" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_cf96fd23-9714-4172-90c4-d80a4b92cef4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1c4d0b24-5b71-4361-9f3e-2295082520ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_cf96fd23-9714-4172-90c4-d80a4b92cef4" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1c4d0b24-5b71-4361-9f3e-2295082520ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_dea8fa4d-719b-44b3-9f49-317f4578dd45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1c4d0b24-5b71-4361-9f3e-2295082520ac" xlink:to="loc_us-gaap_CashMember_dea8fa4d-719b-44b3-9f49-317f4578dd45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_69addab4-1236-4776-a169-16acba7c1372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1c4d0b24-5b71-4361-9f3e-2295082520ac" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_69addab4-1236-4776-a169-16acba7c1372" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_90b4e01c-f5f1-4dd7-81fb-198330b4d211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1c4d0b24-5b71-4361-9f3e-2295082520ac" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_90b4e01c-f5f1-4dd7-81fb-198330b4d211" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_2d573883-1df8-46d6-8da8-d022be4f9ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1c4d0b24-5b71-4361-9f3e-2295082520ac" xlink:to="loc_us-gaap_InvestmentsMember_2d573883-1df8-46d6-8da8-d022be4f9ff7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d6848fcd-e96d-4b96-96a9-1b2d2e8b9213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1c4d0b24-5b71-4361-9f3e-2295082520ac" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d6848fcd-e96d-4b96-96a9-1b2d2e8b9213" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" xlink:type="simple" xlink:href="lxrx-20220630.xsd#CashandCashEquivalentsandInvestmentsDetails2"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" xlink:type="extended" id="i42a3702c7ea4485d86c0980169fb8735_CashandCashEquivalentsandInvestmentsDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_2ae7b3d1-5819-4ab1-b9b9-5c77874de557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_048e9091-0d8c-4f8d-9b6b-43d0f539dd21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_2ae7b3d1-5819-4ab1-b9b9-5c77874de557" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_048e9091-0d8c-4f8d-9b6b-43d0f539dd21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_2df6c0dc-c96c-49e1-813b-57727364c799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_2ae7b3d1-5819-4ab1-b9b9-5c77874de557" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_2df6c0dc-c96c-49e1-813b-57727364c799" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeAxis_f9eb09c2-d680-47bb-ade0-67f44122babd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingActivityByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_2df6c0dc-c96c-49e1-813b-57727364c799" xlink:to="loc_us-gaap_TradingActivityByTypeAxis_f9eb09c2-d680-47bb-ade0-67f44122babd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeDomain_f9eb09c2-d680-47bb-ade0-67f44122babd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TradingActivityByTypeAxis_f9eb09c2-d680-47bb-ade0-67f44122babd" xlink:to="loc_us-gaap_TradingActivityByTypeDomain_f9eb09c2-d680-47bb-ade0-67f44122babd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeDomain_f345742c-1234-4ba2-bcfd-a60bbcc4f10d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TradingActivityByTypeAxis_f9eb09c2-d680-47bb-ade0-67f44122babd" xlink:to="loc_us-gaap_TradingActivityByTypeDomain_f345742c-1234-4ba2-bcfd-a60bbcc4f10d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="lxrx-20220630.xsd#FairValueMeasurementsDetails1"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="extended" id="iba9e621aca894be59048b06fce0c8c70_FairValueMeasurementsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9a1a0057-4259-4a99-8bc0-16e8bfd443c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a97b739d-509c-42b6-b8c0-368dfe8b7f18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9a1a0057-4259-4a99-8bc0-16e8bfd443c6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a97b739d-509c-42b6-b8c0-368dfe8b7f18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_70fbf990-3ae3-44ae-83d4-3840059bb775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9a1a0057-4259-4a99-8bc0-16e8bfd443c6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_70fbf990-3ae3-44ae-83d4-3840059bb775" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_17c64aae-99dc-41eb-a3fa-d83e5c62b041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9a1a0057-4259-4a99-8bc0-16e8bfd443c6" xlink:to="loc_us-gaap_AvailableForSaleSecurities_17c64aae-99dc-41eb-a3fa-d83e5c62b041" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_01af7d24-1685-4495-a991-ae401e12e900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9a1a0057-4259-4a99-8bc0-16e8bfd443c6" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_01af7d24-1685-4495-a991-ae401e12e900" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5a6b14c0-9f15-459c-9d30-b3b065af851a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9a1a0057-4259-4a99-8bc0-16e8bfd443c6" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5a6b14c0-9f15-459c-9d30-b3b065af851a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_67564a55-ef8e-4803-9e51-36378379002c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5a6b14c0-9f15-459c-9d30-b3b065af851a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_67564a55-ef8e-4803-9e51-36378379002c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67564a55-ef8e-4803-9e51-36378379002c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_67564a55-ef8e-4803-9e51-36378379002c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67564a55-ef8e-4803-9e51-36378379002c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e47bba74-ab5d-4f72-8028-0db23af76aae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_67564a55-ef8e-4803-9e51-36378379002c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e47bba74-ab5d-4f72-8028-0db23af76aae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_042484f8-af65-4449-b4a8-b3e2464ba86f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e47bba74-ab5d-4f72-8028-0db23af76aae" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_042484f8-af65-4449-b4a8-b3e2464ba86f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b63fd97d-5df9-441e-bb95-5ebb3544fbf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e47bba74-ab5d-4f72-8028-0db23af76aae" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b63fd97d-5df9-441e-bb95-5ebb3544fbf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a64a508b-06da-44b0-a06f-bae7295b2ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e47bba74-ab5d-4f72-8028-0db23af76aae" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a64a508b-06da-44b0-a06f-bae7295b2ff8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails" xlink:type="simple" xlink:href="lxrx-20220630.xsd#DebtObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails" xlink:type="extended" id="i89b957c15566498cb4d1a0a13ffc7c98_DebtObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_863188e2-40b2-46aa-8c5c-478ce2667113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_863188e2-40b2-46aa-8c5c-478ce2667113" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_9e50525c-cd91-4c02-add0-f14979431479" xlink:href="lxrx-20220630.xsd#lxrx_ConvDebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_9e50525c-cd91-4c02-add0-f14979431479" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_64d54f3e-bfdb-4168-b34c-fb30c8a5a3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_64d54f3e-bfdb-4168-b34c-fb30c8a5a3d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_29ab88d4-b7e0-47c7-91c1-a60dbf411967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_29ab88d4-b7e0-47c7-91c1-a60dbf411967" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_0c91c3e7-b2c5-48f4-9bae-ac914e9cf4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_us-gaap_DebtInstrumentFairValue_0c91c3e7-b2c5-48f4-9bae-ac914e9cf4ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4529efbc-40e4-49aa-a0aa-bfcafb6016a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_us-gaap_CommonStockSharesIssued_4529efbc-40e4-49aa-a0aa-bfcafb6016a5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchange_0909d9ce-64e2-4f99-8dd4-69f096313d4c" xlink:href="lxrx-20220630.xsd#lxrx_ConvertibleDebtExchange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_ConvertibleDebtExchange_0909d9ce-64e2-4f99-8dd4-69f096313d4c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedInterestOnConvertible_1b855fc4-3350-4678-97e5-33e0385e7cb3" xlink:href="lxrx-20220630.xsd#lxrx_AccruedInterestOnConvertible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_AccruedInterestOnConvertible_1b855fc4-3350-4678-97e5-33e0385e7cb3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeRemainingNotes_4a759a0b-e416-4c7d-8f69-7ea6015c4aaa" xlink:href="lxrx-20220630.xsd#lxrx_ConvertibleDebtExchangeRemainingNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_ConvertibleDebtExchangeRemainingNotes_4a759a0b-e416-4c7d-8f69-7ea6015c4aaa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FutureConvertibleDebtExchangeShares_bae124e9-2204-47b9-a38f-eef2ec358ea5" xlink:href="lxrx-20220630.xsd#lxrx_FutureConvertibleDebtExchangeShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_FutureConvertibleDebtExchangeShares_bae124e9-2204-47b9-a38f-eef2ec358ea5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FutureConvertibleDebtExchange_879e03de-2b2c-40c9-b292-3b149a91c115" xlink:href="lxrx-20220630.xsd#lxrx_FutureConvertibleDebtExchange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_FutureConvertibleDebtExchange_879e03de-2b2c-40c9-b292-3b149a91c115" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PrincipalAmountOfConvertibleNotes_e9db3309-c0fd-4ae2-8562-5db84cd77ad1" xlink:href="lxrx-20220630.xsd#lxrx_PrincipalAmountOfConvertibleNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_PrincipalAmountOfConvertibleNotes_e9db3309-c0fd-4ae2-8562-5db84cd77ad1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_e676036b-9aa3-4d43-ab35-d0aa20cf39f6" xlink:href="lxrx-20220630.xsd#lxrx_ConvertibleDebtExchangeTotalPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_e676036b-9aa3-4d43-ab35-d0aa20cf39f6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_1cff167b-b829-4ecf-99d0-1e3a119797ab" xlink:href="lxrx-20220630.xsd#lxrx_ConvertibleDebtExchangeSeptemberCashPortion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_1cff167b-b829-4ecf-99d0-1e3a119797ab" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_e19389e2-f4b2-4ab1-a353-63441551db1b" xlink:href="lxrx-20220630.xsd#lxrx_ConvertibleDebtExchangeSeptemberSharePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_e19389e2-f4b2-4ab1-a353-63441551db1b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_98c616a2-0001-4716-b279-2e23fe0ecc32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_98c616a2-0001-4716-b279-2e23fe0ecc32" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c63e8b1d-1b31-4822-aabc-f946943cf13c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_us-gaap_LongTermDebt_c63e8b1d-1b31-4822-aabc-f946943cf13c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTerm_03490465-eb86-4d6a-a5ab-dd8e04541e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_us-gaap_LongTermDebtTerm_03490465-eb86-4d6a-a5ab-dd8e04541e8f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_927af1ed-623d-4c75-a6c4-dbd6a2d1578a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_927af1ed-623d-4c75-a6c4-dbd6a2d1578a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_029821ba-94b8-4ce5-b5ea-42c4428dbeb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_029821ba-94b8-4ce5-b5ea-42c4428dbeb6" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanB_4a565a80-2fb3-40fe-aefb-eeb3a5e2d418" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_TermLoanB_4a565a80-2fb3-40fe-aefb-eeb3a5e2d418" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanC_e572a1c4-c2b5-495c-a0d2-799bb415f906" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_TermLoanC_e572a1c4-c2b5-495c-a0d2-799bb415f906" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanD_02c1f9d4-31fe-4177-a0cb-34b69288494a" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_TermLoanD_02c1f9d4-31fe-4177-a0cb-34b69288494a" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OxfordLoanFacility_18984c42-2da2-4881-ac7c-ff0dd17e0de7" xlink:href="lxrx-20220630.xsd#lxrx_OxfordLoanFacility"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_OxfordLoanFacility_18984c42-2da2-4881-ac7c-ff0dd17e0de7" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanA_3de6fe26-af1e-41ff-8cc5-c736b4add0d1" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_TermLoanA_3de6fe26-af1e-41ff-8cc5-c736b4add0d1" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanABWarrant_e6e67060-5284-492d-9980-19c689542ddb" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanABWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_TermLoanABWarrant_e6e67060-5284-492d-9980-19c689542ddb" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanCWarrant_e7b5311d-c451-4cf2-9bda-d4c954115709" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanCWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_TermLoanCWarrant_e7b5311d-c451-4cf2-9bda-d4c954115709" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanDWarrant_9d7186db-3321-469e-b1fb-3e3c91953b94" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanDWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_TermLoanDWarrant_9d7186db-3321-469e-b1fb-3e3c91953b94" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAWarrantsNumber_b6b4edfb-b5e3-478d-94ee-a9f8b86afc00" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanAWarrantsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_TermLoanAWarrantsNumber_b6b4edfb-b5e3-478d-94ee-a9f8b86afc00" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAWarrantExercisePrice_2cd4e19f-d140-41c4-af95-03ab9144f9e1" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanAWarrantExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_TermLoanAWarrantExercisePrice_2cd4e19f-d140-41c4-af95-03ab9144f9e1" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_20a5a015-7239-40ea-8c8a-8b2747e52dda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_20a5a015-7239-40ea-8c8a-8b2747e52dda" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_37f44268-8c55-4d28-ac74-9277d515c312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_37f44268-8c55-4d28-ac74-9277d515c312" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5229b9f0-7cb2-44a2-b134-e0e08c5a0885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5229b9f0-7cb2-44a2-b134-e0e08c5a0885" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_a16e215d-a20b-42ca-90ef-4bfb68a00e89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_a16e215d-a20b-42ca-90ef-4bfb68a00e89" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubordinatedBorrowingInterestRate_40a5f2b9-9e7f-43f9-857b-6648f7af5bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubordinatedBorrowingInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_us-gaap_SubordinatedBorrowingInterestRate_40a5f2b9-9e7f-43f9-857b-6648f7af5bd9" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FinalPaymentWithNoExtention_00ac68e2-1727-4c6e-936a-1934e83f1190" xlink:href="lxrx-20220630.xsd#lxrx_FinalPaymentWithNoExtention"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_FinalPaymentWithNoExtention_00ac68e2-1727-4c6e-936a-1934e83f1190" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FinalPaymentWithExtention_2c394a19-c780-4f20-9464-f1af0cd338e4" xlink:href="lxrx-20220630.xsd#lxrx_FinalPaymentWithExtention"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_FinalPaymentWithExtention_2c394a19-c780-4f20-9464-f1af0cd338e4" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAFinalPayment_4cb384db-eb77-4b25-adc5-452ff4d20b08" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanAFinalPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_TermLoanAFinalPayment_4cb384db-eb77-4b25-adc5-452ff4d20b08" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanANetCashReceipt_d20f270b-ab88-4b29-b26a-a941826b79da" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanANetCashReceipt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_TermLoanANetCashReceipt_d20f270b-ab88-4b29-b26a-a941826b79da" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanADebtIssuanceCosts_e16225cd-3894-452b-8418-66e5b8e927e7" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanADebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_TermLoanADebtIssuanceCosts_e16225cd-3894-452b-8418-66e5b8e927e7" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OxfordFacilityFee_b388f073-dc5a-4d32-b9f2-4b0966886c31" xlink:href="lxrx-20220630.xsd#lxrx_OxfordFacilityFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_OxfordFacilityFee_b388f073-dc5a-4d32-b9f2-4b0966886c31" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanADebtDiscount_57425d6e-fcb3-4659-810c-5ba855a7a042" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanADebtDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_TermLoanADebtDiscount_57425d6e-fcb3-4659-810c-5ba855a7a042" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAInterestExpense_561952f8-5dd4-4001-b79a-9925b736cb8b" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanAInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_TermLoanAInterestExpense_561952f8-5dd4-4001-b79a-9925b736cb8b" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2025OxfordPrincipalPayments_68b83c64-0395-41e1-8d66-1a7aff5d3497" xlink:href="lxrx-20220630.xsd#lxrx_A2025OxfordPrincipalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_A2025OxfordPrincipalPayments_68b83c64-0395-41e1-8d66-1a7aff5d3497" xlink:type="arc" order="43"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2026OxfordPrincipalPayments_488ba06f-d645-4eaf-acd2-991273f479b6" xlink:href="lxrx-20220630.xsd#lxrx_A2026OxfordPrincipalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_A2026OxfordPrincipalPayments_488ba06f-d645-4eaf-acd2-991273f479b6" xlink:type="arc" order="44"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2027OxfordPrincipalPayments_cf8247f9-9168-41da-b095-e33a0aa96077" xlink:href="lxrx-20220630.xsd#lxrx_A2027OxfordPrincipalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_A2027OxfordPrincipalPayments_cf8247f9-9168-41da-b095-e33a0aa96077" xlink:type="arc" order="45"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_387a1900-4bc0-4b87-83b7-54aa4a306208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_us-gaap_DebtInstrumentTable_387a1900-4bc0-4b87-83b7-54aa4a306208" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="lxrx-20220630.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="i8057504efe5346ff89bf29384c68b390_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_087bad4e-d8db-43cc-907a-ffb8e75a8277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment_2d602515-b10f-46a9-97f3-dc77831c5b54" xlink:href="lxrx-20220630.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_087bad4e-d8db-43cc-907a-ffb8e75a8277" xlink:to="loc_lxrx_Lxrx_Sanofiterminationcashpayment_2d602515-b10f-46a9-97f3-dc77831c5b54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_5443b848-20e7-408b-bf9b-c9371a776c63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_087bad4e-d8db-43cc-907a-ffb8e75a8277" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_5443b848-20e7-408b-bf9b-c9371a776c63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2fb4d743-ef49-4c1e-bb5a-86adcce9e401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_087bad4e-d8db-43cc-907a-ffb8e75a8277" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2fb4d743-ef49-4c1e-bb5a-86adcce9e401" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9928e80b-c677-484b-bfed-ee75af47a3e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_087bad4e-d8db-43cc-907a-ffb8e75a8277" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9928e80b-c677-484b-bfed-ee75af47a3e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_067e3c66-2747-4f25-96d4-0f4055589e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_087bad4e-d8db-43cc-907a-ffb8e75a8277" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_067e3c66-2747-4f25-96d4-0f4055589e5b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5a703eaf-6ca6-4ae8-b27a-3f00ec46fa2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_087bad4e-d8db-43cc-907a-ffb8e75a8277" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5a703eaf-6ca6-4ae8-b27a-3f00ec46fa2e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_dbb689c2-621f-4ade-873d-87dbe7ef15ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_087bad4e-d8db-43cc-907a-ffb8e75a8277" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_dbb689c2-621f-4ade-873d-87dbe7ef15ff" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2ae3a157-d296-4037-b591-5cf73b8257cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_087bad4e-d8db-43cc-907a-ffb8e75a8277" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2ae3a157-d296-4037-b591-5cf73b8257cd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_99bfe615-9e95-46eb-a8eb-962b091133d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_087bad4e-d8db-43cc-907a-ffb8e75a8277" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_99bfe615-9e95-46eb-a8eb-962b091133d8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_43386971-b7ee-4aba-b889-1f9fc86538eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_087bad4e-d8db-43cc-907a-ffb8e75a8277" xlink:to="loc_us-gaap_OperatingLeaseLiability_43386971-b7ee-4aba-b889-1f9fc86538eb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCommitmentAmount_c23797ef-8771-482c-a376-3e736882b847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCommitmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_087bad4e-d8db-43cc-907a-ffb8e75a8277" xlink:to="loc_us-gaap_ShortTermLeaseCommitmentAmount_c23797ef-8771-482c-a376-3e736882b847" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_738640b0-3a62-4092-8211-02b3b7efad0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_087bad4e-d8db-43cc-907a-ffb8e75a8277" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_738640b0-3a62-4092-8211-02b3b7efad0f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiDisputedCosts_199f99da-b9fd-42e7-a7f0-1337acb55d29" xlink:href="lxrx-20220630.xsd#lxrx_SanofiDisputedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_087bad4e-d8db-43cc-907a-ffb8e75a8277" xlink:to="loc_lxrx_SanofiDisputedCosts_199f99da-b9fd-42e7-a7f0-1337acb55d29" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_4d7d49f4-cd02-494b-b941-2566f829c97f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_087bad4e-d8db-43cc-907a-ffb8e75a8277" xlink:to="loc_us-gaap_OtherCommitmentsTable_4d7d49f4-cd02-494b-b941-2566f829c97f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_6ce322b0-3a35-4e8b-8d33-6543bd0f4642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_4d7d49f4-cd02-494b-b941-2566f829c97f" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_6ce322b0-3a35-4e8b-8d33-6543bd0f4642" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_6ce322b0-3a35-4e8b-8d33-6543bd0f4642_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_6ce322b0-3a35-4e8b-8d33-6543bd0f4642" xlink:to="loc_us-gaap_ReceivableTypeDomain_6ce322b0-3a35-4e8b-8d33-6543bd0f4642_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_5d2cc89d-8406-4660-a7e6-82dcb198d0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_6ce322b0-3a35-4e8b-8d33-6543bd0f4642" xlink:to="loc_us-gaap_ReceivableTypeDomain_5d2cc89d-8406-4660-a7e6-82dcb198d0ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_5a68b1d9-158d-470c-830d-6d2b2c480330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_5d2cc89d-8406-4660-a7e6-82dcb198d0ab" xlink:to="loc_us-gaap_AccountsReceivableMember_5a68b1d9-158d-470c-830d-6d2b2c480330" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>lxrx-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b429ed1f-e365-4ee0-b706-413f731644e3,g:a8252b48-0582-489a-8246-eed3b4e2cfac-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_TreasuryStockShares_fa687dfd-f111-4439-a31b-22f0dbc81e52_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtExchange_98b53a2a-68f7-4dcc-9a82-4f415a707836_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchange_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchange_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchange" xlink:href="lxrx-20220630.xsd#lxrx_ConvertibleDebtExchange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtExchange" xlink:to="lab_lxrx_ConvertibleDebtExchange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01dfac1d-b565-470c-9666-979e02d39c81_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fe1990a2-8adb-4713-ac31-0d9cc1921c78_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_cc0323a9-fce9-451b-98fb-b32cc0dc4d2f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_eed16aeb-44a5-4f03-b641-9dd95b4aad5c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_8e8ad5dd-2876-444c-9179-17a64fb4612a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_FutureConvertibleDebtExchangeShares_63718458-2f3f-468a-bc59-8f1a89d70798_terseLabel_en-US" xlink:label="lab_lxrx_FutureConvertibleDebtExchangeShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Convertible debt exchange shares</link:label>
    <link:label id="lab_lxrx_FutureConvertibleDebtExchangeShares_label_en-US" xlink:label="lab_lxrx_FutureConvertibleDebtExchangeShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Convertible debt exchange shares</link:label>
    <link:label id="lab_lxrx_FutureConvertibleDebtExchangeShares_documentation_en-US" xlink:label="lab_lxrx_FutureConvertibleDebtExchangeShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Convertible debt exchange shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FutureConvertibleDebtExchangeShares" xlink:href="lxrx-20220630.xsd#lxrx_FutureConvertibleDebtExchangeShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FutureConvertibleDebtExchangeShares" xlink:to="lab_lxrx_FutureConvertibleDebtExchangeShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_ca1298f5-ee03-4908-a647-f43a52b70b86_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_GainOnSaleOfNonFinancialAssets_fbef04f2-3cd4-436d-86db-aff90c5935c2_terseLabel_en-US" xlink:label="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of non-financial assets</link:label>
    <link:label id="lab_lxrx_GainOnSaleOfNonFinancialAssets_69ca6d2d-e415-4a0f-97df-2380ca7c478d_negatedTerseLabel_en-US" xlink:label="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of non-financial assets</link:label>
    <link:label id="lab_lxrx_GainOnSaleOfNonFinancialAssets_label_en-US" xlink:label="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of non-financial assets</link:label>
    <link:label id="lab_lxrx_GainOnSaleOfNonFinancialAssets_documentation_en-US" xlink:label="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of non-financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets" xlink:href="lxrx-20220630.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_GainOnSaleOfNonFinancialAssets" xlink:to="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_7fbd06aa-c47a-4667-86c8-d17a941ea228_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DebtObligationsAbstract_b5b50795-24f0-45be-939a-5cc2ef666481_terseLabel_en-US" xlink:label="lab_lxrx_DebtObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Obligations [Abstract]</link:label>
    <link:label id="lab_lxrx_DebtObligationsAbstract_label_en-US" xlink:label="lab_lxrx_DebtObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Obligations [Abstract]</link:label>
    <link:label id="lab_lxrx_DebtObligationsAbstract_documentation_en-US" xlink:label="lab_lxrx_DebtObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Obligations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract" xlink:href="lxrx-20220630.xsd#lxrx_DebtObligationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DebtObligationsAbstract" xlink:to="lab_lxrx_DebtObligationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_e343bb1d-7b4e-429b-a2e5-e3274dd461d4_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales (including finite-lived intangible asset amortization)</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessExitCosts1_5d0ae239-c71d-4c0f-86dc-9f8bcd09f830_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Exit Costs</link:label>
    <link:label id="lab_us-gaap_BusinessExitCosts1_label_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Exit Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessExitCosts1" xlink:to="lab_us-gaap_BusinessExitCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_853f2de1-c997-421e-adfd-5c3913aad350_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_c10a8119-b461-4383-899e-45b285268cef_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3a1a2693-ebaa-4ab0-8b62-f8ee4320308a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization, property and equipment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_1dee6af6-1fc2-4702-b712-6378b9c99fc7_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cash and Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_97eeabea-40d4-453b-bd73-832c524ce66d_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_80237891-f7bc-4768-b3a2-656366757216_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_5117db3b-a0e5-467a-90ea-9751de596a3d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_90f07327-5dc9-4308-b352-ade58838f239_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_4f1b35b4-e3b2-42d2-8d9d-53608fe191fc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash, Cash Equivalents and Short-term Investments [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_LiabilitiesAssumedByTerSera_ef4ce49a-1a8e-46ad-99f7-ab286cf7ab1e_terseLabel_en-US" xlink:label="lab_lxrx_LiabilitiesAssumedByTerSera" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed by TerSera</link:label>
    <link:label id="lab_lxrx_LiabilitiesAssumedByTerSera_label_en-US" xlink:label="lab_lxrx_LiabilitiesAssumedByTerSera" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed by TerSera</link:label>
    <link:label id="lab_lxrx_LiabilitiesAssumedByTerSera_documentation_en-US" xlink:label="lab_lxrx_LiabilitiesAssumedByTerSera" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed by TerSera</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LiabilitiesAssumedByTerSera" xlink:href="lxrx-20220630.xsd#lxrx_LiabilitiesAssumedByTerSera"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_LiabilitiesAssumedByTerSera" xlink:to="lab_lxrx_LiabilitiesAssumedByTerSera" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_63ea803a-7dd8-4624-b561-2c01caf5e1b9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 300,000 shares authorized; 150,114 and 150,082 shares issued, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCommitmentAmount_391e7fe2-03de-490e-a1d4-fc4492ec466c_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease Commitment, Amount</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCommitmentAmount_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease Commitment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCommitmentAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCommitmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCommitmentAmount" xlink:to="lab_us-gaap_ShortTermLeaseCommitmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_507fc426-7328-44fa-b153-94ee54e2478b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_FinalPaymentWithNoExtention_e73c4018-9c4b-40c9-9a67-98e5fdb738a9_terseLabel_en-US" xlink:label="lab_lxrx_FinalPaymentWithNoExtention" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Payment % with no extention</link:label>
    <link:label id="lab_lxrx_FinalPaymentWithNoExtention_label_en-US" xlink:label="lab_lxrx_FinalPaymentWithNoExtention" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Payment % with no extention</link:label>
    <link:label id="lab_lxrx_FinalPaymentWithNoExtention_documentation_en-US" xlink:label="lab_lxrx_FinalPaymentWithNoExtention" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Payment % with no extention</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FinalPaymentWithNoExtention" xlink:href="lxrx-20220630.xsd#lxrx_FinalPaymentWithNoExtention"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FinalPaymentWithNoExtention" xlink:to="lab_lxrx_FinalPaymentWithNoExtention" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_FairValueMeasurementsAbstract_49e9d876-f838-4dee-aa42-1d3559590208_terseLabel_en-US" xlink:label="lab_lxrx_FairValueMeasurementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements [Abstract]</link:label>
    <link:label id="lab_lxrx_FairValueMeasurementsAbstract_label_en-US" xlink:label="lab_lxrx_FairValueMeasurementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements [Abstract]</link:label>
    <link:label id="lab_lxrx_FairValueMeasurementsAbstract_documentation_en-US" xlink:label="lab_lxrx_FairValueMeasurementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract" xlink:href="lxrx-20220630.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FairValueMeasurementsAbstract" xlink:to="lab_lxrx_FairValueMeasurementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_3140abdb-28a7-4a7f-ad3c-f1a917483802_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20220630.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_69dbac46-593c-4a05-9d68-e827600e8ad5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_af027aa3-bf57-4808-9e2a-44bfc98b8f01_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_ad59abca-6663-4047-9e52-57c5dc38a5a1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_dcc40032-cc83-4c8f-8d9b-ea47f739283c_terseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8e560631-48b3-4b49-8b9b-99773c990f94_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Sellinggeneralandadministrativeexpenses_3bd58520-bdec-43b0-ad83-f8696ec872d4_terseLabel_en-US" xlink:label="lab_lxrx_Sellinggeneralandadministrativeexpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative, including stock-based compensation of $1,734, $1,602, $3,474 and $3,167 respectively</link:label>
    <link:label id="lab_lxrx_Sellinggeneralandadministrativeexpenses_label_en-US" xlink:label="lab_lxrx_Sellinggeneralandadministrativeexpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_lxrx_Sellinggeneralandadministrativeexpenses_documentation_en-US" xlink:label="lab_lxrx_Sellinggeneralandadministrativeexpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses - the expenses related to selling Lexicon's product as well as general and administrative costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Sellinggeneralandadministrativeexpenses" xlink:href="lxrx-20220630.xsd#lxrx_Sellinggeneralandadministrativeexpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Sellinggeneralandadministrativeexpenses" xlink:to="lab_lxrx_Sellinggeneralandadministrativeexpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_183c4649-aad1-454f-ab89-5be580d81faf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedCompensationAndBenefitsCurrent_c4f6a32c-4a00-428c-a2cd-cae8aa5ed3ed_terseLabel_en-US" xlink:label="lab_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits current</link:label>
    <link:label id="lab_lxrx_AccruedCompensationAndBenefitsCurrent_label_en-US" xlink:label="lab_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits current</link:label>
    <link:label id="lab_lxrx_AccruedCompensationAndBenefitsCurrent_documentation_en-US" xlink:label="lab_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits current - due within 1 year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:href="lxrx-20220630.xsd#lxrx_AccruedCompensationAndBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:to="lab_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_82330a2f-1712-43e6-91bc-ba3d18b5d3e5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_51606184-9023-4a03-817e-b363c368df2f_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:href="lxrx-20220630.xsd#lxrx_ConsolidatedStatementsOfOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:to="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanDWarrant_b1fb7d91-c182-4a91-a8eb-0e0fdd27eb60_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanDWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan D Warrant %</link:label>
    <link:label id="lab_lxrx_TermLoanDWarrant_label_en-US" xlink:label="lab_lxrx_TermLoanDWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan D Warrant %</link:label>
    <link:label id="lab_lxrx_TermLoanDWarrant_documentation_en-US" xlink:label="lab_lxrx_TermLoanDWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan D Warrant %</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanDWarrant" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanDWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanDWarrant" xlink:to="lab_lxrx_TermLoanDWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4d206f69-3970-4e65-abaa-01b75fc57753_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6bb37ecb-d091-4494-8ada-a116ea145e75_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_501a0958-c162-495b-9ad1-52149f4c5fcf_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c2dec522-6673-4ba1-9879-cdf4da5f28cb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from debt borrowings, net of fees</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_a1bf4427-1b3c-4eb2-945e-9e464d080c9d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d9824931-5e2b-46a1-a175-4e4593e3eb6d_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_ce2aca9d-a315-46a5-b3a1-ff8373361552_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_9a2d0669-553b-4e3c-8c88-e827613c1092_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Maximum Sales Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_label_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Maximum Sales Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_documentation_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum sales milestones payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMaximumSalesMilestones" xlink:href="lxrx-20220630.xsd#lxrx_IpsenMaximumSalesMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMaximumSalesMilestones" xlink:to="lab_lxrx_IpsenMaximumSalesMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_2be67b35-ae82-48a6-9b68-f4d5204142d7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_f9a3486d-ea7a-48ef-a95e-87894545d750_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f1052adb-07c8-4658-bf8f-4d9e4983d423_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_FutureConvertibleDebtExchange_d0534db6-7c89-43be-b688-bd9522a7a6c6_terseLabel_en-US" xlink:label="lab_lxrx_FutureConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">future convertible debt exchange</link:label>
    <link:label id="lab_lxrx_FutureConvertibleDebtExchange_label_en-US" xlink:label="lab_lxrx_FutureConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">future convertible debt exchange</link:label>
    <link:label id="lab_lxrx_FutureConvertibleDebtExchange_documentation_en-US" xlink:label="lab_lxrx_FutureConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">future convertible debt exchange</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FutureConvertibleDebtExchange" xlink:href="lxrx-20220630.xsd#lxrx_FutureConvertibleDebtExchange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FutureConvertibleDebtExchange" xlink:to="lab_lxrx_FutureConvertibleDebtExchange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock_2f5fb614-6485-49ef-8b02-d27db52bdd08_terseLabel_en-US" xlink:label="lab_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of Asset and Liability for Lease of Acquiree</link:label>
    <link:label id="lab_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of Asset and Liability for Lease of Acquiree [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock" xlink:to="lab_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedLiabilitiesAxis_af5b913c-05ed-4026-a601-c6c3be3bce56_terseLabel_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Axis]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesAxis_label_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued liabilities [Axis]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesAxis_documentation_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesAxis" xlink:href="lxrx-20220630.xsd#lxrx_AccruedLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedLiabilitiesAxis" xlink:to="lab_lxrx_AccruedLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_1274a672-a5ba-471a-8ae4-a21528b679e4_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - Total Principal Amount</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - Total Principal Amount</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - Total Principal Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" xlink:href="lxrx-20220630.xsd#lxrx_ConvertibleDebtExchangeTotalPrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" xlink:to="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_44362f76-e779-42c3-956a-a3317d7b2f9a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_55eafec5-8fb0-4116-a94e-146094dd86bb_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_A2027OxfordPrincipalPayments_7302f539-c8d4-437e-9847-03667cd50f13_terseLabel_en-US" xlink:label="lab_lxrx_A2027OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Oxford Principal Payments2</link:label>
    <link:label id="lab_lxrx_A2027OxfordPrincipalPayments_label_en-US" xlink:label="lab_lxrx_A2027OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Oxford Principal Payments</link:label>
    <link:label id="lab_lxrx_A2027OxfordPrincipalPayments_documentation_en-US" xlink:label="lab_lxrx_A2027OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Oxford Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2027OxfordPrincipalPayments" xlink:href="lxrx-20220630.xsd#lxrx_A2027OxfordPrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_A2027OxfordPrincipalPayments" xlink:to="lab_lxrx_A2027OxfordPrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_b8495650-25ef-4b78-a553-c34af247f228_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_67e79283-f3c3-41ec-96da-b4bf7afcc98d_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_debaa8d2-4fd1-4840-89f5-4f2a0aba200f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_6f7346e2-5073-49b4-b937-20beaa8512ed_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20220630.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_6556bcba-aa8d-437b-8c2f-cdb068f7b76c_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_bd40efa4-e1e4-462f-9e06-1268f2648c1b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_974dad34-a0a5-4e04-8d76-a3b8c64c9a38_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_94dbab64-a241-410d-8410-aa760f63beba_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_d3ff23b3-ef0c-438f-897f-b364bfd64f2a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_051058f0-ee45-408e-818a-fcd768c3f429_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_99e599cd-f7e2-498f-8930-1029fed5b98a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8dbcf0f0-86c9-4b9d-ac98-78a7a06cf8b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_f4b6df68-5d42-42d5-9ac4-608798229033_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20220630.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_7070f19b-efb4-461f-8d37-99d54e6b61ff_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_cb246bb3-bc11-47e3-b659-afe286f41cf2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_3b86e2f8-c871-4938-bee1-c7a08c88929a_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_8184b286-2077-45ff-a296-cd6e8ae73703_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_7673ca22-7fa7-4465-b03c-87b1b268dce4_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties and other revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_label_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Income, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:to="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_643ee18e-c6e5-4cbc-8967-d042e024281a_terseLabel_en-US" xlink:label="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]</link:label>
    <link:label id="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_label_en-US" xlink:label="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]</link:label>
    <link:label id="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_documentation_en-US" xlink:label="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:href="lxrx-20220630.xsd#lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:to="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_c8af6b84-45b9-4020-953a-0d97521d3f95_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedLiabilitiesDomain_cd9e8625-071b-48ad-b37c-46a64c8aba62_terseLabel_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Domain]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesDomain_label_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Domain]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesDomain_documentation_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesDomain" xlink:href="lxrx-20220630.xsd#lxrx_AccruedLiabilitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedLiabilitiesDomain" xlink:to="lab_lxrx_AccruedLiabilitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_496002d0-4f64-4e95-9383-9b5d4a68ebfe_terseLabel_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with research and development expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with research and development expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense included in research and development expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:href="lxrx-20220630.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:to="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_648e5a44-6f61-4e35-99cd-8fd36baf1c54_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_e027c0ad-1c80-4afe-93ad-ca06ff725288_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_713f77b0-5852-4bac-9c4c-1575ab0c5cff_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_a8ef16b3-f36b-4a70-ac6a-df488f13fce5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ProceedsFromJuly2022Offering_f8ab4e9a-226a-4f5e-b9d8-c6fbc25f5f0a_terseLabel_en-US" xlink:label="lab_lxrx_ProceedsFromJuly2022Offering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from July 2022 Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromJuly2022Offering_label_en-US" xlink:label="lab_lxrx_ProceedsFromJuly2022Offering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from July 2022 Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromJuly2022Offering_documentation_en-US" xlink:label="lab_lxrx_ProceedsFromJuly2022Offering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from July 2022 Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromJuly2022Offering" xlink:href="lxrx-20220630.xsd#lxrx_ProceedsFromJuly2022Offering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ProceedsFromJuly2022Offering" xlink:to="lab_lxrx_ProceedsFromJuly2022Offering" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharePriceInSeptember2021ATMOfferring_2f80e66f-d03b-48ad-9594-cc8d020f140d_terseLabel_en-US" xlink:label="lab_lxrx_SharePriceInSeptember2021ATMOfferring" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price in September 2021 ATM Offerring</link:label>
    <link:label id="lab_lxrx_SharePriceInSeptember2021ATMOfferring_label_en-US" xlink:label="lab_lxrx_SharePriceInSeptember2021ATMOfferring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price in September 2021 ATM Offerring</link:label>
    <link:label id="lab_lxrx_SharePriceInSeptember2021ATMOfferring_documentation_en-US" xlink:label="lab_lxrx_SharePriceInSeptember2021ATMOfferring" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price in September 2021 ATM Offerring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInSeptember2021ATMOfferring" xlink:href="lxrx-20220630.xsd#lxrx_SharePriceInSeptember2021ATMOfferring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharePriceInSeptember2021ATMOfferring" xlink:to="lab_lxrx_SharePriceInSeptember2021ATMOfferring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40ecb841-7e46-44f5-bb91-707a82e3b71e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_4a134adf-15b0-4272-af4a-c21b73ab821f_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4c0a02bc-052a-45eb-bb44-7386d2ce8cd7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_3de0debb-99f3-43ab-a5ef-475c6b9c96c0_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_62be6e7c-64a1-4d02-bbab-fe3d0c93ef31_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1e7bf14f-9af7-4632-b74d-21e0bb0c052a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation and amortization of $5,070 and $4,853, respectively</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_296c26d8-7344-405f-a80a-a04359fb2176_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_bd36276c-ae61-41c6-9ad4-0b8253fda686_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of debt borrowings, net of fees</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenRevenueRecognized_76090707-aa25-460e-a831-d5b27d665acf_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Recognized</link:label>
    <link:label id="lab_lxrx_IpsenRevenueRecognized_label_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Recognized</link:label>
    <link:label id="lab_lxrx_IpsenRevenueRecognized_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueRecognized" xlink:href="lxrx-20220630.xsd#lxrx_IpsenRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueRecognized" xlink:to="lab_lxrx_IpsenRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_057b1c52-87c6-4967-aca6-9d3772bcd844_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenMilestonePayment_607083b0-26b7-4d2b-ac5f-476936ed36aa_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Milestone Payment</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePayment_label_en-US" xlink:label="lab_lxrx_IpsenMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Milestone Payment</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePayment_documentation_en-US" xlink:label="lab_lxrx_IpsenMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the milestone payments received under the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMilestonePayment" xlink:href="lxrx-20220630.xsd#lxrx_IpsenMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMilestonePayment" xlink:to="lab_lxrx_IpsenMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_c9c15f52-c6f3-4a07-9f55-842edbd11263_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost, 488 and 1,165 shares, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_A2025OxfordPrincipalPayments_142ddd52-78a5-49e9-9e31-2a084fe3817c_terseLabel_en-US" xlink:label="lab_lxrx_A2025OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026 Oxford Principal Payments</link:label>
    <link:label id="lab_lxrx_A2025OxfordPrincipalPayments_label_en-US" xlink:label="lab_lxrx_A2025OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 Oxford Principal Payments</link:label>
    <link:label id="lab_lxrx_A2025OxfordPrincipalPayments_documentation_en-US" xlink:label="lab_lxrx_A2025OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 Oxford Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2025OxfordPrincipalPayments" xlink:href="lxrx-20220630.xsd#lxrx_A2025OxfordPrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_A2025OxfordPrincipalPayments" xlink:to="lab_lxrx_A2025OxfordPrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_eddbfa2f-1429-4c25-adae-fc4b06f13d42_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_780cd6e6-140b-4265-bcee-398c37bea74c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2f77de00-b31d-4fb4-80d2-8e334f1f0941_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_acc40937-dc8b-4eb8-81b3-df68492fcd5b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_07802d98-4352-4c8a-a1e5-fa51f6b7523f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of deferred issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_fbf0e9ca-f68e-4338-9a4e-493970696202_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of deferred issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8785c99f-9707-4212-b360-0fd9ef840401_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_966a7d99-b5f5-4604-a0cc-de5b003ceb96_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanAFinalPayment_852ced2d-e169-440d-8be3-8415455fe573_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanAFinalPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Final Payment</link:label>
    <link:label id="lab_lxrx_TermLoanAFinalPayment_label_en-US" xlink:label="lab_lxrx_TermLoanAFinalPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Final Payment</link:label>
    <link:label id="lab_lxrx_TermLoanAFinalPayment_documentation_en-US" xlink:label="lab_lxrx_TermLoanAFinalPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Final Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAFinalPayment" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanAFinalPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanAFinalPayment" xlink:to="lab_lxrx_TermLoanAFinalPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_0752ca6c-eea0-4aa3-8aa1-fb73a0572faf_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:href="lxrx-20220630.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_aebdaa1e-82e3-4c31-a560-52044880aa9f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_90352801-b72e-4d0c-910f-2276da380e88_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease) (Deprecated 2022)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_3b35d05f-3404-4080-8a8f-d9d619c45657_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_dc601b5a-cb49-4791-b3ec-dde3d7f54d27_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b9db2a5-65fd-432f-9540-d05820aa9197_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_9f96a149-4c34-43b0-84c6-a0b03d7d4407_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9ded2266-d7cd-43b5-b544-c8f4d0bc8155_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aed2dab0-f9c6-4d43-bdaa-68786d409661_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_4fc62a80-797f-4a91-8cc9-f35e5db8dd71_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Equity Incentive Plans, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_fd337e50-f760-4fee-b6b8-99bd9602efbc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Equity Incentive Plans, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_b60e1a12-c7e9-4c2e-a4f5-d6d5613fdf35_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Fair Value of Amount Outstanding</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Fair Value of Amount Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:to="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharePriceInJuly2022Offering_4b55bfc5-92d8-4651-bb40-a4c17dc52016_terseLabel_en-US" xlink:label="lab_lxrx_SharePriceInJuly2022Offering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price in July 2022 Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInJuly2022Offering_label_en-US" xlink:label="lab_lxrx_SharePriceInJuly2022Offering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price in July 2022 Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInJuly2022Offering_documentation_en-US" xlink:label="lab_lxrx_SharePriceInJuly2022Offering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price in July 2022 Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInJuly2022Offering" xlink:href="lxrx-20220630.xsd#lxrx_SharePriceInJuly2022Offering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharePriceInJuly2022Offering" xlink:to="lab_lxrx_SharePriceInJuly2022Offering" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_c3dd694f-5bcf-4c8e-85ea-3727621f43b3_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1dd3eade-d4d6-488e-8d51-990a310f540e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_fcecb7a8-5b59-40d3-98cb-8ccf7cd482ab_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Current</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7eba8158-c749-4ea6-a87a-2aed186a6f8f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ef00a90f-2c4f-48d2-8ffc-7e857b88071b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_a580dea1-f425-43e5-9c4a-bba904a85c05_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_b1f4acd9-30c7-41f1-8d5d-8050a5c02700_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_7754e50a-52d9-4e76-aaa6-290498ec913b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharesSoldInSeptember2021ATMOfferring_1cf68d00-14aa-440e-b8c8-e0a40fc8ee15_terseLabel_en-US" xlink:label="lab_lxrx_SharesSoldInSeptember2021ATMOfferring" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in September 2021 ATM Offerring</link:label>
    <link:label id="lab_lxrx_SharesSoldInSeptember2021ATMOfferring_label_en-US" xlink:label="lab_lxrx_SharesSoldInSeptember2021ATMOfferring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in September 2021 ATM Offerring</link:label>
    <link:label id="lab_lxrx_SharesSoldInSeptember2021ATMOfferring_documentation_en-US" xlink:label="lab_lxrx_SharesSoldInSeptember2021ATMOfferring" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in September 2021 ATM Offerring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInSeptember2021ATMOfferring" xlink:href="lxrx-20220630.xsd#lxrx_SharesSoldInSeptember2021ATMOfferring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesSoldInSeptember2021ATMOfferring" xlink:to="lab_lxrx_SharesSoldInSeptember2021ATMOfferring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_b590ef1d-fb4b-4b2c-866b-1f1c700c7f1f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e725caf8-8b6d-43e8-89b3-eec1c8594cbb_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharePriceInJanuary2021ATMOffering_0b661d92-8c6b-4cd0-aefb-5e8ac52c871e_terseLabel_en-US" xlink:label="lab_lxrx_SharePriceInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in January 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInJanuary2021ATMOffering_label_en-US" xlink:label="lab_lxrx_SharePriceInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in January 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInJanuary2021ATMOffering_documentation_en-US" xlink:label="lab_lxrx_SharePriceInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in January 2021 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInJanuary2021ATMOffering" xlink:href="lxrx-20220630.xsd#lxrx_SharePriceInJanuary2021ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharePriceInJanuary2021ATMOffering" xlink:to="lab_lxrx_SharePriceInJanuary2021ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_35b1ff5b-28ab-44cd-b0e7-f709f6028820_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_4075fa31-d06a-4d5e-9d61-19b6bcb9164a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_61d73a0e-a8eb-4bf6-a983-f80f2d48e7f2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_6aeb9245-ee51-45eb-a650-a4f9d33ebed0_terseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_c8d8fa4d-6a8c-4618-81dc-38a88f3e475f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0204c87a-8fb3-4da1-bfdc-093e9094e69a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_6362e2af-cb4c-4e5e-98e9-4431c04ce53c_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_ca0f330b-2752-4784-8f10-e43ee5b2e88b_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SettlementPaymentFromTermination_4baf8aa3-6b72-446a-907c-577efd976e98_terseLabel_en-US" xlink:label="lab_lxrx_SettlementPaymentFromTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Payment from Termination</link:label>
    <link:label id="lab_lxrx_SettlementPaymentFromTermination_label_en-US" xlink:label="lab_lxrx_SettlementPaymentFromTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Payment from Termination</link:label>
    <link:label id="lab_lxrx_SettlementPaymentFromTermination_documentation_en-US" xlink:label="lab_lxrx_SettlementPaymentFromTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Payment from Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SettlementPaymentFromTermination" xlink:href="lxrx-20220630.xsd#lxrx_SettlementPaymentFromTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SettlementPaymentFromTermination" xlink:to="lab_lxrx_SettlementPaymentFromTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_fa303d2d-3f91-4d8c-b4be-8ac3c7fdd236_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanABWarrant_3019f321-cfe6-4dec-8547-d33b191696af_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanABWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A&amp;B Warrant %</link:label>
    <link:label id="lab_lxrx_TermLoanABWarrant_label_en-US" xlink:label="lab_lxrx_TermLoanABWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A&amp;B Warrant %</link:label>
    <link:label id="lab_lxrx_TermLoanABWarrant_documentation_en-US" xlink:label="lab_lxrx_TermLoanABWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A&amp;B Warrant %</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanABWarrant" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanABWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanABWarrant" xlink:to="lab_lxrx_TermLoanABWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b5d8081d-65f8-4c54-8358-ab61b9d434ca_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanANetCashReceipt_2ecda950-d8b5-4eba-99a1-c9a0479eb4a8_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanANetCashReceipt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Net Cash Receipt</link:label>
    <link:label id="lab_lxrx_TermLoanANetCashReceipt_label_en-US" xlink:label="lab_lxrx_TermLoanANetCashReceipt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Net Cash Receipt</link:label>
    <link:label id="lab_lxrx_TermLoanANetCashReceipt_documentation_en-US" xlink:label="lab_lxrx_TermLoanANetCashReceipt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Net Cash Receipt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanANetCashReceipt" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanANetCashReceipt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanANetCashReceipt" xlink:to="lab_lxrx_TermLoanANetCashReceipt" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ProceedsFromJanuary2021ATMOffering_11a7c143-119c-4545-a796-65765b0df56f_terseLabel_en-US" xlink:label="lab_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from January 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromJanuary2021ATMOffering_label_en-US" xlink:label="lab_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from January 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromJanuary2021ATMOffering_documentation_en-US" xlink:label="lab_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from January 2021 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:href="lxrx-20220630.xsd#lxrx_ProceedsFromJanuary2021ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:to="lab_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_9e002100-d2b7-46af-b658-7669105ec023_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_e122b5f4-4abb-4e83-bdbf-260b661c7221_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_599dbcd5-7e50-4efe-9835-b775449c1f07_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_f9d39ac2-e961-4b14-a02b-bea184996539_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubordinatedBorrowingInterestRate_601548dc-9205-4dc5-acd4-a8deb6fd12b6_terseLabel_en-US" xlink:label="lab_us-gaap_SubordinatedBorrowingInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subordinated Borrowing, Interest Rate</link:label>
    <link:label id="lab_us-gaap_SubordinatedBorrowingInterestRate_label_en-US" xlink:label="lab_us-gaap_SubordinatedBorrowingInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subordinated Borrowing, Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubordinatedBorrowingInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubordinatedBorrowingInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubordinatedBorrowingInterestRate" xlink:to="lab_us-gaap_SubordinatedBorrowingInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_82c79680-5bf4-49f0-8d3c-7e86241de150_terseLabel_en-US" xlink:label="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with selling, general and administrative expense</link:label>
    <link:label id="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_label_en-US" xlink:label="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with selling, general and administrative expense</link:label>
    <link:label id="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_documentation_en-US" xlink:label="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with selling, general and administrative expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:href="lxrx-20220630.xsd#lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:to="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_9a5230f1-84fd-4b4d-883f-2b760d0ef048_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_dd6911db-95a0-4abd-9dfc-b34bdce56ea4_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_5b8feae7-a67b-4779-8a7a-5edf5f5e3773_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_38f82287-e5df-458a-bee0-912cc4722e68_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_936d290c-1efc-4951-847a-8dad6276896b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedBalanceSheetsAbstract_a36f9519-b553-4618-b8e0-b77eb0c0d6fc_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedBalanceSheetsAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedBalanceSheetsAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:href="lxrx-20220630.xsd#lxrx_ConsolidatedBalanceSheetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:to="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_59ea406c-74be-4c08-9f1d-507412f91b56_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_2c514450-96a0-4fb4-b1fb-5d5d30dc3928_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b414120e-49e4-47b7-b6c0-0f6a01c57de0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharesSoldInJanuary2021ATMOffering_2df1670a-bbf3-45cb-b309-9ded5cbafb64_terseLabel_en-US" xlink:label="lab_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in January 2021 ATM offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInJanuary2021ATMOffering_label_en-US" xlink:label="lab_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in January 2021 ATM offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInJanuary2021ATMOffering_documentation_en-US" xlink:label="lab_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in January 2021 ATM offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:href="lxrx-20220630.xsd#lxrx_SharesSoldInJanuary2021ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:to="lab_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_8371f3b2-bdee-47b7-87c6-07e36e5c9e28_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_261b3fa7-2070-4779-b935-e583a9d23c9a_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury Securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_84e5c3d5-aad5-42a8-8f81-984cec2010d9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_753fabd1-271e-4dc3-8ad8-55739fa7ca09_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt, net of deferred issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_742fe530-7176-4bf3-92bb-7fdb33e0db64_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_78316dc9-dad1-4632-b84b-77f78e803db9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_LexiconIncrementalBorrowingRate_94fd04b8-fddf-4655-a27c-292473d71f56_terseLabel_en-US" xlink:label="lab_lxrx_LexiconIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lexicon incremental borrowing rate</link:label>
    <link:label id="lab_lxrx_LexiconIncrementalBorrowingRate_label_en-US" xlink:label="lab_lxrx_LexiconIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lexicon incremental borrowing rate</link:label>
    <link:label id="lab_lxrx_LexiconIncrementalBorrowingRate_documentation_en-US" xlink:label="lab_lxrx_LexiconIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lexicon incremental borrowing rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LexiconIncrementalBorrowingRate" xlink:href="lxrx-20220630.xsd#lxrx_LexiconIncrementalBorrowingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_LexiconIncrementalBorrowingRate" xlink:to="lab_lxrx_LexiconIncrementalBorrowingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeRemainingNotes_48372929-5c49-4501-89bb-a9fe95de919c_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeRemainingNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange Remaining Notes</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeRemainingNotes_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeRemainingNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange Remaining Notes</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeRemainingNotes_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeRemainingNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange Remaining Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeRemainingNotes" xlink:href="lxrx-20220630.xsd#lxrx_ConvertibleDebtExchangeRemainingNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtExchangeRemainingNotes" xlink:to="lab_lxrx_ConvertibleDebtExchangeRemainingNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_3a3992ae-5921-4d33-aa05-2cdb4ef8397b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_321428fe-4dae-452c-8efb-c340a0311974_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenTotalPayments_79c8de7d-c065-4d91-b013-0b589f5cd778_terseLabel_en-US" xlink:label="lab_lxrx_IpsenTotalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Total Payments</link:label>
    <link:label id="lab_lxrx_IpsenTotalPayments_label_en-US" xlink:label="lab_lxrx_IpsenTotalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Total Payments</link:label>
    <link:label id="lab_lxrx_IpsenTotalPayments_documentation_en-US" xlink:label="lab_lxrx_IpsenTotalPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the total payments received to date under the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenTotalPayments" xlink:href="lxrx-20220630.xsd#lxrx_IpsenTotalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenTotalPayments" xlink:to="lab_lxrx_IpsenTotalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_c3a1d302-3e3a-405c-b74c-147db8693106_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_5cd1cb60-2b92-4480-bcc7-0b0dde4da915_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - September share payment</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - September share payment</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - September share payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberSharePayment" xlink:href="lxrx-20220630.xsd#lxrx_ConvertibleDebtExchangeSeptemberSharePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtExchangeSeptemberSharePayment" xlink:to="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ee93cf5e-9309-443f-8e6f-23a34d595dcb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_b608ac11-ca38-466f-a7cb-53319ed2f08d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_bf4a7dba-6b02-4fb5-b2ee-ded9b197b599_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_de4fd53b-b29b-4f7b-862b-338cddda85f2_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_59f4ff47-82ea-4a66-b59a-c6f1e676e53e_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_3004751b-4ecc-4c32-9bbe-a87e16ae449a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_07d6c46f-5f34-40ce-8894-1e04c55c4c7c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing net loss per common share, Basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ab0a87d-4cb9-4fd0-a559-bdb46ea99254_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_3b9a9e9d-0ef9-4999-b1dd-918a1575daba_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_85c2a23d-46a6-41aa-91e0-e9f6572c5d14_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_31184e29-c907-4e79-9920-0283473f2122_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_e10df580-41c9-4b4a-a6b8-8252b6ee2d11_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanAWarrantsNumber_f69a61f6-67bc-4010-9a59-07fd4d8a7f72_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanAWarrantsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Warrants Number</link:label>
    <link:label id="lab_lxrx_TermLoanAWarrantsNumber_label_en-US" xlink:label="lab_lxrx_TermLoanAWarrantsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Warrants Number</link:label>
    <link:label id="lab_lxrx_TermLoanAWarrantsNumber_documentation_en-US" xlink:label="lab_lxrx_TermLoanAWarrantsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Warrants Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAWarrantsNumber" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanAWarrantsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanAWarrantsNumber" xlink:to="lab_lxrx_TermLoanAWarrantsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_add3c208-67d7-40b3-910b-aed59af1e589_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_8ebc5d23-73ff-4db5-8f1b-ce5e951356aa_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c9c3c750-0953-4bf9-be79-acb135cca4af_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30edd245-8e81-434f-8e6b-3828c16e136f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0ab38cdb-299d-458a-94ac-30d623f41e1d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Equity Incentive Plans, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_5f078216-7576-485e-ab5d-b241857e9c6c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_1e980e48-e7d6-49c7-bb1b-b2ef8c968818_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_e384457d-7378-46ca-8cc9-e1ff89f6db90_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.01 par value; 5,000 shares authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanD_1513a22d-b9d5-477e-a568-fc55a505c6b3_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan D</link:label>
    <link:label id="lab_lxrx_TermLoanD_label_en-US" xlink:label="lab_lxrx_TermLoanD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan D</link:label>
    <link:label id="lab_lxrx_TermLoanD_documentation_en-US" xlink:label="lab_lxrx_TermLoanD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan D</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanD" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanD" xlink:to="lab_lxrx_TermLoanD" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_OtherCapitalAgreementsTextBlock_0b30ec99-2ef2-486e-811a-21170fc70777_terseLabel_en-US" xlink:label="lab_lxrx_OtherCapitalAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Capital Agreements</link:label>
    <link:label id="lab_lxrx_OtherCapitalAgreementsTextBlock_label_en-US" xlink:label="lab_lxrx_OtherCapitalAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Capital Agreements [Text Block]</link:label>
    <link:label id="lab_lxrx_OtherCapitalAgreementsTextBlock_documentation_en-US" xlink:label="lab_lxrx_OtherCapitalAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Capital Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OtherCapitalAgreementsTextBlock" xlink:href="lxrx-20220630.xsd#lxrx_OtherCapitalAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OtherCapitalAgreementsTextBlock" xlink:to="lab_lxrx_OtherCapitalAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanC_46d85ef8-168b-4b9c-8a28-872feb8cb915_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan C</link:label>
    <link:label id="lab_lxrx_TermLoanC_label_en-US" xlink:label="lab_lxrx_TermLoanC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan C</link:label>
    <link:label id="lab_lxrx_TermLoanC_documentation_en-US" xlink:label="lab_lxrx_TermLoanC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan C</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanC" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanC" xlink:to="lab_lxrx_TermLoanC" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4d585032-bb93-46fc-aa42-95adb1e3ad08_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreements</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanB_0e560c8a-db5b-4f49-a376-5e05b835c182_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B</link:label>
    <link:label id="lab_lxrx_TermLoanB_label_en-US" xlink:label="lab_lxrx_TermLoanB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B</link:label>
    <link:label id="lab_lxrx_TermLoanB_documentation_en-US" xlink:label="lab_lxrx_TermLoanB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanB" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanB" xlink:to="lab_lxrx_TermLoanB" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_342832d1-6f56-4964-823c-64c1ff552124_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanA_c81faffc-c6fe-4d7d-9133-4a25f699cb57_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A</link:label>
    <link:label id="lab_lxrx_TermLoanA_label_en-US" xlink:label="lab_lxrx_TermLoanA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A</link:label>
    <link:label id="lab_lxrx_TermLoanA_documentation_en-US" xlink:label="lab_lxrx_TermLoanA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanA" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanA" xlink:to="lab_lxrx_TermLoanA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTerm_2e6b0c07-42bc-4470-8cab-6687c1980d9f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Term</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTerm_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTerm" xlink:to="lab_us-gaap_LongTermDebtTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_7a9d620f-a9c7-4d7e-a80c-1e12284de9dd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_ee275227-22b9-4519-a8de-33091d1d1fea_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f88d8d34-fcae-46ac-862b-1639db89f8cb_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, value</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_50e6ab6f-4d39-4803-984c-8016ac022d3f_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, value</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_23d79de7-43b1-49df-a33a-c171c4ebc765_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_bdf66f6f-97f7-47f1-ba5c-68f6a83b4f03_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_5f4fd92c-e85d-421c-b85a-45591052dd04_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_23f9c05e-f30b-4731-843b-f831d6291228_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_b29e461d-8aca-4325-8e07-5fdb6b8a3046_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value per share</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_9e99cc28-057a-4d4a-b2b5-ba060d3f18e5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d5ea3a9a-72e3-41cf-913d-247008d7a773_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateAxis_6a5258b1-2de9-4b66-bbc9-e4f718eef513_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardDateAxis_label_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateAxis" xlink:to="lab_us-gaap_AwardDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_8df15479-1795-4f36-a888-a020f793fadc_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_2ad5d1d4-6db6-47c3-9620-85e6362e421a_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b90d168d-6798-481a-9d7a-54e2ba24957c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_e6472367-9c9b-4454-b893-39850c2df1f3_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The expected term assumption that is used in valuing an option on its own shares for employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:href="lxrx-20220630.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_627219ff-dad4-41df-b9c3-4f00d8815b76_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development, including stock-based compensation of $1,098, $1,184, $2,130 and $2,470 respectively</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_cc30594c-ea73-4a15-919a-eca3afa4f593_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Lxrx_Sanofiterminationcashpayment_85ea5d30-543b-49ab-b164-ccc91374f165_terseLabel_en-US" xlink:label="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi termination cash payment</link:label>
    <link:label id="lab_lxrx_Lxrx_Sanofiterminationcashpayment_label_en-US" xlink:label="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_Sanofi termination cash payment</link:label>
    <link:label id="lab_lxrx_Lxrx_Sanofiterminationcashpayment_documentation_en-US" xlink:label="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_Sanofi termination cash payment - represents the cash payment from Sanofi to terminate the collaboration alliance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:href="lxrx-20220630.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:to="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_224e02fe-aa62-4b27-b675-3d5412d23f18_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate</link:label>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_label_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_7af88293-f9ca-461c-a687-9f38530b249a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_256431cd-1217-428e-9672-a683e3efd06d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_38a55034-a982-4ef4-89b6-aac36cefa10e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_5cdc06a7-922f-4bfb-8d35-5144126c3a54_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:href="lxrx-20220630.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_69cfa86b-2688-479b-8799-bb87191d227c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalIncomeStatementElementsAbstract_f871a102-f789-4875-8e63-cf7c61e3052a_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalIncomeStatementElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Income Statement Elements [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalIncomeStatementElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalIncomeStatementElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Income Statement Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalIncomeStatementElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalIncomeStatementElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalIncomeStatementElementsAbstract" xlink:to="lab_us-gaap_SupplementalIncomeStatementElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_58402074-bd0f-411b-9173-8d6dbdaf57d8_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3ca96ebe-4a31-413a-9825-28834b902920_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_9dbe4ed2-2a19-4e72-afe7-692c18959e35_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_5b33f737-03c2-47c5-9f4c-5e9546d33ba0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_dbefad53-0896-42b0-947a-cf085c6c81ca_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange- September cash portion</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange- September cash portion</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange- September cash portion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberCashPortion" xlink:href="lxrx-20220630.xsd#lxrx_ConvertibleDebtExchangeSeptemberCashPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtExchangeSeptemberCashPortion" xlink:to="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_8caae3af-cd71-44dd-91c5-5b4f4c93313b_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_30fc764f-ec46-4866-9ea0-3f9d2beb5381_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_12aeaf53-7441-46ca-8aad-8791ddf2f215_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to Development Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_label_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to Development Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the development services deliverable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:href="lxrx-20220630.xsd#lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:to="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_fa07ded6-f816-443d-91c4-3676b54c18eb_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8cdbfe41-d1a7-4f0a-ba3a-c0c1340ae7f9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_PrincipalAmountOfConvertibleNotes_bf7f6a7f-acfa-492e-bbdc-057daa4b0c58_terseLabel_en-US" xlink:label="lab_lxrx_PrincipalAmountOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">principal amount of convertible notes</link:label>
    <link:label id="lab_lxrx_PrincipalAmountOfConvertibleNotes_label_en-US" xlink:label="lab_lxrx_PrincipalAmountOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">principal amount of convertible notes</link:label>
    <link:label id="lab_lxrx_PrincipalAmountOfConvertibleNotes_documentation_en-US" xlink:label="lab_lxrx_PrincipalAmountOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">principal amount of convertible notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PrincipalAmountOfConvertibleNotes" xlink:href="lxrx-20220630.xsd#lxrx_PrincipalAmountOfConvertibleNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_PrincipalAmountOfConvertibleNotes" xlink:to="lab_lxrx_PrincipalAmountOfConvertibleNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_41ed4cbf-addc-47ab-a7c3-139eca796473_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ProceedsFromSeptember2021ATMOffering_ce855771-d335-42dd-bb08-b502a68643f7_terseLabel_en-US" xlink:label="lab_lxrx_ProceedsFromSeptember2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from September 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromSeptember2021ATMOffering_label_en-US" xlink:label="lab_lxrx_ProceedsFromSeptember2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from September 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromSeptember2021ATMOffering_documentation_en-US" xlink:label="lab_lxrx_ProceedsFromSeptember2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from September 2021 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromSeptember2021ATMOffering" xlink:href="lxrx-20220630.xsd#lxrx_ProceedsFromSeptember2021ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ProceedsFromSeptember2021ATMOffering" xlink:to="lab_lxrx_ProceedsFromSeptember2021ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_69a03e82-e5ab-4921-b655-345e00f3c7cb_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent_2b6e49a7-c407-42c4-818c-b5301d6001a2_terseLabel_en-US" xlink:label="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development services current</link:label>
    <link:label id="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent_label_en-US" xlink:label="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development services current</link:label>
    <link:label id="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent_documentation_en-US" xlink:label="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development services current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:href="lxrx-20220630.xsd#lxrx_AccruedResearchAndDevelopmentServicesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:to="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharesSoldInNov2020ATMOffering_ba42dae8-07e7-4af1-b165-89b3de30cc42_terseLabel_en-US" xlink:label="lab_lxrx_SharesSoldInNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in Nov 2020 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInNov2020ATMOffering_label_en-US" xlink:label="lab_lxrx_SharesSoldInNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in Nov 2020 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInNov2020ATMOffering_documentation_en-US" xlink:label="lab_lxrx_SharesSoldInNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in Nov 2020 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInNov2020ATMOffering" xlink:href="lxrx-20220630.xsd#lxrx_SharesSoldInNov2020ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesSoldInNov2020ATMOffering" xlink:to="lab_lxrx_SharesSoldInNov2020ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0916396c-9c41-4558-bf9c-16f2f1bd0c7a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5ebfae25-1f76-4c3e-b436-8b4284b434d8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_35c1bb26-20a6-470f-bdf8-ec5803a17bdd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedLiabilitiesTable_9d90208b-3dd5-4f7e-9a2e-8a5a3aa1caa8_terseLabel_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Table]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesTable_label_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued liabilities [Table]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesTable_documentation_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued liabilities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesTable" xlink:href="lxrx-20220630.xsd#lxrx_AccruedLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedLiabilitiesTable" xlink:to="lab_lxrx_AccruedLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredLongTermDebt_a82c6fd4-3dc0-4cc9-a3a2-3610ffb95ee1_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Long-Term Debt, Noncurrent</link:label>
    <link:label id="lab_us-gaap_SecuredLongTermDebt_label_en-US" xlink:label="lab_us-gaap_SecuredLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Long-Term Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredLongTermDebt" xlink:to="lab_us-gaap_SecuredLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bf553d75-fe5d-404d-8731-e856f2528616_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_8352498a-9cf6-4ba8-a0cf-2805a017617a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_02282d9f-f0e2-4d1a-9b64-0a81fc46cafb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per common share, Basic</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_A2026OxfordPrincipalPayments_949e6af3-26b2-4cb3-9091-3d8686800ac8_terseLabel_en-US" xlink:label="lab_lxrx_A2026OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Oxford Principal Payments</link:label>
    <link:label id="lab_lxrx_A2026OxfordPrincipalPayments_label_en-US" xlink:label="lab_lxrx_A2026OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026 Oxford Principal Payments</link:label>
    <link:label id="lab_lxrx_A2026OxfordPrincipalPayments_documentation_en-US" xlink:label="lab_lxrx_A2026OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026 Oxford Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2026OxfordPrincipalPayments" xlink:href="lxrx-20220630.xsd#lxrx_A2026OxfordPrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_A2026OxfordPrincipalPayments" xlink:to="lab_lxrx_A2026OxfordPrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanCWarrant_09091a74-3013-41d4-b654-4d50933b726f_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanCWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan C Warrant %</link:label>
    <link:label id="lab_lxrx_TermLoanCWarrant_label_en-US" xlink:label="lab_lxrx_TermLoanCWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan C Warrant %</link:label>
    <link:label id="lab_lxrx_TermLoanCWarrant_documentation_en-US" xlink:label="lab_lxrx_TermLoanCWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan C Warrant %</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanCWarrant" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanCWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanCWarrant" xlink:to="lab_lxrx_TermLoanCWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_665afc14-23ff-402c-8ccc-3e36bb92dd26_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_7330d352-fd95-4f52-a23b-f70938336ab5_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanADebtIssuanceCosts_459fdede-79ba-4343-b5b5-3d74aaa77f4b_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanADebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Debt Issuance Costs</link:label>
    <link:label id="lab_lxrx_TermLoanADebtIssuanceCosts_label_en-US" xlink:label="lab_lxrx_TermLoanADebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Debt Issuance Costs</link:label>
    <link:label id="lab_lxrx_TermLoanADebtIssuanceCosts_documentation_en-US" xlink:label="lab_lxrx_TermLoanADebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanADebtIssuanceCosts" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanADebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanADebtIssuanceCosts" xlink:to="lab_lxrx_TermLoanADebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_RecentAccountingPronouncementsAbstract_13ea942c-f2c1-42f3-851b-f98e6b32a7f7_terseLabel_en-US" xlink:label="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:label id="lab_lxrx_RecentAccountingPronouncementsAbstract_label_en-US" xlink:label="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:label id="lab_lxrx_RecentAccountingPronouncementsAbstract_documentation_en-US" xlink:label="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RecentAccountingPronouncementsAbstract" xlink:href="lxrx-20220630.xsd#lxrx_RecentAccountingPronouncementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_RecentAccountingPronouncementsAbstract" xlink:to="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_b67e706b-f208-421d-af4c-e3c27f35a3b6_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:href="lxrx-20220630.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_6fc1acc5-aa01-40d7-9109-a45cdc8afc81_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_329e01e1-c1cf-449c-8671-43b06b44f19b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenMilestonePaymentReceived_8d8652e1-b0f4-406c-8309-01c62b593eb7_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Milestone Payment Received</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePaymentReceived_label_en-US" xlink:label="lab_lxrx_IpsenMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Milestone Payment Received</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePaymentReceived_documentation_en-US" xlink:label="lab_lxrx_IpsenMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of milestone payments earned during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMilestonePaymentReceived" xlink:href="lxrx-20220630.xsd#lxrx_IpsenMilestonePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMilestonePaymentReceived" xlink:to="lab_lxrx_IpsenMilestonePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_f6c4f892-aeb6-43d7-9328-5ef4c32f3508_terseLabel_en-US" xlink:label="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:href="lxrx-20220630.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:to="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_15bdf2d8-cfae-434c-8739-73b8d8efd299_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_13d55830-dd2f-49db-a70b-86a859e21a8e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_a533ab3d-7ab7-451f-bc94-ea76d0c4ef5c_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholder's equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6980218f-6c57-47b4-9f83-e8c242554c48_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_4114eca4-e325-4674-ac9f-a9f1f4ed94ef_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_aa11cec6-b3cb-4d0b-8765-8cd4bdc7c808_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsMember_6bd7e33a-5296-4055-bd19-7dc7786ebe14_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cash and Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsMember_label_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsMember" xlink:to="lab_us-gaap_InvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_OxfordLoanFacility_f57ae023-a0bc-4d28-9a84-6df5a0a4d576_terseLabel_en-US" xlink:label="lab_lxrx_OxfordLoanFacility" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Loan Facility</link:label>
    <link:label id="lab_lxrx_OxfordLoanFacility_label_en-US" xlink:label="lab_lxrx_OxfordLoanFacility" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Loan Facility</link:label>
    <link:label id="lab_lxrx_OxfordLoanFacility_documentation_en-US" xlink:label="lab_lxrx_OxfordLoanFacility" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Loan Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OxfordLoanFacility" xlink:href="lxrx-20220630.xsd#lxrx_OxfordLoanFacility"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OxfordLoanFacility" xlink:to="lab_lxrx_OxfordLoanFacility" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_15e61817-68df-4634-ae7f-e497a758a3ce_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_e9142fc4-7d2c-4e4f-9393-a00cefd71b5d_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanADebtDiscount_1560c7c4-2b01-48b9-a253-64accffab76d_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanADebtDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Debt Discount</link:label>
    <link:label id="lab_lxrx_TermLoanADebtDiscount_label_en-US" xlink:label="lab_lxrx_TermLoanADebtDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Debt Discount</link:label>
    <link:label id="lab_lxrx_TermLoanADebtDiscount_documentation_en-US" xlink:label="lab_lxrx_TermLoanADebtDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Debt Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanADebtDiscount" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanADebtDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanADebtDiscount" xlink:to="lab_lxrx_TermLoanADebtDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_92191e0f-0475-4c54-a65c-72ab8e89ed6b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2e9347a8-467a-41b0-8772-18f83ebc2b1d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_cf3295e9-4cc5-40bf-9d60-180568a02a0e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_11c1cb37-8053-4802-81f8-c47288bcd0be_terseLabel_en-US" xlink:label="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments [Abstract]</link:label>
    <link:label id="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_label_en-US" xlink:label="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments [Abstract]</link:label>
    <link:label id="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_documentation_en-US" xlink:label="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:href="lxrx-20220630.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:to="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a36c3ff9-8e3f-4658-8ba9-f3d2fda46253_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_b843f51c-ecdc-4985-b407-6628cb2a1ab2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateDomain_f4b4015b-fa43-4f23-a57c-8f8441796813_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:label id="lab_us-gaap_AwardDateDomain_label_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateDomain" xlink:to="lab_us-gaap_AwardDateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_d339dbaf-d826-475a-b931-756c932783b4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_e751248e-925c-48fd-aee7-88cba3ca1674_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_OxfordFacilityFee_9c5bf5a4-a63e-4071-83b7-16efc6519477_terseLabel_en-US" xlink:label="lab_lxrx_OxfordFacilityFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Facility Fee</link:label>
    <link:label id="lab_lxrx_OxfordFacilityFee_label_en-US" xlink:label="lab_lxrx_OxfordFacilityFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Facility Fee</link:label>
    <link:label id="lab_lxrx_OxfordFacilityFee_documentation_en-US" xlink:label="lab_lxrx_OxfordFacilityFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Facility Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OxfordFacilityFee" xlink:href="lxrx-20220630.xsd#lxrx_OxfordFacilityFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OxfordFacilityFee" xlink:to="lab_lxrx_OxfordFacilityFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8bf06dce-dc64-4c30-8fd0-aa30a4d7ebb1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_c10683e0-2e54-4b4e-a3c6-730bc024a365_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_9ee97ee4-e03e-4a3c-9b16-f1e36b77cdda_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of cash and cash equivalents and investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_054a2d46-9d8c-4412-a99a-0353320d84c1_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_394623a9-c61e-4b04-99ea-6bd11974a2b4_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_b69a8327-01ad-46ad-926b-83b5bfdb8a00_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_677b29c4-7b9f-4391-8614-2a6c5e34df93_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_3614e36f-1445-43e1-a5f7-c1176afdb316_terseLabel_en-US" xlink:label="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_label_en-US" xlink:label="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_documentation_en-US" xlink:label="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:href="lxrx-20220630.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_InitialRecognitionOfRightOfUseAsset_3fd8118e-f380-4dd1-9946-71d6069d29a3_terseLabel_en-US" xlink:label="lab_lxrx_InitialRecognitionOfRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial recognition of right of use asset</link:label>
    <link:label id="lab_lxrx_InitialRecognitionOfRightOfUseAsset_label_en-US" xlink:label="lab_lxrx_InitialRecognitionOfRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial recognition of right of use asset</link:label>
    <link:label id="lab_lxrx_InitialRecognitionOfRightOfUseAsset_documentation_en-US" xlink:label="lab_lxrx_InitialRecognitionOfRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial recognition of right of use asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_InitialRecognitionOfRightOfUseAsset" xlink:href="lxrx-20220630.xsd#lxrx_InitialRecognitionOfRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_InitialRecognitionOfRightOfUseAsset" xlink:to="lab_lxrx_InitialRecognitionOfRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_401ef320-3116-407f-9f25-8e2e7cdaafdf_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_58de3eaa-f671-4db5-85cb-78e88b5e8852_terseLabel_en-US" xlink:label="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conv Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label id="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conv Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label id="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_documentation_en-US" xlink:label="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conv Debt Instrument Interest Rate Stated Percentage - contractual interest rate for convertible debt bonds under the debt agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:href="lxrx-20220630.xsd#lxrx_ConvDebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:to="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingActivityByTypeAxis_d5147bb5-2c5c-4511-a2fb-6bad2e9cf011_terseLabel_en-US" xlink:label="lab_us-gaap_TradingActivityByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Activity, by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_TradingActivityByTypeAxis_label_en-US" xlink:label="lab_us-gaap_TradingActivityByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Activity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingActivityByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingActivityByTypeAxis" xlink:to="lab_us-gaap_TradingActivityByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_d82526c6-efa8-4d2c-8e91-c1216d89e1fc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_f0100b27-3f2e-442f-bfdb-7ff30b751820_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_2b800257-b7b0-483c-b321-410dd7f88ff4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiDisputedCosts_61df5ebb-95da-4765-b51f-a2237d64b1f0_terseLabel_en-US" xlink:label="lab_lxrx_SanofiDisputedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Disputed Costs</link:label>
    <link:label id="lab_lxrx_SanofiDisputedCosts_label_en-US" xlink:label="lab_lxrx_SanofiDisputedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Disputed Costs</link:label>
    <link:label id="lab_lxrx_SanofiDisputedCosts_documentation_en-US" xlink:label="lab_lxrx_SanofiDisputedCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Disputed Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiDisputedCosts" xlink:href="lxrx-20220630.xsd#lxrx_SanofiDisputedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiDisputedCosts" xlink:to="lab_lxrx_SanofiDisputedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_93b7bc10-614b-47dc-84b6-fbcaf2da91e1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Lxrx_sanofiInitialCashPayment_f93e98ce-c52e-4480-bdce-2862ae979d89_terseLabel_en-US" xlink:label="lab_lxrx_Lxrx_sanofiInitialCashPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_sanofi initial cash payment</link:label>
    <link:label id="lab_lxrx_Lxrx_sanofiInitialCashPayment_label_en-US" xlink:label="lab_lxrx_Lxrx_sanofiInitialCashPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_sanofi initial cash payment</link:label>
    <link:label id="lab_lxrx_Lxrx_sanofiInitialCashPayment_documentation_en-US" xlink:label="lab_lxrx_Lxrx_sanofiInitialCashPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_sanofi initial cash payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_sanofiInitialCashPayment" xlink:href="lxrx-20220630.xsd#lxrx_Lxrx_sanofiInitialCashPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Lxrx_sanofiInitialCashPayment" xlink:to="lab_lxrx_Lxrx_sanofiInitialCashPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_8a4ab970-246f-42a1-9334-403be136c97d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_e0f2a89f-df04-4bef-85ca-f1f8c1401831_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_7eb15343-bc5e-4483-a727-05da573e33e7_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_07a7b8e0-f2a1-4aed-bfd1-a3fb02b67a25_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_22100138-e962-40ad-a6f4-4aaa517710fd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_7b5a3771-abab-423f-b16f-aee6c8fc51f9_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0891edc8-e9a8-4acd-bc58-54ba15186948_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharesSoldInJuly2022Offering_ed230478-a06c-4124-9c21-e951ff732e17_terseLabel_en-US" xlink:label="lab_lxrx_SharesSoldInJuly2022Offering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in July 2022 Offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInJuly2022Offering_label_en-US" xlink:label="lab_lxrx_SharesSoldInJuly2022Offering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in July 2022 Offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInJuly2022Offering_documentation_en-US" xlink:label="lab_lxrx_SharesSoldInJuly2022Offering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in July 2022 Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInJuly2022Offering" xlink:href="lxrx-20220630.xsd#lxrx_SharesSoldInJuly2022Offering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesSoldInJuly2022Offering" xlink:to="lab_lxrx_SharesSoldInJuly2022Offering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_97227d13-fb43-4a2f-9080-ec0a33278b47_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_29f962e8-93e8-4c81-9093-03b52b6d0965_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents Disclosure</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_957e35d0-4123-442e-a35b-13ae9bbf80f5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_55e4edf4-91fd-481f-a5de-85d90ea6fe8d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_889e62c2-1058-436a-ad04-54bd847ebd73_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_787d50a3-a77e-4b9a-b8d9-bd5688ea3286_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_7bea21b2-fda9-4913-a25f-b9dc7946bb43_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_5b81e88b-78cd-4711-a3b2-98ad9cf005e1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharePriceInNovember20ATMOffering_96626d9c-8bc8-4c45-811b-e531c11ea4cf_terseLabel_en-US" xlink:label="lab_lxrx_SharePriceInNovember20ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in November 20 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInNovember20ATMOffering_label_en-US" xlink:label="lab_lxrx_SharePriceInNovember20ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in November 20 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInNovember20ATMOffering_documentation_en-US" xlink:label="lab_lxrx_SharePriceInNovember20ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in November 20 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInNovember20ATMOffering" xlink:href="lxrx-20220630.xsd#lxrx_SharePriceInNovember20ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharePriceInNovember20ATMOffering" xlink:to="lab_lxrx_SharePriceInNovember20ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ATMOfferingTotal_ae9a5153-0e75-4b25-ada2-c0af00fb8d49_terseLabel_en-US" xlink:label="lab_lxrx_ATMOfferingTotal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Offering Total</link:label>
    <link:label id="lab_lxrx_ATMOfferingTotal_label_en-US" xlink:label="lab_lxrx_ATMOfferingTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Offering Total</link:label>
    <link:label id="lab_lxrx_ATMOfferingTotal_documentation_en-US" xlink:label="lab_lxrx_ATMOfferingTotal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Offering Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ATMOfferingTotal" xlink:href="lxrx-20220630.xsd#lxrx_ATMOfferingTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ATMOfferingTotal" xlink:to="lab_lxrx_ATMOfferingTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_3cddd16c-9518-4d09-9696-ef3505da1566_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7991a023-bbff-486f-b3eb-05cfd7f7e651_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eb6b9f1f-4bf8-4a98-bfb6-0644dc1fb7cd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_5aa53aa5-3040-488d-9945-0421ef0f33de_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Inputs, Disclosure</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Netproductrevenue_27532259-a1fb-4d7c-8b51-9e4fe9d497b9_terseLabel_en-US" xlink:label="lab_lxrx_Netproductrevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenue</link:label>
    <link:label id="lab_lxrx_Netproductrevenue_label_en-US" xlink:label="lab_lxrx_Netproductrevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenue</link:label>
    <link:label id="lab_lxrx_Netproductrevenue_documentation_en-US" xlink:label="lab_lxrx_Netproductrevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenue - amount of revenue recognized from product sales, net of discounts. Sales process constitutes an earnings process.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Netproductrevenue" xlink:href="lxrx-20220630.xsd#lxrx_Netproductrevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Netproductrevenue" xlink:to="lab_lxrx_Netproductrevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_4540d926-d023-4f15-b832-d10d6eba1859_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_58f6d55d-0558-483b-a8b5-f52d20ce311f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_e9765dc4-63c2-4584-8d40-e97b0a2ed2a0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanAInterestExpense_31298652-f141-4dd9-a06c-a214d5ac8218_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanAInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Interest Expense</link:label>
    <link:label id="lab_lxrx_TermLoanAInterestExpense_label_en-US" xlink:label="lab_lxrx_TermLoanAInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Interest Expense</link:label>
    <link:label id="lab_lxrx_TermLoanAInterestExpense_documentation_en-US" xlink:label="lab_lxrx_TermLoanAInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAInterestExpense" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanAInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanAInterestExpense" xlink:to="lab_lxrx_TermLoanAInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedInterestOnConvertible_9eb532a9-8850-4b04-8947-03282da66ee2_terseLabel_en-US" xlink:label="lab_lxrx_AccruedInterestOnConvertible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued interest on convertible</link:label>
    <link:label id="lab_lxrx_AccruedInterestOnConvertible_label_en-US" xlink:label="lab_lxrx_AccruedInterestOnConvertible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued interest on convertible</link:label>
    <link:label id="lab_lxrx_AccruedInterestOnConvertible_documentation_en-US" xlink:label="lab_lxrx_AccruedInterestOnConvertible" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued interest on convertible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedInterestOnConvertible" xlink:href="lxrx-20220630.xsd#lxrx_AccruedInterestOnConvertible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedInterestOnConvertible" xlink:to="lab_lxrx_AccruedInterestOnConvertible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_34db80db-dba4-45b5-9810-31df133fce05_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_7c66f3a3-1b0d-4454-9429-cd7b98c929d3_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_7505f8d2-f652-4c2e-8581-ee509f4c4dfb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiRevenueRecognized_a2b686a8-e6ae-4a6b-aedb-30db0aae69d6_terseLabel_en-US" xlink:label="lab_lxrx_SanofiRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Recognized</link:label>
    <link:label id="lab_lxrx_SanofiRevenueRecognized_label_en-US" xlink:label="lab_lxrx_SanofiRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Recognized</link:label>
    <link:label id="lab_lxrx_SanofiRevenueRecognized_documentation_en-US" xlink:label="lab_lxrx_SanofiRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the revenue recognized in the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueRecognized" xlink:href="lxrx-20220630.xsd#lxrx_SanofiRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiRevenueRecognized" xlink:to="lab_lxrx_SanofiRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40f01905-23e5-4691-87ed-21b91e0495b1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_60869616-1eb3-4531-a435-30e4b589f4a4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_d42b1b5c-2a29-42a6-b01f-878be8e2cbb2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8f743aa2-1f72-4bdb-9263-76cd7faf207c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_14519492-967b-4241-b9e0-083b18329348_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6612946c-9c44-498e-a1ef-5d07fe9f3b25_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedLiabilitiesLineItems_4133a683-626f-4589-b520-b9a584c7c06b_terseLabel_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Line Items]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesLineItems_label_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Line Items]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesLineItems_documentation_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesLineItems" xlink:href="lxrx-20220630.xsd#lxrx_AccruedLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems" xlink:to="lab_lxrx_AccruedLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_06593400-c223-4414-a4a6-16fc08f70479_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_8720da80-1352-4504-841d-83e1e735d265_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_7676adb3-8d90-4221-aba6-bb1a876df704_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ProceedsFromNov2020ATMOffering_342e5c5f-3999-4513-8bca-553665cb0841_terseLabel_en-US" xlink:label="lab_lxrx_ProceedsFromNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Nov 2020 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromNov2020ATMOffering_label_en-US" xlink:label="lab_lxrx_ProceedsFromNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Nov 2020 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromNov2020ATMOffering_documentation_en-US" xlink:label="lab_lxrx_ProceedsFromNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Nov 2020 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromNov2020ATMOffering" xlink:href="lxrx-20220630.xsd#lxrx_ProceedsFromNov2020ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ProceedsFromNov2020ATMOffering" xlink:to="lab_lxrx_ProceedsFromNov2020ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_FinalPaymentWithExtention_4071d856-079f-4bc6-b754-e66622d623aa_terseLabel_en-US" xlink:label="lab_lxrx_FinalPaymentWithExtention" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Payment % with extention</link:label>
    <link:label id="lab_lxrx_FinalPaymentWithExtention_label_en-US" xlink:label="lab_lxrx_FinalPaymentWithExtention" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Payment % with extention</link:label>
    <link:label id="lab_lxrx_FinalPaymentWithExtention_documentation_en-US" xlink:label="lab_lxrx_FinalPaymentWithExtention" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Payment % with extention</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FinalPaymentWithExtention" xlink:href="lxrx-20220630.xsd#lxrx_FinalPaymentWithExtention"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FinalPaymentWithExtention" xlink:to="lab_lxrx_FinalPaymentWithExtention" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_0d7799b0-efe3-4242-8179-6ebd913b97f2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_efbe18a0-b2b5-4649-b1e7-1e587ed85bb7_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20220630.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_a41c988a-3243-49c2-b494-a727da6b149b_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_22955725-9245-49d3-8686-a97903c30ad2_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_9fec0151-4496-4b9c-9e78-d8b34d0ed709_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Stockholders&#8217; Equity [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Stockholders&#8217; Equity [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Stockholders&#8217; Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:href="lxrx-20220630.xsd#lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:to="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e0173b00-7fe1-435d-afd9-ea5ee412c06f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_79cbd5b9-b28c-47d9-a3e4-55b17eac109f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_896883f6-f150-4af2-977b-cd69de51f83b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_3d10e3bf-742c-4dc1-a686-4062f9f0ad2c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_0f7d4ab4-43b2-4042-b15b-011dca8a664f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_19ed9209-78de-40c2-b555-c37f8c25c9fa_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingActivityByTypeDomain_c14429c6-fa9b-4223-a254-641bec1db832_terseLabel_en-US" xlink:label="lab_us-gaap_TradingActivityByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Activity, by Type [Domain]</link:label>
    <link:label id="lab_us-gaap_TradingActivityByTypeDomain_label_en-US" xlink:label="lab_us-gaap_TradingActivityByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Activity, by Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingActivityByTypeDomain" xlink:to="lab_us-gaap_TradingActivityByTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1d49af7e-2341-42c5-975e-5dfcc48e8cfd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanAWarrantExercisePrice_e732403a-6d8c-41d8-8567-d98dbf182f13_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanAWarrantExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Warrant Exercise Price</link:label>
    <link:label id="lab_lxrx_TermLoanAWarrantExercisePrice_label_en-US" xlink:label="lab_lxrx_TermLoanAWarrantExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Warrant Exercise Price</link:label>
    <link:label id="lab_lxrx_TermLoanAWarrantExercisePrice_documentation_en-US" xlink:label="lab_lxrx_TermLoanAWarrantExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Warrant Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAWarrantExercisePrice" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanAWarrantExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanAWarrantExercisePrice" xlink:to="lab_lxrx_TermLoanAWarrantExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_f69f782f-81ec-432f-ac30-89db758fe54f_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>lxrx-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b429ed1f-e365-4ee0-b706-413f731644e3,g:a8252b48-0582-489a-8246-eed3b4e2cfac-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="lxrx-20220630.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_6d36f08f-4d28-40bf-aa71-82998c21f5b5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_2262c4ef-a6b5-450c-8a59-1999c4531385" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36f08f-4d28-40bf-aa71-82998c21f5b5" xlink:to="loc_dei_DocumentType_2262c4ef-a6b5-450c-8a59-1999c4531385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_0bb84fa6-f6fa-4f98-9c2a-dc36d82d8c3b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36f08f-4d28-40bf-aa71-82998c21f5b5" xlink:to="loc_dei_DocumentFiscalPeriodFocus_0bb84fa6-f6fa-4f98-9c2a-dc36d82d8c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_dfa568c1-bed9-4d0f-9318-1440fe1552b7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36f08f-4d28-40bf-aa71-82998c21f5b5" xlink:to="loc_dei_DocumentQuarterlyReport_dfa568c1-bed9-4d0f-9318-1440fe1552b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_49e09968-3911-4399-a7e9-4813e0c18baa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36f08f-4d28-40bf-aa71-82998c21f5b5" xlink:to="loc_dei_DocumentPeriodEndDate_49e09968-3911-4399-a7e9-4813e0c18baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_8e73ce02-997c-4f5b-ae88-0cb32205d8bc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36f08f-4d28-40bf-aa71-82998c21f5b5" xlink:to="loc_dei_DocumentTransitionReport_8e73ce02-997c-4f5b-ae88-0cb32205d8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_cb087d3c-0806-492f-9467-a058d6e5331c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36f08f-4d28-40bf-aa71-82998c21f5b5" xlink:to="loc_dei_AmendmentFlag_cb087d3c-0806-492f-9467-a058d6e5331c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_670b0b47-9272-4a55-87ff-68ee2e43a523" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36f08f-4d28-40bf-aa71-82998c21f5b5" xlink:to="loc_dei_DocumentFiscalYearFocus_670b0b47-9272-4a55-87ff-68ee2e43a523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_4ffe78f7-e77d-4877-83a5-14c56a8e0897" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36f08f-4d28-40bf-aa71-82998c21f5b5" xlink:to="loc_dei_CurrentFiscalYearEndDate_4ffe78f7-e77d-4877-83a5-14c56a8e0897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1f8d7ab5-fadb-4bee-8ce1-c6dd963870b2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36f08f-4d28-40bf-aa71-82998c21f5b5" xlink:to="loc_dei_EntityFileNumber_1f8d7ab5-fadb-4bee-8ce1-c6dd963870b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_2b37b5ac-db60-4694-bb23-8738d303a415" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36f08f-4d28-40bf-aa71-82998c21f5b5" xlink:to="loc_dei_EntityRegistrantName_2b37b5ac-db60-4694-bb23-8738d303a415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_513e960d-2352-417e-b5f7-443eba463e04" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36f08f-4d28-40bf-aa71-82998c21f5b5" xlink:to="loc_dei_EntityCentralIndexKey_513e960d-2352-417e-b5f7-443eba463e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_890e7a2f-2626-40c3-a551-9a749de662dc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36f08f-4d28-40bf-aa71-82998c21f5b5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_890e7a2f-2626-40c3-a551-9a749de662dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ba584916-b877-49d8-97f7-8a4705accfde" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36f08f-4d28-40bf-aa71-82998c21f5b5" xlink:to="loc_dei_EntityTaxIdentificationNumber_ba584916-b877-49d8-97f7-8a4705accfde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_55f44534-2022-426e-a299-6b6de9634527" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36f08f-4d28-40bf-aa71-82998c21f5b5" xlink:to="loc_dei_EntityAddressAddressLine1_55f44534-2022-426e-a299-6b6de9634527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_6b4ab897-6cd4-48e9-8c0e-3e6f9b2e4ba5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36f08f-4d28-40bf-aa71-82998c21f5b5" xlink:to="loc_dei_EntityAddressAddressLine2_6b4ab897-6cd4-48e9-8c0e-3e6f9b2e4ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a83cbbab-6659-434a-964c-dda2c89c32f7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36f08f-4d28-40bf-aa71-82998c21f5b5" xlink:to="loc_dei_EntityAddressCityOrTown_a83cbbab-6659-434a-964c-dda2c89c32f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_15c9c24d-540e-403f-85fe-e7a8783e6176" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36f08f-4d28-40bf-aa71-82998c21f5b5" xlink:to="loc_dei_EntityAddressStateOrProvince_15c9c24d-540e-403f-85fe-e7a8783e6176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d070fa26-7f05-4ae5-81b2-f154385e6a3c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36f08f-4d28-40bf-aa71-82998c21f5b5" xlink:to="loc_dei_EntityAddressPostalZipCode_d070fa26-7f05-4ae5-81b2-f154385e6a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d213818a-6609-4361-b3db-97e3aa1ce2b1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36f08f-4d28-40bf-aa71-82998c21f5b5" xlink:to="loc_dei_CityAreaCode_d213818a-6609-4361-b3db-97e3aa1ce2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_3c0fbb7c-71fb-4105-af0f-ffe23005060e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36f08f-4d28-40bf-aa71-82998c21f5b5" xlink:to="loc_dei_LocalPhoneNumber_3c0fbb7c-71fb-4105-af0f-ffe23005060e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8816f5f9-9a39-4e04-839e-f316fab83a74" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36f08f-4d28-40bf-aa71-82998c21f5b5" xlink:to="loc_dei_Security12bTitle_8816f5f9-9a39-4e04-839e-f316fab83a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_752a2123-eac4-4e1e-ae48-bf9af9ff2e20" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36f08f-4d28-40bf-aa71-82998c21f5b5" xlink:to="loc_dei_TradingSymbol_752a2123-eac4-4e1e-ae48-bf9af9ff2e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a73beaee-2d92-47d0-8bbd-e668185283fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36f08f-4d28-40bf-aa71-82998c21f5b5" xlink:to="loc_dei_SecurityExchangeName_a73beaee-2d92-47d0-8bbd-e668185283fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_bd713bec-de0e-4f58-b978-6b8a665dc73a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36f08f-4d28-40bf-aa71-82998c21f5b5" xlink:to="loc_dei_EntityCurrentReportingStatus_bd713bec-de0e-4f58-b978-6b8a665dc73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_7e1f5f7b-1223-45f4-ae1c-58a862975ede" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36f08f-4d28-40bf-aa71-82998c21f5b5" xlink:to="loc_dei_EntityInteractiveDataCurrent_7e1f5f7b-1223-45f4-ae1c-58a862975ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_2e95981a-13f3-4dda-bd5a-2ab8af3fbffc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36f08f-4d28-40bf-aa71-82998c21f5b5" xlink:to="loc_dei_EntityFilerCategory_2e95981a-13f3-4dda-bd5a-2ab8af3fbffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_fcbe28f1-4c60-4fe3-9b72-605cb3aaae64" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36f08f-4d28-40bf-aa71-82998c21f5b5" xlink:to="loc_dei_EntitySmallBusiness_fcbe28f1-4c60-4fe3-9b72-605cb3aaae64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d0d04e63-cee9-4f43-a313-67a1fcc7e8bd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36f08f-4d28-40bf-aa71-82998c21f5b5" xlink:to="loc_dei_EntityEmergingGrowthCompany_d0d04e63-cee9-4f43-a313-67a1fcc7e8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d8e2cbd6-39d6-4748-b33f-ce8f3f21a315" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36f08f-4d28-40bf-aa71-82998c21f5b5" xlink:to="loc_dei_EntityShellCompany_d8e2cbd6-39d6-4748-b33f-ce8f3f21a315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_0f16f9ff-fd9d-4354-a16e-59848fa4f83b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36f08f-4d28-40bf-aa71-82998c21f5b5" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_0f16f9ff-fd9d-4354-a16e-59848fa4f83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="lxrx-20220630.xsd#ConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedBalanceSheetsAbstract_1c7e9eae-4276-4f74-b599-4ffa55095180" xlink:href="lxrx-20220630.xsd#lxrx_ConsolidatedBalanceSheetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1b991bd3-5363-4651-af27-db2bb07bc958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_1c7e9eae-4276-4f74-b599-4ffa55095180" xlink:to="loc_us-gaap_StatementTable_1b991bd3-5363-4651-af27-db2bb07bc958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_1124981f-d9c6-4b21-8792-4c6e82f11636" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1b991bd3-5363-4651-af27-db2bb07bc958" xlink:to="loc_srt_StatementScenarioAxis_1124981f-d9c6-4b21-8792-4c6e82f11636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_571a8d8a-5b26-4d2d-93a1-4bebaa829474" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_1124981f-d9c6-4b21-8792-4c6e82f11636" xlink:to="loc_srt_ScenarioUnspecifiedDomain_571a8d8a-5b26-4d2d-93a1-4bebaa829474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_af0dcc4c-1518-475c-9639-5dc5992fe8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1b991bd3-5363-4651-af27-db2bb07bc958" xlink:to="loc_us-gaap_StatementClassOfStockAxis_af0dcc4c-1518-475c-9639-5dc5992fe8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5ca6f65a-ebfe-44c6-9ae1-ed7f2d7eac48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_af0dcc4c-1518-475c-9639-5dc5992fe8a5" xlink:to="loc_us-gaap_ClassOfStockDomain_5ca6f65a-ebfe-44c6-9ae1-ed7f2d7eac48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0c86062b-b016-4722-bd32-51719ecf25c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1b991bd3-5363-4651-af27-db2bb07bc958" xlink:to="loc_us-gaap_StatementLineItems_0c86062b-b016-4722-bd32-51719ecf25c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_e4a6d208-3136-45fe-a1b4-4694ef0f1c64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c86062b-b016-4722-bd32-51719ecf25c9" xlink:to="loc_us-gaap_AssetsCurrentAbstract_e4a6d208-3136-45fe-a1b4-4694ef0f1c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f46aae83-4b22-46ed-8dd3-dd7864865cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e4a6d208-3136-45fe-a1b4-4694ef0f1c64" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f46aae83-4b22-46ed-8dd3-dd7864865cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_c70a5494-cc70-4346-a5f2-d143e6afd7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e4a6d208-3136-45fe-a1b4-4694ef0f1c64" xlink:to="loc_us-gaap_ShortTermInvestments_c70a5494-cc70-4346-a5f2-d143e6afd7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5dfa00db-c448-4ae1-94df-1718f49f1da0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e4a6d208-3136-45fe-a1b4-4694ef0f1c64" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5dfa00db-c448-4ae1-94df-1718f49f1da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_8d40c42d-07c6-40ba-bd8d-843a549c1976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e4a6d208-3136-45fe-a1b4-4694ef0f1c64" xlink:to="loc_us-gaap_OtherAssetsCurrent_8d40c42d-07c6-40ba-bd8d-843a549c1976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2a216622-7b57-48ed-b182-0ed92a017328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e4a6d208-3136-45fe-a1b4-4694ef0f1c64" xlink:to="loc_us-gaap_AssetsCurrent_2a216622-7b57-48ed-b182-0ed92a017328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d3b0cb88-a87b-4455-bc9e-32369683ed63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c86062b-b016-4722-bd32-51719ecf25c9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d3b0cb88-a87b-4455-bc9e-32369683ed63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_493dc247-1061-41c5-ab21-2e80dc7afc53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c86062b-b016-4722-bd32-51719ecf25c9" xlink:to="loc_us-gaap_Goodwill_493dc247-1061-41c5-ab21-2e80dc7afc53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1a4f9eb7-797d-48d0-9836-8f2d8a8340d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c86062b-b016-4722-bd32-51719ecf25c9" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1a4f9eb7-797d-48d0-9836-8f2d8a8340d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_bd8cda3f-62e8-4a71-939d-fae1d0eb3ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c86062b-b016-4722-bd32-51719ecf25c9" xlink:to="loc_us-gaap_Assets_bd8cda3f-62e8-4a71-939d-fae1d0eb3ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_073b2a7c-3e99-4c25-88b3-8d610f2dd3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c86062b-b016-4722-bd32-51719ecf25c9" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_073b2a7c-3e99-4c25-88b3-8d610f2dd3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8d2097b6-6568-429e-a33a-681fe68008f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_073b2a7c-3e99-4c25-88b3-8d610f2dd3ba" xlink:to="loc_us-gaap_AccountsPayableCurrent_8d2097b6-6568-429e-a33a-681fe68008f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1e0a3129-c162-4051-8279-19d6f103fe8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_073b2a7c-3e99-4c25-88b3-8d610f2dd3ba" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1e0a3129-c162-4051-8279-19d6f103fe8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_62aca060-ec7e-4f74-b931-d8eb0aa55893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_073b2a7c-3e99-4c25-88b3-8d610f2dd3ba" xlink:to="loc_us-gaap_LongTermDebtCurrent_62aca060-ec7e-4f74-b931-d8eb0aa55893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_cd7cf309-4153-4562-b757-ab3862a67b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_073b2a7c-3e99-4c25-88b3-8d610f2dd3ba" xlink:to="loc_us-gaap_LiabilitiesCurrent_cd7cf309-4153-4562-b757-ab3862a67b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt_7eff40b5-e3c0-4f5f-b6ef-eea3b58c0c86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_073b2a7c-3e99-4c25-88b3-8d610f2dd3ba" xlink:to="loc_us-gaap_SecuredLongTermDebt_7eff40b5-e3c0-4f5f-b6ef-eea3b58c0c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7a9048c1-0fcf-4ca4-8164-15389e75018c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c86062b-b016-4722-bd32-51719ecf25c9" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7a9048c1-0fcf-4ca4-8164-15389e75018c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0de9bf6c-f02f-45ba-8114-c9e44d8748c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c86062b-b016-4722-bd32-51719ecf25c9" xlink:to="loc_us-gaap_Liabilities_0de9bf6c-f02f-45ba-8114-c9e44d8748c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_d089dd92-dc3c-4275-8114-45cc822b0883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c86062b-b016-4722-bd32-51719ecf25c9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_d089dd92-dc3c-4275-8114-45cc822b0883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_78e9dcf6-3537-41f8-a61c-aa3f6b35c990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c86062b-b016-4722-bd32-51719ecf25c9" xlink:to="loc_us-gaap_EquityAbstract_78e9dcf6-3537-41f8-a61c-aa3f6b35c990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_6b118a98-1ab4-4a03-85b5-5d7652d95b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_78e9dcf6-3537-41f8-a61c-aa3f6b35c990" xlink:to="loc_us-gaap_PreferredStockValue_6b118a98-1ab4-4a03-85b5-5d7652d95b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d6bccdeb-0d31-4f32-9ca1-7e821f4d936a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_78e9dcf6-3537-41f8-a61c-aa3f6b35c990" xlink:to="loc_us-gaap_CommonStockValue_d6bccdeb-0d31-4f32-9ca1-7e821f4d936a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_cd6f7a2b-bdd1-4ef7-8cfb-97c720bf9b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_78e9dcf6-3537-41f8-a61c-aa3f6b35c990" xlink:to="loc_us-gaap_AdditionalPaidInCapital_cd6f7a2b-bdd1-4ef7-8cfb-97c720bf9b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d41b32b0-b39b-496d-8a0d-025aeab24a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_78e9dcf6-3537-41f8-a61c-aa3f6b35c990" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d41b32b0-b39b-496d-8a0d-025aeab24a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_228c8647-c919-4360-bdc0-e9de7db3b8eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_78e9dcf6-3537-41f8-a61c-aa3f6b35c990" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_228c8647-c919-4360-bdc0-e9de7db3b8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_807c1586-7ac8-42a0-8f61-bddf9d14fb40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_78e9dcf6-3537-41f8-a61c-aa3f6b35c990" xlink:to="loc_us-gaap_TreasuryStockValue_807c1586-7ac8-42a0-8f61-bddf9d14fb40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_23005fcc-abcc-4c8d-b258-ac39a5ee2c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_78e9dcf6-3537-41f8-a61c-aa3f6b35c990" xlink:to="loc_us-gaap_StockholdersEquity_23005fcc-abcc-4c8d-b258-ac39a5ee2c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_97936db4-c2ea-465a-962a-10b90b73e629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c86062b-b016-4722-bd32-51719ecf25c9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_97936db4-c2ea-465a-962a-10b90b73e629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_bfa6b837-1f66-4701-aa7e-e2a0791d2b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c86062b-b016-4722-bd32-51719ecf25c9" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_bfa6b837-1f66-4701-aa7e-e2a0791d2b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="simple" xlink:href="lxrx-20220630.xsd#ConsolidatedBalanceSheetsParentheticals"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedBalanceSheetsAbstract_326b2bae-3060-4c02-9019-46c7e470eaf8" xlink:href="lxrx-20220630.xsd#lxrx_ConsolidatedBalanceSheetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_acdbeeba-c87e-474c-9bbd-b74485607574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_326b2bae-3060-4c02-9019-46c7e470eaf8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_acdbeeba-c87e-474c-9bbd-b74485607574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6bc8cf2c-56b7-4dc5-bee0-4d0d63ed54ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_326b2bae-3060-4c02-9019-46c7e470eaf8" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6bc8cf2c-56b7-4dc5-bee0-4d0d63ed54ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ffb9c528-2f15-4df9-ba93-1ecdd1ac6412" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_326b2bae-3060-4c02-9019-46c7e470eaf8" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ffb9c528-2f15-4df9-ba93-1ecdd1ac6412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_dd293fca-d457-4383-8c96-9d1f91befee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_326b2bae-3060-4c02-9019-46c7e470eaf8" xlink:to="loc_us-gaap_PreferredStockSharesIssued_dd293fca-d457-4383-8c96-9d1f91befee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_74e53f6a-476d-479a-b6fe-9744a4b7ca23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_326b2bae-3060-4c02-9019-46c7e470eaf8" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_74e53f6a-476d-479a-b6fe-9744a4b7ca23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9cec5e00-a894-43a9-88b5-e7e0c78dd15d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_326b2bae-3060-4c02-9019-46c7e470eaf8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9cec5e00-a894-43a9-88b5-e7e0c78dd15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_266193d2-c702-4074-9297-eb92d5385da9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_326b2bae-3060-4c02-9019-46c7e470eaf8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_266193d2-c702-4074-9297-eb92d5385da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_052062ab-de33-419d-ac82-292342e76f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_326b2bae-3060-4c02-9019-46c7e470eaf8" xlink:to="loc_us-gaap_CommonStockSharesIssued_052062ab-de33-419d-ac82-292342e76f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_aabab19b-8d72-4ad1-aacc-c99174f39449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_326b2bae-3060-4c02-9019-46c7e470eaf8" xlink:to="loc_us-gaap_TreasuryStockShares_aabab19b-8d72-4ad1-aacc-c99174f39449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="lxrx-20220630.xsd#ConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_245e8230-4cae-451a-9a67-b83b97edf306" xlink:href="lxrx-20220630.xsd#lxrx_ConsolidatedStatementsOfOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b57dd605-964b-4824-b0b5-dc6e2dc5a9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_245e8230-4cae-451a-9a67-b83b97edf306" xlink:to="loc_us-gaap_StatementTable_b57dd605-964b-4824-b0b5-dc6e2dc5a9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_9e2c8054-7de3-45aa-8b85-a110873e6ad6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b57dd605-964b-4824-b0b5-dc6e2dc5a9f5" xlink:to="loc_srt_StatementScenarioAxis_9e2c8054-7de3-45aa-8b85-a110873e6ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_c28583f6-2d01-47ca-b91b-49d151e6554d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_9e2c8054-7de3-45aa-8b85-a110873e6ad6" xlink:to="loc_srt_ScenarioUnspecifiedDomain_c28583f6-2d01-47ca-b91b-49d151e6554d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b57dd605-964b-4824-b0b5-dc6e2dc5a9f5" xlink:to="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_49784fb1-b0bb-4714-b5e4-ff9d2d9534f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_us-gaap_RevenuesAbstract_49784fb1-b0bb-4714-b5e4-ff9d2d9534f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Netproductrevenue_55655bbd-e731-4200-9093-23104d1c8035" xlink:href="lxrx-20220630.xsd#lxrx_Netproductrevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_49784fb1-b0bb-4714-b5e4-ff9d2d9534f3" xlink:to="loc_lxrx_Netproductrevenue_55655bbd-e731-4200-9093-23104d1c8035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_07148494-57b8-4683-9f92-16b3f66209ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_49784fb1-b0bb-4714-b5e4-ff9d2d9534f3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_07148494-57b8-4683-9f92-16b3f66209ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_cbb48fa7-3327-432c-8d62-831d2dfa5652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_49784fb1-b0bb-4714-b5e4-ff9d2d9534f3" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_cbb48fa7-3327-432c-8d62-831d2dfa5652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_443076d9-6dc1-461e-9107-ad467701bc2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_49784fb1-b0bb-4714-b5e4-ff9d2d9534f3" xlink:to="loc_us-gaap_Revenues_443076d9-6dc1-461e-9107-ad467701bc2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_650e3138-aedf-4129-986b-bbc6a81a77f1" xlink:href="lxrx-20220630.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_49784fb1-b0bb-4714-b5e4-ff9d2d9534f3" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_650e3138-aedf-4129-986b-bbc6a81a77f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_e642cc79-bf48-4564-974a-9b106ee0acd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_us-gaap_OperatingExpensesAbstract_e642cc79-bf48-4564-974a-9b106ee0acd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_cba7a722-077a-479e-9355-6e498bad5322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e642cc79-bf48-4564-974a-9b106ee0acd0" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_cba7a722-077a-479e-9355-6e498bad5322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3757934c-3626-484e-9530-a37d5319bfb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e642cc79-bf48-4564-974a-9b106ee0acd0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3757934c-3626-484e-9530-a37d5319bfb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Sellinggeneralandadministrativeexpenses_d0ad27da-f736-4acb-8742-0407fa3a9424" xlink:href="lxrx-20220630.xsd#lxrx_Sellinggeneralandadministrativeexpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e642cc79-bf48-4564-974a-9b106ee0acd0" xlink:to="loc_lxrx_Sellinggeneralandadministrativeexpenses_d0ad27da-f736-4acb-8742-0407fa3a9424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_e38a94b6-e646-4dfd-af75-0e89aa5d1df4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e642cc79-bf48-4564-974a-9b106ee0acd0" xlink:to="loc_us-gaap_AssetImpairmentCharges_e38a94b6-e646-4dfd-af75-0e89aa5d1df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_70a72080-a4e6-43c8-9594-7f1c88414469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e642cc79-bf48-4564-974a-9b106ee0acd0" xlink:to="loc_us-gaap_OperatingExpenses_70a72080-a4e6-43c8-9594-7f1c88414469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_7dad1cf0-d90c-4b40-bcac-e9591585b441" xlink:href="lxrx-20220630.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_7dad1cf0-d90c-4b40-bcac-e9591585b441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e3bd9c76-34a9-442a-bfd2-3fd64546246d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_us-gaap_OperatingIncomeLoss_e3bd9c76-34a9-442a-bfd2-3fd64546246d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_53fc0625-82aa-4fcc-93fa-f785bf346cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_53fc0625-82aa-4fcc-93fa-f785bf346cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_5566a152-a335-400c-8278-1f60cf0066f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_us-gaap_InterestExpense_5566a152-a335-400c-8278-1f60cf0066f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_086c543a-eac8-495d-9762-cde01c8afd83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_086c543a-eac8-495d-9762-cde01c8afd83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_baff95e6-3b9a-4477-b2cf-a6822d53cd7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_us-gaap_NetIncomeLoss_baff95e6-3b9a-4477-b2cf-a6822d53cd7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a083a79c-11c8-4916-bf3d-bba789a6f84a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_us-gaap_EarningsPerShareBasic_a083a79c-11c8-4916-bf3d-bba789a6f84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f36b5887-37f7-4035-8f30-57b81bae6177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f36b5887-37f7-4035-8f30-57b81bae6177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d6d18d28-07df-42ad-a312-2e6c32f2507b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d6d18d28-07df-42ad-a312-2e6c32f2507b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b6136d49-b408-4f7d-91d2-58904651495f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b6136d49-b408-4f7d-91d2-58904651495f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3fada8ed-97a9-4ef7-86e6-2a136686970d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3fada8ed-97a9-4ef7-86e6-2a136686970d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6d3bbb0a-df06-42e3-8cdc-48673457d918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_6d3bbb0a-df06-42e3-8cdc-48673457d918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalIncomeStatementElementsAbstract_357ed768-f27f-437e-972d-da9fc0bc9b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalIncomeStatementElementsAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_us-gaap_SupplementalIncomeStatementElementsAbstract_357ed768-f27f-437e-972d-da9fc0bc9b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_139ae493-fbed-4ded-bbd9-8d0c9f2a37f4" xlink:href="lxrx-20220630.xsd#lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalIncomeStatementElementsAbstract_357ed768-f27f-437e-972d-da9fc0bc9b6e" xlink:to="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_139ae493-fbed-4ded-bbd9-8d0c9f2a37f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_cc2eea7b-b2c2-468e-97bf-7e7b64d60631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3856455c-a0f9-4f13-be6b-a8c12cea6d88" xlink:to="loc_us-gaap_BusinessExitCosts1_cc2eea7b-b2c2-468e-97bf-7e7b64d60631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals" xlink:type="simple" xlink:href="lxrx-20220630.xsd#ConsolidatedStatementsofComprehensiveLossParentheticals"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_214f0989-18bb-476e-8a3a-09c6bf71d875" xlink:href="lxrx-20220630.xsd#lxrx_ConsolidatedStatementsOfOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_eab5c157-e5c7-41bc-8413-fe23f766fbda" xlink:href="lxrx-20220630.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_214f0989-18bb-476e-8a3a-09c6bf71d875" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_eab5c157-e5c7-41bc-8413-fe23f766fbda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_60a9e002-a10a-448e-a197-ca04a2aa2fae" xlink:href="lxrx-20220630.xsd#lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_214f0989-18bb-476e-8a3a-09c6bf71d875" xlink:to="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_60a9e002-a10a-448e-a197-ca04a2aa2fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="lxrx-20220630.xsd#ConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_59d3d2d0-d93a-45ab-82a3-252dc39d39fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a8b98563-7500-4582-a2f5-6a1b5ccd070a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_59d3d2d0-d93a-45ab-82a3-252dc39d39fd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a8b98563-7500-4582-a2f5-6a1b5ccd070a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a3ccae51-6f0e-4b3a-869a-020c61d670ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a8b98563-7500-4582-a2f5-6a1b5ccd070a" xlink:to="loc_us-gaap_NetIncomeLoss_a3ccae51-6f0e-4b3a-869a-020c61d670ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db77c02b-0ff7-4ebb-b768-7570d81c2276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a8b98563-7500-4582-a2f5-6a1b5ccd070a" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db77c02b-0ff7-4ebb-b768-7570d81c2276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f0fb9552-947c-4115-b8ed-fe721bf6d5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db77c02b-0ff7-4ebb-b768-7570d81c2276" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f0fb9552-947c-4115-b8ed-fe721bf6d5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ade05abf-4935-43dd-b023-0a049d922495" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db77c02b-0ff7-4ebb-b768-7570d81c2276" xlink:to="loc_us-gaap_ShareBasedCompensation_ade05abf-4935-43dd-b023-0a049d922495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_35156498-1255-41fd-a414-84218684b86d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db77c02b-0ff7-4ebb-b768-7570d81c2276" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_35156498-1255-41fd-a414-84218684b86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_2a6f9fa6-8f70-4566-86a2-34aac8712901" xlink:href="lxrx-20220630.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db77c02b-0ff7-4ebb-b768-7570d81c2276" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_2a6f9fa6-8f70-4566-86a2-34aac8712901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_5a2b02a5-7570-4675-a287-1437e2d70454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db77c02b-0ff7-4ebb-b768-7570d81c2276" xlink:to="loc_us-gaap_AssetImpairmentCharges_5a2b02a5-7570-4675-a287-1437e2d70454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c0d9a2d2-11a3-42ab-8f91-a2dc01f5fdb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db77c02b-0ff7-4ebb-b768-7570d81c2276" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c0d9a2d2-11a3-42ab-8f91-a2dc01f5fdb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42f67302-39f3-4d3f-adb1-44010977ae8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db77c02b-0ff7-4ebb-b768-7570d81c2276" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42f67302-39f3-4d3f-adb1-44010977ae8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ccbffbd7-fc7c-479f-8bc1-ac960d57d75e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42f67302-39f3-4d3f-adb1-44010977ae8f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ccbffbd7-fc7c-479f-8bc1-ac960d57d75e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_fc61bb36-83ec-4c6f-aefa-d5e2803a1e92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42f67302-39f3-4d3f-adb1-44010977ae8f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_fc61bb36-83ec-4c6f-aefa-d5e2803a1e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a95141ad-8c59-412d-a46d-a3c11d5ad8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42f67302-39f3-4d3f-adb1-44010977ae8f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a95141ad-8c59-412d-a46d-a3c11d5ad8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_b299dccf-ff52-47f0-a16b-41fba161e781" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42f67302-39f3-4d3f-adb1-44010977ae8f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_b299dccf-ff52-47f0-a16b-41fba161e781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ce961895-af24-4c6a-9758-22487f4f78bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42f67302-39f3-4d3f-adb1-44010977ae8f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ce961895-af24-4c6a-9758-22487f4f78bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b83e5030-3aa8-45fd-a520-805fd3fcd3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a8b98563-7500-4582-a2f5-6a1b5ccd070a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b83e5030-3aa8-45fd-a520-805fd3fcd3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_6a5074bf-de4d-46d5-b1af-97a6d49e1937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a8b98563-7500-4582-a2f5-6a1b5ccd070a" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_6a5074bf-de4d-46d5-b1af-97a6d49e1937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_76e7d6f1-f104-4870-b22f-c836006eb572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a8b98563-7500-4582-a2f5-6a1b5ccd070a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_76e7d6f1-f104-4870-b22f-c836006eb572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_c6c257d9-6fe0-4bbc-ae7c-6ff3316e08e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a8b98563-7500-4582-a2f5-6a1b5ccd070a" xlink:to="loc_us-gaap_InterestPaidNet_c6c257d9-6fe0-4bbc-ae7c-6ff3316e08e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_InitialRecognitionOfRightOfUseAsset_4dde250b-8f6e-41fc-add8-f629fb18b6c0" xlink:href="lxrx-20220630.xsd#lxrx_InitialRecognitionOfRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a8b98563-7500-4582-a2f5-6a1b5ccd070a" xlink:to="loc_lxrx_InitialRecognitionOfRightOfUseAsset_4dde250b-8f6e-41fc-add8-f629fb18b6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_1a849016-1260-4d93-9f9d-b528d68bc33e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a8b98563-7500-4582-a2f5-6a1b5ccd070a" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_1a849016-1260-4d93-9f9d-b528d68bc33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6f5d2ead-1d8e-4ec4-9de7-f2a483e705b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a8b98563-7500-4582-a2f5-6a1b5ccd070a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6f5d2ead-1d8e-4ec4-9de7-f2a483e705b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_6ae857e2-3679-4806-92f1-e1160ecdf1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a8b98563-7500-4582-a2f5-6a1b5ccd070a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_6ae857e2-3679-4806-92f1-e1160ecdf1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_a1494d55-3954-4153-a4b8-caf88bacba72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a8b98563-7500-4582-a2f5-6a1b5ccd070a" xlink:to="loc_us-gaap_BusinessExitCosts1_a1494d55-3954-4153-a4b8-caf88bacba72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_28e3d806-8f66-4c29-b4f5-098073eff1df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a8b98563-7500-4582-a2f5-6a1b5ccd070a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_28e3d806-8f66-4c29-b4f5-098073eff1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7a5e639c-6bf1-41d5-a4e1-7abba171cee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_59d3d2d0-d93a-45ab-82a3-252dc39d39fd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7a5e639c-6bf1-41d5-a4e1-7abba171cee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d2bb3103-8140-4b7d-a83e-23a51152c0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7a5e639c-6bf1-41d5-a4e1-7abba171cee7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d2bb3103-8140-4b7d-a83e-23a51152c0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_47ec627c-c7a1-41d5-8be1-023eb5417794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7a5e639c-6bf1-41d5-a4e1-7abba171cee7" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_47ec627c-c7a1-41d5-8be1-023eb5417794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_4a2be543-147a-4e30-8400-1f575b4072eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7a5e639c-6bf1-41d5-a4e1-7abba171cee7" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_4a2be543-147a-4e30-8400-1f575b4072eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_bd2be330-9d25-47cd-92ee-b713f1ae9cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7a5e639c-6bf1-41d5-a4e1-7abba171cee7" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_bd2be330-9d25-47cd-92ee-b713f1ae9cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6e5b0d14-3fc4-4cde-940a-dadc7bde1214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7a5e639c-6bf1-41d5-a4e1-7abba171cee7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6e5b0d14-3fc4-4cde-940a-dadc7bde1214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97a9a43b-2504-410d-8149-1c09dc30684c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_59d3d2d0-d93a-45ab-82a3-252dc39d39fd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97a9a43b-2504-410d-8149-1c09dc30684c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d548acf6-cb10-4ae9-856a-5240ec6783ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97a9a43b-2504-410d-8149-1c09dc30684c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d548acf6-cb10-4ae9-856a-5240ec6783ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ff92a39f-cac0-427e-90f5-d97da2a13fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97a9a43b-2504-410d-8149-1c09dc30684c" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ff92a39f-cac0-427e-90f5-d97da2a13fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_cd2de2b0-4d33-4c9c-84b9-95d0555d2c13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97a9a43b-2504-410d-8149-1c09dc30684c" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_cd2de2b0-4d33-4c9c-84b9-95d0555d2c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8bafa65d-52f2-4aa9-aaa1-e2a77c5d6bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97a9a43b-2504-410d-8149-1c09dc30684c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8bafa65d-52f2-4aa9-aaa1-e2a77c5d6bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a50c4f2c-5060-4b99-bcd6-f9d3afc96ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97a9a43b-2504-410d-8149-1c09dc30684c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a50c4f2c-5060-4b99-bcd6-f9d3afc96ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d1c95bb4-1889-4b22-a8f6-7e027645a5c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97a9a43b-2504-410d-8149-1c09dc30684c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d1c95bb4-1889-4b22-a8f6-7e027645a5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_59308d6b-9d29-4e7e-8afc-3864b3e27308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_59d3d2d0-d93a-45ab-82a3-252dc39d39fd" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_59308d6b-9d29-4e7e-8afc-3864b3e27308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b301f2d6-7081-43da-ad6c-17cfebc6b7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_59d3d2d0-d93a-45ab-82a3-252dc39d39fd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b301f2d6-7081-43da-ad6c-17cfebc6b7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2ac33b44-42ba-41e6-a5f4-73ff0ec755b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_59d3d2d0-d93a-45ab-82a3-252dc39d39fd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2ac33b44-42ba-41e6-a5f4-73ff0ec755b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_93248fb4-7105-42b3-b8af-04db444b7e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_59d3d2d0-d93a-45ab-82a3-252dc39d39fd" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_93248fb4-7105-42b3-b8af-04db444b7e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_3583ac0e-423f-4509-bc7f-f7293aaafd6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_93248fb4-7105-42b3-b8af-04db444b7e4a" xlink:to="loc_us-gaap_InterestPaidNet_3583ac0e-423f-4509-bc7f-f7293aaafd6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_InitialRecognitionOfRightOfUseAsset_08566adc-b154-4392-988d-c75343982fc2" xlink:href="lxrx-20220630.xsd#lxrx_InitialRecognitionOfRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_93248fb4-7105-42b3-b8af-04db444b7e4a" xlink:to="loc_lxrx_InitialRecognitionOfRightOfUseAsset_08566adc-b154-4392-988d-c75343982fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LiabilitiesAssumedByTerSera_2b7be08f-a050-4707-b5f2-f15b53bb582e" xlink:href="lxrx-20220630.xsd#lxrx_LiabilitiesAssumedByTerSera"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_93248fb4-7105-42b3-b8af-04db444b7e4a" xlink:to="loc_lxrx_LiabilitiesAssumedByTerSera_2b7be08f-a050-4707-b5f2-f15b53bb582e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_51ded218-999c-4f8b-b407-a3a696a5d14c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_93248fb4-7105-42b3-b8af-04db444b7e4a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_51ded218-999c-4f8b-b407-a3a696a5d14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="simple" xlink:href="lxrx-20220630.xsd#ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_9a98dfe4-728e-4963-9306-902326c806b5" xlink:href="lxrx-20220630.xsd#lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e46f24d5-7d6d-4c63-bdbe-e8dd00ebb9b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_9a98dfe4-728e-4963-9306-902326c806b5" xlink:to="loc_us-gaap_StatementTable_e46f24d5-7d6d-4c63-bdbe-e8dd00ebb9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_a2e799c9-4d11-4a4e-9072-d91289ee4122" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e46f24d5-7d6d-4c63-bdbe-e8dd00ebb9b0" xlink:to="loc_srt_StatementScenarioAxis_a2e799c9-4d11-4a4e-9072-d91289ee4122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_cce16fd7-3b6c-45fb-999e-a0313211f317" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_a2e799c9-4d11-4a4e-9072-d91289ee4122" xlink:to="loc_srt_ScenarioUnspecifiedDomain_cce16fd7-3b6c-45fb-999e-a0313211f317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6291fa1c-7952-472e-9316-b3243130e164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e46f24d5-7d6d-4c63-bdbe-e8dd00ebb9b0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6291fa1c-7952-472e-9316-b3243130e164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2d377a89-9c13-47f4-9839-3680529e7a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6291fa1c-7952-472e-9316-b3243130e164" xlink:to="loc_us-gaap_EquityComponentDomain_2d377a89-9c13-47f4-9839-3680529e7a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_fe02f790-10b0-437a-9789-3a6aea2d1e14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2d377a89-9c13-47f4-9839-3680529e7a7a" xlink:to="loc_us-gaap_CommonStockMember_fe02f790-10b0-437a-9789-3a6aea2d1e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_cfc6d2c3-d11b-4b5d-a736-9121a27a6562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2d377a89-9c13-47f4-9839-3680529e7a7a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_cfc6d2c3-d11b-4b5d-a736-9121a27a6562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2843b2da-c732-4eb9-b94f-230667211c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2d377a89-9c13-47f4-9839-3680529e7a7a" xlink:to="loc_us-gaap_RetainedEarningsMember_2843b2da-c732-4eb9-b94f-230667211c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_45e071d4-f85e-4420-bb23-6f9547451ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2d377a89-9c13-47f4-9839-3680529e7a7a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_45e071d4-f85e-4420-bb23-6f9547451ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_9edfdc74-2112-4804-948d-e6d18ad8dd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2d377a89-9c13-47f4-9839-3680529e7a7a" xlink:to="loc_us-gaap_TreasuryStockMember_9edfdc74-2112-4804-948d-e6d18ad8dd4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6786a67d-47de-4382-8ef1-5a75d155aa83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e46f24d5-7d6d-4c63-bdbe-e8dd00ebb9b0" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6786a67d-47de-4382-8ef1-5a75d155aa83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6dcb2e36-84df-47a6-98a4-ebea59e32200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6786a67d-47de-4382-8ef1-5a75d155aa83" xlink:to="loc_us-gaap_ClassOfStockDomain_6dcb2e36-84df-47a6-98a4-ebea59e32200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e46f24d5-7d6d-4c63-bdbe-e8dd00ebb9b0" xlink:to="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_43713b90-ed38-43ac-b5b3-6dbd32f27054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:to="loc_us-gaap_CommonStockSharesIssued_43713b90-ed38-43ac-b5b3-6dbd32f27054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6222d627-b093-489b-9a24-9c5a955567b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6222d627-b093-489b-9a24-9c5a955567b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_cb71eb52-1415-4e55-a098-d6807cd90a82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_cb71eb52-1415-4e55-a098-d6807cd90a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1bda53b3-3500-4523-95a3-480f0c049451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1bda53b3-3500-4523-95a3-480f0c049451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_77968a00-660d-4ad9-9105-b8de82dc6f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_77968a00-660d-4ad9-9105-b8de82dc6f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_5e669e8c-1f30-4815-b662-c65f5358af75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_5e669e8c-1f30-4815-b662-c65f5358af75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_1c22a1c2-f0d8-4412-b231-3d3e8dcaa9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_1c22a1c2-f0d8-4412-b231-3d3e8dcaa9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9a6e477a-0386-4fb6-90a2-a624295fba9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:to="loc_us-gaap_NetIncomeLoss_9a6e477a-0386-4fb6-90a2-a624295fba9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_cedbc5d9-5ebd-434e-9419-90e84fbe67a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_cedbc5d9-5ebd-434e-9419-90e84fbe67a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_fe311055-be8e-465f-ae08-dc01233c9bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_fe311055-be8e-465f-ae08-dc01233c9bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_9c0bcf58-17b8-4ac1-890c-438598712033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:to="loc_us-gaap_CommonStockSharesIssued_9c0bcf58-17b8-4ac1-890c-438598712033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bbf5aac6-26ce-4f74-86bc-045730cd1b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bbf5aac6-26ce-4f74-86bc-045730cd1b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_6cc6a73c-a166-4544-8cea-91a5b89cc71e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_6cc6a73c-a166-4544-8cea-91a5b89cc71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_568509d9-8112-4290-9846-7638346a3702" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_568509d9-8112-4290-9846-7638346a3702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_98749da0-6e11-4015-a014-74c23bc2c8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_98749da0-6e11-4015-a014-74c23bc2c8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_08324122-75b9-4eee-b7af-f94323d95afd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6b6f31b3-d3b8-4929-8d16-d4336e1adc9b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_08324122-75b9-4eee-b7af-f94323d95afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes" xlink:type="simple" xlink:href="lxrx-20220630.xsd#SummaryofSignificantAccountingPoliciesNotes"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_99b5deda-7eb6-4506-8d18-47f58ce3895a" xlink:href="lxrx-20220630.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_b4b2c259-60a4-4f17-a830-14e081bad889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_99b5deda-7eb6-4506-8d18-47f58ce3895a" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_b4b2c259-60a4-4f17-a830-14e081bad889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lxrx-20220630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_0e38d7da-dfb9-41df-ba4c-d97aee01530e" xlink:href="lxrx-20220630.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_84c68f23-a99e-4a92-a656-1e27191da09b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_0e38d7da-dfb9-41df-ba4c-d97aee01530e" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_84c68f23-a99e-4a92-a656-1e27191da09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_06592be2-4830-43fc-af53-50b2ae58bb63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_0e38d7da-dfb9-41df-ba4c-d97aee01530e" xlink:to="loc_us-gaap_UseOfEstimates_06592be2-4830-43fc-af53-50b2ae58bb63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_7fbc8f77-d8e5-4990-bb90-59886e174a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_0e38d7da-dfb9-41df-ba4c-d97aee01530e" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_7fbc8f77-d8e5-4990-bb90-59886e174a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_0f53499c-ff30-4fbe-9f7c-6aeb68b7ae98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_0e38d7da-dfb9-41df-ba4c-d97aee01530e" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_0f53499c-ff30-4fbe-9f7c-6aeb68b7ae98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_26885757-2b90-47a3-b321-b5c33dd989de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_0e38d7da-dfb9-41df-ba4c-d97aee01530e" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_26885757-2b90-47a3-b321-b5c33dd989de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_36d82501-1940-4563-9a98-035b70316820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_0e38d7da-dfb9-41df-ba4c-d97aee01530e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_36d82501-1940-4563-9a98-035b70316820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_d27d6209-e962-47f4-a7df-3a3113529724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_0e38d7da-dfb9-41df-ba4c-d97aee01530e" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_d27d6209-e962-47f4-a7df-3a3113529724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_9f25b3e3-b6e3-41d0-97c2-d0521aa746e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_0e38d7da-dfb9-41df-ba4c-d97aee01530e" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_9f25b3e3-b6e3-41d0-97c2-d0521aa746e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock_9b0e7a66-46d0-4231-acec-f8a672f25daa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_0e38d7da-dfb9-41df-ba4c-d97aee01530e" xlink:to="loc_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock_9b0e7a66-46d0-4231-acec-f8a672f25daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" xlink:type="simple" xlink:href="lxrx-20220630.xsd#SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_257511fc-c897-4e34-ac27-5afd4945b147" xlink:href="lxrx-20220630.xsd#lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_70b71785-0e03-4960-aabb-beaaa9900972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_257511fc-c897-4e34-ac27-5afd4945b147" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_70b71785-0e03-4960-aabb-beaaa9900972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6b391aed-2852-4d44-aa3b-afb5d08997ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_257511fc-c897-4e34-ac27-5afd4945b147" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6b391aed-2852-4d44-aa3b-afb5d08997ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b5185128-18c5-47a1-9315-94c73fa9270a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_257511fc-c897-4e34-ac27-5afd4945b147" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b5185128-18c5-47a1-9315-94c73fa9270a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_879690ef-7686-41bd-936b-ef4d65209c93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_257511fc-c897-4e34-ac27-5afd4945b147" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_879690ef-7686-41bd-936b-ef4d65209c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" xlink:type="simple" xlink:href="lxrx-20220630.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_1bb9d58f-23b2-4f9e-8eb9-0771ced818ce" xlink:href="lxrx-20220630.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11df94fb-c900-447f-98ca-2e664e004c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_1bb9d58f-23b2-4f9e-8eb9-0771ced818ce" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11df94fb-c900-447f-98ca-2e664e004c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9488df0f-d121-441f-a7fb-248ea87d5dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11df94fb-c900-447f-98ca-2e664e004c5f" xlink:to="loc_us-gaap_PlanNameAxis_9488df0f-d121-441f-a7fb-248ea87d5dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8102b90a-dc5a-4673-bca9-5c9310295427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_9488df0f-d121-441f-a7fb-248ea87d5dc4" xlink:to="loc_us-gaap_PlanNameDomain_8102b90a-dc5a-4673-bca9-5c9310295427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_e4b9dff4-9151-4091-a859-426b20d8d6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11df94fb-c900-447f-98ca-2e664e004c5f" xlink:to="loc_us-gaap_AwardDateAxis_e4b9dff4-9151-4091-a859-426b20d8d6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_f58a71f4-2977-4e01-9650-41800f1423a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_e4b9dff4-9151-4091-a859-426b20d8d6c6" xlink:to="loc_us-gaap_AwardDateDomain_f58a71f4-2977-4e01-9650-41800f1423a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_65dc3fd5-4b9b-4f73-9b99-9c3c95118d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11df94fb-c900-447f-98ca-2e664e004c5f" xlink:to="loc_us-gaap_AwardTypeAxis_65dc3fd5-4b9b-4f73-9b99-9c3c95118d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be7a9fb1-9a87-43e8-8448-b8a276623689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_65dc3fd5-4b9b-4f73-9b99-9c3c95118d4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be7a9fb1-9a87-43e8-8448-b8a276623689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_6a27d246-5557-4ae1-9ebd-29bb780820d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be7a9fb1-9a87-43e8-8448-b8a276623689" xlink:to="loc_us-gaap_StockOptionMember_6a27d246-5557-4ae1-9ebd-29bb780820d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f3367119-1571-45c1-b441-4357f3586a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11df94fb-c900-447f-98ca-2e664e004c5f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f3367119-1571-45c1-b441-4357f3586a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_487bec15-3407-47d0-931b-1c6cb0ed8bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f3367119-1571-45c1-b441-4357f3586a5e" xlink:to="loc_us-gaap_ClassOfStockDomain_487bec15-3407-47d0-931b-1c6cb0ed8bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7981b66c-6827-425f-bab4-41aaa564b05d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11df94fb-c900-447f-98ca-2e664e004c5f" xlink:to="loc_srt_RangeAxis_7981b66c-6827-425f-bab4-41aaa564b05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_51b5fe3e-aa7f-4454-9061-d9e5180dd3d9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7981b66c-6827-425f-bab4-41aaa564b05d" xlink:to="loc_srt_RangeMember_51b5fe3e-aa7f-4454-9061-d9e5180dd3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_ed212d83-ebf3-4f5c-b133-d0cbf4980e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11df94fb-c900-447f-98ca-2e664e004c5f" xlink:to="loc_us-gaap_VestingAxis_ed212d83-ebf3-4f5c-b133-d0cbf4980e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_5b46ebc9-d21f-4ea9-8211-110938ea7845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_ed212d83-ebf3-4f5c-b133-d0cbf4980e5f" xlink:to="loc_us-gaap_VestingDomain_5b46ebc9-d21f-4ea9-8211-110938ea7845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59b889b7-9f56-4e25-bedc-d95c48c57178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11df94fb-c900-447f-98ca-2e664e004c5f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59b889b7-9f56-4e25-bedc-d95c48c57178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_e9692fbb-5e9f-4232-97bc-e1cb7e5a0595" xlink:href="lxrx-20220630.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59b889b7-9f56-4e25-bedc-d95c48c57178" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_e9692fbb-5e9f-4232-97bc-e1cb7e5a0595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_978f087f-bc4a-47dc-bc03-0ef3c62f1d06" xlink:href="lxrx-20220630.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59b889b7-9f56-4e25-bedc-d95c48c57178" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_978f087f-bc4a-47dc-bc03-0ef3c62f1d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_fb6290cf-bdf1-4632-8308-3b4e704429b6" xlink:href="lxrx-20220630.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59b889b7-9f56-4e25-bedc-d95c48c57178" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_fb6290cf-bdf1-4632-8308-3b4e704429b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_9cf68706-2cdb-4408-9107-c32739b5d9d8" xlink:href="lxrx-20220630.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59b889b7-9f56-4e25-bedc-d95c48c57178" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_9cf68706-2cdb-4408-9107-c32739b5d9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_3ad3a028-d99b-414d-a88a-50bd92004d80" xlink:href="lxrx-20220630.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59b889b7-9f56-4e25-bedc-d95c48c57178" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_3ad3a028-d99b-414d-a88a-50bd92004d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_867f778b-4239-4668-95da-dba012bad13b" xlink:href="lxrx-20220630.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59b889b7-9f56-4e25-bedc-d95c48c57178" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_867f778b-4239-4668-95da-dba012bad13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_69f2049f-4ff7-4d4a-a3d8-33b26efab683" xlink:href="lxrx-20220630.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59b889b7-9f56-4e25-bedc-d95c48c57178" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_69f2049f-4ff7-4d4a-a3d8-33b26efab683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_63daa51b-270b-4d57-b38e-171eb8f88950" xlink:href="lxrx-20220630.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59b889b7-9f56-4e25-bedc-d95c48c57178" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_63daa51b-270b-4d57-b38e-171eb8f88950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" xlink:type="simple" xlink:href="lxrx-20220630.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_510dae69-0ce1-4f21-879e-072669021d6f" xlink:href="lxrx-20220630.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18f39341-e74f-4def-8b3a-41cb32404b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_510dae69-0ce1-4f21-879e-072669021d6f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18f39341-e74f-4def-8b3a-41cb32404b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e823fd89-436c-4b2c-b665-90a7c795db0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18f39341-e74f-4def-8b3a-41cb32404b0f" xlink:to="loc_us-gaap_PlanNameAxis_e823fd89-436c-4b2c-b665-90a7c795db0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9d6d44f7-e5a5-4c05-b8c8-73fab638d732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_e823fd89-436c-4b2c-b665-90a7c795db0e" xlink:to="loc_us-gaap_PlanNameDomain_9d6d44f7-e5a5-4c05-b8c8-73fab638d732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_9b782563-a72b-4816-b012-5a87303545b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18f39341-e74f-4def-8b3a-41cb32404b0f" xlink:to="loc_us-gaap_AwardDateAxis_9b782563-a72b-4816-b012-5a87303545b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_8aef8362-12e3-4890-9f64-d2b737c9af28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_9b782563-a72b-4816-b012-5a87303545b2" xlink:to="loc_us-gaap_AwardDateDomain_8aef8362-12e3-4890-9f64-d2b737c9af28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b6e9c90c-04a2-4fba-8337-73393f6c8f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18f39341-e74f-4def-8b3a-41cb32404b0f" xlink:to="loc_us-gaap_AwardTypeAxis_b6e9c90c-04a2-4fba-8337-73393f6c8f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb247acc-70d6-4627-a7b9-270c79b29da0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b6e9c90c-04a2-4fba-8337-73393f6c8f20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb247acc-70d6-4627-a7b9-270c79b29da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_24b423fd-72ff-4ca7-ac80-c402ace3a84c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb247acc-70d6-4627-a7b9-270c79b29da0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_24b423fd-72ff-4ca7-ac80-c402ace3a84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f201813c-6659-4450-be43-062b01f6bd76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb247acc-70d6-4627-a7b9-270c79b29da0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f201813c-6659-4450-be43-062b01f6bd76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7260f618-cc9a-447d-9696-92fd0995ac22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18f39341-e74f-4def-8b3a-41cb32404b0f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7260f618-cc9a-447d-9696-92fd0995ac22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e3f17c49-49ec-4963-af52-3f9ac7e49eed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7260f618-cc9a-447d-9696-92fd0995ac22" xlink:to="loc_us-gaap_ClassOfStockDomain_e3f17c49-49ec-4963-af52-3f9ac7e49eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0fd8b85b-729d-44de-ba01-25b0c5c2eb15" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18f39341-e74f-4def-8b3a-41cb32404b0f" xlink:to="loc_srt_RangeAxis_0fd8b85b-729d-44de-ba01-25b0c5c2eb15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_248f57ef-aca4-476e-8281-23b0c00395d1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0fd8b85b-729d-44de-ba01-25b0c5c2eb15" xlink:to="loc_srt_RangeMember_248f57ef-aca4-476e-8281-23b0c00395d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_9edfc4e8-4fdb-40d3-bf94-2536b967bc56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18f39341-e74f-4def-8b3a-41cb32404b0f" xlink:to="loc_us-gaap_VestingAxis_9edfc4e8-4fdb-40d3-bf94-2536b967bc56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_a5e273df-307c-4119-a874-03244eb1e99c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_9edfc4e8-4fdb-40d3-bf94-2536b967bc56" xlink:to="loc_us-gaap_VestingDomain_a5e273df-307c-4119-a874-03244eb1e99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18f39341-e74f-4def-8b3a-41cb32404b0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4516ef08-fbf1-4947-a3e3-116476a195d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4516ef08-fbf1-4947-a3e3-116476a195d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_266a464f-f9b4-4dbe-8011-a66d6e7b5d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_266a464f-f9b4-4dbe-8011-a66d6e7b5d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_f5b079b7-66d9-492e-8111-38e406915572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_f5b079b7-66d9-492e-8111-38e406915572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f691addb-d136-468a-a8b4-85187800b145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f691addb-d136-468a-a8b4-85187800b145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a41a2d8f-1ba2-45ce-b4b4-cfbd6cadaf8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a41a2d8f-1ba2-45ce-b4b4-cfbd6cadaf8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_21d58633-9bdd-4c4f-a216-d0c04a7c0f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_21d58633-9bdd-4c4f-a216-d0c04a7c0f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_57a3c849-9f95-4de2-8a3e-647a6413cdbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_57a3c849-9f95-4de2-8a3e-647a6413cdbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_8846c010-d7a9-4171-9e5e-215cc6f5ae90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_8846c010-d7a9-4171-9e5e-215cc6f5ae90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3383f907-ff37-480f-91df-abe1d3374fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3383f907-ff37-480f-91df-abe1d3374fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_cb6ec240-77ed-4535-aacc-4b379ba0fffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_cb6ec240-77ed-4535-aacc-4b379ba0fffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_51347d04-4440-456a-9c5c-d4fd6f79fd31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_51347d04-4440-456a-9c5c-d4fd6f79fd31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c016828e-cc39-4566-a282-d273294f7157" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c016828e-cc39-4566-a282-d273294f7157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_affa8079-16ec-4f59-84f6-a5ec3a2da2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_affa8079-16ec-4f59-84f6-a5ec3a2da2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cfa8e225-6202-4cdb-be82-1cb66d8f7507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cfa8e225-6202-4cdb-be82-1cb66d8f7507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4d9b5161-1a42-4d37-99f1-0bf65e24b61a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4d9b5161-1a42-4d37-99f1-0bf65e24b61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0a1f7f76-7f34-4583-a25b-e4bf705fb6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0a1f7f76-7f34-4583-a25b-e4bf705fb6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f1fe0475-81f9-4d3b-baae-b3501edc16ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f1fe0475-81f9-4d3b-baae-b3501edc16ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1d3b6085-ecd3-4f17-8dd9-b03b290b2165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1d3b6085-ecd3-4f17-8dd9-b03b290b2165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7e9ea4b3-46ab-42d5-80e3-4167b1c53d20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7e9ea4b3-46ab-42d5-80e3-4167b1c53d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_953ce2d2-c329-4f84-81c0-66e77a5718d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efbc18a6-a032-41eb-80ff-aaa32a3750be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_953ce2d2-c329-4f84-81c0-66e77a5718d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" xlink:type="simple" xlink:href="lxrx-20220630.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_a18cb259-2983-430a-a079-65ede1a6d76d" xlink:href="lxrx-20220630.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b925c0cb-507d-44fd-9bcd-56d1da991707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_a18cb259-2983-430a-a079-65ede1a6d76d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b925c0cb-507d-44fd-9bcd-56d1da991707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_8f7dd62a-3e1f-4619-8ae8-f2b5cc2dc935" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b925c0cb-507d-44fd-9bcd-56d1da991707" xlink:to="loc_us-gaap_PlanNameAxis_8f7dd62a-3e1f-4619-8ae8-f2b5cc2dc935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6e5dd3a4-f103-4381-b767-e3c08d86d017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_8f7dd62a-3e1f-4619-8ae8-f2b5cc2dc935" xlink:to="loc_us-gaap_PlanNameDomain_6e5dd3a4-f103-4381-b767-e3c08d86d017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_26362f1b-21fb-458b-9485-1d812a27e1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b925c0cb-507d-44fd-9bcd-56d1da991707" xlink:to="loc_us-gaap_AwardTypeAxis_26362f1b-21fb-458b-9485-1d812a27e1cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c4de23a-1b5e-42f3-9910-1a632e4650cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_26362f1b-21fb-458b-9485-1d812a27e1cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c4de23a-1b5e-42f3-9910-1a632e4650cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_514d1647-4faf-4265-ac2c-475f0f382f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b925c0cb-507d-44fd-9bcd-56d1da991707" xlink:to="loc_us-gaap_StatementClassOfStockAxis_514d1647-4faf-4265-ac2c-475f0f382f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3687b1b5-3329-4126-852e-f985411e3fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_514d1647-4faf-4265-ac2c-475f0f382f0f" xlink:to="loc_us-gaap_ClassOfStockDomain_3687b1b5-3329-4126-852e-f985411e3fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7f24899f-5853-4323-bf4c-4633a21bfeba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b925c0cb-507d-44fd-9bcd-56d1da991707" xlink:to="loc_srt_RangeAxis_7f24899f-5853-4323-bf4c-4633a21bfeba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_12560469-8c2b-444e-8fcf-b473c1ae3c7a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7f24899f-5853-4323-bf4c-4633a21bfeba" xlink:to="loc_srt_RangeMember_12560469-8c2b-444e-8fcf-b473c1ae3c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a5668b0-bd6a-4d69-9a0f-1140789687c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b925c0cb-507d-44fd-9bcd-56d1da991707" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a5668b0-bd6a-4d69-9a0f-1140789687c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lxrx-20220630.xsd#SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_de4a9bf4-949e-473d-93c1-328104b546b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesTable_1be11f5e-ec80-4009-837c-20847810cf17" xlink:href="lxrx-20220630.xsd#lxrx_AccruedLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_de4a9bf4-949e-473d-93c1-328104b546b0" xlink:to="loc_lxrx_AccruedLiabilitiesTable_1be11f5e-ec80-4009-837c-20847810cf17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesAxis_5cb4ede5-d356-4512-864d-d459cb55ffbb" xlink:href="lxrx-20220630.xsd#lxrx_AccruedLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesTable_1be11f5e-ec80-4009-837c-20847810cf17" xlink:to="loc_lxrx_AccruedLiabilitiesAxis_5cb4ede5-d356-4512-864d-d459cb55ffbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesDomain_3626e788-7ecb-4a63-8bd6-106aeecad34f" xlink:href="lxrx-20220630.xsd#lxrx_AccruedLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesAxis_5cb4ede5-d356-4512-864d-d459cb55ffbb" xlink:to="loc_lxrx_AccruedLiabilitiesDomain_3626e788-7ecb-4a63-8bd6-106aeecad34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesLineItems_292cc32b-01db-477f-8359-62c7b71fade1" xlink:href="lxrx-20220630.xsd#lxrx_AccruedLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesTable_1be11f5e-ec80-4009-837c-20847810cf17" xlink:to="loc_lxrx_AccruedLiabilitiesLineItems_292cc32b-01db-477f-8359-62c7b71fade1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent_7462c153-2bc1-4671-91c6-e015a63555a5" xlink:href="lxrx-20220630.xsd#lxrx_AccruedResearchAndDevelopmentServicesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_292cc32b-01db-477f-8359-62c7b71fade1" xlink:to="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent_7462c153-2bc1-4671-91c6-e015a63555a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedCompensationAndBenefitsCurrent_113c5b0c-e370-45d4-a691-34b6d1085f9c" xlink:href="lxrx-20220630.xsd#lxrx_AccruedCompensationAndBenefitsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_292cc32b-01db-477f-8359-62c7b71fade1" xlink:to="loc_lxrx_AccruedCompensationAndBenefitsCurrent_113c5b0c-e370-45d4-a691-34b6d1085f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_bbb749d8-f07a-4b00-b12e-304fb6856043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_292cc32b-01db-477f-8359-62c7b71fade1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_bbb749d8-f07a-4b00-b12e-304fb6856043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_968e5fa9-c31c-4c8f-810a-469706ff5db0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_292cc32b-01db-477f-8359-62c7b71fade1" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_968e5fa9-c31c-4c8f-810a-469706ff5db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_41cada58-5c45-4662-8222-12a9e27a6c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_292cc32b-01db-477f-8359-62c7b71fade1" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_41cada58-5c45-4662-8222-12a9e27a6c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LexiconIncrementalBorrowingRate_a5c560e8-e29c-4eeb-86b5-bacb368b4ecc" xlink:href="lxrx-20220630.xsd#lxrx_LexiconIncrementalBorrowingRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_292cc32b-01db-477f-8359-62c7b71fade1" xlink:to="loc_lxrx_LexiconIncrementalBorrowingRate_a5c560e8-e29c-4eeb-86b5-bacb368b4ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="simple" xlink:href="lxrx-20220630.xsd#SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_835dd8e7-cc98-4b6c-b4f1-0f2006389098" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_44f61862-f8cd-44a7-9115-dae2741befb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_835dd8e7-cc98-4b6c-b4f1-0f2006389098" xlink:to="loc_us-gaap_AssetImpairmentCharges_44f61862-f8cd-44a7-9115-dae2741befb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes" xlink:type="simple" xlink:href="lxrx-20220630.xsd#RecentAccountingPronouncementsLevel1Notes"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RecentAccountingPronouncementsAbstract_b0ce2821-b832-4cf2-8559-f398ce868a8d" xlink:href="lxrx-20220630.xsd#lxrx_RecentAccountingPronouncementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0f16807e-1fcd-4c03-ba25-b3649c402cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_RecentAccountingPronouncementsAbstract_b0ce2821-b832-4cf2-8559-f398ce868a8d" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0f16807e-1fcd-4c03-ba25-b3649c402cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="simple" xlink:href="lxrx-20220630.xsd#CashandCashEquivalentsandInvestments"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_d0c0fb9e-5b4a-4156-8057-c74e61582d53" xlink:href="lxrx-20220630.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_6040525f-93b1-4834-9ab9-cc57900141db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_d0c0fb9e-5b4a-4156-8057-c74e61582d53" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_6040525f-93b1-4834-9ab9-cc57900141db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="simple" xlink:href="lxrx-20220630.xsd#CashandCashEquivalentsandInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_69fb87f9-cb0a-4dcd-b3db-35585ed28c7d" xlink:href="lxrx-20220630.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_96a1cb17-38d1-41dd-81b8-728197ebd186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_69fb87f9-cb0a-4dcd-b3db-35585ed28c7d" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_96a1cb17-38d1-41dd-81b8-728197ebd186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" xlink:type="simple" xlink:href="lxrx-20220630.xsd#CashandCashEquivalentsandInvestmentsDetails1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_3518016b-90f9-4ffa-a293-bfee78e0122d" xlink:href="lxrx-20220630.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_71a7b952-0556-46d1-8710-f11a12d9c184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_3518016b-90f9-4ffa-a293-bfee78e0122d" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_71a7b952-0556-46d1-8710-f11a12d9c184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_cf96fd23-9714-4172-90c4-d80a4b92cef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_71a7b952-0556-46d1-8710-f11a12d9c184" xlink:to="loc_us-gaap_InvestmentTypeAxis_cf96fd23-9714-4172-90c4-d80a4b92cef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1c4d0b24-5b71-4361-9f3e-2295082520ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_cf96fd23-9714-4172-90c4-d80a4b92cef4" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1c4d0b24-5b71-4361-9f3e-2295082520ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_dea8fa4d-719b-44b3-9f49-317f4578dd45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1c4d0b24-5b71-4361-9f3e-2295082520ac" xlink:to="loc_us-gaap_CashMember_dea8fa4d-719b-44b3-9f49-317f4578dd45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_69addab4-1236-4776-a169-16acba7c1372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1c4d0b24-5b71-4361-9f3e-2295082520ac" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_69addab4-1236-4776-a169-16acba7c1372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_90b4e01c-f5f1-4dd7-81fb-198330b4d211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1c4d0b24-5b71-4361-9f3e-2295082520ac" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_90b4e01c-f5f1-4dd7-81fb-198330b4d211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_2d573883-1df8-46d6-8da8-d022be4f9ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1c4d0b24-5b71-4361-9f3e-2295082520ac" xlink:to="loc_us-gaap_InvestmentsMember_2d573883-1df8-46d6-8da8-d022be4f9ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d6848fcd-e96d-4b96-96a9-1b2d2e8b9213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1c4d0b24-5b71-4361-9f3e-2295082520ac" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d6848fcd-e96d-4b96-96a9-1b2d2e8b9213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2df58ceb-afa5-461d-8e71-5197bb07a2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_71a7b952-0556-46d1-8710-f11a12d9c184" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2df58ceb-afa5-461d-8e71-5197bb07a2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bc4aa511-7d66-4ec3-ba5a-99ebf2a35f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2df58ceb-afa5-461d-8e71-5197bb07a2ba" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bc4aa511-7d66-4ec3-ba5a-99ebf2a35f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ed2583c9-505b-4936-8589-3476d1ec6b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2df58ceb-afa5-461d-8e71-5197bb07a2ba" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ed2583c9-505b-4936-8589-3476d1ec6b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_964d7c1d-6ca6-4f83-8425-b118704a9e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2df58ceb-afa5-461d-8e71-5197bb07a2ba" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_964d7c1d-6ca6-4f83-8425-b118704a9e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_611a5523-1dbc-42d5-a638-1407f0f0f997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2df58ceb-afa5-461d-8e71-5197bb07a2ba" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_611a5523-1dbc-42d5-a638-1407f0f0f997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9c6ce87a-a5f4-4094-8750-1a80808d1ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2df58ceb-afa5-461d-8e71-5197bb07a2ba" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9c6ce87a-a5f4-4094-8750-1a80808d1ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_7acfb4b6-abac-45c6-ab43-43a7a30a3873" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2df58ceb-afa5-461d-8e71-5197bb07a2ba" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_7acfb4b6-abac-45c6-ab43-43a7a30a3873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_707bce71-46d0-4c4b-90e9-e939751d239c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2df58ceb-afa5-461d-8e71-5197bb07a2ba" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_707bce71-46d0-4c4b-90e9-e939751d239c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" xlink:type="simple" xlink:href="lxrx-20220630.xsd#CashandCashEquivalentsandInvestmentsDetails2"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_f1f1d57d-0455-47bf-aabe-544feda30c31" xlink:href="lxrx-20220630.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_2df6c0dc-c96c-49e1-813b-57727364c799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_f1f1d57d-0455-47bf-aabe-544feda30c31" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_2df6c0dc-c96c-49e1-813b-57727364c799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeAxis_f9eb09c2-d680-47bb-ade0-67f44122babd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingActivityByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_2df6c0dc-c96c-49e1-813b-57727364c799" xlink:to="loc_us-gaap_TradingActivityByTypeAxis_f9eb09c2-d680-47bb-ade0-67f44122babd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeDomain_f345742c-1234-4ba2-bcfd-a60bbcc4f10d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TradingActivityByTypeAxis_f9eb09c2-d680-47bb-ade0-67f44122babd" xlink:to="loc_us-gaap_TradingActivityByTypeDomain_f345742c-1234-4ba2-bcfd-a60bbcc4f10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_2ae7b3d1-5819-4ab1-b9b9-5c77874de557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_2df6c0dc-c96c-49e1-813b-57727364c799" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_2ae7b3d1-5819-4ab1-b9b9-5c77874de557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_048e9091-0d8c-4f8d-9b6b-43d0f539dd21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_2ae7b3d1-5819-4ab1-b9b9-5c77874de557" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_048e9091-0d8c-4f8d-9b6b-43d0f539dd21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="lxrx-20220630.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_fb3e304b-43ed-4bc2-ae13-19585ec07e16" xlink:href="lxrx-20220630.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_e5884a03-fc12-4722-a6f2-35422bf8f95a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_fb3e304b-43ed-4bc2-ae13-19585ec07e16" xlink:to="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_e5884a03-fc12-4722-a6f2-35422bf8f95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="lxrx-20220630.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_ca405ba7-f640-42cb-b1fd-0bdc10f83ef1" xlink:href="lxrx-20220630.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_8b931f19-5986-459f-b7ca-acc8627327f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_ca405ba7-f640-42cb-b1fd-0bdc10f83ef1" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_8b931f19-5986-459f-b7ca-acc8627327f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="lxrx-20220630.xsd#FairValueMeasurementsDetails1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_c056c2de-5bfe-45a1-8fbf-1e586d6d72ab" xlink:href="lxrx-20220630.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5a6b14c0-9f15-459c-9d30-b3b065af851a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_c056c2de-5bfe-45a1-8fbf-1e586d6d72ab" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5a6b14c0-9f15-459c-9d30-b3b065af851a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_67564a55-ef8e-4803-9e51-36378379002c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5a6b14c0-9f15-459c-9d30-b3b065af851a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_67564a55-ef8e-4803-9e51-36378379002c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e47bba74-ab5d-4f72-8028-0db23af76aae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_67564a55-ef8e-4803-9e51-36378379002c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e47bba74-ab5d-4f72-8028-0db23af76aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_042484f8-af65-4449-b4a8-b3e2464ba86f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e47bba74-ab5d-4f72-8028-0db23af76aae" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_042484f8-af65-4449-b4a8-b3e2464ba86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b63fd97d-5df9-441e-bb95-5ebb3544fbf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e47bba74-ab5d-4f72-8028-0db23af76aae" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b63fd97d-5df9-441e-bb95-5ebb3544fbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a64a508b-06da-44b0-a06f-bae7295b2ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e47bba74-ab5d-4f72-8028-0db23af76aae" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a64a508b-06da-44b0-a06f-bae7295b2ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9a1a0057-4259-4a99-8bc0-16e8bfd443c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5a6b14c0-9f15-459c-9d30-b3b065af851a" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9a1a0057-4259-4a99-8bc0-16e8bfd443c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a97b739d-509c-42b6-b8c0-368dfe8b7f18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9a1a0057-4259-4a99-8bc0-16e8bfd443c6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a97b739d-509c-42b6-b8c0-368dfe8b7f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_70fbf990-3ae3-44ae-83d4-3840059bb775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9a1a0057-4259-4a99-8bc0-16e8bfd443c6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_70fbf990-3ae3-44ae-83d4-3840059bb775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_17c64aae-99dc-41eb-a3fa-d83e5c62b041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9a1a0057-4259-4a99-8bc0-16e8bfd443c6" xlink:to="loc_us-gaap_AvailableForSaleSecurities_17c64aae-99dc-41eb-a3fa-d83e5c62b041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_01af7d24-1685-4495-a991-ae401e12e900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9a1a0057-4259-4a99-8bc0-16e8bfd443c6" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_01af7d24-1685-4495-a991-ae401e12e900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligations" xlink:type="simple" xlink:href="lxrx-20220630.xsd#DebtObligations"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract_ffd9bdcf-0a9e-4736-82e2-2399f05b4ce0" xlink:href="lxrx-20220630.xsd#lxrx_DebtObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_04aea084-373d-47ff-b9cf-37953a8872f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_ffd9bdcf-0a9e-4736-82e2-2399f05b4ce0" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_04aea084-373d-47ff-b9cf-37953a8872f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsTables" xlink:type="simple" xlink:href="lxrx-20220630.xsd#DebtObligationsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails" xlink:type="simple" xlink:href="lxrx-20220630.xsd#DebtObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract_6cb8b7b2-dfaa-4268-a14c-e8f5587a30c5" xlink:href="lxrx-20220630.xsd#lxrx_DebtObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_387a1900-4bc0-4b87-83b7-54aa4a306208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_6cb8b7b2-dfaa-4268-a14c-e8f5587a30c5" xlink:to="loc_us-gaap_DebtInstrumentTable_387a1900-4bc0-4b87-83b7-54aa4a306208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_387a1900-4bc0-4b87-83b7-54aa4a306208" xlink:to="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_863188e2-40b2-46aa-8c5c-478ce2667113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_863188e2-40b2-46aa-8c5c-478ce2667113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_9e50525c-cd91-4c02-add0-f14979431479" xlink:href="lxrx-20220630.xsd#lxrx_ConvDebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_9e50525c-cd91-4c02-add0-f14979431479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_64d54f3e-bfdb-4168-b34c-fb30c8a5a3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_64d54f3e-bfdb-4168-b34c-fb30c8a5a3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_29ab88d4-b7e0-47c7-91c1-a60dbf411967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_29ab88d4-b7e0-47c7-91c1-a60dbf411967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_0c91c3e7-b2c5-48f4-9bae-ac914e9cf4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_us-gaap_DebtInstrumentFairValue_0c91c3e7-b2c5-48f4-9bae-ac914e9cf4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4529efbc-40e4-49aa-a0aa-bfcafb6016a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_us-gaap_CommonStockSharesIssued_4529efbc-40e4-49aa-a0aa-bfcafb6016a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchange_0909d9ce-64e2-4f99-8dd4-69f096313d4c" xlink:href="lxrx-20220630.xsd#lxrx_ConvertibleDebtExchange"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_ConvertibleDebtExchange_0909d9ce-64e2-4f99-8dd4-69f096313d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedInterestOnConvertible_1b855fc4-3350-4678-97e5-33e0385e7cb3" xlink:href="lxrx-20220630.xsd#lxrx_AccruedInterestOnConvertible"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_AccruedInterestOnConvertible_1b855fc4-3350-4678-97e5-33e0385e7cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeRemainingNotes_4a759a0b-e416-4c7d-8f69-7ea6015c4aaa" xlink:href="lxrx-20220630.xsd#lxrx_ConvertibleDebtExchangeRemainingNotes"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_ConvertibleDebtExchangeRemainingNotes_4a759a0b-e416-4c7d-8f69-7ea6015c4aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FutureConvertibleDebtExchangeShares_bae124e9-2204-47b9-a38f-eef2ec358ea5" xlink:href="lxrx-20220630.xsd#lxrx_FutureConvertibleDebtExchangeShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_FutureConvertibleDebtExchangeShares_bae124e9-2204-47b9-a38f-eef2ec358ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FutureConvertibleDebtExchange_879e03de-2b2c-40c9-b292-3b149a91c115" xlink:href="lxrx-20220630.xsd#lxrx_FutureConvertibleDebtExchange"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_FutureConvertibleDebtExchange_879e03de-2b2c-40c9-b292-3b149a91c115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PrincipalAmountOfConvertibleNotes_e9db3309-c0fd-4ae2-8562-5db84cd77ad1" xlink:href="lxrx-20220630.xsd#lxrx_PrincipalAmountOfConvertibleNotes"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_PrincipalAmountOfConvertibleNotes_e9db3309-c0fd-4ae2-8562-5db84cd77ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_e676036b-9aa3-4d43-ab35-d0aa20cf39f6" xlink:href="lxrx-20220630.xsd#lxrx_ConvertibleDebtExchangeTotalPrincipalAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_e676036b-9aa3-4d43-ab35-d0aa20cf39f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_1cff167b-b829-4ecf-99d0-1e3a119797ab" xlink:href="lxrx-20220630.xsd#lxrx_ConvertibleDebtExchangeSeptemberCashPortion"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_1cff167b-b829-4ecf-99d0-1e3a119797ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_e19389e2-f4b2-4ab1-a353-63441551db1b" xlink:href="lxrx-20220630.xsd#lxrx_ConvertibleDebtExchangeSeptemberSharePayment"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_e19389e2-f4b2-4ab1-a353-63441551db1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_98c616a2-0001-4716-b279-2e23fe0ecc32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_98c616a2-0001-4716-b279-2e23fe0ecc32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c63e8b1d-1b31-4822-aabc-f946943cf13c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_us-gaap_LongTermDebt_c63e8b1d-1b31-4822-aabc-f946943cf13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTerm_03490465-eb86-4d6a-a5ab-dd8e04541e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTerm"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_us-gaap_LongTermDebtTerm_03490465-eb86-4d6a-a5ab-dd8e04541e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_927af1ed-623d-4c75-a6c4-dbd6a2d1578a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_927af1ed-623d-4c75-a6c4-dbd6a2d1578a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_029821ba-94b8-4ce5-b5ea-42c4428dbeb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_029821ba-94b8-4ce5-b5ea-42c4428dbeb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanB_4a565a80-2fb3-40fe-aefb-eeb3a5e2d418" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanB"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_TermLoanB_4a565a80-2fb3-40fe-aefb-eeb3a5e2d418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanC_e572a1c4-c2b5-495c-a0d2-799bb415f906" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanC"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_TermLoanC_e572a1c4-c2b5-495c-a0d2-799bb415f906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanD_02c1f9d4-31fe-4177-a0cb-34b69288494a" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanD"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_TermLoanD_02c1f9d4-31fe-4177-a0cb-34b69288494a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OxfordLoanFacility_18984c42-2da2-4881-ac7c-ff0dd17e0de7" xlink:href="lxrx-20220630.xsd#lxrx_OxfordLoanFacility"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_OxfordLoanFacility_18984c42-2da2-4881-ac7c-ff0dd17e0de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanA_3de6fe26-af1e-41ff-8cc5-c736b4add0d1" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanA"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_TermLoanA_3de6fe26-af1e-41ff-8cc5-c736b4add0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanABWarrant_e6e67060-5284-492d-9980-19c689542ddb" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanABWarrant"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_TermLoanABWarrant_e6e67060-5284-492d-9980-19c689542ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanCWarrant_e7b5311d-c451-4cf2-9bda-d4c954115709" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanCWarrant"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_TermLoanCWarrant_e7b5311d-c451-4cf2-9bda-d4c954115709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanDWarrant_9d7186db-3321-469e-b1fb-3e3c91953b94" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanDWarrant"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_TermLoanDWarrant_9d7186db-3321-469e-b1fb-3e3c91953b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAWarrantsNumber_b6b4edfb-b5e3-478d-94ee-a9f8b86afc00" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanAWarrantsNumber"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_TermLoanAWarrantsNumber_b6b4edfb-b5e3-478d-94ee-a9f8b86afc00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAWarrantExercisePrice_2cd4e19f-d140-41c4-af95-03ab9144f9e1" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanAWarrantExercisePrice"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_TermLoanAWarrantExercisePrice_2cd4e19f-d140-41c4-af95-03ab9144f9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_20a5a015-7239-40ea-8c8a-8b2747e52dda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_20a5a015-7239-40ea-8c8a-8b2747e52dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_37f44268-8c55-4d28-ac74-9277d515c312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_37f44268-8c55-4d28-ac74-9277d515c312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5229b9f0-7cb2-44a2-b134-e0e08c5a0885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5229b9f0-7cb2-44a2-b134-e0e08c5a0885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_a16e215d-a20b-42ca-90ef-4bfb68a00e89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_a16e215d-a20b-42ca-90ef-4bfb68a00e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubordinatedBorrowingInterestRate_40a5f2b9-9e7f-43f9-857b-6648f7af5bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubordinatedBorrowingInterestRate"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_us-gaap_SubordinatedBorrowingInterestRate_40a5f2b9-9e7f-43f9-857b-6648f7af5bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FinalPaymentWithNoExtention_00ac68e2-1727-4c6e-936a-1934e83f1190" xlink:href="lxrx-20220630.xsd#lxrx_FinalPaymentWithNoExtention"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_FinalPaymentWithNoExtention_00ac68e2-1727-4c6e-936a-1934e83f1190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FinalPaymentWithExtention_2c394a19-c780-4f20-9464-f1af0cd338e4" xlink:href="lxrx-20220630.xsd#lxrx_FinalPaymentWithExtention"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_FinalPaymentWithExtention_2c394a19-c780-4f20-9464-f1af0cd338e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAFinalPayment_4cb384db-eb77-4b25-adc5-452ff4d20b08" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanAFinalPayment"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_TermLoanAFinalPayment_4cb384db-eb77-4b25-adc5-452ff4d20b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanANetCashReceipt_d20f270b-ab88-4b29-b26a-a941826b79da" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanANetCashReceipt"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_TermLoanANetCashReceipt_d20f270b-ab88-4b29-b26a-a941826b79da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanADebtIssuanceCosts_e16225cd-3894-452b-8418-66e5b8e927e7" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanADebtIssuanceCosts"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_TermLoanADebtIssuanceCosts_e16225cd-3894-452b-8418-66e5b8e927e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OxfordFacilityFee_b388f073-dc5a-4d32-b9f2-4b0966886c31" xlink:href="lxrx-20220630.xsd#lxrx_OxfordFacilityFee"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_OxfordFacilityFee_b388f073-dc5a-4d32-b9f2-4b0966886c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanADebtDiscount_57425d6e-fcb3-4659-810c-5ba855a7a042" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanADebtDiscount"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_TermLoanADebtDiscount_57425d6e-fcb3-4659-810c-5ba855a7a042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAInterestExpense_561952f8-5dd4-4001-b79a-9925b736cb8b" xlink:href="lxrx-20220630.xsd#lxrx_TermLoanAInterestExpense"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_TermLoanAInterestExpense_561952f8-5dd4-4001-b79a-9925b736cb8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2025OxfordPrincipalPayments_68b83c64-0395-41e1-8d66-1a7aff5d3497" xlink:href="lxrx-20220630.xsd#lxrx_A2025OxfordPrincipalPayments"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_A2025OxfordPrincipalPayments_68b83c64-0395-41e1-8d66-1a7aff5d3497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2026OxfordPrincipalPayments_488ba06f-d645-4eaf-acd2-991273f479b6" xlink:href="lxrx-20220630.xsd#lxrx_A2026OxfordPrincipalPayments"/>
    <link:presentationArc order="45" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_A2026OxfordPrincipalPayments_488ba06f-d645-4eaf-acd2-991273f479b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2027OxfordPrincipalPayments_cf8247f9-9168-41da-b095-e33a0aa96077" xlink:href="lxrx-20220630.xsd#lxrx_A2027OxfordPrincipalPayments"/>
    <link:presentationArc order="46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_59e1c399-1820-4bee-9238-614ce72a29d5" xlink:to="loc_lxrx_A2027OxfordPrincipalPayments_cf8247f9-9168-41da-b095-e33a0aa96077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="lxrx-20220630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6ae28e8a-85bd-4492-9eb7-acf6db2288c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1eec497b-3718-4a31-8378-ca3e65794186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6ae28e8a-85bd-4492-9eb7-acf6db2288c4" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1eec497b-3718-4a31-8378-ca3e65794186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="lxrx-20220630.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9692ff4a-c73a-4ec2-8e2d-49773cd2570c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment_b261496f-6e69-4139-b977-aa8cac0fac0d" xlink:href="lxrx-20220630.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9692ff4a-c73a-4ec2-8e2d-49773cd2570c" xlink:to="loc_lxrx_Lxrx_Sanofiterminationcashpayment_b261496f-6e69-4139-b977-aa8cac0fac0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_4d7d49f4-cd02-494b-b941-2566f829c97f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9692ff4a-c73a-4ec2-8e2d-49773cd2570c" xlink:to="loc_us-gaap_OtherCommitmentsTable_4d7d49f4-cd02-494b-b941-2566f829c97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_6ce322b0-3a35-4e8b-8d33-6543bd0f4642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_4d7d49f4-cd02-494b-b941-2566f829c97f" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_6ce322b0-3a35-4e8b-8d33-6543bd0f4642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_5d2cc89d-8406-4660-a7e6-82dcb198d0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_6ce322b0-3a35-4e8b-8d33-6543bd0f4642" xlink:to="loc_us-gaap_ReceivableTypeDomain_5d2cc89d-8406-4660-a7e6-82dcb198d0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_5a68b1d9-158d-470c-830d-6d2b2c480330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_5d2cc89d-8406-4660-a7e6-82dcb198d0ab" xlink:to="loc_us-gaap_AccountsReceivableMember_5a68b1d9-158d-470c-830d-6d2b2c480330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_087bad4e-d8db-43cc-907a-ffb8e75a8277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_4d7d49f4-cd02-494b-b941-2566f829c97f" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_087bad4e-d8db-43cc-907a-ffb8e75a8277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment_2d602515-b10f-46a9-97f3-dc77831c5b54" xlink:href="lxrx-20220630.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_087bad4e-d8db-43cc-907a-ffb8e75a8277" xlink:to="loc_lxrx_Lxrx_Sanofiterminationcashpayment_2d602515-b10f-46a9-97f3-dc77831c5b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_5443b848-20e7-408b-bf9b-c9371a776c63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_087bad4e-d8db-43cc-907a-ffb8e75a8277" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_5443b848-20e7-408b-bf9b-c9371a776c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2fb4d743-ef49-4c1e-bb5a-86adcce9e401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_087bad4e-d8db-43cc-907a-ffb8e75a8277" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2fb4d743-ef49-4c1e-bb5a-86adcce9e401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9928e80b-c677-484b-bfed-ee75af47a3e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_087bad4e-d8db-43cc-907a-ffb8e75a8277" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9928e80b-c677-484b-bfed-ee75af47a3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_067e3c66-2747-4f25-96d4-0f4055589e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_087bad4e-d8db-43cc-907a-ffb8e75a8277" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_067e3c66-2747-4f25-96d4-0f4055589e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5a703eaf-6ca6-4ae8-b27a-3f00ec46fa2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_087bad4e-d8db-43cc-907a-ffb8e75a8277" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5a703eaf-6ca6-4ae8-b27a-3f00ec46fa2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_dbb689c2-621f-4ade-873d-87dbe7ef15ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_087bad4e-d8db-43cc-907a-ffb8e75a8277" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_dbb689c2-621f-4ade-873d-87dbe7ef15ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2ae3a157-d296-4037-b591-5cf73b8257cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_087bad4e-d8db-43cc-907a-ffb8e75a8277" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2ae3a157-d296-4037-b591-5cf73b8257cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_99bfe615-9e95-46eb-a8eb-962b091133d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_087bad4e-d8db-43cc-907a-ffb8e75a8277" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_99bfe615-9e95-46eb-a8eb-962b091133d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_43386971-b7ee-4aba-b889-1f9fc86538eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_087bad4e-d8db-43cc-907a-ffb8e75a8277" xlink:to="loc_us-gaap_OperatingLeaseLiability_43386971-b7ee-4aba-b889-1f9fc86538eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCommitmentAmount_c23797ef-8771-482c-a376-3e736882b847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCommitmentAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_087bad4e-d8db-43cc-907a-ffb8e75a8277" xlink:to="loc_us-gaap_ShortTermLeaseCommitmentAmount_c23797ef-8771-482c-a376-3e736882b847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_738640b0-3a62-4092-8211-02b3b7efad0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_087bad4e-d8db-43cc-907a-ffb8e75a8277" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_738640b0-3a62-4092-8211-02b3b7efad0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiDisputedCosts_199f99da-b9fd-42e7-a7f0-1337acb55d29" xlink:href="lxrx-20220630.xsd#lxrx_SanofiDisputedCosts"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_087bad4e-d8db-43cc-907a-ffb8e75a8277" xlink:to="loc_lxrx_SanofiDisputedCosts_199f99da-b9fd-42e7-a7f0-1337acb55d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="lxrx-20220630.xsd#CollaborationandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_02dcc02d-a8bd-4297-8e16-20d11744610d" xlink:href="lxrx-20220630.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_014b0dc0-bec1-4840-ad85-84751eddd580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_02dcc02d-a8bd-4297-8e16-20d11744610d" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_014b0dc0-bec1-4840-ad85-84751eddd580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsTables" xlink:type="simple" xlink:href="lxrx-20220630.xsd#CollaborationandLicenseAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="simple" xlink:href="lxrx-20220630.xsd#CollaborationandLicenseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_14f4f761-3f1f-455f-8b3d-41dd764a5247" xlink:href="lxrx-20220630.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment_96396ad6-2eac-4b60-acf4-29ed12c8c58f" xlink:href="lxrx-20220630.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_14f4f761-3f1f-455f-8b3d-41dd764a5247" xlink:to="loc_lxrx_Lxrx_Sanofiterminationcashpayment_96396ad6-2eac-4b60-acf4-29ed12c8c58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueRecognized_1aeb990a-7442-4ec5-9af2-673ea500c943" xlink:href="lxrx-20220630.xsd#lxrx_SanofiRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_14f4f761-3f1f-455f-8b3d-41dd764a5247" xlink:to="loc_lxrx_SanofiRevenueRecognized_1aeb990a-7442-4ec5-9af2-673ea500c943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenTotalPayments_0eed4856-774f-4c0c-a52d-753ec8791d8a" xlink:href="lxrx-20220630.xsd#lxrx_IpsenTotalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_14f4f761-3f1f-455f-8b3d-41dd764a5247" xlink:to="loc_lxrx_IpsenTotalPayments_0eed4856-774f-4c0c-a52d-753ec8791d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMaximumSalesMilestones_62d72fe1-de34-4842-ae40-37d5499eca3e" xlink:href="lxrx-20220630.xsd#lxrx_IpsenMaximumSalesMilestones"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_14f4f761-3f1f-455f-8b3d-41dd764a5247" xlink:to="loc_lxrx_IpsenMaximumSalesMilestones_62d72fe1-de34-4842-ae40-37d5499eca3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMilestonePayment_c4e9de20-388c-4e8d-a76c-0ea317329d87" xlink:href="lxrx-20220630.xsd#lxrx_IpsenMilestonePayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_14f4f761-3f1f-455f-8b3d-41dd764a5247" xlink:to="loc_lxrx_IpsenMilestonePayment_c4e9de20-388c-4e8d-a76c-0ea317329d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMilestonePaymentReceived_b1bf84eb-ebcd-4b7f-991f-6b8f536f5616" xlink:href="lxrx-20220630.xsd#lxrx_IpsenMilestonePaymentReceived"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_14f4f761-3f1f-455f-8b3d-41dd764a5247" xlink:to="loc_lxrx_IpsenMilestonePaymentReceived_b1bf84eb-ebcd-4b7f-991f-6b8f536f5616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_a874be55-00c5-4d95-8405-5f900e63b76b" xlink:href="lxrx-20220630.xsd#lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_14f4f761-3f1f-455f-8b3d-41dd764a5247" xlink:to="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_a874be55-00c5-4d95-8405-5f900e63b76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueRecognized_a4e9fdcf-4c76-46b7-841d-e8364e7dda16" xlink:href="lxrx-20220630.xsd#lxrx_IpsenRevenueRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_14f4f761-3f1f-455f-8b3d-41dd764a5247" xlink:to="loc_lxrx_IpsenRevenueRecognized_a4e9fdcf-4c76-46b7-841d-e8364e7dda16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_sanofiInitialCashPayment_47dffd28-a071-4ba8-bd8a-ed1ffe463b54" xlink:href="lxrx-20220630.xsd#lxrx_Lxrx_sanofiInitialCashPayment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_14f4f761-3f1f-455f-8b3d-41dd764a5247" xlink:to="loc_lxrx_Lxrx_sanofiInitialCashPayment_47dffd28-a071-4ba8-bd8a-ed1ffe463b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SettlementPaymentFromTermination_9d1a3bf1-ec83-43f9-be29-f731b63a5a24" xlink:href="lxrx-20220630.xsd#lxrx_SettlementPaymentFromTermination"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_14f4f761-3f1f-455f-8b3d-41dd764a5247" xlink:to="loc_lxrx_SettlementPaymentFromTermination_9d1a3bf1-ec83-43f9-be29-f731b63a5a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalAgreements" xlink:type="simple" xlink:href="lxrx-20220630.xsd#OtherCapitalAgreements"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/OtherCapitalAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d55a08f4-334d-4e89-9008-d07263ce483d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OtherCapitalAgreementsTextBlock_7594d672-5833-493a-b9a4-f8a85c8d71c7" xlink:href="lxrx-20220630.xsd#lxrx_OtherCapitalAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d55a08f4-334d-4e89-9008-d07263ce483d" xlink:to="loc_lxrx_OtherCapitalAgreementsTextBlock_7594d672-5833-493a-b9a4-f8a85c8d71c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_0a7e1ac3-2afd-4933-9120-6ff2f0d5fc14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d55a08f4-334d-4e89-9008-d07263ce483d" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_0a7e1ac3-2afd-4933-9120-6ff2f0d5fc14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails" xlink:type="simple" xlink:href="lxrx-20220630.xsd#OtherCapitalAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b70c98cf-91cb-49da-b9fc-c8a92d78e8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ATMOfferingTotal_581ed826-675a-4354-b926-b3c7743ee6de" xlink:href="lxrx-20220630.xsd#lxrx_ATMOfferingTotal"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b70c98cf-91cb-49da-b9fc-c8a92d78e8bc" xlink:to="loc_lxrx_ATMOfferingTotal_581ed826-675a-4354-b926-b3c7743ee6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInNov2020ATMOffering_64cec102-45f3-43eb-bc85-bde5bb6f7100" xlink:href="lxrx-20220630.xsd#lxrx_SharesSoldInNov2020ATMOffering"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b70c98cf-91cb-49da-b9fc-c8a92d78e8bc" xlink:to="loc_lxrx_SharesSoldInNov2020ATMOffering_64cec102-45f3-43eb-bc85-bde5bb6f7100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInNovember20ATMOffering_63704955-4161-412c-9c37-11765208700b" xlink:href="lxrx-20220630.xsd#lxrx_SharePriceInNovember20ATMOffering"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b70c98cf-91cb-49da-b9fc-c8a92d78e8bc" xlink:to="loc_lxrx_SharePriceInNovember20ATMOffering_63704955-4161-412c-9c37-11765208700b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromNov2020ATMOffering_9396ef41-0088-444a-8320-26eaa6a1d16b" xlink:href="lxrx-20220630.xsd#lxrx_ProceedsFromNov2020ATMOffering"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b70c98cf-91cb-49da-b9fc-c8a92d78e8bc" xlink:to="loc_lxrx_ProceedsFromNov2020ATMOffering_9396ef41-0088-444a-8320-26eaa6a1d16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInJanuary2021ATMOffering_c3ca8a46-f670-4c00-b816-e5707f36b7aa" xlink:href="lxrx-20220630.xsd#lxrx_SharesSoldInJanuary2021ATMOffering"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b70c98cf-91cb-49da-b9fc-c8a92d78e8bc" xlink:to="loc_lxrx_SharesSoldInJanuary2021ATMOffering_c3ca8a46-f670-4c00-b816-e5707f36b7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInJanuary2021ATMOffering_12de253f-f2ce-48e3-8d31-fde599cd84e9" xlink:href="lxrx-20220630.xsd#lxrx_SharePriceInJanuary2021ATMOffering"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b70c98cf-91cb-49da-b9fc-c8a92d78e8bc" xlink:to="loc_lxrx_SharePriceInJanuary2021ATMOffering_12de253f-f2ce-48e3-8d31-fde599cd84e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromJanuary2021ATMOffering_a1a87c41-edf4-4f50-b7dd-d96654afe76f" xlink:href="lxrx-20220630.xsd#lxrx_ProceedsFromJanuary2021ATMOffering"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b70c98cf-91cb-49da-b9fc-c8a92d78e8bc" xlink:to="loc_lxrx_ProceedsFromJanuary2021ATMOffering_a1a87c41-edf4-4f50-b7dd-d96654afe76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInSeptember2021ATMOfferring_4a81c416-1c0c-4d80-b653-54b495517faf" xlink:href="lxrx-20220630.xsd#lxrx_SharesSoldInSeptember2021ATMOfferring"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b70c98cf-91cb-49da-b9fc-c8a92d78e8bc" xlink:to="loc_lxrx_SharesSoldInSeptember2021ATMOfferring_4a81c416-1c0c-4d80-b653-54b495517faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInSeptember2021ATMOfferring_ee0ea40b-24cf-4c8a-9485-e6f905a3666f" xlink:href="lxrx-20220630.xsd#lxrx_SharePriceInSeptember2021ATMOfferring"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b70c98cf-91cb-49da-b9fc-c8a92d78e8bc" xlink:to="loc_lxrx_SharePriceInSeptember2021ATMOfferring_ee0ea40b-24cf-4c8a-9485-e6f905a3666f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromSeptember2021ATMOffering_ca47c12c-c111-4768-a4a3-253ff37e3057" xlink:href="lxrx-20220630.xsd#lxrx_ProceedsFromSeptember2021ATMOffering"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b70c98cf-91cb-49da-b9fc-c8a92d78e8bc" xlink:to="loc_lxrx_ProceedsFromSeptember2021ATMOffering_ca47c12c-c111-4768-a4a3-253ff37e3057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInJuly2022Offering_efcc2597-3c4c-44ad-bfd6-78d3f6e3eba8" xlink:href="lxrx-20220630.xsd#lxrx_SharePriceInJuly2022Offering"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b70c98cf-91cb-49da-b9fc-c8a92d78e8bc" xlink:to="loc_lxrx_SharePriceInJuly2022Offering_efcc2597-3c4c-44ad-bfd6-78d3f6e3eba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromJuly2022Offering_a639414d-e4fc-4aad-94bc-cce5072dbfda" xlink:href="lxrx-20220630.xsd#lxrx_ProceedsFromJuly2022Offering"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b70c98cf-91cb-49da-b9fc-c8a92d78e8bc" xlink:to="loc_lxrx_ProceedsFromJuly2022Offering_a639414d-e4fc-4aad-94bc-cce5072dbfda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails_1" xlink:type="simple" xlink:href="lxrx-20220630.xsd#OtherCapitalAgreementsDetails_1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9ce405f5-a806-46d5-8727-49bed44c0214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInJuly2022Offering_344210a7-47f9-4f60-b590-5f1d7e43cc04" xlink:href="lxrx-20220630.xsd#lxrx_SharesSoldInJuly2022Offering"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9ce405f5-a806-46d5-8727-49bed44c0214" xlink:to="loc_lxrx_SharesSoldInJuly2022Offering_344210a7-47f9-4f60-b590-5f1d7e43cc04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139649788850640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Aug. 03, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lexicon Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001062822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">76-0474169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2445 Technology Forest Blvd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">11th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">The Woodlands<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">863-3000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LXRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,625,743<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139649788907760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets-Unaudited - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 21,450<span></span>
</td>
<td class="nump">$ 64,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">40,518<span></span>
</td>
<td class="nump">22,678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,896<span></span>
</td>
<td class="nump">2,164<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">64,898<span></span>
</td>
<td class="nump">88,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation and amortization of $5,070 and $4,853, respectively</a></td>
<td class="nump">1,035<span></span>
</td>
<td class="nump">1,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">44,543<span></span>
</td>
<td class="nump">44,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,849<span></span>
</td>
<td class="nump">2,269<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">112,325<span></span>
</td>
<td class="nump">136,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">7,347<span></span>
</td>
<td class="nump">9,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">9,515<span></span>
</td>
<td class="nump">12,972<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">16,862<span></span>
</td>
<td class="nump">22,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,002<span></span>
</td>
<td class="nump">1,190<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">41,495<span></span>
</td>
<td class="nump">23,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value; 5,000 shares authorized; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 300,000 shares authorized; 150,114 and 150,082 shares issued, respectively</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,608,730<span></span>
</td>
<td class="nump">1,608,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,535,839)<span></span>
</td>
<td class="num">(1,487,776)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(150)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost, 488 and 1,165 shares, respectively</a></td>
<td class="num">(2,061)<span></span>
</td>
<td class="num">(7,518)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholder's equity (deficit)</a></td>
<td class="nump">70,830<span></span>
</td>
<td class="nump">113,595<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">112,325<span></span>
</td>
<td class="nump">136,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of deferred issuance costs</a></td>
<td class="nump">$ 23,631<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139649788743392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets Parentheticals - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConsolidatedBalanceSheetsAbstract', window );"><strong>Consolidated Balance Sheets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization, property and equipment</a></td>
<td class="nump">$ 5,070<span></span>
</td>
<td class="nump">$ 4,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">150,114<span></span>
</td>
<td class="nump">150,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">488<span></span>
</td>
<td class="nump">1,165<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConsolidatedBalanceSheetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidated Balance Sheets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConsolidatedBalanceSheetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139649789350112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss-Unaudited - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyIncomeNonoperating', window );">Royalties and other revenue</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">$ 234,000<span></span>
</td>
<td class="nump">$ 72,000<span></span>
</td>
<td class="nump">$ 261,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense', window );">Stock-based compensation expense associated with research and development expense</a></td>
<td class="nump">1,098,000<span></span>
</td>
<td class="nump">1,184,000<span></span>
</td>
<td class="nump">2,130,000<span></span>
</td>
<td class="nump">2,470,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, including stock-based compensation of $1,098, $1,184, $2,130 and $2,470 respectively</a></td>
<td class="nump">13,356,000<span></span>
</td>
<td class="nump">10,257,000<span></span>
</td>
<td class="nump">28,282,000<span></span>
</td>
<td class="nump">22,866,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Sellinggeneralandadministrativeexpenses', window );">Selling, general and administrative, including stock-based compensation of $1,734, $1,602, $3,474 and $3,167 respectively</a></td>
<td class="nump">10,686,000<span></span>
</td>
<td class="nump">7,936,000<span></span>
</td>
<td class="nump">19,177,000<span></span>
</td>
<td class="nump">16,193,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="num">(24,042,000)<span></span>
</td>
<td class="nump">18,193,000<span></span>
</td>
<td class="nump">47,459,000<span></span>
</td>
<td class="nump">39,059,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(24,007,000)<span></span>
</td>
<td class="num">(17,959,000)<span></span>
</td>
<td class="num">(47,387,000)<span></span>
</td>
<td class="num">(38,798,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(703,000)<span></span>
</td>
<td class="num">(169,000)<span></span>
</td>
<td class="num">(813,000)<span></span>
</td>
<td class="num">(336,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="nump">123,000<span></span>
</td>
<td class="nump">61,000<span></span>
</td>
<td class="nump">137,000<span></span>
</td>
<td class="nump">109,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (24,587,000)<span></span>
</td>
<td class="num">$ (18,067,000)<span></span>
</td>
<td class="num">$ (48,063,000)<span></span>
</td>
<td class="num">$ (39,025,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per common share, Basic</a></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.32)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing net loss per common share, Basic</a></td>
<td class="nump">149,616<span></span>
</td>
<td class="nump">144,451<span></span>
</td>
<td class="nump">149,384<span></span>
</td>
<td class="nump">143,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="num">$ (113,000)<span></span>
</td>
<td class="num">$ (10,000)<span></span>
</td>
<td class="num">$ (140,000)<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(24,700,000)<span></span>
</td>
<td class="num">(18,077,000)<span></span>
</td>
<td class="num">(48,203,000)<span></span>
</td>
<td class="num">(39,024,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalIncomeStatementElementsAbstract', window );"><strong>Supplemental Income Statement Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense', window );">Stock-based compensation expense associated with selling, general and administrative expense</a></td>
<td class="nump">$ 1,734,000<span></span>
</td>
<td class="nump">$ 1,602,000<span></span>
</td>
<td class="nump">3,474,000<span></span>
</td>
<td class="nump">3,167,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Business Exit Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Sellinggeneralandadministrativeexpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Selling, general and administrative expenses - the expenses related to selling Lexicon's product as well as general and administrative costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Sellinggeneralandadministrativeexpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense included in research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense associated with selling, general and administrative expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessExitCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessExitCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalIncomeStatementElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalIncomeStatementElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139649788851328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss Parentheticals - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConsolidatedStatementsOfOperationsAbstract', window );"><strong>Consolidated Statements of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense', window );">Stock-based compensation expense associated with research and development expense</a></td>
<td class="nump">$ 1,098<span></span>
</td>
<td class="nump">$ 1,184<span></span>
</td>
<td class="nump">$ 2,130<span></span>
</td>
<td class="nump">$ 2,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense', window );">Stock-based compensation expense associated with selling, general and administrative expense</a></td>
<td class="nump">$ 1,734<span></span>
</td>
<td class="nump">$ 1,602<span></span>
</td>
<td class="nump">$ 3,474<span></span>
</td>
<td class="nump">$ 3,167<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConsolidatedStatementsOfOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidated Statements of Operations [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConsolidatedStatementsOfOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense included in research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense associated with selling, general and administrative expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139649787942672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (24,587,000)<span></span>
</td>
<td class="num">$ (48,063,000)<span></span>
</td>
<td class="num">$ (39,025,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,000<span></span>
</td>
<td class="nump">79,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,604,000<span></span>
</td>
<td class="nump">5,637,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,000<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">(Increase) decrease in accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
<td class="nump">236,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">(Increase) decrease in prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(732,000)<span></span>
</td>
<td class="nump">451,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Decrease in other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420,000<span></span>
</td>
<td class="nump">261,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Decrease in accounts payable and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,447,000)<span></span>
</td>
<td class="num">(14,707,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,843,000)<span></span>
</td>
<td class="num">(47,039,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">21,450,000<span></span>
</td>
<td class="nump">21,450,000<span></span>
</td>
<td class="nump">89,887,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">634,000<span></span>
</td>
<td class="nump">307,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_InitialRecognitionOfRightOfUseAsset', window );">Initial recognition of right of use asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,704,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of Stock and Warrants for Services or Claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Adjustments to Additional Paid in Capital, Warrant Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Stock Issued During Period, Value, Treasury Stock Reissued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,321<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Business Exit Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76,000)<span></span>
</td>
<td class="num">(985,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,171,000)<span></span>
</td>
<td class="num">(24,373,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Maturities of investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,191,000<span></span>
</td>
<td class="nump">21,772,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,056,000)<span></span>
</td>
<td class="num">(3,586,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,924,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(864,000)<span></span>
</td>
<td class="num">(2,675,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from debt borrowings, net of fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,148,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,284,000<span></span>
</td>
<td class="nump">14,249,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,615,000)<span></span>
</td>
<td class="num">(36,376,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,065,000<span></span>
</td>
<td class="nump">126,263,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">21,450,000<span></span>
</td>
<td class="nump">21,450,000<span></span>
</td>
<td class="nump">89,887,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">634,000<span></span>
</td>
<td class="nump">307,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_InitialRecognitionOfRightOfUseAsset', window );">Initial recognition of right of use asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,704,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_InitialRecognitionOfRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial recognition of right of use asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_InitialRecognitionOfRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessExitCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessExitCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139649784049040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity/Deficit-Unaudited - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Gain (Loss)</div></th>
<th class="th"><div>Treasury Stock</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 156,371,000<span></span>
</td>
<td class="nump">$ 142,000<span></span>
</td>
<td class="nump">$ 1,561,096,000<span></span>
</td>
<td class="num">$ (1,400,018,000)<span></span>
</td>
<td class="num">$ (6,000)<span></span>
</td>
<td class="num">$ (4,843,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,851,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,851,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under Equity Incentive Plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
<td class="num">(16,399,000)<span></span>
</td>
<td class="num">$ (2,000)<span></span>
</td>
<td class="num">(16,397,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(2,675,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,675,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(20,958,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="nump">11,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Mar. 31, 2021</a></td>
<td class="nump">152,547,000<span></span>
</td>
<td class="nump">$ 145,000<span></span>
</td>
<td class="nump">1,580,891,000<span></span>
</td>
<td class="num">(1,420,976,000)<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="num">(7,518,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">548,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">547,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Dec. 31, 2020</a></td>
<td class="nump">156,371,000<span></span>
</td>
<td class="nump">$ 142,000<span></span>
</td>
<td class="nump">1,561,096,000<span></span>
</td>
<td class="num">(1,400,018,000)<span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
<td class="num">(4,843,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(39,025,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Jun. 30, 2021</a></td>
<td class="nump">137,233,000<span></span>
</td>
<td class="nump">$ 146,000<span></span>
</td>
<td class="nump">1,583,653,000<span></span>
</td>
<td class="num">(1,439,043,000)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="num">(7,518,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Stock Issued During Period, Value, Treasury Stock Reissued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Mar. 31, 2021</a></td>
<td class="nump">152,547,000<span></span>
</td>
<td class="nump">$ 145,000<span></span>
</td>
<td class="nump">1,580,891,000<span></span>
</td>
<td class="num">(1,420,976,000)<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="num">(7,518,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,786,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,786,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="num">(31,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(31,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(18,067,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(18,067,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="num">(10,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Jun. 30, 2021</a></td>
<td class="nump">137,233,000<span></span>
</td>
<td class="nump">$ 146,000<span></span>
</td>
<td class="nump">1,583,653,000<span></span>
</td>
<td class="num">(1,439,043,000)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="num">(7,518,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">150,082<span></span>
</td>
<td class="nump">150,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 113,595,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">1,608,749,000<span></span>
</td>
<td class="num">(1,487,776,000)<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="num">(7,518,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,772,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,772,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under Equity Incentive Plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
<td class="num">(864,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">864,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(23,476,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(23,476,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="num">(27,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(27,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Mar. 31, 2022</a></td>
<td class="nump">92,698,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">1,605,898,000<span></span>
</td>
<td class="num">(1,511,252,000)<span></span>
</td>
<td class="num">(37,000)<span></span>
</td>
<td class="num">(2,061,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">698,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">698,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Stock Issued During Period, Value, Treasury Stock Reissued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(6,321,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,321,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Stock Issued During Period, Shares, Treasury Stock Reissued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">150,082<span></span>
</td>
<td class="nump">150,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 113,595,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">1,608,749,000<span></span>
</td>
<td class="num">(1,487,776,000)<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="num">(7,518,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(48,063,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="num">$ (140,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Jun. 30, 2022</a></td>
<td class="nump">150,114<span></span>
</td>
<td class="nump">150,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Jun. 30, 2022</a></td>
<td class="nump">$ 70,830,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">1,608,730,000<span></span>
</td>
<td class="num">(1,535,839,000)<span></span>
</td>
<td class="num">(150,000)<span></span>
</td>
<td class="num">(2,061,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Stock Issued During Period, Value, Treasury Stock Reissued</a></td>
<td class="num">(6,321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Mar. 31, 2022</a></td>
<td class="nump">92,698,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">1,605,898,000<span></span>
</td>
<td class="num">(1,511,252,000)<span></span>
</td>
<td class="num">(37,000)<span></span>
</td>
<td class="num">(2,061,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,832,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,832,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under Equity Incentive Plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(24,587,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(24,587,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="num">$ (113,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(113,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Jun. 30, 2022</a></td>
<td class="nump">150,114<span></span>
</td>
<td class="nump">150,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Jun. 30, 2022</a></td>
<td class="nump">$ 70,830,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 1,608,730,000<span></span>
</td>
<td class="num">$ (1,535,839,000)<span></span>
</td>
<td class="num">$ (150,000)<span></span>
</td>
<td class="num">$ (2,061,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139649792234016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Notes)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accompanying unaudited condensed consolidated financial statements of Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221; or the &#8220;Company&#8221;) have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the six-month period ended June&#160;30, 2022 are not necessarily indicative of the results that may be expected for the year ended December&#160;31, 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further information, refer to the financial statements and footnotes thereto included in Lexicon&#8217;s annual report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC.&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents and Short-Term Investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of June&#160;30, 2022 and December&#160;31, 2021, short-term investments consisted of U.S. treasury bills and corporate debt securities. The Company&#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations as they all contain maturities of less than one year.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued liabilities: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accrued liabilities consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:60.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.961%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.963%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,515&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,972&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon determines if a contract is or contains a lease at inception or upon modification of the contract. A contract is or contains a lease if it conveys the right to control the use of an identified asset for a period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset. Lexicon does not apply this accounting to those leases with terms of twelve (12) months or less.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and associated lease liabilities are recorded in the balance sheet at the lease commencement date based on the present value of future lease payments to be made over the expected lease term. As the implicit rate is not determinable in its leases, Lexicon used a borrowing rate of 9% at the commencement date in determining the present value of future payments. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performs the following five steps in determining the amount of revenue to recognize as its performance obligations under each of its contracts with customers: (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) we satisfy the performance obligation. At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those milestones are achieved.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In agreements in which a license to the Company&#8217;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under the relevant agreement.  Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units granted to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">behaviors, resulting in a change in the assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#8217;s stock price.&#160;&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilized the Black-Scholes valuation model for estimating the fair value of the stock option compensation granted, with the following weighted-average assumptions for stock options granted in the six months ended June&#160;30, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:51.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.916%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Risk-free Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dividend<br/>Rate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2022:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock option activity under Lexicon&#8217;s stock-based compensation plans for the six months ended June&#160;30, 2022:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:66.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(353)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,423&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022, Lexicon granted its employees and non-employee directors annual restricted stock units. Outstanding employee restricted stock units vest in three annual installments.  Outstanding non-employee director restricted stock units vest fully on the first anniversary of the grant.  The following is a summary of restricted stock units activity under Lexicon&#8217;s stock-based compensation plans for the six months ended June&#160;30, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,012)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,919&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div>Net Loss per Common Share: Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139649792356928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements Level 1 (Notes)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_RecentAccountingPronouncementsAbstract', window );"><strong>Recent Accounting Pronouncements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy</a></td>
<td class="text">Recent Accounting Pronouncements<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2019-12, Income Taxes (Topic 740) Simplifying Accounting for Income Taxes, as part of its initiative to reduce complexity in the accounting standards. The guidance amended certain disclosure requirements that had become redundant, outdated or superseded. Additionally, this guidance amends accounting for the interim period effects of changes in tax laws or rates, and simplifies aspects of the accounting for franchise taxes. The guidance is effective for annual periods beginning after December 15, 2020, including interim periods therein. The adoption of ASU 2019-12 in the first quarter of 2021 did not have a material impact on the condensed consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40), which removes the separation models for convertible debt with cash conversion or beneficial conversion features. ASU 2020-06 also requires the application of the if-converted method for calculating earnings per diluted share, as the treasury stock method will no longer be permitted for convertible instruments. The adoption of ASU 2020-06 during the first quarter of 2022 did not have a material impact on the condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_RecentAccountingPronouncementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recent Accounting Pronouncements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_RecentAccountingPronouncementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139649792386512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract', window );"><strong>Cash and Cash Equivalents and Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and Cash Equivalents Disclosure</a></td>
<td class="text">Cash and Cash Equivalents and Investments<div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of cash and cash equivalents and investments held at June&#160;30, 2022 and December&#160;31, 2021 are as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:52.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,118&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,968&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,687&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,678&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,753&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,743&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no realized losses during either of the six months ended June&#160;30, 2022 and 2021, respectively.  The cost of securities sold is based on the specific identification method.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents and Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CashAndCashEquivalentsAndInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139649793696832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_FairValueMeasurementsAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value, Measurement Inputs, Disclosure</a></td>
<td class="text">Fair Value Measurements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.  Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.  The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - quoted prices in active markets for identical investments, which include U.S. treasury securities </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which includes corporate debt securities</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - significant unobservable inputs </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.  The following table provides the fair value measurements of applicable Company assets that are measured at fair value on a recurring basis according to the fair value levels defined above as of June&#160;30, 2022 and December&#160;31, 2021.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:46.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,780&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,188&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,968&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:46.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,626&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,117&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,743&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any Level 3 assets or liabilities as of June&#160;30, 2022 or December&#160;31, 2021. Transfers between levels are recognized at the actual date of the circumstance that caused the transfer.  There were no transfers between Level 1 and Level 2 during the periods presented.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 5, Debt Obligations, for fair value measurements of debt obligations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FairValueMeasurementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FairValueMeasurementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI https://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139649792165168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DebtObligationsAbstract', window );"><strong>Debt Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure</a></td>
<td class="text">Debt Obligations<div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2022, Lexicon and one of its subsidiaries entered into a loan and security agreement with Oxford Finance LLC (&#8220;Oxford&#8221;) that provides up to $150&#160;million in borrowing capacity (the &#8220;Oxford Term Loans&#8221;) available in four tranches, each maturing in March 2027. Monthly interest-only payments are due during an initial 36-month period, which may be extended at Lexicon&#8217;s option to 48 months if Lexicon maintains compliance with a financial covenant relating to net sales of sotagliflozin following regulatory approval. The interest-only period will be followed by principal payments of $8.7&#160;million, $13.0&#160;million, and $4.8&#160;million during the fiscal years ended December 31, 2025, December 31, 2026 and December 31, 2027, respectively. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first $25&#160;million tranche was funded at closing. The second $25&#160;million tranche is available for draw at Lexicon&#8217;s option prior to August 25, 2022. The third $50&#160;million tranche is available for draw at Lexicon&#8217;s option prior to June 30, 2023, but within 60 days of U.S. regulatory approval of sotagliflozin for heart failure. The fourth $50&#160;million tranche is available for draw at Lexicon&#8217;s option, subject to Oxford&#8217;s consent, at any time prior to the expiration of the interest-only payment period.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loan and security agreement provides that, upon funding of the first three tranches, Lexicon will grant Oxford a warrant to purchase shares of its common stock having a value equal to 3.50%, 1.75% and 0.875%, respectively, of each such tranche, as determined by reference to a 10-day average closing price of the shares. Each warrant will have an exercise price equal to such average closing price, be exercisable for a five-year period from the date of issuance and feature a net cashless exercise provision. Concurrent with the funding of the first tranche, Lexicon granted Oxford a warrant to purchase 420,673 shares of Lexicon&#8217;s common stock at an exercise price of $2.08 per share. The warrant is exercisable through March 1, 2027 and is classified as an equity instrument.  The Company allocated the proceeds from the first tranche to the warrant using the relative fair value method and used the Black-Scholes model to calculate the fair value of the warrants.  The fair value of the warrant of $0.7&#160;million was recognized as equity with a corresponding debt discount of $0.7&#160;million.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Oxford Term Loans bear interest at a floating rate equal to the 30-day U.S. Dollar LIBOR plus 7.90%, but not less than 8.01%, subject to additional interest if an event of default occurs and is continuing.  As of June&#160;30, 2022, the interest rate was 9.02%. If an event of default occurs and is continuing, Oxford may declare all amounts outstanding under the loan and security agreement to be immediately due and payable. Lexicon may prepay the Oxford Term Loans in whole at its option at any time. Any prepayment of the Oxford Term Loans is subject to prepayment fees for up to three years after the funding of each tranche of the loans.  A final payment exit fee equal to 6% of the amount funded under the Oxford Term Loans is due upon prepayment or maturity, which final payment will be adjusted to 7% of the amount funded upon extension of the interest-only payment period.  The final payment exit fee of $1.5&#160;million was recorded as a debt discount on the closing date of the first tranche.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During March 2022, in connection with the first tranche of the loan and security agreement, the Company received cash proceeds of $24.2&#160;million, net of debt issuance costs of $0.4&#160;million and a facility fee of $0.5&#160;million. The debt issuance costs and facility fee have been recorded as a debt discount on the Company&#8217;s condensed consolidated balance sheet, which together with the final payment exit fee of $1.5&#160;million and warrant fair value of $0.7&#160;million are being amortized to interest expense throughout the life of the term loan using the effective interest rate method.  As of June&#160;30, 2022, the balance of the debt discount was $2.9&#160;million. During the six months ended June&#160;30, 2022, the Company recognized interest expense of $0.8&#160;million.  As of  June&#160;30, 2022, the carrying value of the Oxford Term Loans was $23.6&#160;million.  The fair value of the Oxford Term Loans approximates its carrying value and was determined using Level 2 inputs using discounted cash flow analysis, based on the Company&#8217;s estimated current incremental borrowing rate.       </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon&#8217;s obligations under the Oxford Term Loans are secured by a first lien security interest in all of the assets of the Company and its subsidiaries. The loan and security agreement contains certain customary representations and warranties, affirmative and negative covenants and events of default applicable to Lexicon and its subsidiaries. In addition to the financial covenant, additional covenants include those restricting dispositions, fundamental changes to its business, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt. The Company was in compliance with its debt covenants as of June&#160;30, 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Debt.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In November 2014, Lexicon completed an offering of $87.5 million in aggregate principal amount of its 5.25% Convertible Senior Notes due 2021 (the &#8220;Convertible Notes&#8221;).  The conversion feature did not meet the criteria for bifurcation as required by generally accepted accounting principles and the entire principal amount was recorded as long-term debt on the Company&#8217;s condensed consolidated balance sheets.  </span></div>In 2020, the Company entered into separate, privately negotiated exchange agreements to exchange $75.8 million aggregate principal amount of the Convertible Notes for consideration valued at 85% of the principal amount of the Convertible Notes. In 2020, the Company issued 10,368,956 shares of the Company&#8217;s common stock and paid $50.0 million in cash, which included $1.3 million of accrued interest, to exchange such Convertible Notes. In December 2021, the remaining balance of $11.6 million was repaid in cash.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DebtObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Obligations [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DebtObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139649792251152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure</a></td>
<td class="text">Commitments and Contingencies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Lease Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;Lexicon&#8217;s operating leases include office space in The Woodlands, Texas and Basking Ridge, New Jersey and will expire in August 2025 and December 2022, respectively. Under its lease agreements, Lexicon is obligated to pay property taxes, insurance, and maintenance costs. In July 2022, the Company entered into a lease agreement for a 22,000 square-foot office space in Bridgewater, New Jersey to which it plans to relocate the New Jersey offices.  The term of the lease is expected to commence in December 2022, will extend for ten years and 11 months from such commencement date and provides for escalating yearly base rent payments starting at $820,000 and increasing to $986,000 in the final year of the lease.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the right-of-use assets for the office space leases had a balance of $1.8 million, which is included in other assets in the condensed consolidated balance sheet. Current and non-current liabilities relating to the leases were $0.8 million and $1.0 million, respectively, which are included in accrued liabilities and other long-term liabilities in the condensed consolidated balance sheet, respectively.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the undiscounted cash flows of the operating lease liability to the recorded lease liability at June&#160;30, 2022:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"/><td style="width:80.632%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.168%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,028&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,791&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: short-term operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(789)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139649792153008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangement Disclosure</a></td>
<td class="text">Collaboration and License Agreements&#160;Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, product sales, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales, as well as from commercial sales of its XERMELO product following its commercial launch in February 2017 until its sale of XERMELO and related assets to TerSera Therapeutics, LLC in September 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and License Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139649792585216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Capital Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_OtherCapitalAgreementsTextBlock', window );">Other Capital Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other Capital Agreements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  In 2020, Lexicon entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Sales Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;) relating to the shares of its common stock. In January 2021, Lexicon sold 2,000,000 shares of its common stock at a price of $8.463 per share pursuant to the Sales Agreement, resulting in net proceeds of $16.4&#160;million. In August and September 2021, Lexicon sold an aggregate of 4,176,953 shares of its common stock at a price of $4.732 per share pursuant to the Sales Agreement, resulting in net proceeds of $19.1 million. The net proceeds are reflected as issuances of common stock in the accompanying condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  In August 2022, Lexicon sold an aggregate of 34,000,000 shares of its common stock at a price of $2.50 per share in a public offering and concurrent private placement to two affiliates of Invus, L.P., resulting in net proceeds of approximately $82.2&#160;million, after deducting underwriting discounts and commissions and estimated offering expenses.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OtherCapitalAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Capital Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_OtherCapitalAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139649788787968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
<td class="text">The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents and Short-Term Investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of June&#160;30, 2022 and December&#160;31, 2021, short-term investments consisted of U.S. treasury bills and corporate debt securities. The Company&#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations as they all contain maturities of less than one year.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue [Policy Text Block]</a></td>
<td class="text"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performs the following five steps in determining the amount of revenue to recognize as its performance obligations under each of its contracts with customers: (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) we satisfy the performance obligation. At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those milestones are achieved.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In agreements in which a license to the Company&#8217;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  </span></div>The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under the relevant agreement.  Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units granted to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination </span></div>behaviors, resulting in a change in the assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#8217;s stock price.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text">Net Loss per Common Share: Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock', window );">Recognition of Asset and Liability for Lease of Acquiree</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon determines if a contract is or contains a lease at inception or upon modification of the contract. A contract is or contains a lease if it conveys the right to control the use of an identified asset for a period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset. Lexicon does not apply this accounting to those leases with terms of twelve (12) months or less.</span>Operating lease right-of-use assets and associated lease liabilities are recorded in the balance sheet at the lease commencement date based on the present value of future lease payments to be made over the expected lease term. As the implicit rate is not determinable in its leases, Lexicon used a borrowing rate of 9% at the commencement date in determining the present value of future payments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy election not to recognize asset and liability at acquisition for lease with remaining lease term of one year or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 25<br> -Paragraph 28B<br> -URI https://asc.fasb.org/extlink&amp;oid=128091968&amp;loc=SL77931625-128468<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139649793026880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Equity Incentive Awards (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract', window );"><strong>Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued liabilities: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accrued liabilities consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:60.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.961%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.963%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,515&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,972&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:51.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.916%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Risk-free Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dividend<br/>Rate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2022:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:66.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(353)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,423&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,012)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,919&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139649792396240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract', window );"><strong>Cash and Cash Equivalents and Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash, Cash Equivalents and Short-term Investments [Table Text Block]</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:52.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,118&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,968&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,687&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,678&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,753&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,743&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents and Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CashAndCashEquivalentsAndInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139649792221664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_FairValueMeasurementsAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Fair Value, by Balance Sheet Grouping [Table Text Block]</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:46.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,780&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,188&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,968&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:46.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,626&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,117&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,743&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FairValueMeasurementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FairValueMeasurementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139649788888384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details) - Equity Option [Member]<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees</a></td>
<td class="nump">106.00%<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</a></td>
<td class="nump">91.00%<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected term assumption that is used in valuing an option on its own shares for employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139649783955088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">12,108<span></span>
</td>
<td class="nump">8,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 5.34<span></span>
</td>
<td class="nump">$ 6.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</a></td>
<td class="nump">4,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 3.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</a></td>
<td class="nump">163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</a></td>
<td class="nump">353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 9.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</a></td>
<td class="nump">5,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 7.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</a></td>
<td class="nump">2,919<span></span>
</td>
<td class="nump">1,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 3.17<span></span>
</td>
<td class="nump">$ 5.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="nump">2,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</a></td>
<td class="nump">1,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 4.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</a></td>
<td class="nump">108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 3.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139649789247200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Accrued Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_AccruedLiabilitiesLineItems', window );"><strong>Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_AccruedResearchAndDevelopmentServicesCurrent', window );">Accrued research and development services current</a></td>
<td class="nump">$ 3,920,000<span></span>
</td>
<td class="nump">$ 3,669,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_AccruedCompensationAndBenefitsCurrent', window );">Accrued compensation and benefits current</a></td>
<td class="nump">4,329,000<span></span>
</td>
<td class="nump">5,711,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating Lease, Liability, Current</a></td>
<td class="num">(789,000)<span></span>
</td>
<td class="num">(1,089,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other Accrued Liabilities, Current</a></td>
<td class="nump">477,000<span></span>
</td>
<td class="nump">2,503,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued Liabilities</a></td>
<td class="nump">$ 9,515,000<span></span>
</td>
<td class="nump">$ 12,972,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_LexiconIncrementalBorrowingRate', window );">Lexicon incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_AccruedCompensationAndBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued compensation and benefits current - due within 1 year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_AccruedCompensationAndBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_AccruedLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_AccruedLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_AccruedResearchAndDevelopmentServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development services current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_AccruedResearchAndDevelopmentServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_LexiconIncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lexicon incremental borrowing rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_LexiconIncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139649789640208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt Securities, Available-for-Sale, Current</a></td>
<td class="nump">$ 40,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Debt Securities, Available-for-Sale, Amortized Cost, Current</a></td>
<td class="nump">21,450<span></span>
</td>
<td class="nump">64,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt Securities, Available-for-Sale, Current</a></td>
<td class="nump">21,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Debt Securities, Available-for-Sale, Amortized Cost, Current</a></td>
<td class="nump">30,419<span></span>
</td>
<td class="nump">7,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt Securities, Available-for-Sale, Current</a></td>
<td class="nump">30,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Total Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Debt Securities, Available-for-Sale, Amortized Cost, Current</a></td>
<td class="nump">40,668<span></span>
</td>
<td class="nump">22,687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt Securities, Available-for-Sale, Current</a></td>
<td class="nump">40,518<span></span>
</td>
<td class="nump">22,678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_InvestmentsMember', window );">Total Cash and Cash Equivalents and Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</a></td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Debt Securities, Available-for-Sale, Amortized Cost, Current</a></td>
<td class="nump">62,118<span></span>
</td>
<td class="nump">86,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt Securities, Available-for-Sale, Current</a></td>
<td class="nump">61,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Debt Securities, Available-for-Sale, Amortized Cost, Current</a></td>
<td class="nump">10,249<span></span>
</td>
<td class="nump">$ 15,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt Securities, Available-for-Sale, Current</a></td>
<td class="nump">$ 10,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139649792182800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Realized Investment Gains (Losses)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139649789365024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">$ 21,450<span></span>
</td>
<td class="nump">$ 64,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt Securities, Available-for-Sale, Current</a></td>
<td class="nump">40,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Cash and Cash Equivalents and Investments</a></td>
<td class="nump">61,968<span></span>
</td>
<td class="nump">86,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">21,450<span></span>
</td>
<td class="nump">64,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt Securities, Available-for-Sale, Current</a></td>
<td class="nump">30,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Cash and Cash Equivalents and Investments</a></td>
<td class="nump">51,780<span></span>
</td>
<td class="nump">71,626<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt Securities, Available-for-Sale, Current</a></td>
<td class="nump">10,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Cash and Cash Equivalents and Investments</a></td>
<td class="nump">10,188<span></span>
</td>
<td class="nump">15,117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt Securities, Available-for-Sale, Current</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Cash and Cash Equivalents and Investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139649784371088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2014</div></th>
<th class="th"><div>Mar. 31, 2028</div></th>
<th class="th"><div>Mar. 31, 2027</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 28, 2020</div></th>
<th class="th"><div>Nov. 20, 2014</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
<td class="nump">$ 87,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConvDebtInstrumentInterestRateStatedPercentage', window );">Conv Debt Instrument Interest Rate Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,114,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,082,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConvertibleDebtExchangeRemainingNotes', window );">Convertible debt exchange Remaining Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount', window );">Convertible debt exchange - Total Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of deferred issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (23,631,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TermLoanB', window );">Term Loan B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TermLoanC', window );">Term Loan C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TermLoanD', window );">Term Loan D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_OxfordLoanFacility', window );">Oxford Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TermLoanA', window );">Term Loan A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TermLoanABWarrant', window );">Term Loan A&amp;B Warrant %</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TermLoanCWarrant', window );">Term Loan C Warrant %</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TermLoanDWarrant', window );">Term Loan D Warrant %</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TermLoanAWarrantsNumber', window );">Term Loan A Warrants Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TermLoanAWarrantExercisePrice', window );">Term Loan A Warrant Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Adjustments to Additional Paid in Capital, Warrant Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingInterestRate', window );">Subordinated Borrowing, Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.02%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_FinalPaymentWithNoExtention', window );">Final Payment % with no extention</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_FinalPaymentWithExtention', window );">Final Payment % with extention</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TermLoanAFinalPayment', window );">Term Loan A Final Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TermLoanANetCashReceipt', window );">Term Loan A Net Cash Receipt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TermLoanADebtIssuanceCosts', window );">Term Loan A Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_OxfordFacilityFee', window );">Oxford Facility Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TermLoanADebtDiscount', window );">Term Loan A Debt Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TermLoanAInterestExpense', window );">Term Loan A Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_A2026OxfordPrincipalPayments', window );">2027 Oxford Principal Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_A2027OxfordPrincipalPayments', window );">2027 Oxford Principal Payments2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_A2026OxfordPrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>2026 Oxford Principal Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_A2026OxfordPrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_A2027OxfordPrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>2027 Oxford Principal Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_A2027OxfordPrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConvDebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conv Debt Instrument Interest Rate Stated Percentage - contractual interest rate for convertible debt bonds under the debt agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConvDebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConvertibleDebtExchangeRemainingNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible debt exchange Remaining Notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConvertibleDebtExchangeRemainingNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible debt exchange - Total Principal Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConvertibleDebtExchangeTotalPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FinalPaymentWithExtention">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Final Payment % with extention</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FinalPaymentWithExtention</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FinalPaymentWithNoExtention">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Final Payment % with no extention</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FinalPaymentWithNoExtention</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OxfordFacilityFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Oxford Facility Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_OxfordFacilityFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OxfordLoanFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Oxford Loan Facility</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_OxfordLoanFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Loan A</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanABWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Loan A&amp;B Warrant %</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanABWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanADebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Loan A Debt Discount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanADebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanADebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Loan A Debt Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanADebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanAFinalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Loan A Final Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanAFinalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanAInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Loan A Interest Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanAInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanANetCashReceipt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Loan A Net Cash Receipt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanANetCashReceipt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanAWarrantExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Loan A Warrant Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanAWarrantExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanAWarrantsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Loan A Warrants Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanAWarrantsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Loan B</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Loan C</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanCWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Loan C Warrant %</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanCWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Loan D</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanDWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Loan D Warrant %</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanDWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubordinatedBorrowingInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stated interest rate of the subordinated debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubordinatedBorrowingInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139649788912160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term Debt and Lease Obligation</a></td>
<td class="nump">$ 1,002,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</a></td>
<td class="nump">583,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Lessee, Operating Lease, Liability, Payments, Due Year Two</a></td>
<td class="nump">531,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Lessee, Operating Lease, Liability, Payments, Due Year Three</a></td>
<td class="nump">544,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Lessee, Operating Lease, Liability, Payments, Due Year Four</a></td>
<td class="nump">370,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Lessee, Operating Lease, Liability, Payments, Due after Year Five</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Lessee, Operating Lease, Liability, Payments, Due</a></td>
<td class="nump">2,028,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</a></td>
<td class="nump">237,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="nump">1,791,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCommitmentAmount', window );">Short-term Lease Commitment, Amount</a></td>
<td class="nump">800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918705-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139649789628864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Capital Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesSoldInJanuary2021ATMOffering', window );">Shares sold in January 2021 ATM offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharePriceInJanuary2021ATMOffering', window );">Share price in January 2021 ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ProceedsFromJanuary2021ATMOffering', window );">Proceeds from January 2021 ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesSoldInSeptember2021ATMOfferring', window );">Shares sold in September 2021 ATM Offerring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,176,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharePriceInSeptember2021ATMOfferring', window );">Share Price in September 2021 ATM Offerring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ProceedsFromSeptember2021ATMOffering', window );">Proceeds from September 2021 ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharePriceInJuly2022Offering', window );">Share Price in July 2022 Offering</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ProceedsFromJuly2022Offering', window );">Proceeds from July 2022 Offering</a></td>
<td class="nump">$ 82,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ProceedsFromJanuary2021ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from January 2021 ATM Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ProceedsFromJanuary2021ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ProceedsFromJuly2022Offering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from July 2022 Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ProceedsFromJuly2022Offering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ProceedsFromSeptember2021ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from September 2021 ATM Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ProceedsFromSeptember2021ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharePriceInJanuary2021ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share price in January 2021 ATM Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharePriceInJanuary2021ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharePriceInJuly2022Offering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Price in July 2022 Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharePriceInJuly2022Offering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharePriceInSeptember2021ATMOfferring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Price in September 2021 ATM Offerring</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharePriceInSeptember2021ATMOfferring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesSoldInJanuary2021ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares sold in January 2021 ATM offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesSoldInJanuary2021ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesSoldInSeptember2021ATMOfferring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares sold in September 2021 ATM Offerring</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesSoldInSeptember2021ATMOfferring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139649793969616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Capital Agreements (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesSoldInJuly2022Offering', window );">Shares sold in July 2022 Offering</a></td>
<td class="nump">34,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesSoldInJuly2022Offering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares sold in July 2022 Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesSoldInJuly2022Offering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>lxrx-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lxrx="http://www.lexpharma.com/20220630"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lxrx-20220630.xsd" xlink:type="simple"/>
    <context id="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if7a0858cf5024c25bf4b6aaa1fb4a8ca_I20220803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2022-08-03</instant>
        </period>
    </context>
    <context id="i8f9d4917340c4a8a8775c9336387b2a9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if0442bec3f404e9aa34207eb1d897a99_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i219835b855164c3eb8447d1975735bec_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie8a7ca19bc1a4556a6e59951312a250b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iebb39511180847c6b73ea2044b1bbc86_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1bfe69c4a75a471ab0ff5ee12bde76cc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i45657a0096954cda95b6dd011117c958_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i159bdd976c5a411daa2d75f84b7d64a6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib3ab6ec7ca184c0b98f71ea5fbc23b66_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6294895f68fb461d8a0149ff1352660b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i64b8f1ab07f04390b4b79e6f8c6eb68e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2f6fc7cd72c34badba8bff35c5c227ac_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4ea8108d1eb5464fb0ec1f1c33b681cd_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iab6948c85b864af88b2035a19dd666a2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib6cf877d5e034cbe9a21bc4654ebb5f6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i067eeafe353e47bc8c8d21624e5bafe8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iaabab49ebc5c4a4a9b6b4ef4966aefcd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6d665691473c45ecb646640a37531cf4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iafe0378736e444aab2cfabe4f48ecbb9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4de99efa8fac4a1e9b601bcb9a760fad_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id997a83da5644f6987121d06d68d06ae_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i70f53509a43b46f7918ad0068ee464f4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia6a00923dd164c3185de2bb3200711b3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ieaf692e06bd247aebe797f2c2d1665d7_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id974764582f944f191de99110577719e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i436bb19a139f4e90a3435d0ce8396f1d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i84c6845ef1af474d99b31053aaec57d8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic04a7ab6695e4594b37dbd4ef6202519_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib1997cf5cac44c6eb336f27c85ee57c4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7fc68f10369542aaafc82c10cdef36a8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4921c0cb0fbb40faa165f5a6e62d660d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="icdf3d3ccc7584900aada54e1568caba4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4a7c2141afe24e7f83e4d67a5ccdfff8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic4163eee5a3740f5846f34cdd0ae242b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i191fd4fe2f08479884c4e65d4e9cfdff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i42fe192fe5ca436e9ed23d15187dbe84_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i75b83c9dc24f45598d1213d5e8d33a7e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib4de86438d8b40de8534780d8f45dbf0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaa991937faa74a41905808343286e8d9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0ede75339061443d9b99e442e4e84e69_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i781fc25c166b4fe180c4b24a19f09109_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id1fe783955bb4f568c7b32b3eb3734e4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i225dda2db10c426f89723c6eb6264105_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iff773ff7f7f9457f9791bde81fb05630_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i47c159cf741e4073a1ff14f684d085d7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7d8b5096b7ac4e1fa83572cd7c51c76b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id0a99ce76ff74360997f9515e9e301b9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iaeb348ef20a2445c8833795108ee3835_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8b20225add3d49819abcc6c8ffa1f6c2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i172ba7c5c11849e1b3e8f93623452a80_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9ab63a6a7f16414f93ebff593d6bd562_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibbe2a09570334122960c7e63bb722f5c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4bd35a0adb644d578ef0843d8d92e8f2_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i25a8adb9e6404469bce5c119cc2f7260_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic77941f6de784e4bb794c54a3abaf069_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i22f4f9fb2c4b49c99b790d66a23b28ae_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i46ba5caa20034a00b88a7290fc681f9a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7d2be377b37d4ddb9010f544cecc5772_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3de097a4f4c24c0083c05150f6b098a0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i152ac39e5811437cb0ee3de3ef7041ea_I20210301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2021-03-01</instant>
        </period>
    </context>
    <context id="if8c71021eb1240e190c19cb072abf3f6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8144b5bc25dd4902831fa92228fd7f51_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7be8ac7d31ef4e4f9fdbd039f264c959_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff0b3ea9ca3c45e1b81425040542255e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i32d0edfce10547eaa9f6a4a37c3c0e9e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id14ea6e6ad9241c2a3f636b30639bd35_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib6ff6b135bf9430bb09afc4a228eb9cd_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if0e56591afc54f4ebeb3c8aa3ab4fbe1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8a2a8f5d314144a884fb86491fc334b7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i310d9b9a89454544b9e9d7c6399db39a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib2834e4b26174a4a8a9f1d26de96cce2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6bf59d25162d4274b7c672eb48a47901_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib76a1e00d0be407f9aad476b9558aa02_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i537aa7da0127497a9ab35f8f1601120c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a1de474406c4d5ca2bd60c12dcee520_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia5d0942946ce4b92a48bd388374cd857_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iab52133a24a345c2b5b462deff22d656_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie2d670c1a5724338a60501f42187b7e0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i082b646328b744be992ad3f152baee86_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ieb00505b86b4445ea664e50b7f30071c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5a860a8253cc468dab9782964e9008d2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iafe66fc19ba44522a7249f23c4348b8c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d359c13687c4b70afe72962c41749e1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i308c9eedd5de4813af1e34bfdc45b87d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2dd8b9f384214850b5f4fd852ba9f217_D20260101-20260331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="i7fc078bde80e4f5eaa692435aa8a2da3_D20270101-20270331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2027-01-01</startDate>
            <endDate>2027-03-31</endDate>
        </period>
    </context>
    <context id="i20828fea2889439ba7af1b8a7dcb42eb_D20280101-20280331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2028-01-01</startDate>
            <endDate>2028-03-31</endDate>
        </period>
    </context>
    <context id="i71a46b4fd0da412cbd90061ff289cf49_D20141101-20141130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2014-11-01</startDate>
            <endDate>2014-11-30</endDate>
        </period>
    </context>
    <context id="i0cc6e78d37b6446ba787713f65cd8666_I20141120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2014-11-20</instant>
        </period>
    </context>
    <context id="i1fa52b6205c847e4888033f43b0077d3_I20200928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2020-09-28</instant>
        </period>
    </context>
    <context id="idedefb7f68d74e2aa8370ccd51445b1d_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie65c2031672c436c9ffb9020a455b7c6_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="rate">
        <measure>utr:Rate</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180L2ZyYWc6NGRiMDJhZjdhOTc4NDdkOWIyNTQzNjI2MTA1MTcyNmEvdGFibGU6N2ZkOWVhYzAyN2JkNDBjM2E3YmY5Mjg2MDUxODYxZDEvdGFibGVyYW5nZTo3ZmQ5ZWFjMDI3YmQ0MGMzYTdiZjkyODYwNTE4NjFkMV81LTQtMS0xLTI4NTMy_bc5a2254-012d-4c3d-9b54-55793c249b9c">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180L2ZyYWc6NGRiMDJhZjdhOTc4NDdkOWIyNTQzNjI2MTA1MTcyNmEvdGFibGU6N2ZkOWVhYzAyN2JkNDBjM2E3YmY5Mjg2MDUxODYxZDEvdGFibGVyYW5nZTo3ZmQ5ZWFjMDI3YmQ0MGMzYTdiZjkyODYwNTE4NjFkMV85LTQtMS0xLTI4NTMy_a2ebeaaa-45eb-47a9-a8e9-4ffb33cf4c10">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180L2ZyYWc6NGRiMDJhZjdhOTc4NDdkOWIyNTQzNjI2MTA1MTcyNmEvdGFibGU6N2ZkOWVhYzAyN2JkNDBjM2E3YmY5Mjg2MDUxODYxZDEvdGFibGVyYW5nZTo3ZmQ5ZWFjMDI3YmQ0MGMzYTdiZjkyODYwNTE4NjFkMV8xMC00LTEtMS0yODUzMg_3af84fd7-7115-447e-9f8f-332dce878ea1">2022</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180L2ZyYWc6NGRiMDJhZjdhOTc4NDdkOWIyNTQzNjI2MTA1MTcyNmEvdGFibGU6N2ZkOWVhYzAyN2JkNDBjM2E3YmY5Mjg2MDUxODYxZDEvdGFibGVyYW5nZTo3ZmQ5ZWFjMDI3YmQ0MGMzYTdiZjkyODYwNTE4NjFkMV8xMS00LTEtMS0yODUzMg_7b8ebde5-2eec-4d55-af98-ee58e5314b9d">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180L2ZyYWc6NGRiMDJhZjdhOTc4NDdkOWIyNTQzNjI2MTA1MTcyNmEvdGFibGU6N2ZkOWVhYzAyN2JkNDBjM2E3YmY5Mjg2MDUxODYxZDEvdGFibGVyYW5nZTo3ZmQ5ZWFjMDI3YmQ0MGMzYTdiZjkyODYwNTE4NjFkMV8xNC00LTEtMS0yODUzMg_32bce68b-185a-47ba-ab96-cf2223ed8e78">0001062822</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGV4dHJlZ2lvbjpmYTUwOWRmNjYyN2U0MTI2YTA5Y2EzOWQ4MjJlNDVkN184Mg_f491a7b6-1ac3-4952-bada-24dbca72e6cd">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGFibGU6NjM3OGVhOTI1ZDNhNGViZTgzY2M0OTFkOWFlYWM1MzgvdGFibGVyYW5nZTo2Mzc4ZWE5MjVkM2E0ZWJlODNjYzQ5MWQ5YWVhYzUzOF8wLTAtMS0xLTI4NTMy_7d984397-6965-4185-b016-28af5341de9c">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGV4dHJlZ2lvbjpmYTUwOWRmNjYyN2U0MTI2YTA5Y2EzOWQ4MjJlNDVkN18xMjk_84c53058-412b-4f91-ae50-faf6b6eff04d">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGFibGU6NzQ1MTZmZjEzZDQyNDcwNzg4YjRhMDhhYmFlMTUyNWIvdGFibGVyYW5nZTo3NDUxNmZmMTNkNDI0NzA3ODhiNGEwOGFiYWUxNTI1Yl8wLTAtMS0xLTI4NTMy_8c49ebbe-caac-4f33-9c07-10c57c67d439">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGV4dHJlZ2lvbjpmYTUwOWRmNjYyN2U0MTI2YTA5Y2EzOWQ4MjJlNDVkN18yMjU_b5e2a817-8223-498f-9bed-22e3776b50dc">000-30111</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGV4dHJlZ2lvbjpmYTUwOWRmNjYyN2U0MTI2YTA5Y2EzOWQ4MjJlNDVkN18yMjg_6d355f25-ac72-4f9b-8f3a-5bd32e350b3e">Lexicon Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGFibGU6YjdmMWVjYzJjZDNhNGJlZDk3MjQzZTUzOGVmOWJiZDYvdGFibGVyYW5nZTpiN2YxZWNjMmNkM2E0YmVkOTcyNDNlNTM4ZWY5YmJkNl8wLTAtMS0xLTI4NTMy_667cf7de-153c-4f38-b854-c4631fc780b7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGFibGU6YjdmMWVjYzJjZDNhNGJlZDk3MjQzZTUzOGVmOWJiZDYvdGFibGVyYW5nZTpiN2YxZWNjMmNkM2E0YmVkOTcyNDNlNTM4ZWY5YmJkNl8wLTEtMS0xLTI4NTMy_6d849c4c-d0a1-4813-8703-fad182c62350">76-0474169</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGV4dHJlZ2lvbjpmYTUwOWRmNjYyN2U0MTI2YTA5Y2EzOWQ4MjJlNDVkN18yODc_c094ecb2-b09a-423e-9f12-5c226a1a9811">2445 Technology Forest Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGV4dHJlZ2lvbjpmYTUwOWRmNjYyN2U0MTI2YTA5Y2EzOWQ4MjJlNDVkN18yOTA_4cf07eb7-0022-46bc-b588-1b14f2611d84">11th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGV4dHJlZ2lvbjpmYTUwOWRmNjYyN2U0MTI2YTA5Y2EzOWQ4MjJlNDVkN18yOTM_2244889a-b48d-4d17-9d39-8b0a9045a9f7">The Woodlands</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGV4dHJlZ2lvbjpmYTUwOWRmNjYyN2U0MTI2YTA5Y2EzOWQ4MjJlNDVkN18yOTc_871652e2-61a1-454b-a6a3-77acb48d7579">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGV4dHJlZ2lvbjpmYTUwOWRmNjYyN2U0MTI2YTA5Y2EzOWQ4MjJlNDVkN18zMDA_516e246f-3639-4125-a6a0-f8ec4ef69cd8">77381</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGV4dHJlZ2lvbjpmYTUwOWRmNjYyN2U0MTI2YTA5Y2EzOWQ4MjJlNDVkN18zNTg_99c8711c-8b87-4f3f-82ef-d0a6f60a4a22">281</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGV4dHJlZ2lvbjpmYTUwOWRmNjYyN2U0MTI2YTA5Y2EzOWQ4MjJlNDVkN18zNjI_4f1e07bf-860d-4665-85b7-05a84cbd98cd">863-3000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGFibGU6NDA1ZjEzYzk5M2EyNDdmYTk5OWMyZWI1ZWE3Y2JjNTcvdGFibGVyYW5nZTo0MDVmMTNjOTkzYTI0N2ZhOTk5YzJlYjVlYTdjYmM1N18xLTAtMS0xLTI4NTMy_d0df40d8-88c5-4e97-af74-54bbe94ba7d7">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGFibGU6NDA1ZjEzYzk5M2EyNDdmYTk5OWMyZWI1ZWE3Y2JjNTcvdGFibGVyYW5nZTo0MDVmMTNjOTkzYTI0N2ZhOTk5YzJlYjVlYTdjYmM1N18xLTEtMS0xLTI4NTMy_fdc4ab1f-78ba-443e-bab6-e4355b741b91">LXRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGFibGU6NDA1ZjEzYzk5M2EyNDdmYTk5OWMyZWI1ZWE3Y2JjNTcvdGFibGVyYW5nZTo0MDVmMTNjOTkzYTI0N2ZhOTk5YzJlYjVlYTdjYmM1N18xLTItMS0xLTI4NTMy_ab4ef2f6-6d56-4615-8dd9-8d61188bc542">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGFibGU6YWRiZDI3NjBmZWEyNDk0Yjk0N2YwNThjZjNhNmNhYWYvdGFibGVyYW5nZTphZGJkMjc2MGZlYTI0OTRiOTQ3ZjA1OGNmM2E2Y2FhZl8wLTAtMS0xLTI4NTMy_3516d004-f823-4a44-a083-23b32c7211d7">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGFibGU6MjY0Nzc3OTBhZmQxNDRlMmExZjljMmIxZTUwOWUzMzYvdGFibGVyYW5nZToyNjQ3Nzc5MGFmZDE0NGUyYTFmOWMyYjFlNTA5ZTMzNl8wLTAtMS0xLTI4NTMy_7a0a74cf-8835-41fd-a181-8246a93c37b9">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGV4dHJlZ2lvbjpmYTUwOWRmNjYyN2U0MTI2YTA5Y2EzOWQ4MjJlNDVkN18yMzAz_9f246df0-125c-4f1a-bb9b-b949746cfc93">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGV4dHJlZ2lvbjpmYTUwOWRmNjYyN2U0MTI2YTA5Y2EzOWQ4MjJlNDVkN18yMzA0_fd7d26e7-cb47-4733-a293-eb187d0f6bd4">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGV4dHJlZ2lvbjpmYTUwOWRmNjYyN2U0MTI2YTA5Y2EzOWQ4MjJlNDVkN18yMzA1_22939e8a-8ecc-40ec-91ee-8ea4dc47aaa8">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGFibGU6NmI1YTYzYjcxMzA3NGUyYWFiOGVmYWM2ODcxZmRjMTkvdGFibGVyYW5nZTo2YjVhNjNiNzEzMDc0ZTJhYWI4ZWZhYzY4NzFmZGMxOV8wLTEtMS0xLTI4NTMy_823643cb-f878-42e9-aeb9-bdd3f9df7715">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="if7a0858cf5024c25bf4b6aaa1fb4a8ca_I20220803"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xL2ZyYWc6ZmE1MDlkZjY2MjdlNDEyNmEwOWNhMzlkODIyZTQ1ZDcvdGV4dHJlZ2lvbjpmYTUwOWRmNjYyN2U0MTI2YTA5Y2EzOWQ4MjJlNDVkN18xMDk5NTExNjMwMTQ1_84aa1295-2a71-4c49-9664-34764ecd74d4"
      unitRef="shares">183625743</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfNC0yLTEtMS0yODUzMg_77d5b4e0-6851-46ae-a26d-0a64683033e7"
      unitRef="usd">21450000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfNC00LTEtMS0yODUzMg_2234961d-57fc-4436-b890-92f848bb53a7"
      unitRef="usd">64065000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfNS0yLTEtMS0yODUzMg_0a0f1740-9d8e-4905-842a-d14317b2c9e5"
      unitRef="usd">40518000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfNS00LTEtMS0yODUzMg_5b364e5a-4856-4779-b165-649bfb753723"
      unitRef="usd">22678000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfNi0yLTEtMS0yODUzMg_4653b1ea-7080-4fcd-aaeb-462cc715d56c"
      unitRef="usd">34000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfNi00LTEtMS0yODUzMg_e9f64683-31c4-4b3f-9014-509908eecc8c"
      unitRef="usd">14000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfNy0yLTEtMS0yODUzMg_711c11f5-9e8e-40c5-abbc-b2c049999117"
      unitRef="usd">2896000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfNy00LTEtMS0yODUzMg_36532764-2d6d-4915-b258-7949b4133d1c"
      unitRef="usd">2164000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfOC0yLTEtMS0yODUzMg_15e55abd-dd07-4bfb-b0eb-dbb2faae88af"
      unitRef="usd">64898000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfOC00LTEtMS0yODUzMg_eca4886f-6cf7-4fd6-acb5-b8ea860c0f2d"
      unitRef="usd">88921000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfOS0wLTEtMS0yODUzMi90ZXh0cmVnaW9uOmNkMzk3NGVjZTE4OTRlYzg4NDg4OWYzY2U1NmY5MGIxXzgw_30472e2d-1829-4ace-a6e6-a999991974bf"
      unitRef="usd">5070000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfOS0wLTEtMS0yODUzMi90ZXh0cmVnaW9uOmNkMzk3NGVjZTE4OTRlYzg4NDg4OWYzY2U1NmY5MGIxXzg3_9ac2f7bc-183a-48a0-8947-0677c745b7e6"
      unitRef="usd">4853000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfOS0yLTEtMS0yODUzMg_de0c67d0-828b-4ac0-bf24-33e330af0760"
      unitRef="usd">1035000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfOS00LTEtMS0yODUzMg_f9d40d11-678b-44e3-b113-4706bc4313f2"
      unitRef="usd">1176000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTAtMi0xLTEtMjg1MzI_d6442466-eac0-47f7-af25-fb6a7434eef2"
      unitRef="usd">44543000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTAtNC0xLTEtMjg1MzI_773767d5-9452-4e50-a327-49ee7994c16d"
      unitRef="usd">44543000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTEtMi0xLTEtMjg1MzI_062dc6e9-0798-442c-82fa-2bfe8abccb18"
      unitRef="usd">1849000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTEtNC0xLTEtMjg1MzI_169d9e8e-0e32-4122-b5e3-b4a1f97bcdc3"
      unitRef="usd">2269000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTItMi0xLTEtMjg1MzI_11487860-e01a-4b06-80d9-6ce1fe988d2d"
      unitRef="usd">112325000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTItNC0xLTEtMjg1MzI_ff588c79-9013-4af5-93a0-88df1d8fb037"
      unitRef="usd">136909000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTUtMi0xLTEtMjg1MzI_d97671ae-b43d-42ea-ba5d-14dfae7faab1"
      unitRef="usd">7347000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTUtNC0xLTEtMjg1MzI_c8b94bae-2ca1-43c1-9a6e-5fa26b5fa983"
      unitRef="usd">9152000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTYtMi0xLTEtMjg1MzI_71a7c63c-d37d-4c35-baf1-b955b60657fb"
      unitRef="usd">9515000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTYtNC0xLTEtMjg1MzI_125667a8-210d-4ec8-bc82-91b6837d7729"
      unitRef="usd">12972000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTctMi0xLTEtMjg1MzI_7213e881-c35c-4054-995f-b9b5c12044f2"
      unitRef="usd">16862000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTctNC0xLTEtMjg1MzI_f1ce8a98-be6c-4cff-8c24-1af7d9c0fb84"
      unitRef="usd">22124000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTgtMi0xLTEtMjg1MzI_20ab8795-83ef-4a86-9c8e-6b5c8a924f3f"
      unitRef="usd">23631000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTgtNC0xLTEtMjg1MzI_0033569a-77f0-481d-8951-0a689242accd"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTktMi0xLTEtMjg1MzI_22e8e8ee-7a19-4056-a2e1-493c1873976d"
      unitRef="usd">1002000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMTktNC0xLTEtMjg1MzI_28a969f5-9b82-4211-84ea-32a9c862477e"
      unitRef="usd">1190000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjAtMi0xLTEtMjg1MzI_f752ac1b-5ce1-4c3d-abe5-ae658f4ced86"
      unitRef="usd">41495000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjAtNC0xLTEtMjg1MzI_3362a604-9cbb-4c74-a4ac-1307e6604f99"
      unitRef="usd">23314000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjEtMi0xLTEtMjg1MzI_c1253264-a35b-4c98-bd15-4c38ade131ad"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjEtNC0xLTEtMjg1MzI_2d734a23-d78c-4d75-9123-6c5b86b2e88e"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjMtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjpjZjdhMWUwODFiNWI0ZjkwYjZhODE1OGJkZDFkYTkwM18yMQ_32e64d52-db2f-4351-9e85-71af08aa2191"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjMtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjpjZjdhMWUwODFiNWI0ZjkwYjZhODE1OGJkZDFkYTkwM18yMQ_c6ebf5df-9fbe-48a5-af6d-3831b4d3b6e2"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjMtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjpjZjdhMWUwODFiNWI0ZjkwYjZhODE1OGJkZDFkYTkwM18zNQ_738abc9b-4d0b-424a-a5c9-4d5315687d16"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjMtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjpjZjdhMWUwODFiNWI0ZjkwYjZhODE1OGJkZDFkYTkwM18zNQ_84c6f3c5-c804-4d63-a156-6861e658738b"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjMtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjpjZjdhMWUwODFiNWI0ZjkwYjZhODE1OGJkZDFkYTkwM181Nw_126951d5-1f6f-41e1-9115-71afeacfb86f"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjMtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjpjZjdhMWUwODFiNWI0ZjkwYjZhODE1OGJkZDFkYTkwM181Nw_4df0f957-d925-4be8-a85d-8cc64fff7e3f"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjMtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjpjZjdhMWUwODFiNWI0ZjkwYjZhODE1OGJkZDFkYTkwM181Nw_5db56796-3ae6-4aeb-bb34-4e1dc9fb68b0"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjMtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjpjZjdhMWUwODFiNWI0ZjkwYjZhODE1OGJkZDFkYTkwM181Nw_856455aa-56d7-4419-9d17-3fde7e9a635a"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjMtMi0xLTEtMjg1MzI_79b3f591-ff8d-4fa3-9035-82e55228042d"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjMtNC0xLTEtMjg1MzI_6a3335b8-aadc-4a8b-96e5-0c64e5295078"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjQtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjo0YzNiNTFhYWUwM2Q0M2Y3OGE3Yzc0MWMxMWRlMWUwYV8xOA_0bd9cf32-873b-480d-b16d-9f78acdf6a9a"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjQtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjo0YzNiNTFhYWUwM2Q0M2Y3OGE3Yzc0MWMxMWRlMWUwYV8xOA_c47dc128-9097-4e11-8398-acf5d6958721"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjQtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjo0YzNiNTFhYWUwM2Q0M2Y3OGE3Yzc0MWMxMWRlMWUwYV8zMg_4d6efa4e-14d1-4076-b6d4-991682e0ac37"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjQtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjo0YzNiNTFhYWUwM2Q0M2Y3OGE3Yzc0MWMxMWRlMWUwYV8zMg_77347186-5cf2-453b-a716-c8fe7ba95bba"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjQtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjo0YzNiNTFhYWUwM2Q0M2Y3OGE3Yzc0MWMxMWRlMWUwYV81NA_02a7fd6b-f211-4591-9e8e-d9c5bd155e9c"
      unitRef="shares">150114000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjQtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjo0YzNiNTFhYWUwM2Q0M2Y3OGE3Yzc0MWMxMWRlMWUwYV82MQ_216e637d-bcf7-4c9d-b0fb-0bd6e985be21"
      unitRef="shares">150082000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjQtMi0xLTEtMjg1MzI_811afe06-5d4a-4a89-9242-24e277edba3f"
      unitRef="usd">150000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjQtNC0xLTEtMjg1MzI_5eeeff97-5eee-4fd8-8314-31bab60bff0b"
      unitRef="usd">150000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjUtMi0xLTEtMjg1MzI_4e4e1206-29d0-40e1-92fc-c3ee12e2b3de"
      unitRef="usd">1608730000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjUtNC0xLTEtMjg1MzI_13947c8a-d4c8-4d1e-ac81-4bd76ce934d5"
      unitRef="usd">1608749000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjYtMi0xLTEtMjg1MzI_80779c10-45e8-4c27-8ebe-e6889bb20249"
      unitRef="usd">-1535839000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjYtNC0xLTEtMjg1MzI_33e6a2ee-6463-4b56-9bb1-929a139230c5"
      unitRef="usd">-1487776000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjctMi0xLTEtMjg1MzI_039e7fb7-e273-4655-8e40-ba3ce2848b53"
      unitRef="usd">-150000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjctNC0xLTEtMjg1MzI_57ba7a6e-06e1-45f8-91dd-97f8c1294dfa"
      unitRef="usd">-10000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockShares
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjgtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjo4NDRkMzA1NWUwMzQ0MzY4YjU1NjJkNDdmMDU5NjA1ZF8yOQ_c6e50378-d43b-4599-9bbb-2331f2ed01f0"
      unitRef="shares">488000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjgtMC0xLTEtMjg1MzIvdGV4dHJlZ2lvbjo4NDRkMzA1NWUwMzQ0MzY4YjU1NjJkNDdmMDU5NjA1ZF8zNg_1f32c62b-9344-4d8e-a0ab-b06831c114c5"
      unitRef="shares">1165000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjgtMi0xLTEtMjg1MzI_0e9f4779-945d-4919-8661-6cb366654fc8"
      unitRef="usd">2061000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjgtNC0xLTEtMjg1MzI_6845a6a0-06c0-4e65-a08d-90295f1d2d3b"
      unitRef="usd">7518000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjktMi0xLTEtMjg1MzI_4a22a3df-4339-4808-b1be-78d1614be526"
      unitRef="usd">70830000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMjktNC0xLTEtMjg1MzI_c0b13884-dccc-4eda-a9d0-c55ef4caf106"
      unitRef="usd">113595000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMzAtMi0xLTEtMjg1MzI_6fb72bd8-73a1-489c-8658-b8e36349954f"
      unitRef="usd">112325000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18xOS9mcmFnOmVkMDU0NDE4NThmZDRjYjRhYWJmOWU0ZjljMjlkNWFjL3RhYmxlOjY1N2E0NjVkOWM5NDQwYjA4ZWJhYTNmMTA5Mjc2OTk1L3RhYmxlcmFuZ2U6NjU3YTQ2NWQ5Yzk0NDBiMDhlYmFhM2YxMDkyNzY5OTVfMzAtNC0xLTEtMjg1MzI_03c72681-04e7-4236-b8da-cd84b8c26fb3"
      unitRef="usd">136909000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMy0xLTEtMS0yODg5OQ_59a6f2b0-1070-473a-9a3b-4d229b8a22ef"
      unitRef="usd">35000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMy0zLTEtMS0yODg5OQ_cc378f0e-10d6-45ac-b965-af8ca7744582"
      unitRef="usd">234000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMy0yLTEtMS0yODUzMg_874ff920-285c-4ab0-ae86-5997d5dfa04b"
      unitRef="usd">72000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMy00LTEtMS0yODUzMg_7aacfedb-c619-4606-b4ef-89db0e80b1e4"
      unitRef="usd">261000</us-gaap:RoyaltyIncomeNonoperating>
    <lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
      contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNi0wLTEtMS0yODUzMi90ZXh0cmVnaW9uOjIyMzQ5MjY4MTc1MjQ1ZThhNjY3MTQ2Yjc5MzA5MTNhXzY4_ff941083-fd5f-4d2a-a905-843c1784c1fe"
      unitRef="usd">1098000</lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense>
    <lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
      contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNi0wLTEtMS0yODUzMi90ZXh0cmVnaW9uOjIyMzQ5MjY4MTc1MjQ1ZThhNjY3MTQ2Yjc5MzA5MTNhXzc2_cf0dacaf-794f-4ab8-abe7-82d52449842b"
      unitRef="usd">1184000</lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense>
    <lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNi0wLTEtMS0yODUzMi90ZXh0cmVnaW9uOjIyMzQ5MjY4MTc1MjQ1ZThhNjY3MTQ2Yjc5MzA5MTNhXzEwOTk1MTE2Mjc4Njk_2ce8c3b3-f8fe-4a9e-be38-246852f9957c"
      unitRef="usd">2130000</lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense>
    <lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNi0wLTEtMS0yODUzMi90ZXh0cmVnaW9uOjIyMzQ5MjY4MTc1MjQ1ZThhNjY3MTQ2Yjc5MzA5MTNhXzEwOTk1MTE2Mjc4OTE_485d5a35-0576-40b7-88f6-c83b0ccf6c9b"
      unitRef="usd">2470000</lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNi0xLTEtMS0yODg3MA_2aacb8a4-024f-4649-9586-7e189e759302"
      unitRef="usd">13356000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNi0zLTEtMS0yODg5OQ_c844052f-4739-4eae-a766-44aeee18e9f1"
      unitRef="usd">10257000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNi0yLTEtMS0yODUzMg_f39de704-3d74-487d-90d0-bd13bb45b0ec"
      unitRef="usd">28282000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNi00LTEtMS0yODUzMg_070ff337-b9a1-40fd-93c4-927e4b19692a"
      unitRef="usd">22866000</us-gaap:ResearchAndDevelopmentExpense>
    <lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
      contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNy0wLTEtMS0yODUzMi90ZXh0cmVnaW9uOmU2ZTYyOTBjMDkzMzQ0NjlhZTA4NDhmNWQ2NGM5NzA4Xzc5_167152e8-e3f3-4308-a877-1b9a75ac1fef"
      unitRef="usd">1734000</lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense>
    <lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
      contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNy0wLTEtMS0yODUzMi90ZXh0cmVnaW9uOmU2ZTYyOTBjMDkzMzQ0NjlhZTA4NDhmNWQ2NGM5NzA4Xzg3_df9fc65c-f4f4-43b9-9972-b558c8690251"
      unitRef="usd">1602000</lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense>
    <lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNy0wLTEtMS0yODUzMi90ZXh0cmVnaW9uOmU2ZTYyOTBjMDkzMzQ0NjlhZTA4NDhmNWQ2NGM5NzA4XzEwOTk1MTE2Mjc4ODI_b6b0d29f-b024-457e-9acf-ae82a793d8a8"
      unitRef="usd">3474000</lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense>
    <lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNy0wLTEtMS0yODUzMi90ZXh0cmVnaW9uOmU2ZTYyOTBjMDkzMzQ0NjlhZTA4NDhmNWQ2NGM5NzA4XzEwOTk1MTE2Mjc5MDA_d3491de5-6918-4933-9de8-dedc1a1fd3a7"
      unitRef="usd">3167000</lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense>
    <lxrx:Sellinggeneralandadministrativeexpenses
      contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNy0xLTEtMS0yODg5OQ_c1cbf0b7-efab-4ffa-bc3f-1ce30b349c90"
      unitRef="usd">10686000</lxrx:Sellinggeneralandadministrativeexpenses>
    <lxrx:Sellinggeneralandadministrativeexpenses
      contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNy0zLTEtMS0yODg5OQ_3f106904-f6e0-440c-a15b-cd44aaf3ccfa"
      unitRef="usd">7936000</lxrx:Sellinggeneralandadministrativeexpenses>
    <lxrx:Sellinggeneralandadministrativeexpenses
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNy0yLTEtMS0yODUzMg_17fd5f2f-c943-4f57-b725-4ea928808d78"
      unitRef="usd">19177000</lxrx:Sellinggeneralandadministrativeexpenses>
    <lxrx:Sellinggeneralandadministrativeexpenses
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfNy00LTEtMS0yODUzMg_f35e45ed-973b-41f5-82e4-0d4a406fd17c"
      unitRef="usd">16193000</lxrx:Sellinggeneralandadministrativeexpenses>
    <us-gaap:OperatingExpenses
      contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfOC0xLTEtMS0yODg5OQ_95732398-d8c1-45c0-8c15-a01d02305f53"
      unitRef="usd">-24042000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfOC0zLTEtMS0yODg5OQ_efed90a6-724e-4fc4-865e-5edbcee633a2"
      unitRef="usd">18193000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfOC0yLTEtMS0yODUzMg_06544e8f-1c9d-41b5-b05a-5d956407006e"
      unitRef="usd">47459000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfOC00LTEtMS0yODUzMg_0d8d55b4-aad4-469b-a140-e2580d0c6e6a"
      unitRef="usd">39059000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfOS0xLTEtMS0yODg5OQ_e4623195-5e97-4927-b953-3d884d8b70c7"
      unitRef="usd">-24007000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfOS0zLTEtMS0yODg5OQ_effefc49-9be8-4e7e-acb0-57f0237991c7"
      unitRef="usd">-17959000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfOS0yLTEtMS0yODUzMg_3ca20b5b-6eb8-48f0-ace1-3b7163bc078a"
      unitRef="usd">-47387000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfOS00LTEtMS0yODUzMg_48ec2880-e87b-4865-a232-6b85b594225a"
      unitRef="usd">-38798000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTAtMS0xLTEtMjg4OTk_5f13e14a-1142-41d1-b84c-4f5ef1035868"
      unitRef="usd">703000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTAtMy0xLTEtMjg4OTk_ce7fa173-ea43-446c-a138-64168d9d07e8"
      unitRef="usd">169000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTAtMi0xLTEtMjg1MzI_25029430-9c4a-400c-a3bf-ad0b42f6ebbd"
      unitRef="usd">813000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTAtNC0xLTEtMjg1MzI_5d4901a4-5739-4435-b5c1-c19760b2001f"
      unitRef="usd">336000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTEtMS0xLTEtMjg4OTk_ab50d8e5-f36f-4355-b1f3-2c08448336b3"
      unitRef="usd">123000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTEtMy0xLTEtMjg4OTk_6b97abec-4732-4fb9-b25a-3da297266b9b"
      unitRef="usd">61000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTEtMi0xLTEtMjg1MzI_d176085b-0d03-45c2-aed4-e8177131ec6a"
      unitRef="usd">137000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTEtNC0xLTEtMjg1MzI_15a62279-8aac-4137-b998-4c7da522066f"
      unitRef="usd">109000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTItMS0xLTEtMjg4OTk_2be46468-a990-4a1b-abfc-9e857b5f8e6d"
      unitRef="usd">-24587000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTItMy0xLTEtMjg4OTk_17c0e601-ec6d-4284-9546-7a07e389475b"
      unitRef="usd">-18067000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTItMi0xLTEtMjg1MzI_a6fb63e1-276b-4f88-be61-48059bdb9d5e"
      unitRef="usd">-48063000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTItNC0xLTEtMjg1MzI_a0b96d8c-18fa-4255-a493-e016ea62694d"
      unitRef="usd">-39025000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTMtMS0xLTEtMjg4OTk_9a2e54ab-c4db-4d04-9fce-797a077afbfc"
      unitRef="usdPerShare">-0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTMtMy0xLTEtMjg4OTk_e04df881-3276-4962-a57f-10597852941f"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTMtMi0xLTEtMjg1MzI_8f6832fd-792a-42f7-bd0d-99b579da90a9"
      unitRef="usdPerShare">-0.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTMtNC0xLTEtMjg1MzI_301f29c7-9cc4-46f3-b18b-7c8c7acb651d"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTUtMS0xLTEtMjg4OTk_21162575-f134-4b69-8ef1-081945df33da"
      unitRef="shares">149616000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTUtMy0xLTEtMjg4OTk_b4061548-ec90-42c8-90f4-f9340b6c198a"
      unitRef="shares">144451000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTUtMi0xLTEtMjg1MzI_512f4fff-9d32-47f9-a0de-b5e6fa351d03"
      unitRef="shares">149384000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTUtNC0xLTEtMjg1MzI_f3def612-7a5b-4463-bf5c-092889ed1910"
      unitRef="shares">143917000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTgtMS0xLTEtMjg4OTk_10fece99-96c4-4ce1-babc-5f429fffddcc"
      unitRef="usd">-113000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTgtMy0xLTEtMjg4OTk_ba8e7898-b48c-4b78-a16c-9573515ac8f5"
      unitRef="usd">-10000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTgtMi0xLTEtMjg1MzI_3d6713b2-0320-469d-9c36-ce3bca32350d"
      unitRef="usd">-140000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTgtNC0xLTEtMjg1MzI_de5c4deb-8f1c-4964-aaa6-d9b091b739f8"
      unitRef="usd">1000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTktMS0xLTEtMjg4OTk_26912a5a-6e5f-4a02-91a6-57aa0c184fac"
      unitRef="usd">-24700000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTktMy0xLTEtMjg4OTk_ca0c0161-f77b-4571-81e1-e618880c6974"
      unitRef="usd">-18077000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTktMi0xLTEtMjg1MzI_8c022fd4-da90-42b7-90bf-917eb4d2bd98"
      unitRef="usd">-48203000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yMi9mcmFnOmJjNWMxNmM2ZGJiZDRkOTU5ZTI1MWVjZWMyMDI2YjU2L3RhYmxlOjk3ODc0Y2ZiZmQ4MzQzMTg5NGVkNGU1NGZhMWFmNWIyL3RhYmxlcmFuZ2U6OTc4NzRjZmJmZDgzNDMxODk0ZWQ0ZTU0ZmExYWY1YjJfMTktNC0xLTEtMjg1MzI_ed883fd0-25e3-4f7c-abf0-81991800df9b"
      unitRef="usd">-39024000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie8a7ca19bc1a4556a6e59951312a250b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMi0yLTEtMS0yODUzMg_2220c302-ac81-40c5-b005-d82d3a7c5b3a"
      unitRef="shares">142289000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie8a7ca19bc1a4556a6e59951312a250b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMi00LTEtMS0yODUzMg_d6b9432a-0641-4651-851b-aabd3860f852"
      unitRef="usd">142000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iebb39511180847c6b73ea2044b1bbc86_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMi02LTEtMS0yODUzMg_19588b21-2cb0-4d03-a719-066e8caaf228"
      unitRef="usd">1561096000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1bfe69c4a75a471ab0ff5ee12bde76cc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMi04LTEtMS0yODUzMg_6f198aeb-52b7-4964-b500-a17ab70d3293"
      unitRef="usd">-1400018000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i45657a0096954cda95b6dd011117c958_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMi0xMC0xLTEtMjg1MzI_2d03a709-1c38-4252-8522-00db234d6082"
      unitRef="usd">-6000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i159bdd976c5a411daa2d75f84b7d64a6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMi0xMi0xLTEtMjg1MzI_da7ff6e8-91e9-4f08-9fef-078ad3e78cbf"
      unitRef="usd">-4843000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib3ab6ec7ca184c0b98f71ea5fbc23b66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMi0xNC0xLTEtMjg1MzI_c8461bd1-75ce-493f-8dfc-416613e05f47"
      unitRef="usd">156371000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6294895f68fb461d8a0149ff1352660b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMy00LTEtMS0yODUzMg_c2b21f48-3337-4749-9ca3-1da34da150e8"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i64b8f1ab07f04390b4b79e6f8c6eb68e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMy02LTEtMS0yODUzMg_37adeeaa-b62d-49b5-9a49-024e867b74e0"
      unitRef="usd">2851000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2f6fc7cd72c34badba8bff35c5c227ac_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMy04LTEtMS0yODUzMg_9a72dcbd-0a58-4136-8666-44e321c61f35"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4ea8108d1eb5464fb0ec1f1c33b681cd_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMy0xMC0xLTEtMjg1MzI_88e9ede7-5e26-47cb-b8c8-c752e6f0b8d0"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iab6948c85b864af88b2035a19dd666a2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMy0xMi0xLTEtMjg1MzI_01eb8e36-f6c4-4d05-9a40-3141a58effe0"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib6cf877d5e034cbe9a21bc4654ebb5f6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMy0xNC0xLTEtMjg1MzI_fa25b0f8-92b2-448a-85a4-5456b8f0ffc5"
      unitRef="usd">2851000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i6294895f68fb461d8a0149ff1352660b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNC0yLTEtMS0yODUzMg_7d841876-2c37-4cfb-9130-3610025ab472"
      unitRef="shares">1263000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6294895f68fb461d8a0149ff1352660b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNC00LTEtMS0yODUzMg_0e522a01-2d49-470c-9f27-bc5e23d47b74"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i64b8f1ab07f04390b4b79e6f8c6eb68e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNC02LTEtMS0yODUzMg_3c0cbb00-51f4-47fc-bed3-17de6497b633"
      unitRef="usd">547000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2f6fc7cd72c34badba8bff35c5c227ac_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNC04LTEtMS0yODUzMg_a0055175-0804-453a-9843-0c0aa51cd903"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4ea8108d1eb5464fb0ec1f1c33b681cd_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNC0xMC0xLTEtMjg1MzI_960a8bd7-5982-42f4-b1b3-1659e7250b88"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iab6948c85b864af88b2035a19dd666a2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNC0xMi0xLTEtMjg1MzI_9cfbf7a9-953f-480c-b3e2-21c7709a31f9"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib6cf877d5e034cbe9a21bc4654ebb5f6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNC0xNC0xLTEtMjg1MzI_2139c497-3dc0-4ac5-b899-849ffd33d1aa"
      unitRef="usd">548000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i6294895f68fb461d8a0149ff1352660b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNS0yLTEtMS0yODUzMg_048e134e-7e40-4090-b08e-174666fc18e5"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6294895f68fb461d8a0149ff1352660b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNS00LTEtMS0yODUzMg_0c4223d9-c105-4f9d-bcfc-5be29317135a"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i64b8f1ab07f04390b4b79e6f8c6eb68e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNS02LTEtMS0yODUzMg_d77f5d97-3ef1-4b29-bd24-2852ddb49ac8"
      unitRef="usd">16397000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2f6fc7cd72c34badba8bff35c5c227ac_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNS04LTEtMS0yODUzMg_c706d5c5-105d-4384-bcb1-b19f8167159f"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4ea8108d1eb5464fb0ec1f1c33b681cd_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNS0xMC0xLTEtMjg1MzI_3af66d28-1b88-43d8-ad6c-9cf4915d35b6"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iab6948c85b864af88b2035a19dd666a2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNS0xMi0xLTEtMjg1MzI_34a29b38-95ab-401b-b616-48d05114fc10"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib6cf877d5e034cbe9a21bc4654ebb5f6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNS0xNC0xLTEtMjg1MzI_57efcd5b-f276-439f-a4ac-9fa4919f13ba"
      unitRef="usd">16399000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i6294895f68fb461d8a0149ff1352660b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNi00LTEtMS0yODUzMg_cebfff6c-c8bf-48b0-9080-221a0aa74f57"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i64b8f1ab07f04390b4b79e6f8c6eb68e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNi02LTEtMS0yODUzMg_3625b257-15c5-45fc-bd05-d2e90b112974"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i2f6fc7cd72c34badba8bff35c5c227ac_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNi04LTEtMS0yODUzMg_fb2384db-8195-4b90-9067-2dcbc1bbbe10"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i4ea8108d1eb5464fb0ec1f1c33b681cd_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNi0xMC0xLTEtMjg1MzI_35d48530-f7dd-411a-a5d2-ed96129a454f"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="iab6948c85b864af88b2035a19dd666a2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNi0xMi0xLTEtMjg1MzI_c22b8dc7-795c-42a5-8be6-d1d4c089b0ff"
      unitRef="usd">2675000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ib6cf877d5e034cbe9a21bc4654ebb5f6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNi0xNC0xLTEtMjg1MzI_779f620a-b8cb-463e-ae58-bacd973cf619"
      unitRef="usd">2675000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:NetIncomeLoss
      contextRef="i6294895f68fb461d8a0149ff1352660b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNy00LTEtMS0yODUzMg_04ba4053-2d8b-45e9-a9b1-75199c03f310"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i64b8f1ab07f04390b4b79e6f8c6eb68e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNy02LTEtMS0yODUzMg_1e2f59fa-681a-47b1-bc21-f2824ad47717"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2f6fc7cd72c34badba8bff35c5c227ac_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNy04LTEtMS0yODUzMg_f6548439-fa01-4389-99f7-f5ef8850ff3f"
      unitRef="usd">-20958000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4ea8108d1eb5464fb0ec1f1c33b681cd_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNy0xMC0xLTEtMjg1MzI_c0f4f23a-e3fa-4152-85fc-cb7833a04778"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iab6948c85b864af88b2035a19dd666a2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNy0xMi0xLTEtMjg1MzI_9221848f-7379-456e-9c1b-10b3924e48fd"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2f6fc7cd72c34badba8bff35c5c227ac_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfNy0xNC0xLTEtMjg1MzI_8d4fee09-aebd-4c8f-b634-322f3687e596"
      unitRef="usd">-20958000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i6294895f68fb461d8a0149ff1352660b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfOC00LTEtMS0yODUzMg_504e2022-df03-4c64-a36d-a545bd96f7ae"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i64b8f1ab07f04390b4b79e6f8c6eb68e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfOC02LTEtMS0yODUzMg_92066640-cacc-4605-ba8a-7f8d145d5893"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i2f6fc7cd72c34badba8bff35c5c227ac_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfOC04LTEtMS0yODUzMg_025d68ac-a566-490c-abc2-02332615afdc"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4ea8108d1eb5464fb0ec1f1c33b681cd_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfOC0xMC0xLTEtMjg1MzI_9c600128-64ec-4edd-aca8-12f054065253"
      unitRef="usd">11000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iab6948c85b864af88b2035a19dd666a2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfOC0xMi0xLTEtMjg1MzI_47d25843-6623-4fce-a6bf-d1916f02548b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ib6cf877d5e034cbe9a21bc4654ebb5f6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfOC0xNC0xLTEtMjg1MzI_1e01d3e4-fb53-4a53-9aa1-630f3365393d"
      unitRef="usd">11000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i067eeafe353e47bc8c8d21624e5bafe8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfOS0yLTEtMS0yODUzMg_bc8d06ad-288e-4768-85de-407265c86f49"
      unitRef="shares">145552000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i067eeafe353e47bc8c8d21624e5bafe8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfOS00LTEtMS0yODUzMg_824d23d3-1246-48cd-8a87-54f4c1925128"
      unitRef="usd">145000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaabab49ebc5c4a4a9b6b4ef4966aefcd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfOS02LTEtMS0yODUzMg_bf15cbe6-6df1-43e7-83e0-33aaac70498c"
      unitRef="usd">1580891000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6d665691473c45ecb646640a37531cf4_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfOS04LTEtMS0yODUzMg_e83896a9-c0a6-4695-a818-d96c1a398182"
      unitRef="usd">-1420976000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iafe0378736e444aab2cfabe4f48ecbb9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfOS0xMC0xLTEtMjg1MzI_08621d85-883b-4778-9e7b-d69e6f35dfe3"
      unitRef="usd">5000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4de99efa8fac4a1e9b601bcb9a760fad_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfOS0xMi0xLTEtMjg1MzI_d2f94e04-e441-48d9-aacc-c50a036d883d"
      unitRef="usd">-7518000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id997a83da5644f6987121d06d68d06ae_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfOS0xNC0xLTEtMjg1MzI_384473c3-4fca-466d-9146-eaddca1c95ad"
      unitRef="usd">152547000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i70f53509a43b46f7918ad0068ee464f4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTAtNC0xLTEtMjkzNzA_d88371c5-b1db-4f16-a963-2d0c684ade56"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia6a00923dd164c3185de2bb3200711b3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTAtNi0xLTEtMjkzNzA_c6d947fe-28d5-4011-b584-e32a2943a4ae"
      unitRef="usd">2786000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ieaf692e06bd247aebe797f2c2d1665d7_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTAtOC0xLTEtMjkzNzA_992ebafd-dae3-4d77-8e8d-93e14b09ce01"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id974764582f944f191de99110577719e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTAtMTAtMS0xLTI5Mzcw_237c264c-c9c2-45f7-b3d2-be0a1986c04d"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i436bb19a139f4e90a3435d0ce8396f1d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTAtMTItMS0xLTI5Mzcw_3425f010-b7b9-49fe-963d-f26029d8304d"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTAtMTQtMS0xLTI5Mzcw_dad2908a-a0fd-4732-8793-71bf260b7d27"
      unitRef="usd">2786000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i70f53509a43b46f7918ad0068ee464f4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTEtMi0xLTEtMjkzNzc_7cd6e608-233d-4541-94e9-47a9c4d4fe18"
      unitRef="shares">88000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i70f53509a43b46f7918ad0068ee464f4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTEtNC0xLTEtMjkzNzc_c1ee76c2-0d9d-4514-8ae7-ef7f80328166"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia6a00923dd164c3185de2bb3200711b3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTEtNi0xLTEtMjkzNzc_15eae2a2-079f-4060-9990-0e22e6610e1e"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ieaf692e06bd247aebe797f2c2d1665d7_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTEtOC0xLTEtMjkzNzc_437e26ab-70b3-46a4-a05f-337ee4c5c1a4"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id974764582f944f191de99110577719e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTEtMTAtMS0xLTI5Mzc3_d543b3cb-5548-4060-8462-ac66f82f3a12"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i436bb19a139f4e90a3435d0ce8396f1d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTEtMTItMS0xLTI5Mzc3_fa0af13d-66c4-4a2c-b596-148327581357"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTEtMTQtMS0xLTI5Mzc3_8d4c68e7-c009-4b7a-99be-b4446761697f"
      unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i70f53509a43b46f7918ad0068ee464f4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTItNC0xLTEtMjkzNzc_e5d09575-02c3-424b-b311-0a5f24657bf6"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="ia6a00923dd164c3185de2bb3200711b3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTItNi0xLTEtMjkzNzc_9ed165f6-f650-4968-be37-7664730b6b5a"
      unitRef="usd">31000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="ieaf692e06bd247aebe797f2c2d1665d7_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTItOC0xLTEtMjkzNzc_26094e47-da9f-465d-a6dd-cb7713a46cdb"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="id974764582f944f191de99110577719e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTItMTAtMS0xLTI5Mzc3_57fe6e07-3f65-4769-abd1-abb5cd0dca64"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i436bb19a139f4e90a3435d0ce8396f1d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTItMTItMS0xLTI5Mzc3_cced0343-6bbf-4bf9-8394-a234564508b7"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTItMTQtMS0xLTI5Mzc3_0c2a887b-45e5-41a6-b56a-b89d94411678"
      unitRef="usd">31000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:NetIncomeLoss
      contextRef="i70f53509a43b46f7918ad0068ee464f4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTMtNC0xLTEtMjkzNzc_10d924b9-8bf7-40e7-bc0a-1b8a6554c9ee"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia6a00923dd164c3185de2bb3200711b3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTMtNi0xLTEtMjkzNzc_ad79ea33-d268-4ac2-8764-78a0e3503172"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ieaf692e06bd247aebe797f2c2d1665d7_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTMtOC0xLTEtMjkzNzc_9360782d-fcd0-4288-a0a7-ab9977854f7f"
      unitRef="usd">-18067000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id974764582f944f191de99110577719e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTMtMTAtMS0xLTI5Mzc3_82a3c27c-d4bb-4793-9352-bde79c3eecbd"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i436bb19a139f4e90a3435d0ce8396f1d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTMtMTItMS0xLTI5Mzc3_b699e879-6045-402b-aa49-c0089b7b8ce6"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ieaf692e06bd247aebe797f2c2d1665d7_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTMtMTQtMS0xLTI5Mzc3_95a223d6-73d0-46a7-90e1-2724499f6d18"
      unitRef="usd">-18067000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i70f53509a43b46f7918ad0068ee464f4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTQtNC0xLTEtMjkzNzc_c4997f2c-3935-4d4d-bd14-7d760a068108"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia6a00923dd164c3185de2bb3200711b3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTQtNi0xLTEtMjkzNzc_20a46528-dac8-422a-8d1f-292d72efebf2"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ieaf692e06bd247aebe797f2c2d1665d7_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTQtOC0xLTEtMjkzNzc_8222a6e5-cb06-4b73-9358-deb3cc2c5eb0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id974764582f944f191de99110577719e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTQtMTAtMS0xLTI5Mzc3_a28285e3-f83e-471e-8cb0-1112aae0b338"
      unitRef="usd">-10000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i436bb19a139f4e90a3435d0ce8396f1d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTQtMTItMS0xLTI5Mzc3_fac551ff-01fa-4325-8114-fd04bf11f79d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTQtMTQtMS0xLTI5Mzc3_c921b9d9-8552-41ac-8dda-7dac179a5da6"
      unitRef="usd">-10000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i84c6845ef1af474d99b31053aaec57d8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTUtMi0xLTEtMjkzODQ_67bfc03b-2a2e-4305-9909-cde83541c07a"
      unitRef="shares">145640000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i84c6845ef1af474d99b31053aaec57d8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTUtNC0xLTEtMjkzODQ_7c9129b0-5762-4308-a513-df21a4493b98"
      unitRef="usd">146000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic04a7ab6695e4594b37dbd4ef6202519_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTUtNi0xLTEtMjkzODQ_b3c112ea-128f-45fa-83fa-ea6d877ff9dc"
      unitRef="usd">1583653000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib1997cf5cac44c6eb336f27c85ee57c4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTUtOC0xLTEtMjkzODQ_b834c816-5c15-4a77-a77c-56aea03819b9"
      unitRef="usd">-1439043000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7fc68f10369542aaafc82c10cdef36a8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTUtMTAtMS0xLTI5Mzg0_f16ace37-f218-4353-887e-0ad499506d42"
      unitRef="usd">-5000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4921c0cb0fbb40faa165f5a6e62d660d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTUtMTItMS0xLTI5Mzg0_6ada1a4d-3080-46c4-92e4-60a07cd9d7d1"
      unitRef="usd">-7518000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icdf3d3ccc7584900aada54e1568caba4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjZhNjQ4YmFjNTQ0MTQwODM5NDYyMzgyOWJmZmM3OTFlL3RhYmxlcmFuZ2U6NmE2NDhiYWM1NDQxNDA4Mzk0NjIzODI5YmZmYzc5MWVfMTUtMTQtMS0xLTI5Mzg0_86554c8a-0a80-429b-8eb1-489e63f16c8b"
      unitRef="usd">137233000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i4a7c2141afe24e7f83e4d67a5ccdfff8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMi0yLTEtMS0yODUzMg_4266d56a-e8b7-4f8a-be9c-5160d0082757"
      unitRef="shares">150082000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4a7c2141afe24e7f83e4d67a5ccdfff8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMi00LTEtMS0yODUzMg_49dcd07a-becd-4a8e-8415-a3028d13b735"
      unitRef="usd">150000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic4163eee5a3740f5846f34cdd0ae242b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMi02LTEtMS0yODUzMg_5dc3641f-1690-498d-9d6f-a1758c21f7ab"
      unitRef="usd">1608749000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i191fd4fe2f08479884c4e65d4e9cfdff_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMi04LTEtMS0yODUzMg_7a779c89-3acb-408e-972e-f8d0f286fef2"
      unitRef="usd">-1487776000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i42fe192fe5ca436e9ed23d15187dbe84_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMi0xMC0xLTEtMjg1MzI_b5f8ae45-bc33-4b3a-a3b7-f169e871cb47"
      unitRef="usd">-10000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i75b83c9dc24f45598d1213d5e8d33a7e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMi0xMi0xLTEtMjg1MzI_1df94bb1-7333-459d-92ab-0972dd32c799"
      unitRef="usd">-7518000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMi0xNC0xLTEtMjg1MzI_a734c274-ae55-4493-9189-2d43bc383ef8"
      unitRef="usd">113595000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib4de86438d8b40de8534780d8f45dbf0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMy00LTEtMS0yODUzMg_81c39e55-3990-4539-b06d-0a3d687ee56d"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iaa991937faa74a41905808343286e8d9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMy02LTEtMS0yODUzMg_b35a7a18-1482-4597-aad3-7e5cf888d5b7"
      unitRef="usd">2772000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0ede75339061443d9b99e442e4e84e69_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMy04LTEtMS0yODUzMg_24940dbe-0a44-407f-9621-71e471bc73bf"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i781fc25c166b4fe180c4b24a19f09109_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMy0xMC0xLTEtMjg1MzI_e0b4228a-b2fa-4999-a145-a2ff2a9e3e29"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id1fe783955bb4f568c7b32b3eb3734e4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMy0xMi0xLTEtMjg1MzI_278eb36b-2628-4d25-9abf-fe8bb6bec04c"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i225dda2db10c426f89723c6eb6264105_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMy0xNC0xLTEtMjg1MzI_c3e97b02-35f6-4254-bd4c-9ed0dd7a21fa"
      unitRef="usd">2772000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ib4de86438d8b40de8534780d8f45dbf0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNC0yLTEtMS0yODUzMg_4221708c-a0bb-409c-b4f5-5b2e2eb31e8b"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib4de86438d8b40de8534780d8f45dbf0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNC00LTEtMS0yODUzMg_b5629663-add1-45a6-bf21-771be27f8b6d"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iaa991937faa74a41905808343286e8d9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNC02LTEtMS0yODUzMg_d43a8a9e-5fee-4ee7-813f-7a2204baec2c"
      unitRef="usd">698000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0ede75339061443d9b99e442e4e84e69_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNC04LTEtMS0yODUzMg_6a3fad34-0425-427f-9187-32e716c3c915"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i781fc25c166b4fe180c4b24a19f09109_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNC0xMC0xLTEtMjg1MzI_0f8286a8-1373-4832-8bfb-d75e3099b78f"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id1fe783955bb4f568c7b32b3eb3734e4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNC0xMi0xLTEtMjg1MzI_e0f05e4e-2368-4d58-9e41-a57b92e2167f"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i225dda2db10c426f89723c6eb6264105_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNC0xNC0xLTEtMjg1MzI_87ec316a-d14b-4cb0-874a-77484fa6fa38"
      unitRef="usd">698000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="ib4de86438d8b40de8534780d8f45dbf0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNS0yLTEtMS0yOTQ4NQ_ad7ef893-ef46-4582-bad5-e281abf0238a"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ib4de86438d8b40de8534780d8f45dbf0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNS00LTEtMS0yOTQ4NQ_d8f30651-f786-4b46-a862-fce81eca8372"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="iaa991937faa74a41905808343286e8d9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNS02LTEtMS0yOTQ4NQ_a15e3f8a-9125-4048-bafb-29d60ce3a1d3"
      unitRef="usd">6321000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i0ede75339061443d9b99e442e4e84e69_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNS04LTEtMS0yOTQ4NQ_07c93eaa-df88-48cf-9633-db0a2714a625"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i781fc25c166b4fe180c4b24a19f09109_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNS0xMC0xLTEtMjk0ODU_9e7e8cde-953c-4a64-b150-659304bfa0ef"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="id1fe783955bb4f568c7b32b3eb3734e4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNS0xMi0xLTEtMjk0ODU_e888a37a-817b-4634-98b1-440f536c5357"
      unitRef="usd">6321000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i225dda2db10c426f89723c6eb6264105_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNS0xNC0xLTEtMjk0ODU_6a463359-9f11-4250-924e-be71ae95d36a"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib4de86438d8b40de8534780d8f45dbf0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNi0yLTEtMS0yODUzMg_e64bc8c0-e008-418e-ac78-cb56bd53823e"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib4de86438d8b40de8534780d8f45dbf0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNi00LTEtMS0yODUzMg_67e3da9b-07e8-408c-9724-438b79f3a13e"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iaa991937faa74a41905808343286e8d9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNi02LTEtMS0yODUzMg_26d5602c-9b3d-4e46-9ba7-e5e3243a03ad"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0ede75339061443d9b99e442e4e84e69_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNi04LTEtMS0yODUzMg_5f53d8d2-9d6f-4273-89be-65207f83bd15"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i781fc25c166b4fe180c4b24a19f09109_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNi0xMC0xLTEtMjg1MzI_f4158780-ac97-47f2-994a-18145653271e"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id1fe783955bb4f568c7b32b3eb3734e4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNi0xMi0xLTEtMjg1MzI_3b77eda0-814f-44bd-968c-3e9507789878"
      unitRef="usd">-864000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i225dda2db10c426f89723c6eb6264105_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNi0xNC0xLTEtMjg1MzI_f3876ff4-7435-4e81-9e34-56d8024b5851"
      unitRef="usd">864000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="ib4de86438d8b40de8534780d8f45dbf0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNy00LTEtMS0yODUzMg_d0e2e91b-9e25-43a5-906e-68decbe3a89a"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaa991937faa74a41905808343286e8d9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNy02LTEtMS0yODUzMg_5757fd09-4750-4aa4-b8fd-102ba2e5adf9"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0ede75339061443d9b99e442e4e84e69_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNy04LTEtMS0yODUzMg_50585fb1-ccd7-43af-a5ca-85e264d22a3d"
      unitRef="usd">-23476000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i781fc25c166b4fe180c4b24a19f09109_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNy0xMC0xLTEtMjg1MzI_91256753-9b57-4c1a-ae1e-666cf9da4ae6"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id1fe783955bb4f568c7b32b3eb3734e4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNy0xMi0xLTEtMjg1MzI_de2cad58-6135-4138-97c4-ba1f8923465f"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i225dda2db10c426f89723c6eb6264105_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfNy0xNC0xLTEtMjg1MzI_16f6330c-1c22-4154-9acf-47146f4c26b7"
      unitRef="usd">-23476000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ib4de86438d8b40de8534780d8f45dbf0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfOC00LTEtMS0yODUzMg_1a63c666-92de-4864-846a-426eb2baa8ac"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iaa991937faa74a41905808343286e8d9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfOC02LTEtMS0yODUzMg_cece9910-7b49-4259-8dfd-bde6dab09d23"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0ede75339061443d9b99e442e4e84e69_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfOC04LTEtMS0yODUzMg_e7e6259d-921e-4df6-bf04-5f775abfd593"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i781fc25c166b4fe180c4b24a19f09109_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfOC0xMC0xLTEtMjg1MzI_d42b78a1-5c83-4bca-9164-74980dee4e79"
      unitRef="usd">-27000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id1fe783955bb4f568c7b32b3eb3734e4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfOC0xMi0xLTEtMjg1MzI_99bed58d-53db-4089-b8cc-b2952509f56a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i225dda2db10c426f89723c6eb6264105_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfOC0xNC0xLTEtMjg1MzI_567a387a-44a0-4ef4-9534-0a423d9937ec"
      unitRef="usd">-27000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="iff773ff7f7f9457f9791bde81fb05630_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfOS0yLTEtMS0yODUzMg_7adb9f93-fd6f-4af1-9391-8ad54a3b803f"
      unitRef="shares">150082000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iff773ff7f7f9457f9791bde81fb05630_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfOS00LTEtMS0yODUzMg_f9d1b8e8-3a62-40d2-a463-ff514e920597"
      unitRef="usd">150000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i47c159cf741e4073a1ff14f684d085d7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfOS02LTEtMS0yODUzMg_91a23ac8-bf55-480b-be70-74e984598579"
      unitRef="usd">1605898000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7d8b5096b7ac4e1fa83572cd7c51c76b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfOS04LTEtMS0yODUzMg_c8b39a32-8f53-4bda-9931-5c12459bbdab"
      unitRef="usd">-1511252000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id0a99ce76ff74360997f9515e9e301b9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfOS0xMC0xLTEtMjg1MzI_bb8a0ebb-0bc3-4dcd-afcd-24ba959965d7"
      unitRef="usd">-37000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaeb348ef20a2445c8833795108ee3835_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfOS0xMi0xLTEtMjg1MzI_1228e653-b4df-47b9-a399-6dc08a5ed5b1"
      unitRef="usd">-2061000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8b20225add3d49819abcc6c8ffa1f6c2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfOS0xNC0xLTEtMjg1MzI_87d9bddc-f436-49fb-b908-94e7fa39ca84"
      unitRef="usd">92698000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i172ba7c5c11849e1b3e8f93623452a80_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTAtMi0xLTEtMzA1MDk_e18ca65e-9f93-4fad-a328-ac96a47e518b"
      unitRef="shares">32000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i172ba7c5c11849e1b3e8f93623452a80_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTAtNC0xLTEtMzA1MDk_16d067a4-83cd-4c24-a015-9e5f4525461d"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9ab63a6a7f16414f93ebff593d6bd562_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTAtNi0xLTEtMzA1MDk_37c195fb-6b36-485e-a0b0-cf9368861a2b"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibbe2a09570334122960c7e63bb722f5c_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTAtOC0xLTEtMzA1MDk_1b8d271b-7214-4e11-9d68-87159915b3d5"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4bd35a0adb644d578ef0843d8d92e8f2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTAtMTAtMS0xLTMwNTA5_dba52ca0-6003-4721-b03f-f1c409f79079"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i25a8adb9e6404469bce5c119cc2f7260_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTAtMTItMS0xLTMwNTA5_80467fcd-eb03-448e-acb8-944a4fc1d6df"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTAtMTQtMS0xLTMwNTA5_f6243b1e-0ade-4e6e-97a9-242525dc8469"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i172ba7c5c11849e1b3e8f93623452a80_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTAtNC0xLTEtMjk0NTg_859e4a02-79a4-44d2-9b52-ea8750c18f57"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9ab63a6a7f16414f93ebff593d6bd562_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTAtNi0xLTEtMjk0NTg_9f65d428-9e35-4e9e-a388-650b0f5182f8"
      unitRef="usd">2832000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibbe2a09570334122960c7e63bb722f5c_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTAtOC0xLTEtMjk0NTg_500e589b-23bd-4ddf-80b1-f3814c55ffaa"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4bd35a0adb644d578ef0843d8d92e8f2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTAtMTAtMS0xLTI5NDU4_5a099ed3-8416-467d-ada2-34ab31c2297a"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i25a8adb9e6404469bce5c119cc2f7260_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTAtMTItMS0xLTI5NDU4_0fbf14ed-7db0-42cc-a416-c5b5c02bdf2f"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTAtMTQtMS0xLTI5NDU4_d0be37a8-3c50-4270-9b24-dba5295ee208"
      unitRef="usd">2832000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i172ba7c5c11849e1b3e8f93623452a80_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTEtNC0xLTEtMjk0ODE_5fa0e94c-cd2c-4223-8843-7a8b78f6c4fa"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9ab63a6a7f16414f93ebff593d6bd562_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTEtNi0xLTEtMjk0ODE_a5bcd319-6074-4ff2-866a-4da04055a851"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibbe2a09570334122960c7e63bb722f5c_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTEtOC0xLTEtMjk0ODE_5d430b02-7f65-43a5-835d-62b29b72b883"
      unitRef="usd">-24587000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4bd35a0adb644d578ef0843d8d92e8f2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTEtMTAtMS0xLTI5NDgx_b41e0717-8258-4a62-9a6d-13bb2d6a17e7"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i25a8adb9e6404469bce5c119cc2f7260_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTEtMTItMS0xLTI5NDgx_4af3d408-08ea-4835-8cd2-b54e4b3bb521"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTEtMTQtMS0xLTI5NDgx_874cfbc3-e3cc-4bda-b363-f84d17936a7a"
      unitRef="usd">-24587000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i172ba7c5c11849e1b3e8f93623452a80_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTItNC0xLTEtMjk0ODE_8c8e5fe0-cc73-48a1-81e6-4f622c7ea8f3"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9ab63a6a7f16414f93ebff593d6bd562_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTItNi0xLTEtMjk0ODE_b50b76a1-e7bc-4a48-b361-692f8391bd22"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ibbe2a09570334122960c7e63bb722f5c_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTItOC0xLTEtMjk0ODE_80d66bec-df94-4dda-9330-b74c26009614"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4bd35a0adb644d578ef0843d8d92e8f2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTItMTAtMS0xLTI5NDgx_ff7cafde-d305-4942-be2a-d75f9784c3f7"
      unitRef="usd">-113000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i25a8adb9e6404469bce5c119cc2f7260_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTItMTItMS0xLTI5NDgx_17c33181-3481-4e3e-980f-7ae7882b9649"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id7499383fea84c358f938bdc6560e4ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTItMTQtMS0xLTI5NDgx_f4de9313-7abf-4e0d-98e4-5251e66fcd22"
      unitRef="usd">-113000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic77941f6de784e4bb794c54a3abaf069_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTMtMi0xLTEtMjk0ODE_4d453c17-46c0-4a50-bc92-cae4aebbc70b"
      unitRef="shares">150114000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic77941f6de784e4bb794c54a3abaf069_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTMtNC0xLTEtMjk0ODE_dd8caf93-e168-4310-8c12-f9db3af1f5b3"
      unitRef="usd">150000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i22f4f9fb2c4b49c99b790d66a23b28ae_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTMtNi0xLTEtMjk0ODE_353d0956-30dc-4032-9162-d8bfb008fe83"
      unitRef="usd">1608730000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i46ba5caa20034a00b88a7290fc681f9a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTMtOC0xLTEtMjk0ODE_944cf5c2-1c92-4325-a02e-00be5da64f26"
      unitRef="usd">-1535839000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7d2be377b37d4ddb9010f544cecc5772_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTMtMTAtMS0xLTI5NDgx_fb95185d-9ef2-43ae-852c-b4fa13cc31e2"
      unitRef="usd">-150000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3de097a4f4c24c0083c05150f6b098a0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTMtMTItMS0xLTI5NDgx_bb79d0e3-652b-4418-9cb1-05472f4316ba"
      unitRef="usd">-2061000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yNS9mcmFnOjcxNDI3Nzc4NmNiNTQ5MWE5MzNiMTM1NTc3OTg5MjZkL3RhYmxlOjU4NjlhNzBjNDc0OTRlMzM5NTIyM2UzZTQ4MGExMzAxL3RhYmxlcmFuZ2U6NTg2OWE3MGM0NzQ5NGUzMzk1MjIzZTNlNDgwYTEzMDFfMTMtMTQtMS0xLTI5NDgx_cb948a79-c4e0-4a28-ac54-8f2ec802ff38"
      unitRef="usd">70830000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMy0yLTEtMS0yODUzMg_b6484a55-cf49-4f3a-8952-cca795c0b345"
      unitRef="usd">-48063000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMy00LTEtMS0yODUzMg_f60f4ad7-b5cf-4844-8e87-61473dca93ac"
      unitRef="usd">-39025000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfNS0yLTEtMS0yODUzMg_fe050e6e-5498-45c7-b590-a3ff2d7f172e"
      unitRef="usd">216000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfNS00LTEtMS0yODUzMg_8e80c5c6-ec73-4f5e-9caa-768de35bd7ef"
      unitRef="usd">79000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfNi0yLTEtMS0yODUzMg_697ba210-08a6-4a53-89b3-d5a10343666c"
      unitRef="usd">5604000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfNi00LTEtMS0yODUzMg_8f345aa4-4c29-448e-a8f9-f7842a57c0af"
      unitRef="usd">5637000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfNy0yLTEtMS0yODUzMg_d40977fb-7c4a-4504-bb87-c7bc56d41675"
      unitRef="usd">179000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfNy00LTEtMS0yODUzMg_1a6bc7db-3826-4cd8-a484-387a0c732e54"
      unitRef="usd">29000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfOS0yLTEtMS0yODUzMg_f3df7bbd-fb74-44d8-96d6-a0ec7bb66b01"
      unitRef="usd">20000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfOS00LTEtMS0yODUzMg_d143fbd3-aa6a-4441-91ab-1ad721e65ee0"
      unitRef="usd">-236000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTAtMi0xLTEtMjg1MzI_64dd435e-7739-4864-880a-ad689987023c"
      unitRef="usd">732000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTAtNC0xLTEtMjg1MzI_fea4eb0a-b094-45d1-83f6-2a10bf7396f0"
      unitRef="usd">-451000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTEtMi0xLTEtMjg1MzI_1e6c024d-3bb4-4a70-92aa-487782ae2169"
      unitRef="usd">-420000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTEtNC0xLTEtMjg1MzI_8277e05d-dc5b-4da1-81fe-2ea3449df11b"
      unitRef="usd">-261000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTItMi0xLTEtMjg1MzI_684400a8-9de3-4ef1-bb52-598d73dfba52"
      unitRef="usd">-5447000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTItNC0xLTEtMjg1MzI_38df5188-0f0e-4fd1-9349-ca4f3764080b"
      unitRef="usd">-14707000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTMtMi0xLTEtMjg1MzI_4b4014cb-3fcc-482c-8549-f5c722e9b906"
      unitRef="usd">-47843000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTMtNC0xLTEtMjg1MzI_52f96633-c053-4336-bd9a-8b1442e76f35"
      unitRef="usd">-47039000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTUtMi0xLTEtMjg1MzI_45636158-79a4-4488-9132-07d4b69d225f"
      unitRef="usd">76000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTUtNC0xLTEtMjg1MzI_3477eae0-bc90-4dd9-b756-24fa68aa1d12"
      unitRef="usd">985000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTYtMi0xLTEtMjg1MzI_c22a097a-17ef-4225-8c58-2782777a3286"
      unitRef="usd">40171000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTYtNC0xLTEtMjg1MzI_f12fd463-c0fb-43a4-91e4-319f4b56b3d0"
      unitRef="usd">24373000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTctMi0xLTEtMjg1MzI_8cd4d404-cabd-415e-80ed-0ec72e00746a"
      unitRef="usd">22191000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTctNC0xLTEtMjg1MzI_62a4de1c-5fe7-43af-9eb2-39a5b2a71dda"
      unitRef="usd">21772000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTgtMi0xLTEtMjg1MzI_2d60321c-6831-482d-af39-0041563ba5cc"
      unitRef="usd">-18056000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMTgtNC0xLTEtMjg1MzI_285b3683-8033-4d46-b4a9-bcbe118aa318"
      unitRef="usd">-3586000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjAtMi0xLTEtMjg1MzI_9cbf141d-898b-434f-a2b0-ab70920a5e0b"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjAtNC0xLTEtMjg1MzI_470deb30-20e7-45a8-b6c0-e134006a3650"
      unitRef="usd">16924000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjEtMi0xLTEtMjg1MzI_76cb7201-cb99-411f-aa00-e7f805fffa75"
      unitRef="usd">864000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjEtNC0xLTEtMjg1MzI_2a5a1a2e-afb5-4822-9d39-940c7b383c57"
      unitRef="usd">2675000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjItMi0xLTEtMjg1MzI_288551d0-3601-4342-80e3-ad964321eb3f"
      unitRef="usd">24148000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjItNC0xLTEtMjg1MzI_2d71bfe3-75a1-4aee-9286-4ce5d607336c"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjMtMi0xLTEtMjg1MzI_433468d7-2cfc-4775-8caa-56dec77c5d60"
      unitRef="usd">23284000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjMtNC0xLTEtMjg1MzI_f0231fa7-5815-4e7f-bf23-5018d0507839"
      unitRef="usd">14249000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjQtMi0xLTEtMjg1MzI_37ef0615-680a-4c09-a879-f92a3aa6b4f3"
      unitRef="usd">-42615000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjQtNC0xLTEtMjg1MzI_802afd89-7831-4c32-bed7-c4e0d1893934"
      unitRef="usd">-36376000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjUtMi0xLTEtMjg1MzI_f392f832-1d7d-4908-8fe9-76d02e30e44a"
      unitRef="usd">64065000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib3ab6ec7ca184c0b98f71ea5fbc23b66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjUtNC0xLTEtMjg1MzI_bddc0c6d-7b2f-4df3-bd98-e990c3f556a8"
      unitRef="usd">126263000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjYtMi0xLTEtMjg1MzI_a0ff7b43-9ece-4818-9eeb-8bbf9bc86775"
      unitRef="usd">21450000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="icdf3d3ccc7584900aada54e1568caba4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjYtNC0xLTEtMjg1MzI_cb265799-ddc1-498e-b6c7-945aa2acce77"
      unitRef="usd">89887000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InterestPaidNet
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjktMi0xLTEtMjg1MzI_2026f0cf-7324-482f-ade1-e60a676959c4"
      unitRef="usd">634000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMjktNC0xLTEtMjg1MzI_2289a7c1-d968-4f42-b94d-3a3f34cf570d"
      unitRef="usd">307000</us-gaap:InterestPaidNet>
    <lxrx:InitialRecognitionOfRightOfUseAsset
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMzItMi0xLTEtMjg1MzI_99c72670-3e31-457e-8220-757c2f561243"
      unitRef="usd">0</lxrx:InitialRecognitionOfRightOfUseAsset>
    <lxrx:InitialRecognitionOfRightOfUseAsset
      contextRef="icdf3d3ccc7584900aada54e1568caba4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMzItNC0xLTEtMjg1MzI_ce363d35-5f1d-41cb-bf49-3f272c359f5c"
      unitRef="usd">1704000</lxrx:InitialRecognitionOfRightOfUseAsset>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMzMtMi0xLTEtMjg1MzI_f60874b6-5448-478d-a3ae-11abb4b4217e"
      unitRef="usd">698</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMzMtNC0xLTEtMjg1MzI_a0accbc6-bdc1-48eb-9398-b167bdb7a386"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMzQtMi0xLTEtMjg1MzI_56bdd94e-2e74-4671-993e-8c0bd45fafa7"
      unitRef="usd">6321</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMzQtNC0xLTEtMjg1MzI_4bee89a1-9956-4140-8a96-cfd669708a6c"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:BusinessExitCosts1
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMzUtMi0xLTEtMjg1MzI_a18a288c-8588-444c-be87-65f319c81310"
      unitRef="usd">1500</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18yOC9mcmFnOjg5NDY5MDQ4NmVlNjRkZjJhNWU5OWY1NTJkYjkyMjQ3L3RhYmxlOmY1ZTNiMjZhNTIyODRhNGE4N2ZlNzQ1ZjQ5YTU0MTk3L3RhYmxlcmFuZ2U6ZjVlM2IyNmE1MjI4NGE0YTg3ZmU3NDVmNDlhNTQxOTdfMzUtNC0xLTEtMjg1MzI_30c0d94d-8b6f-4ce6-aa75-441ca16dd789"
      unitRef="usd">0</us-gaap:BusinessExitCosts1>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RleHRyZWdpb246MDU2MjlmZWEyNDI1NDkyODhjYTNlYTM4MzM5MTI0MGRfMTAxOTE_89ad0ae4-7e02-4ccb-aa88-3ca60e06a5bf">Summary of Significant Accounting Policies&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The accompanying unaudited condensed consolidated financial statements of Lexicon Pharmaceuticals, Inc. (&#x201c;Lexicon&#x201d; or the &#x201c;Company&#x201d;) have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the six-month period ended June&#160;30, 2022 are not necessarily indicative of the results that may be expected for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For further information, refer to the financial statements and footnotes thereto included in Lexicon&#x2019;s annual report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash, Cash Equivalents and Short-Term Investments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of June&#160;30, 2022 and December&#160;31, 2021, short-term investments consisted of U.S. treasury bills and corporate debt securities. The Company&#x2019;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations as they all contain maturities of less than one year.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#x2019; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued liabilities: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Accrued liabilities consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.961%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short term lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Lexicon determines if a contract is or contains a lease at inception or upon modification of the contract. A contract is or contains a lease if it conveys the right to control the use of an identified asset for a period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset. Lexicon does not apply this accounting to those leases with terms of twelve (12) months or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets and associated lease liabilities are recorded in the balance sheet at the lease commencement date based on the present value of future lease payments to be made over the expected lease term. As the implicit rate is not determinable in its leases, Lexicon used a borrowing rate of 9% at the commencement date in determining the present value of future payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performs the following five steps in determining the amount of revenue to recognize as its performance obligations under each of its contracts with customers: (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) we satisfy the performance obligation. At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those milestones are achieved.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In agreements in which a license to the Company&#x2019;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under the relevant agreement.  Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#x2019;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#x2019;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units granted to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#x2019;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#x2019;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;behaviors, resulting in a change in the assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#x2019;s stock price.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilized the Black-Scholes valuation model for estimating the fair value of the stock option compensation granted, with the following weighted-average assumptions for stock options granted in the six months ended June&#160;30, 2022 and 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Risk-free Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expected Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Dividend&lt;br/&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of stock option activity under Lexicon&#x2019;s stock-based compensation plans for the six months ended June&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(353)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2022, Lexicon granted its employees and non-employee directors annual restricted stock units. Outstanding employee restricted stock units vest in three annual installments.  Outstanding non-employee director restricted stock units vest fully on the first anniversary of the grant.  The following is a summary of restricted stock units activity under Lexicon&#x2019;s stock-based compensation plans for the six months ended June&#160;30, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;Net Loss per Common Share: Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RleHRyZWdpb246MDU2MjlmZWEyNDI1NDkyODhjYTNlYTM4MzM5MTI0MGRfMTAxNjA_8b1f30f8-3072-44ea-987b-062a3fef9892">The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RleHRyZWdpb246MDU2MjlmZWEyNDI1NDkyODhjYTNlYTM4MzM5MTI0MGRfMTAxOTM_2746736f-dc72-4ab5-95a4-8a993c933a29">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RleHRyZWdpb246MDU2MjlmZWEyNDI1NDkyODhjYTNlYTM4MzM5MTI0MGRfMTAxODA_9b0343d8-97f6-4e74-87bd-8f2b367519c0">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash, Cash Equivalents and Short-Term Investments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of June&#160;30, 2022 and December&#160;31, 2021, short-term investments consisted of U.S. treasury bills and corporate debt securities. The Company&#x2019;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations as they all contain maturities of less than one year.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#x2019; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RleHRyZWdpb246MDU2MjlmZWEyNDI1NDkyODhjYTNlYTM4MzM5MTI0MGRfMTAxNjI_5aaa2198-5786-485b-b322-a1de5a46274f">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued liabilities: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Accrued liabilities consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.961%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short term lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <lxrx:AccruedResearchAndDevelopmentServicesCurrent
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmYxYjZhNjEwYjJlNzRiYjNiZTY5NDI5MmJjZmY4MjVhL3RhYmxlcmFuZ2U6ZjFiNmE2MTBiMmU3NGJiM2JlNjk0MjkyYmNmZjgyNWFfMy0yLTEtMS0yODUzMg_40926279-2c2d-44c7-86ab-ebff8ba5b9f1"
      unitRef="usd">3920000</lxrx:AccruedResearchAndDevelopmentServicesCurrent>
    <lxrx:AccruedResearchAndDevelopmentServicesCurrent
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmYxYjZhNjEwYjJlNzRiYjNiZTY5NDI5MmJjZmY4MjVhL3RhYmxlcmFuZ2U6ZjFiNmE2MTBiMmU3NGJiM2JlNjk0MjkyYmNmZjgyNWFfMy00LTEtMS0yODUzMg_f7658add-daed-4e6f-b6a7-22d107d0db94"
      unitRef="usd">3669000</lxrx:AccruedResearchAndDevelopmentServicesCurrent>
    <lxrx:AccruedCompensationAndBenefitsCurrent
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmYxYjZhNjEwYjJlNzRiYjNiZTY5NDI5MmJjZmY4MjVhL3RhYmxlcmFuZ2U6ZjFiNmE2MTBiMmU3NGJiM2JlNjk0MjkyYmNmZjgyNWFfNC0yLTEtMS0yODUzMg_b3417b73-d68b-4445-944c-39f9e1506754"
      unitRef="usd">4329000</lxrx:AccruedCompensationAndBenefitsCurrent>
    <lxrx:AccruedCompensationAndBenefitsCurrent
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmYxYjZhNjEwYjJlNzRiYjNiZTY5NDI5MmJjZmY4MjVhL3RhYmxlcmFuZ2U6ZjFiNmE2MTBiMmU3NGJiM2JlNjk0MjkyYmNmZjgyNWFfNC00LTEtMS0yODUzMg_ace6c056-2b26-4d3c-a483-30d840aeb463"
      unitRef="usd">5711000</lxrx:AccruedCompensationAndBenefitsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmYxYjZhNjEwYjJlNzRiYjNiZTY5NDI5MmJjZmY4MjVhL3RhYmxlcmFuZ2U6ZjFiNmE2MTBiMmU3NGJiM2JlNjk0MjkyYmNmZjgyNWFfNS0yLTEtMS0yODUzMg_72c8a61c-9243-4121-84c2-ce0e6e7beda0"
      unitRef="usd">789000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmYxYjZhNjEwYjJlNzRiYjNiZTY5NDI5MmJjZmY4MjVhL3RhYmxlcmFuZ2U6ZjFiNmE2MTBiMmU3NGJiM2JlNjk0MjkyYmNmZjgyNWFfNS00LTEtMS0yODUzMg_8448a7f3-41af-48c3-b8a0-3dcb6bf0fbee"
      unitRef="usd">1089000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmYxYjZhNjEwYjJlNzRiYjNiZTY5NDI5MmJjZmY4MjVhL3RhYmxlcmFuZ2U6ZjFiNmE2MTBiMmU3NGJiM2JlNjk0MjkyYmNmZjgyNWFfNi0yLTEtMS0yODUzMg_4ecba26f-61ed-4642-ba63-f46e8948a3ef"
      unitRef="usd">477000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmYxYjZhNjEwYjJlNzRiYjNiZTY5NDI5MmJjZmY4MjVhL3RhYmxlcmFuZ2U6ZjFiNmE2MTBiMmU3NGJiM2JlNjk0MjkyYmNmZjgyNWFfNi00LTEtMS0yODUzMg_69a57b98-f8ff-4906-bbe6-8161880aef85"
      unitRef="usd">2503000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmYxYjZhNjEwYjJlNzRiYjNiZTY5NDI5MmJjZmY4MjVhL3RhYmxlcmFuZ2U6ZjFiNmE2MTBiMmU3NGJiM2JlNjk0MjkyYmNmZjgyNWFfNy0yLTEtMS0yODUzMg_a3ce92c1-452e-4458-be7e-13f6fa4eef6a"
      unitRef="usd">9515000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmYxYjZhNjEwYjJlNzRiYjNiZTY5NDI5MmJjZmY4MjVhL3RhYmxlcmFuZ2U6ZjFiNmE2MTBiMmU3NGJiM2JlNjk0MjkyYmNmZjgyNWFfNy00LTEtMS0yODUzMg_76af3003-6c29-4d9e-ab52-96439b8ffa36"
      unitRef="usd">12972000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RleHRyZWdpb246MDU2MjlmZWEyNDI1NDkyODhjYTNlYTM4MzM5MTI0MGRfMTAxNzg_6dec981b-b965-4806-821d-e5fe150bf6fc">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Lexicon determines if a contract is or contains a lease at inception or upon modification of the contract. A contract is or contains a lease if it conveys the right to control the use of an identified asset for a period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset. Lexicon does not apply this accounting to those leases with terms of twelve (12) months or less.&lt;/span&gt;Operating lease right-of-use assets and associated lease liabilities are recorded in the balance sheet at the lease commencement date based on the present value of future lease payments to be made over the expected lease term. As the implicit rate is not determinable in its leases, Lexicon used a borrowing rate of 9% at the commencement date in determining the present value of future payments.</us-gaap:RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock>
    <lxrx:LexiconIncrementalBorrowingRate
      contextRef="i152ac39e5811437cb0ee3de3ef7041ea_I20210301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RleHRyZWdpb246MDU2MjlmZWEyNDI1NDkyODhjYTNlYTM4MzM5MTI0MGRfMTAxODI_2d18eb22-a010-46c6-9903-eb0f0e5e402a"
      unitRef="number">9</lxrx:LexiconIncrementalBorrowingRate>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RleHRyZWdpb246MDU2MjlmZWEyNDI1NDkyODhjYTNlYTM4MzM5MTI0MGRfMTAxNzU_7d83284e-1ab6-43ff-9102-841bbf58826b">&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performs the following five steps in determining the amount of revenue to recognize as its performance obligations under each of its contracts with customers: (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) we satisfy the performance obligation. At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those milestones are achieved.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In agreements in which a license to the Company&#x2019;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  &lt;/span&gt;&lt;/div&gt;The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under the relevant agreement.  Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional.</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RleHRyZWdpb246MDU2MjlmZWEyNDI1NDkyODhjYTNlYTM4MzM5MTI0MGRfMTAxOTQ_78677fde-5995-41b1-a5a1-f66bdae6921c">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#x2019;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#x2019;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.&lt;/span&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RleHRyZWdpb246MDU2MjlmZWEyNDI1NDkyODhjYTNlYTM4MzM5MTI0MGRfMTAxNDk_5a9c5da5-2e9e-47e6-9fa2-7b7ad7db32eb">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units granted to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#x2019;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#x2019;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination &lt;/span&gt;&lt;/div&gt;behaviors, resulting in a change in the assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#x2019;s stock price.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RleHRyZWdpb246MDU2MjlmZWEyNDI1NDkyODhjYTNlYTM4MzM5MTI0MGRfMTAxODc_f53baedb-5481-4efd-bd40-779ed6836f3a">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Risk-free Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expected Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Dividend&lt;br/&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees
      contextRef="if8c71021eb1240e190c19cb072abf3f6_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfMi0yLTEtMS0yODUzMg_01b31b23-576d-4468-ac98-9369228d777d"
      unitRef="number">1.06</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee
      contextRef="if8c71021eb1240e190c19cb072abf3f6_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfMi00LTEtMS0yODUzMg_097751ff-d949-4dd6-be03-970156e0d6ae"
      unitRef="number">0.021</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees
      contextRef="if8c71021eb1240e190c19cb072abf3f6_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfMi02LTEtMS0yODUzMg_d6ee7195-caf3-46f3-a3ec-65853e37b9ee">P4Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees
      contextRef="if8c71021eb1240e190c19cb072abf3f6_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfMi04LTEtMS0yODUzMg_58266e39-2191-4976-8837-6975d1ccbd39"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors
      contextRef="if8c71021eb1240e190c19cb072abf3f6_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfMy0yLTEtMS0yODUzMg_192571af-24e3-4953-8eca-1bb3def8ee64"
      unitRef="number">0.91</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors
      contextRef="if8c71021eb1240e190c19cb072abf3f6_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfMy00LTEtMS0yODUzMg_55461a53-2b29-4f16-9855-906bf578f3e0"
      unitRef="number">0.019</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors
      contextRef="if8c71021eb1240e190c19cb072abf3f6_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfMy02LTEtMS0yODUzMg_8a01a6ad-e0e2-4feb-85c2-27704cbf3387">P7Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors
      contextRef="if8c71021eb1240e190c19cb072abf3f6_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfMy04LTEtMS0yODUzMg_ecc5f6f1-27de-4075-b647-69534cdf3b7c"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees
      contextRef="i8144b5bc25dd4902831fa92228fd7f51_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfNS0yLTEtMS0yODUzMg_197bc3b6-5a93-4216-93e2-12b36014b237"
      unitRef="number">1.01</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee
      contextRef="i8144b5bc25dd4902831fa92228fd7f51_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfNS00LTEtMS0yODUzMg_59357a61-de9c-4737-9792-89dad05a67a7"
      unitRef="number">0.006</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees
      contextRef="i8144b5bc25dd4902831fa92228fd7f51_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfNS02LTEtMS0yODUzMg_36778f28-877f-4709-8309-80e54668971a">P4Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees
      contextRef="i8144b5bc25dd4902831fa92228fd7f51_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfNS04LTEtMS0yODUzMg_766d9f31-1710-4daf-9713-5a0fafd24d95"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors
      contextRef="i8144b5bc25dd4902831fa92228fd7f51_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfNi0yLTEtMS0yODUzMg_0eaaa8b3-400f-40e5-ab17-12f1ea3c6ed3"
      unitRef="number">0.90</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors
      contextRef="i8144b5bc25dd4902831fa92228fd7f51_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfNi00LTEtMS0yODUzMg_e70ea4e2-87db-4b0e-b72c-7ac0489f8e75"
      unitRef="number">0.011</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors
      contextRef="i8144b5bc25dd4902831fa92228fd7f51_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfNi02LTEtMS0yODUzMg_465e39bd-7385-4db7-aabc-b76aca4c9566">P7Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors
      contextRef="i8144b5bc25dd4902831fa92228fd7f51_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmM0NjA3MjliMjQ1OTRlOGRhNGZlZjY1Y2QzZTFhMWIxL3RhYmxlcmFuZ2U6YzQ2MDcyOWIyNDU5NGU4ZGE0ZmVmNjVjZDNlMWExYjFfNi04LTEtMS0yODUzMg_fb2a88cd-e27c-4f2c-9198-8a22fb931238"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RleHRyZWdpb246MDU2MjlmZWEyNDI1NDkyODhjYTNlYTM4MzM5MTI0MGRfMTAxNjU_32da5f2b-e043-49af-a176-9fa7e8f9ec64">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(353)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7be8ac7d31ef4e4f9fdbd039f264c959_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOjhmM2Y1MWRkZWVkYjQxYTg4ZGU5OWExNmQ5ZTM5MjI4L3RhYmxlcmFuZ2U6OGYzZjUxZGRlZWRiNDFhODhkZTk5YTE2ZDllMzkyMjhfMi0yLTEtMS0yODUzMg_c40c72c6-73b6-4efd-b25b-67f5c990684b"
      unitRef="shares">8367000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i7be8ac7d31ef4e4f9fdbd039f264c959_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOjhmM2Y1MWRkZWVkYjQxYTg4ZGU5OWExNmQ5ZTM5MjI4L3RhYmxlcmFuZ2U6OGYzZjUxZGRlZWRiNDFhODhkZTk5YTE2ZDllMzkyMjhfMi00LTEtMS0yODUzMg_d020b281-a9f0-4b51-b0bb-c08185bb9e6f"
      unitRef="usdPerShare">6.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="iff0b3ea9ca3c45e1b81425040542255e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOjhmM2Y1MWRkZWVkYjQxYTg4ZGU5OWExNmQ5ZTM5MjI4L3RhYmxlcmFuZ2U6OGYzZjUxZGRlZWRiNDFhODhkZTk5YTE2ZDllMzkyMjhfMy0yLTEtMS0yODUzMg_079d3ae6-0fc9-4126-a48a-e40ca85e4a27"
      unitRef="shares">4257000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="iff0b3ea9ca3c45e1b81425040542255e_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOjhmM2Y1MWRkZWVkYjQxYTg4ZGU5OWExNmQ5ZTM5MjI4L3RhYmxlcmFuZ2U6OGYzZjUxZGRlZWRiNDFhODhkZTk5YTE2ZDllMzkyMjhfMy00LTEtMS0yODUzMg_76cf5a5f-c093-4a29-abc9-9fa4370a675c"
      unitRef="usdPerShare">3.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="iff0b3ea9ca3c45e1b81425040542255e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOjhmM2Y1MWRkZWVkYjQxYTg4ZGU5OWExNmQ5ZTM5MjI4L3RhYmxlcmFuZ2U6OGYzZjUxZGRlZWRiNDFhODhkZTk5YTE2ZDllMzkyMjhfNS0yLTEtMS0yODUzMg_5867cae8-1d68-4cc2-84d4-877ca70f5654"
      unitRef="shares">163000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="iff0b3ea9ca3c45e1b81425040542255e_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOjhmM2Y1MWRkZWVkYjQxYTg4ZGU5OWExNmQ5ZTM5MjI4L3RhYmxlcmFuZ2U6OGYzZjUxZGRlZWRiNDFhODhkZTk5YTE2ZDllMzkyMjhfNS00LTEtMS0yODUzMg_27295cec-bb54-480c-9979-c463f39c6ade"
      unitRef="usdPerShare">12.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="iff0b3ea9ca3c45e1b81425040542255e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOjhmM2Y1MWRkZWVkYjQxYTg4ZGU5OWExNmQ5ZTM5MjI4L3RhYmxlcmFuZ2U6OGYzZjUxZGRlZWRiNDFhODhkZTk5YTE2ZDllMzkyMjhfNi0yLTEtMS0yODUzMg_ef7f78b1-dc1d-47fc-bc13-d8f56f964e34"
      unitRef="shares">353000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="iff0b3ea9ca3c45e1b81425040542255e_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOjhmM2Y1MWRkZWVkYjQxYTg4ZGU5OWExNmQ5ZTM5MjI4L3RhYmxlcmFuZ2U6OGYzZjUxZGRlZWRiNDFhODhkZTk5YTE2ZDllMzkyMjhfNi00LTEtMS0yODUzMg_6a500511-a903-48d8-b844-64aadf9292f3"
      unitRef="usdPerShare">9.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i32d0edfce10547eaa9f6a4a37c3c0e9e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOjhmM2Y1MWRkZWVkYjQxYTg4ZGU5OWExNmQ5ZTM5MjI4L3RhYmxlcmFuZ2U6OGYzZjUxZGRlZWRiNDFhODhkZTk5YTE2ZDllMzkyMjhfNy0yLTEtMS0yODUzMg_1af71e72-cb0b-4d84-a219-7780131a2800"
      unitRef="shares">12108000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i32d0edfce10547eaa9f6a4a37c3c0e9e_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOjhmM2Y1MWRkZWVkYjQxYTg4ZGU5OWExNmQ5ZTM5MjI4L3RhYmxlcmFuZ2U6OGYzZjUxZGRlZWRiNDFhODhkZTk5YTE2ZDllMzkyMjhfNy00LTEtMS0yODUzMg_6b50e21d-099b-43c3-8116-f1ab8bcc71f9"
      unitRef="usdPerShare">5.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i32d0edfce10547eaa9f6a4a37c3c0e9e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOjhmM2Y1MWRkZWVkYjQxYTg4ZGU5OWExNmQ5ZTM5MjI4L3RhYmxlcmFuZ2U6OGYzZjUxZGRlZWRiNDFhODhkZTk5YTE2ZDllMzkyMjhfOC0yLTEtMS0yODUzMg_eca58980-7fa9-457a-9d92-0a92bb7cea32"
      unitRef="shares">5423000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i32d0edfce10547eaa9f6a4a37c3c0e9e_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOjhmM2Y1MWRkZWVkYjQxYTg4ZGU5OWExNmQ5ZTM5MjI4L3RhYmxlcmFuZ2U6OGYzZjUxZGRlZWRiNDFhODhkZTk5YTE2ZDllMzkyMjhfOC00LTEtMS0yODUzMg_a8fc159f-51f3-45cc-972f-8f471382ba60"
      unitRef="usdPerShare">7.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RleHRyZWdpb246MDU2MjlmZWEyNDI1NDkyODhjYTNlYTM4MzM5MTI0MGRfMTAxODg_1fa38e76-7797-4b81-bad4-dbfc909910d7">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id14ea6e6ad9241c2a3f636b30639bd35_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmMzYTYzOTI1NjUxYzQzYzNhY2UzZjc3MjBjOWE4ZjdmL3RhYmxlcmFuZ2U6YzNhNjM5MjU2NTFjNDNjM2FjZTNmNzcyMGM5YThmN2ZfMi0yLTEtMS0yODUzMg_cd2f1860-a6f5-40a3-ac9c-0b992d485aac"
      unitRef="shares">1854000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="id14ea6e6ad9241c2a3f636b30639bd35_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmMzYTYzOTI1NjUxYzQzYzNhY2UzZjc3MjBjOWE4ZjdmL3RhYmxlcmFuZ2U6YzNhNjM5MjU2NTFjNDNjM2FjZTNmNzcyMGM5YThmN2ZfMi00LTEtMS0yODUzMg_3443e28c-5a11-422d-b931-523244976a40"
      unitRef="usdPerShare">5.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ib6ff6b135bf9430bb09afc4a228eb9cd_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmMzYTYzOTI1NjUxYzQzYzNhY2UzZjc3MjBjOWE4ZjdmL3RhYmxlcmFuZ2U6YzNhNjM5MjU2NTFjNDNjM2FjZTNmNzcyMGM5YThmN2ZfMy0yLTEtMS0yODUzMg_7eb31d19-27d1-4595-a5e6-96180b8bdda6"
      unitRef="shares">2185000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib6ff6b135bf9430bb09afc4a228eb9cd_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmMzYTYzOTI1NjUxYzQzYzNhY2UzZjc3MjBjOWE4ZjdmL3RhYmxlcmFuZ2U6YzNhNjM5MjU2NTFjNDNjM2FjZTNmNzcyMGM5YThmN2ZfMy00LTEtMS0yODUzMg_0f2d2aed-52de-4cac-ac92-ddbfc92fa066"
      unitRef="usdPerShare">2.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ib6ff6b135bf9430bb09afc4a228eb9cd_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmMzYTYzOTI1NjUxYzQzYzNhY2UzZjc3MjBjOWE4ZjdmL3RhYmxlcmFuZ2U6YzNhNjM5MjU2NTFjNDNjM2FjZTNmNzcyMGM5YThmN2ZfNC0yLTEtMS0yODUzMg_95b434a6-a0d6-4b30-b9d1-b9ea132f3c76"
      unitRef="shares">1012000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib6ff6b135bf9430bb09afc4a228eb9cd_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmMzYTYzOTI1NjUxYzQzYzNhY2UzZjc3MjBjOWE4ZjdmL3RhYmxlcmFuZ2U6YzNhNjM5MjU2NTFjNDNjM2FjZTNmNzcyMGM5YThmN2ZfNC00LTEtMS0yODUzMg_fb383c11-9190-456e-85b6-ffd9586e293d"
      unitRef="usdPerShare">4.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ib6ff6b135bf9430bb09afc4a228eb9cd_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmMzYTYzOTI1NjUxYzQzYzNhY2UzZjc3MjBjOWE4ZjdmL3RhYmxlcmFuZ2U6YzNhNjM5MjU2NTFjNDNjM2FjZTNmNzcyMGM5YThmN2ZfNS0yLTEtMS0yODUzMg_f85aaedf-2880-4519-aed1-fd39e7709452"
      unitRef="shares">108000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ib6ff6b135bf9430bb09afc4a228eb9cd_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmMzYTYzOTI1NjUxYzQzYzNhY2UzZjc3MjBjOWE4ZjdmL3RhYmxlcmFuZ2U6YzNhNjM5MjU2NTFjNDNjM2FjZTNmNzcyMGM5YThmN2ZfNS00LTEtMS0yODUzMg_0c631cb6-52a0-4902-9a5f-3c5207a58682"
      unitRef="usdPerShare">3.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="if0e56591afc54f4ebeb3c8aa3ab4fbe1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmMzYTYzOTI1NjUxYzQzYzNhY2UzZjc3MjBjOWE4ZjdmL3RhYmxlcmFuZ2U6YzNhNjM5MjU2NTFjNDNjM2FjZTNmNzcyMGM5YThmN2ZfNi0yLTEtMS0yODUzMg_ebfbfd13-01cc-46cb-bd6c-8416306d9ebf"
      unitRef="shares">2919000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="if0e56591afc54f4ebeb3c8aa3ab4fbe1_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RhYmxlOmMzYTYzOTI1NjUxYzQzYzNhY2UzZjc3MjBjOWE4ZjdmL3RhYmxlcmFuZ2U6YzNhNjM5MjU2NTFjNDNjM2FjZTNmNzcyMGM5YThmN2ZfNi00LTEtMS0yODUzMg_d8fa5a7b-2039-456b-a702-1b0de2d347de"
      unitRef="usdPerShare">3.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNC9mcmFnOjA1NjI5ZmVhMjQyNTQ5Mjg4Y2EzZWEzODMzOTEyNDBkL3RleHRyZWdpb246MDU2MjlmZWEyNDI1NDkyODhjYTNlYTM4MzM5MTI0MGRfMTAxOTA_a38c26da-1f15-4a20-b92f-63402adbf204">Net Loss per Common Share: Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY18zNy9mcmFnOjY0NDI4ZWZmOTU5ZjQzNDFiMjg3MjM0OTdhMzhjY2IwL3RleHRyZWdpb246NjQ0MjhlZmY5NTlmNDM0MWIyODcyMzQ5N2EzOGNjYjBfMTQ1OA_5240a1b7-9ff3-4194-89ea-bf199dbcc386">Recent Accounting Pronouncements&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2019-12, Income Taxes (Topic 740) Simplifying Accounting for Income Taxes, as part of its initiative to reduce complexity in the accounting standards. The guidance amended certain disclosure requirements that had become redundant, outdated or superseded. Additionally, this guidance amends accounting for the interim period effects of changes in tax laws or rates, and simplifies aspects of the accounting for franchise taxes. The guidance is effective for annual periods beginning after December 15, 2020, including interim periods therein. The adoption of ASU 2019-12 in the first quarter of 2021 did not have a material impact on the condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40), which removes the separation models for convertible debt with cash conversion or beneficial conversion features. ASU 2020-06 also requires the application of the if-converted method for calculating earnings per diluted share, as the treasury stock method will no longer be permitted for convertible instruments. The adoption of ASU 2020-06 during the first quarter of 2022 did not have a material impact on the condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RleHRyZWdpb246NDkyMWQyNGY1NjM3NDE3NDliNDIyMDY2YmI4ZjA3MTlfMzM5_d8f8faf3-24e8-45d6-9a13-d75dd813459b">Cash and Cash Equivalents and Investments&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of cash and cash equivalents and investments held at June&#160;30, 2022 and December&#160;31, 2021 are as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no realized losses during either of the six months ended June&#160;30, 2022 and 2021, respectively.  The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RleHRyZWdpb246NDkyMWQyNGY1NjM3NDE3NDliNDIyMDY2YmI4ZjA3MTlfMzM1_b7a300f4-0650-4d37-b7ea-534287c1a3bc">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i8a2a8f5d314144a884fb86491fc334b7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMy0yLTEtMS0yODUzMg_2cd73880-ed6f-4479-8e16-8126d1cd2e07"
      unitRef="usd">21450000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8a2a8f5d314144a884fb86491fc334b7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMy00LTEtMS0yODUzMg_d1d8011f-bb84-4b89-86ba-f423144a03fd"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8a2a8f5d314144a884fb86491fc334b7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMy02LTEtMS0yODUzMg_8762c165-00ba-44a0-bfac-d5a4171267a1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8a2a8f5d314144a884fb86491fc334b7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMy04LTEtMS0yODUzMg_4c23bfa3-d085-4ab8-8724-a92782c9b43c"
      unitRef="usd">21450000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i310d9b9a89454544b9e9d7c6399db39a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfNS0yLTEtMS0yODUzMg_e2300cc3-79d7-4655-86dc-35ef3b7620fe"
      unitRef="usd">30419000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i310d9b9a89454544b9e9d7c6399db39a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfNS00LTEtMS0yODUzMg_0af30178-219a-4efc-88c6-48cd4c8e1f30"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i310d9b9a89454544b9e9d7c6399db39a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfNS02LTEtMS0yODUzMg_4bc08765-45fb-42f8-abed-fe8233d1ad21"
      unitRef="usd">89000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i310d9b9a89454544b9e9d7c6399db39a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfNS04LTEtMS0yODUzMg_5df22a9c-7ec3-4b99-8bdd-b5522cb20150"
      unitRef="usd">30330000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ib2834e4b26174a4a8a9f1d26de96cce2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfNi0yLTEtMS0yODUzMg_c5a5feac-fc85-4cf1-9803-5c2a08ef342f"
      unitRef="usd">10249000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib2834e4b26174a4a8a9f1d26de96cce2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfNi00LTEtMS0yODUzMg_9241a012-d0cc-4c51-a98a-d79d7d27b0d0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib2834e4b26174a4a8a9f1d26de96cce2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfNi02LTEtMS0yODUzMg_ad48d469-823e-437d-8810-0f4fc2965681"
      unitRef="usd">61000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib2834e4b26174a4a8a9f1d26de96cce2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfNi04LTEtMS0yODUzMg_c40ec321-e216-4e7d-bee1-23b0dd393f37"
      unitRef="usd">10188000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i6bf59d25162d4274b7c672eb48a47901_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfNy0yLTEtMS0yODUzMg_55c2b97d-7e39-40f5-9db7-eee0cf6a619a"
      unitRef="usd">40668000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6bf59d25162d4274b7c672eb48a47901_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfNy00LTEtMS0yODUzMg_1e248aa4-6855-4706-a7fd-fe2f2a76518a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6bf59d25162d4274b7c672eb48a47901_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfNy02LTEtMS0yODUzMg_37f286ab-5812-40d6-9227-e94c4f85625f"
      unitRef="usd">150000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6bf59d25162d4274b7c672eb48a47901_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfNy04LTEtMS0yODUzMg_2226c6e5-b914-4690-981b-16d3238e078b"
      unitRef="usd">40518000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ib76a1e00d0be407f9aad476b9558aa02_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfOC0yLTEtMS0yODUzMg_7a72ee2b-f993-4d1c-9fd9-286031f8dbc6"
      unitRef="usd">62118000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib76a1e00d0be407f9aad476b9558aa02_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfOC00LTEtMS0yODUzMg_87197e92-ddc5-445a-a402-6c1dc623979b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib76a1e00d0be407f9aad476b9558aa02_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfOC02LTEtMS0yODUzMg_bc54aca8-f299-4d3b-b2c6-43a823f73031"
      unitRef="usd">150000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib76a1e00d0be407f9aad476b9558aa02_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfOC04LTEtMS0yODUzMg_e8c47230-5258-4bb6-85d4-8a60fa4db7ed"
      unitRef="usd">61968000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i537aa7da0127497a9ab35f8f1601120c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTMtMi0xLTEtMjg1MzI_a5aa0102-2f64-463c-9d6e-0885d3a067d4"
      unitRef="usd">64066000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i537aa7da0127497a9ab35f8f1601120c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTMtNC0xLTEtMjg1MzI_6b803c69-5d10-49a6-9f10-ecfdc0702a9f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i537aa7da0127497a9ab35f8f1601120c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTMtNi0xLTEtMjg1MzI_d4917b33-cca3-46a2-89c1-5db3628a9d64"
      unitRef="usd">1000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i537aa7da0127497a9ab35f8f1601120c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTMtOC0xLTEtMjg1MzI_ab22538c-0eee-43d3-b170-c8cdc5a54d91"
      unitRef="usd">64065000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i8a1de474406c4d5ca2bd60c12dcee520_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTUtMi0xLTEtMjg1MzI_b29b9bd0-1612-48de-b978-1e3aa8e0f2d6"
      unitRef="usd">7562000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8a1de474406c4d5ca2bd60c12dcee520_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTUtNC0xLTEtMjg1MzI_26462da1-50af-444a-8a59-22ac9d0b7f4b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8a1de474406c4d5ca2bd60c12dcee520_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTUtNi0xLTEtMjg1MzI_c667c6df-8022-4b12-860a-d632eaff7614"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i8a1de474406c4d5ca2bd60c12dcee520_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTUtOC0xLTEtMjg1MzI_f23fc81d-ef27-4743-ba6f-002eacdcbeeb"
      unitRef="usd">7561000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ia5d0942946ce4b92a48bd388374cd857_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTYtMi0xLTEtMjg1MzI_492e245d-c84c-47cc-9f6e-6ad8e9b6a2fa"
      unitRef="usd">15125000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia5d0942946ce4b92a48bd388374cd857_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTYtNC0xLTEtMjg1MzI_859aada4-4057-4d57-a5fb-7dd61d597205"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia5d0942946ce4b92a48bd388374cd857_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTYtNi0xLTEtMjg1MzI_93cba72b-9ab7-4849-874f-42d44349561a"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="ia5d0942946ce4b92a48bd388374cd857_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTYtOC0xLTEtMjg1MzI_2f09cdfa-90f1-412f-9e82-b7846c1fcf82"
      unitRef="usd">15117000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="iab52133a24a345c2b5b462deff22d656_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTctMi0xLTEtMjg1MzI_fbb3f3e0-1d48-40f2-8171-d57fd3aa0c9a"
      unitRef="usd">22687000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iab52133a24a345c2b5b462deff22d656_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTctNC0xLTEtMjg1MzI_84f0e150-d6b4-4e83-bfed-4094fbb65652"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iab52133a24a345c2b5b462deff22d656_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTctNi0xLTEtMjg1MzI_bd7378d2-d9e8-4b49-ba1e-4fc886138e3e"
      unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iab52133a24a345c2b5b462deff22d656_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTctOC0xLTEtMjg1MzI_4ae4f56a-efa1-485f-b7f2-2c4d9bf92b87"
      unitRef="usd">22678000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ie2d670c1a5724338a60501f42187b7e0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTgtMi0xLTEtMjg1MzI_972f849b-cbf2-4841-8846-66e75131b2ae"
      unitRef="usd">86753000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie2d670c1a5724338a60501f42187b7e0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTgtNC0xLTEtMjg1MzI_9064268f-45fe-4f33-a63d-5d0c9aa52261"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie2d670c1a5724338a60501f42187b7e0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTgtNi0xLTEtMjg1MzI_10dc8565-3d9b-45b3-be40-25a9f6d70069"
      unitRef="usd">10000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="ie2d670c1a5724338a60501f42187b7e0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RhYmxlOmEyNWU5ZGY4ZGQ5YzQ1ZDI5M2M2ZmU1MGRjNTFhOTRhL3RhYmxlcmFuZ2U6YTI1ZTlkZjhkZDljNDVkMjkzYzZmZTUwZGM1MWE5NGFfMTgtOC0xLTEtMjg1MzI_2bc50af0-a90b-475e-afa0-f15ac14d8eb6"
      unitRef="usd">86743000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i219835b855164c3eb8447d1975735bec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RleHRyZWdpb246NDkyMWQyNGY1NjM3NDE3NDliNDIyMDY2YmI4ZjA3MTlfMTcw_9b27b9d9-56e3-4e8c-a13e-39f03daa436f"
      unitRef="usd">0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180MC9mcmFnOjQ5MjFkMjRmNTYzNzQxNzQ5YjQyMjA2NmJiOGYwNzE5L3RleHRyZWdpb246NDkyMWQyNGY1NjM3NDE3NDliNDIyMDY2YmI4ZjA3MTlfMTcw_cfbec8e5-077c-4b1f-af75-227354fb2faa"
      unitRef="usd">0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RleHRyZWdpb246M2ZjOGM2YzBhZjExNGFiYTkzNmM1ZWY5OTAyZDQ2ZmZfMTU3Ng_f89cd076-436f-45d7-8194-088489f18d40">Fair Value Measurements&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.  Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.  The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - quoted prices in active markets for identical investments, which include U.S. treasury securities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which includes corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - significant unobservable inputs &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.  The following table provides the fair value measurements of applicable Company assets that are measured at fair value on a recurring basis according to the fair value levels defined above as of June&#160;30, 2022 and December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets and Liabilities at Fair Value as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets and Liabilities at Fair Value as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have any Level 3 assets or liabilities as of June&#160;30, 2022 or December&#160;31, 2021. Transfers between levels are recognized at the actual date of the circumstance that caused the transfer.  There were no transfers between Level 1 and Level 2 during the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 5, Debt Obligations, for fair value measurements of debt obligations.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RleHRyZWdpb246M2ZjOGM2YzBhZjExNGFiYTkzNmM1ZWY5OTAyZDQ2ZmZfMTU2NQ_c81d5415-c898-4490-ab4e-0bd5b969f9bf">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets and Liabilities at Fair Value as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets and Liabilities at Fair Value as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i082b646328b744be992ad3f152baee86_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjRjZjQ3YTQ3ZmM0NTQwY2JiMzVmZGU3ZTM1YjhiMTExL3RhYmxlcmFuZ2U6NGNmNDdhNDdmYzQ1NDBjYmIzNWZkZTdlMzViOGIxMTFfNC0yLTEtMS0yODUzMg_9aa323cb-f858-43c5-8dfb-709cbfb9c08b"
      unitRef="usd">21450000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ieb00505b86b4445ea664e50b7f30071c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjRjZjQ3YTQ3ZmM0NTQwY2JiMzVmZGU3ZTM1YjhiMTExL3RhYmxlcmFuZ2U6NGNmNDdhNDdmYzQ1NDBjYmIzNWZkZTdlMzViOGIxMTFfNC00LTEtMS0yODUzMg_441005ff-0ed1-4c95-be6a-1e3aa17b24c8"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5a860a8253cc468dab9782964e9008d2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjRjZjQ3YTQ3ZmM0NTQwY2JiMzVmZGU3ZTM1YjhiMTExL3RhYmxlcmFuZ2U6NGNmNDdhNDdmYzQ1NDBjYmIzNWZkZTdlMzViOGIxMTFfNC02LTEtMS0yODUzMg_47e69394-890b-4fd8-a4a1-e5f99ea1deb9"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjRjZjQ3YTQ3ZmM0NTQwY2JiMzVmZGU3ZTM1YjhiMTExL3RhYmxlcmFuZ2U6NGNmNDdhNDdmYzQ1NDBjYmIzNWZkZTdlMzViOGIxMTFfNC04LTEtMS0yODUzMg_39a1896c-20b5-4c6b-9770-1f6eb9570354"
      unitRef="usd">21450000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i082b646328b744be992ad3f152baee86_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjRjZjQ3YTQ3ZmM0NTQwY2JiMzVmZGU3ZTM1YjhiMTExL3RhYmxlcmFuZ2U6NGNmNDdhNDdmYzQ1NDBjYmIzNWZkZTdlMzViOGIxMTFfNS0yLTEtMS0yODUzMg_cef3d6bf-95f1-40a0-8c02-b378fdbadc75"
      unitRef="usd">30330000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ieb00505b86b4445ea664e50b7f30071c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjRjZjQ3YTQ3ZmM0NTQwY2JiMzVmZGU3ZTM1YjhiMTExL3RhYmxlcmFuZ2U6NGNmNDdhNDdmYzQ1NDBjYmIzNWZkZTdlMzViOGIxMTFfNS00LTEtMS0yODUzMg_402f076b-f93c-4691-94d1-2ed09429b55f"
      unitRef="usd">10188000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5a860a8253cc468dab9782964e9008d2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjRjZjQ3YTQ3ZmM0NTQwY2JiMzVmZGU3ZTM1YjhiMTExL3RhYmxlcmFuZ2U6NGNmNDdhNDdmYzQ1NDBjYmIzNWZkZTdlMzViOGIxMTFfNS02LTEtMS0yODUzMg_b5f62a3f-a47d-49f9-b9d5-9006ae3cca98"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjRjZjQ3YTQ3ZmM0NTQwY2JiMzVmZGU3ZTM1YjhiMTExL3RhYmxlcmFuZ2U6NGNmNDdhNDdmYzQ1NDBjYmIzNWZkZTdlMzViOGIxMTFfNS04LTEtMS0yODUzMg_8fa9cce8-a6dd-4d97-9451-74763d1231a8"
      unitRef="usd">40518000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i082b646328b744be992ad3f152baee86_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjRjZjQ3YTQ3ZmM0NTQwY2JiMzVmZGU3ZTM1YjhiMTExL3RhYmxlcmFuZ2U6NGNmNDdhNDdmYzQ1NDBjYmIzNWZkZTdlMzViOGIxMTFfNi0yLTEtMS0yODUzMg_6127bd4c-98cd-473b-99bd-9421226e4fd0"
      unitRef="usd">51780000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ieb00505b86b4445ea664e50b7f30071c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjRjZjQ3YTQ3ZmM0NTQwY2JiMzVmZGU3ZTM1YjhiMTExL3RhYmxlcmFuZ2U6NGNmNDdhNDdmYzQ1NDBjYmIzNWZkZTdlMzViOGIxMTFfNi00LTEtMS0yODUzMg_82aa39fa-adec-46e5-98cd-e249cc0653ed"
      unitRef="usd">10188000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i5a860a8253cc468dab9782964e9008d2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjRjZjQ3YTQ3ZmM0NTQwY2JiMzVmZGU3ZTM1YjhiMTExL3RhYmxlcmFuZ2U6NGNmNDdhNDdmYzQ1NDBjYmIzNWZkZTdlMzViOGIxMTFfNi02LTEtMS0yODUzMg_9cc58301-5b9a-43ac-a493-54464922da73"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjRjZjQ3YTQ3ZmM0NTQwY2JiMzVmZGU3ZTM1YjhiMTExL3RhYmxlcmFuZ2U6NGNmNDdhNDdmYzQ1NDBjYmIzNWZkZTdlMzViOGIxMTFfNi04LTEtMS0yODUzMg_de0ba131-de32-4115-b9fc-49a326096791"
      unitRef="usd">61968000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iafe66fc19ba44522a7249f23c4348b8c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjc4OWUwOWVkZTBhZTRlMmE5YjNjZDk0ZjFiN2Y4MGMzL3RhYmxlcmFuZ2U6Nzg5ZTA5ZWRlMGFlNGUyYTliM2NkOTRmMWI3ZjgwYzNfNC0yLTEtMS0yODUzMg_b450bc73-0850-4dd5-b2ab-c2edeb148b2e"
      unitRef="usd">64065000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4d359c13687c4b70afe72962c41749e1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjc4OWUwOWVkZTBhZTRlMmE5YjNjZDk0ZjFiN2Y4MGMzL3RhYmxlcmFuZ2U6Nzg5ZTA5ZWRlMGFlNGUyYTliM2NkOTRmMWI3ZjgwYzNfNC00LTEtMS0yODUzMg_9f679044-4260-4bfa-8dd2-86fd5c4141f9"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i308c9eedd5de4813af1e34bfdc45b87d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjc4OWUwOWVkZTBhZTRlMmE5YjNjZDk0ZjFiN2Y4MGMzL3RhYmxlcmFuZ2U6Nzg5ZTA5ZWRlMGFlNGUyYTliM2NkOTRmMWI3ZjgwYzNfNC02LTEtMS0yODUzMg_4feb449b-9d6e-46d1-81ed-a166141c6334"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjc4OWUwOWVkZTBhZTRlMmE5YjNjZDk0ZjFiN2Y4MGMzL3RhYmxlcmFuZ2U6Nzg5ZTA5ZWRlMGFlNGUyYTliM2NkOTRmMWI3ZjgwYzNfNC04LTEtMS0yODUzMg_f21e623f-89c2-4a8d-8708-5803186fb7f8"
      unitRef="usd">64065000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecurities
      contextRef="iafe66fc19ba44522a7249f23c4348b8c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjc4OWUwOWVkZTBhZTRlMmE5YjNjZDk0ZjFiN2Y4MGMzL3RhYmxlcmFuZ2U6Nzg5ZTA5ZWRlMGFlNGUyYTliM2NkOTRmMWI3ZjgwYzNfNS0yLTEtMS0yODUzMg_a72ea26e-ba80-46a3-ae70-9e276c7c47f1"
      unitRef="usd">7561000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i4d359c13687c4b70afe72962c41749e1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjc4OWUwOWVkZTBhZTRlMmE5YjNjZDk0ZjFiN2Y4MGMzL3RhYmxlcmFuZ2U6Nzg5ZTA5ZWRlMGFlNGUyYTliM2NkOTRmMWI3ZjgwYzNfNS00LTEtMS0yODUzMg_71752661-ecdd-4fce-a3a6-0b40182687e0"
      unitRef="usd">15117000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i308c9eedd5de4813af1e34bfdc45b87d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjc4OWUwOWVkZTBhZTRlMmE5YjNjZDk0ZjFiN2Y4MGMzL3RhYmxlcmFuZ2U6Nzg5ZTA5ZWRlMGFlNGUyYTliM2NkOTRmMWI3ZjgwYzNfNS02LTEtMS0yODUzMg_561532e8-ccde-4ce8-ae85-f512bcdf9d94"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjc4OWUwOWVkZTBhZTRlMmE5YjNjZDk0ZjFiN2Y4MGMzL3RhYmxlcmFuZ2U6Nzg5ZTA5ZWRlMGFlNGUyYTliM2NkOTRmMWI3ZjgwYzNfNS04LTEtMS0yODUzMg_dab90c24-da80-4d9a-a79c-63f5ee005d56"
      unitRef="usd">22678000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="iafe66fc19ba44522a7249f23c4348b8c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjc4OWUwOWVkZTBhZTRlMmE5YjNjZDk0ZjFiN2Y4MGMzL3RhYmxlcmFuZ2U6Nzg5ZTA5ZWRlMGFlNGUyYTliM2NkOTRmMWI3ZjgwYzNfNi0yLTEtMS0yODUzMg_5af9d284-f6a1-4910-b84f-4c15bc94b586"
      unitRef="usd">71626000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i4d359c13687c4b70afe72962c41749e1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjc4OWUwOWVkZTBhZTRlMmE5YjNjZDk0ZjFiN2Y4MGMzL3RhYmxlcmFuZ2U6Nzg5ZTA5ZWRlMGFlNGUyYTliM2NkOTRmMWI3ZjgwYzNfNi00LTEtMS0yODUzMg_505424db-2555-4f8b-8e3e-362ec227058e"
      unitRef="usd">15117000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i308c9eedd5de4813af1e34bfdc45b87d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjc4OWUwOWVkZTBhZTRlMmE5YjNjZDk0ZjFiN2Y4MGMzL3RhYmxlcmFuZ2U6Nzg5ZTA5ZWRlMGFlNGUyYTliM2NkOTRmMWI3ZjgwYzNfNi02LTEtMS0yODUzMg_2e018a4a-7d79-4ecd-80b9-0abadb232ed8"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180My9mcmFnOjNmYzhjNmMwYWYxMTRhYmE5MzZjNWVmOTkwMmQ0NmZmL3RhYmxlOjc4OWUwOWVkZTBhZTRlMmE5YjNjZDk0ZjFiN2Y4MGMzL3RhYmxlcmFuZ2U6Nzg5ZTA5ZWRlMGFlNGUyYTliM2NkOTRmMWI3ZjgwYzNfNi04LTEtMS0yODUzMg_81bae742-ea0a-47b3-9bc2-5d3f1adc40b6"
      unitRef="usd">86743000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfNTkzMA_d86e95bf-b830-4a4d-9c18-2fd7dd6fbedd">Debt Obligations&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 17, 2022, Lexicon and one of its subsidiaries entered into a loan and security agreement with Oxford Finance LLC (&#x201c;Oxford&#x201d;) that provides up to $150&#160;million in borrowing capacity (the &#x201c;Oxford Term Loans&#x201d;) available in four tranches, each maturing in March 2027. Monthly interest-only payments are due during an initial 36-month period, which may be extended at Lexicon&#x2019;s option to 48 months if Lexicon maintains compliance with a financial covenant relating to net sales of sotagliflozin following regulatory approval. The interest-only period will be followed by principal payments of $8.7&#160;million, $13.0&#160;million, and $4.8&#160;million during the fiscal years ended December 31, 2025, December 31, 2026 and December 31, 2027, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The first $25&#160;million tranche was funded at closing. The second $25&#160;million tranche is available for draw at Lexicon&#x2019;s option prior to August 25, 2022. The third $50&#160;million tranche is available for draw at Lexicon&#x2019;s option prior to June 30, 2023, but within 60 days of U.S. regulatory approval of sotagliflozin for heart failure. The fourth $50&#160;million tranche is available for draw at Lexicon&#x2019;s option, subject to Oxford&#x2019;s consent, at any time prior to the expiration of the interest-only payment period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The loan and security agreement provides that, upon funding of the first three tranches, Lexicon will grant Oxford a warrant to purchase shares of its common stock having a value equal to 3.50%, 1.75% and 0.875%, respectively, of each such tranche, as determined by reference to a 10-day average closing price of the shares. Each warrant will have an exercise price equal to such average closing price, be exercisable for a five-year period from the date of issuance and feature a net cashless exercise provision. Concurrent with the funding of the first tranche, Lexicon granted Oxford a warrant to purchase 420,673 shares of Lexicon&#x2019;s common stock at an exercise price of $2.08 per share. The warrant is exercisable through March 1, 2027 and is classified as an equity instrument.  The Company allocated the proceeds from the first tranche to the warrant using the relative fair value method and used the Black-Scholes model to calculate the fair value of the warrants.  The fair value of the warrant of $0.7&#160;million was recognized as equity with a corresponding debt discount of $0.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Oxford Term Loans bear interest at a floating rate equal to the 30-day U.S. Dollar LIBOR plus 7.90%, but not less than 8.01%, subject to additional interest if an event of default occurs and is continuing.  As of June&#160;30, 2022, the interest rate was 9.02%. If an event of default occurs and is continuing, Oxford may declare all amounts outstanding under the loan and security agreement to be immediately due and payable. Lexicon may prepay the Oxford Term Loans in whole at its option at any time. Any prepayment of the Oxford Term Loans is subject to prepayment fees for up to three years after the funding of each tranche of the loans.  A final payment exit fee equal to 6% of the amount funded under the Oxford Term Loans is due upon prepayment or maturity, which final payment will be adjusted to 7% of the amount funded upon extension of the interest-only payment period.  The final payment exit fee of $1.5&#160;million was recorded as a debt discount on the closing date of the first tranche.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During March 2022, in connection with the first tranche of the loan and security agreement, the Company received cash proceeds of $24.2&#160;million, net of debt issuance costs of $0.4&#160;million and a facility fee of $0.5&#160;million. The debt issuance costs and facility fee have been recorded as a debt discount on the Company&#x2019;s condensed consolidated balance sheet, which together with the final payment exit fee of $1.5&#160;million and warrant fair value of $0.7&#160;million are being amortized to interest expense throughout the life of the term loan using the effective interest rate method.  As of June&#160;30, 2022, the balance of the debt discount was $2.9&#160;million. During the six months ended June&#160;30, 2022, the Company recognized interest expense of $0.8&#160;million.  As of  June&#160;30, 2022, the carrying value of the Oxford Term Loans was $23.6&#160;million.  The fair value of the Oxford Term Loans approximates its carrying value and was determined using Level 2 inputs using discounted cash flow analysis, based on the Company&#x2019;s estimated current incremental borrowing rate.       &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lexicon&#x2019;s obligations under the Oxford Term Loans are secured by a first lien security interest in all of the assets of the Company and its subsidiaries. The loan and security agreement contains certain customary representations and warranties, affirmative and negative covenants and events of default applicable to Lexicon and its subsidiaries. In addition to the financial covenant, additional covenants include those restricting dispositions, fundamental changes to its business, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt. The Company was in compliance with its debt covenants as of June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Debt.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In November 2014, Lexicon completed an offering of $87.5 million in aggregate principal amount of its 5.25% Convertible Senior Notes due 2021 (the &#x201c;Convertible Notes&#x201d;).  The conversion feature did not meet the criteria for bifurcation as required by generally accepted accounting principles and the entire principal amount was recorded as long-term debt on the Company&#x2019;s condensed consolidated balance sheets.  &lt;/span&gt;&lt;/div&gt;In 2020, the Company entered into separate, privately negotiated exchange agreements to exchange $75.8 million aggregate principal amount of the Convertible Notes for consideration valued at 85% of the principal amount of the Convertible Notes. In 2020, the Company issued 10,368,956 shares of the Company&#x2019;s common stock and paid $50.0 million in cash, which included $1.3 million of accrued interest, to exchange such Convertible Notes. In December 2021, the remaining balance of $11.6 million was repaid in cash.</us-gaap:DebtDisclosureTextBlock>
    <lxrx:OxfordLoanFacility
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMTg4_cf7a68b0-f837-4201-95f4-c2ba733472bd"
      unitRef="usd">150000000</lxrx:OxfordLoanFacility>
    <lxrx:A2027OxfordPrincipalPayments
      contextRef="i2dd8b9f384214850b5f4fd852ba9f217_D20260101-20260331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfNjIw_192f41fe-63bd-4bc6-991a-a916cdd09cb2"
      unitRef="usd">8700000</lxrx:A2027OxfordPrincipalPayments>
    <lxrx:A2026OxfordPrincipalPayments
      contextRef="i7fc078bde80e4f5eaa692435aa8a2da3_D20270101-20270331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfNjI0_638f1723-6c2f-4bd0-85d6-969ea1f6b1a2"
      unitRef="usd">13000000</lxrx:A2026OxfordPrincipalPayments>
    <lxrx:A2027OxfordPrincipalPayments
      contextRef="i20828fea2889439ba7af1b8a7dcb42eb_D20280101-20280331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfNjMy_4915804b-cf27-4766-a0aa-005281b82e78"
      unitRef="usd">4800000</lxrx:A2027OxfordPrincipalPayments>
    <lxrx:TermLoanA
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfNzA1_b029b1b9-0c64-4af5-8949-5258e8ac6d8e"
      unitRef="usd">25000000</lxrx:TermLoanA>
    <lxrx:TermLoanB
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfNzUw_38c6cb91-8b01-45f8-a2c0-d40fc6a638e3"
      unitRef="usd">25000000</lxrx:TermLoanB>
    <lxrx:TermLoanC
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMTAzMw_f62e8304-db79-489b-94af-eae6ba447aa6"
      unitRef="usd">50000000</lxrx:TermLoanC>
    <lxrx:TermLoanD
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMTIwNA_49c1560b-33ac-41e2-9120-e4abac0be2ed"
      unitRef="usd">50000000</lxrx:TermLoanD>
    <lxrx:TermLoanABWarrant
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMTU0OQ_d6302572-e799-4097-b424-1f04ecf22692"
      unitRef="number">0.0350</lxrx:TermLoanABWarrant>
    <lxrx:TermLoanCWarrant
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMTU1Mw_968120e0-b008-4183-b9bb-86d006723f83"
      unitRef="number">0.0175</lxrx:TermLoanCWarrant>
    <lxrx:TermLoanDWarrant
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMTU2MA_e42704dd-9613-4b87-a4b2-06e74cfbf7de"
      unitRef="number">0.00875</lxrx:TermLoanDWarrant>
    <lxrx:TermLoanAWarrantsNumber
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMTk2MA_18fe741e-233b-4c91-a0a1-256b62ba7d48"
      unitRef="shares">420673</lxrx:TermLoanAWarrantsNumber>
    <lxrx:TermLoanAWarrantExercisePrice
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMjAyMA_d6d0e76d-2dcc-4e1c-bbaa-ca12e8cd773c"
      unitRef="usdPerShare">2.08</lxrx:TermLoanAWarrantExercisePrice>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMjM0OQ_5e6f5fd1-9968-4a12-b66b-87375cdc51ea"
      unitRef="usd">700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMjQxNQ_5e6f5fd1-9968-4a12-b66b-87375cdc51ea"
      unitRef="usd">700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMjUxOA_c1902510-a7b6-4c0c-a49f-e639d1798631"
      unitRef="number">0.0790</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMjU0MA_6e11940c-3a98-4b70-9d1f-a167fc7b3ed3"
      unitRef="number">0.0801</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:SubordinatedBorrowingInterestRate
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMjY1Nw_28640bae-60e4-4b58-a486-7a6151171df2"
      unitRef="number">0.0902</us-gaap:SubordinatedBorrowingInterestRate>
    <lxrx:FinalPaymentWithNoExtention
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMzA3OA_c87519e4-2cfb-4a86-8505-ab747084de03"
      unitRef="rate">0.06</lxrx:FinalPaymentWithNoExtention>
    <lxrx:FinalPaymentWithExtention
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMzIwNg_c55f3ea7-4e2a-4dbf-86d3-ffc9743e1014"
      unitRef="rate">0.07</lxrx:FinalPaymentWithExtention>
    <lxrx:TermLoanAFinalPayment
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMzMxMw_78de98f0-55cb-46e9-a97a-0d4cf62192df"
      unitRef="usd">1500000</lxrx:TermLoanAFinalPayment>
    <lxrx:TermLoanANetCashReceipt
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMzUyMQ_20787ff4-0538-47a3-b6a6-79f496ce5c36"
      unitRef="usd">24200000</lxrx:TermLoanANetCashReceipt>
    <lxrx:TermLoanADebtIssuanceCosts
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMzU1NQ_1d5b0a8b-af77-4c5c-a944-3869096c51c3"
      unitRef="usd">400000</lxrx:TermLoanADebtIssuanceCosts>
    <lxrx:OxfordFacilityFee
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMzU4MA_e34b337a-fc15-4a54-ac56-6247af2f920e"
      unitRef="usd">500000</lxrx:OxfordFacilityFee>
    <lxrx:TermLoanAFinalPayment
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMzc2OA_78de98f0-55cb-46e9-a97a-0d4cf62192df"
      unitRef="usd">1500000</lxrx:TermLoanAFinalPayment>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMzc5Nw_5e6f5fd1-9968-4a12-b66b-87375cdc51ea"
      unitRef="usd">700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <lxrx:TermLoanADebtDiscount
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfMzk2Nw_e5c7c50d-c995-4ff6-80e5-8009dd88c36f"
      unitRef="usd">2900000</lxrx:TermLoanADebtDiscount>
    <lxrx:TermLoanAInterestExpense
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfNDA0NQ_450f26b1-1340-4725-a7ec-e591284d116e"
      unitRef="usd">800000</lxrx:TermLoanAInterestExpense>
    <us-gaap:LongTermDebt
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfNDEwOQ_271f79bc-b6f3-4ff0-b759-0ccfcf129aaf"
      unitRef="usd">23600000</us-gaap:LongTermDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i71a46b4fd0da412cbd90061ff289cf49_D20141101-20141130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfNTA5MA_5ae74f49-1487-45f4-a313-e85400fc35d9"
      unitRef="usd">87500000</us-gaap:ProceedsFromConvertibleDebt>
    <lxrx:ConvDebtInstrumentInterestRateStatedPercentage
      contextRef="i0cc6e78d37b6446ba787713f65cd8666_I20141120"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfNTEzMA_fb1b0668-6ffd-4320-9391-b600ae7a2158"
      unitRef="number">0.0525</lxrx:ConvDebtInstrumentInterestRateStatedPercentage>
    <lxrx:ConvertibleDebtExchangeTotalPrincipalAmount
      contextRef="i1fa52b6205c847e4888033f43b0077d3_I20200928"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfNTUzNA_28b617f9-08aa-42d7-8354-3fa6fc22112b"
      unitRef="usd">75800000</lxrx:ConvertibleDebtExchangeTotalPrincipalAmount>
    <lxrx:ConvertibleDebtExchangeRemainingNotes
      contextRef="if0442bec3f404e9aa34207eb1d897a99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180Ni9mcmFnOjMwYjQ2NmUzY2Q2MzQ5NTg4MjliOGEzMDY2NGJhZGIxL3RleHRyZWdpb246MzBiNDY2ZTNjZDYzNDk1ODgyOWI4YTMwNjY0YmFkYjFfNTkwNw_8cb1b6eb-45b8-4c03-8162-fac3033fda74"
      unitRef="usd">11600000</lxrx:ConvertibleDebtExchangeRemainingNotes>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180OS9mcmFnOmIyNGYwMWRiMTZlMzQyZDJhODBiYTBkMWNhZmMyNTMzL3RleHRyZWdpb246YjI0ZjAxZGIxNmUzNDJkMmE4MGJhMGQxY2FmYzI1MzNfMTE3Mw_3a173c94-c3cf-4efc-a9e3-218937670652">Commitments and Contingencies&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Operating Lease Obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;Lexicon&#x2019;s operating leases include office space in The Woodlands, Texas and Basking Ridge, New Jersey and will expire in August 2025 and December 2022, respectively. Under its lease agreements, Lexicon is obligated to pay property taxes, insurance, and maintenance costs. In July 2022, the Company entered into a lease agreement for a 22,000 square-foot office space in Bridgewater, New Jersey to which it plans to relocate the New Jersey offices.  The term of the lease is expected to commence in December 2022, will extend for ten years and 11 months from such commencement date and provides for escalating yearly base rent payments starting at $820,000 and increasing to $986,000 in the final year of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, the right-of-use assets for the office space leases had a balance of $1.8 million, which is included in other assets in the condensed consolidated balance sheet. Current and non-current liabilities relating to the leases were $0.8 million and $1.0 million, respectively, which are included in accrued liabilities and other long-term liabilities in the condensed consolidated balance sheet, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the undiscounted cash flows of the operating lease liability to the recorded lease liability at June&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.168%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: amount of lease payments representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: short-term operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(789)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Legal Proceedings.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180OS9mcmFnOmIyNGYwMWRiMTZlMzQyZDJhODBiYTBkMWNhZmMyNTMzL3RleHRyZWdpb246YjI0ZjAxZGIxNmUzNDJkMmE4MGJhMGQxY2FmYzI1MzNfNDMz_1662c838-f5d4-4f47-8a3f-aa43141eeb7c"
      unitRef="usd">1800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:ShortTermLeaseCommitmentAmount
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180OS9mcmFnOmIyNGYwMWRiMTZlMzQyZDJhODBiYTBkMWNhZmMyNTMzL3RleHRyZWdpb246YjI0ZjAxZGIxNmUzNDJkMmE4MGJhMGQxY2FmYzI1MzNfNTgw_6b7c25b6-f948-4df1-8db7-55ed244aafea"
      unitRef="usd">800000</us-gaap:ShortTermLeaseCommitmentAmount>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180OS9mcmFnOmIyNGYwMWRiMTZlMzQyZDJhODBiYTBkMWNhZmMyNTMzL3RleHRyZWdpb246YjI0ZjAxZGIxNmUzNDJkMmE4MGJhMGQxY2FmYzI1MzNfNTg3_daf5453e-4729-4664-9c99-d1511d16fb6d"
      unitRef="usd">1000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180OS9mcmFnOmIyNGYwMWRiMTZlMzQyZDJhODBiYTBkMWNhZmMyNTMzL3RhYmxlOmQyMWYzODBlM2M2ZDQ0OWNiNmZiMjYxNDhiNGVhZmYzL3RhYmxlcmFuZ2U6ZDIxZjM4MGUzYzZkNDQ5Y2I2ZmIyNjE0OGI0ZWFmZjNfMi0xLTEtMS0yODUzMg_84c81fe5-4329-4814-a67d-88debda3c4ac"
      unitRef="usd">583000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180OS9mcmFnOmIyNGYwMWRiMTZlMzQyZDJhODBiYTBkMWNhZmMyNTMzL3RhYmxlOmQyMWYzODBlM2M2ZDQ0OWNiNmZiMjYxNDhiNGVhZmYzL3RhYmxlcmFuZ2U6ZDIxZjM4MGUzYzZkNDQ5Y2I2ZmIyNjE0OGI0ZWFmZjNfMy0xLTEtMS0yODUzMg_73c7708d-d6ee-431d-a3ef-4d16a4b20918"
      unitRef="usd">531000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180OS9mcmFnOmIyNGYwMWRiMTZlMzQyZDJhODBiYTBkMWNhZmMyNTMzL3RhYmxlOmQyMWYzODBlM2M2ZDQ0OWNiNmZiMjYxNDhiNGVhZmYzL3RhYmxlcmFuZ2U6ZDIxZjM4MGUzYzZkNDQ5Y2I2ZmIyNjE0OGI0ZWFmZjNfNC0xLTEtMS0yODUzMg_ed0ddac3-2df4-418a-a134-4178e78c7ce4"
      unitRef="usd">544000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180OS9mcmFnOmIyNGYwMWRiMTZlMzQyZDJhODBiYTBkMWNhZmMyNTMzL3RhYmxlOmQyMWYzODBlM2M2ZDQ0OWNiNmZiMjYxNDhiNGVhZmYzL3RhYmxlcmFuZ2U6ZDIxZjM4MGUzYzZkNDQ5Y2I2ZmIyNjE0OGI0ZWFmZjNfNS0xLTEtMS0yODUzMg_097478a7-fb98-4f46-803d-7d4bb2ce02c3"
      unitRef="usd">370000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180OS9mcmFnOmIyNGYwMWRiMTZlMzQyZDJhODBiYTBkMWNhZmMyNTMzL3RhYmxlOmQyMWYzODBlM2M2ZDQ0OWNiNmZiMjYxNDhiNGVhZmYzL3RhYmxlcmFuZ2U6ZDIxZjM4MGUzYzZkNDQ5Y2I2ZmIyNjE0OGI0ZWFmZjNfNi0xLTEtMS0yODUzMg_8ab1adaa-2fe8-45bb-9e0e-7b89f144a5f4"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180OS9mcmFnOmIyNGYwMWRiMTZlMzQyZDJhODBiYTBkMWNhZmMyNTMzL3RhYmxlOmQyMWYzODBlM2M2ZDQ0OWNiNmZiMjYxNDhiNGVhZmYzL3RhYmxlcmFuZ2U6ZDIxZjM4MGUzYzZkNDQ5Y2I2ZmIyNjE0OGI0ZWFmZjNfOC0xLTEtMS0yODUzMg_d82b02aa-1099-4cd3-ba21-fbe6fdad9972"
      unitRef="usd">2028000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180OS9mcmFnOmIyNGYwMWRiMTZlMzQyZDJhODBiYTBkMWNhZmMyNTMzL3RhYmxlOmQyMWYzODBlM2M2ZDQ0OWNiNmZiMjYxNDhiNGVhZmYzL3RhYmxlcmFuZ2U6ZDIxZjM4MGUzYzZkNDQ5Y2I2ZmIyNjE0OGI0ZWFmZjNfOS0xLTEtMS0yODUzMg_988d950b-127f-4698-957b-f0b69515be28"
      unitRef="usd">237000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180OS9mcmFnOmIyNGYwMWRiMTZlMzQyZDJhODBiYTBkMWNhZmMyNTMzL3RhYmxlOmQyMWYzODBlM2M2ZDQ0OWNiNmZiMjYxNDhiNGVhZmYzL3RhYmxlcmFuZ2U6ZDIxZjM4MGUzYzZkNDQ5Y2I2ZmIyNjE0OGI0ZWFmZjNfMTAtMS0xLTEtMjg1MzI_e29e3701-00ae-4f5c-99aa-b2281cbaa721"
      unitRef="usd">1791000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180OS9mcmFnOmIyNGYwMWRiMTZlMzQyZDJhODBiYTBkMWNhZmMyNTMzL3RhYmxlOmQyMWYzODBlM2M2ZDQ0OWNiNmZiMjYxNDhiNGVhZmYzL3RhYmxlcmFuZ2U6ZDIxZjM4MGUzYzZkNDQ5Y2I2ZmIyNjE0OGI0ZWFmZjNfMTEtMS0xLTEtMjg1MzI_841f9368-49d9-4ed8-8174-5c587d565c1b"
      unitRef="usd">789000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i8f9d4917340c4a8a8775c9336387b2a9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY180OS9mcmFnOmIyNGYwMWRiMTZlMzQyZDJhODBiYTBkMWNhZmMyNTMzL3RhYmxlOmQyMWYzODBlM2M2ZDQ0OWNiNmZiMjYxNDhiNGVhZmYzL3RhYmxlcmFuZ2U6ZDIxZjM4MGUzYzZkNDQ5Y2I2ZmIyNjE0OGI0ZWFmZjNfMTItMS0xLTEtMjg1MzI_0f6ecd3c-0c76-49f7-925e-3a0b5387c7a5"
      unitRef="usd">1002000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY181Mi9mcmFnOjRlNDEyMjcxYmQ0OTRjZjViMGRiZjNhYTdkMzY3MjZiL3RleHRyZWdpb246NGU0MTIyNzFiZDQ5NGNmNWIwZGJmM2FhN2QzNjcyNmJfNjM5_720bfd23-d594-4a8c-b59f-cc7f785b3f92">Collaboration and License Agreements&#160;Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, product sales, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales, as well as from commercial sales of its XERMELO product following its commercial launch in February 2017 until its sale of XERMELO and related assets to TerSera Therapeutics, LLC in September 2020.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <lxrx:OtherCapitalAgreementsTextBlock
      contextRef="ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY181NS9mcmFnOjYzMGM4NGIzZTQ2MTQ5NWNiMjUyMGYxNDVmNWI2ZWZhL3RleHRyZWdpb246NjMwYzg0YjNlNDYxNDk1Y2IyNTIwZjE0NWY1YjZlZmFfNjg1_85fa4c6e-324f-444d-b209-b9718f1ddabc">Other Capital Agreements&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  In 2020, Lexicon entered into an Open Market Sale Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (the &#x201c;Sales Agreement&#x201d;) with Jefferies LLC (&#x201c;Jefferies&#x201d;) relating to the shares of its common stock. In January 2021, Lexicon sold 2,000,000 shares of its common stock at a price of $8.463 per share pursuant to the Sales Agreement, resulting in net proceeds of $16.4&#160;million. In August and September 2021, Lexicon sold an aggregate of 4,176,953 shares of its common stock at a price of $4.732 per share pursuant to the Sales Agreement, resulting in net proceeds of $19.1 million. The net proceeds are reflected as issuances of common stock in the accompanying condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</lxrx:OtherCapitalAgreementsTextBlock>
    <lxrx:SharesSoldInJanuary2021ATMOffering
      contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY181NS9mcmFnOjYzMGM4NGIzZTQ2MTQ5NWNiMjUyMGYxNDVmNWI2ZWZhL3RleHRyZWdpb246NjMwYzg0YjNlNDYxNDk1Y2IyNTIwZjE0NWY1YjZlZmFfMjQ0_4b1f8f70-fcab-4062-a205-01d18240c3cd"
      unitRef="shares">2000000</lxrx:SharesSoldInJanuary2021ATMOffering>
    <lxrx:SharePriceInJanuary2021ATMOffering
      contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY181NS9mcmFnOjYzMGM4NGIzZTQ2MTQ5NWNiMjUyMGYxNDVmNWI2ZWZhL3RleHRyZWdpb246NjMwYzg0YjNlNDYxNDk1Y2IyNTIwZjE0NWY1YjZlZmFfMjg4_579ed04a-e4d0-4fc2-80ac-7114c3a8cb16"
      unitRef="shares">8.463</lxrx:SharePriceInJanuary2021ATMOffering>
    <lxrx:ProceedsFromJanuary2021ATMOffering
      contextRef="idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY181NS9mcmFnOjYzMGM4NGIzZTQ2MTQ5NWNiMjUyMGYxNDVmNWI2ZWZhL3RleHRyZWdpb246NjMwYzg0YjNlNDYxNDk1Y2IyNTIwZjE0NWY1YjZlZmFfMzYz_72e40c72-d4d6-4e7c-94ce-0ab8acf97d5c"
      unitRef="usd">16400000</lxrx:ProceedsFromJanuary2021ATMOffering>
    <lxrx:SharesSoldInSeptember2021ATMOfferring
      contextRef="idedefb7f68d74e2aa8370ccd51445b1d_D20211001-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY181NS9mcmFnOjYzMGM4NGIzZTQ2MTQ5NWNiMjUyMGYxNDVmNWI2ZWZhL3RleHRyZWdpb246NjMwYzg0YjNlNDYxNDk1Y2IyNTIwZjE0NWY1YjZlZmFfNTUz_899e8c0c-7782-437b-9fc2-45967f2885de"
      unitRef="shares">4176953</lxrx:SharesSoldInSeptember2021ATMOfferring>
    <lxrx:SharePriceInSeptember2021ATMOfferring
      contextRef="idedefb7f68d74e2aa8370ccd51445b1d_D20211001-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY181NS9mcmFnOjYzMGM4NGIzZTQ2MTQ5NWNiMjUyMGYxNDVmNWI2ZWZhL3RleHRyZWdpb246NjMwYzg0YjNlNDYxNDk1Y2IyNTIwZjE0NWY1YjZlZmFfNTk3_a06b075d-4a3e-461c-a312-8f18369eac2f"
      unitRef="usd">4.732</lxrx:SharePriceInSeptember2021ATMOfferring>
    <lxrx:ProceedsFromSeptember2021ATMOffering
      contextRef="idedefb7f68d74e2aa8370ccd51445b1d_D20211001-20211231"
      decimals="6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY181NS9mcmFnOjYzMGM4NGIzZTQ2MTQ5NWNiMjUyMGYxNDVmNWI2ZWZhL3RleHRyZWdpb246NjMwYzg0YjNlNDYxNDk1Y2IyNTIwZjE0NWY1YjZlZmFfNjcz_42beddf3-faa1-4613-bc28-9090184a6203"
      unitRef="usd">19.1</lxrx:ProceedsFromSeptember2021ATMOffering>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ie65c2031672c436c9ffb9020a455b7c6_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY184NzkvZnJhZzphZmY1ZDM2MjAwZWQ0ODRkOTM4YmZlM2ZlMTkwYzc3OC90ZXh0cmVnaW9uOmFmZjVkMzYyMDBlZDQ4NGQ5MzhiZmUzZmUxOTBjNzc4XzM2OA_e699efce-2048-49a1-a93c-923bc64e2713">Subsequent Events&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  In August 2022, Lexicon sold an aggregate of 34,000,000 shares of its common stock at a price of $2.50 per share in a public offering and concurrent private placement to two affiliates of Invus, L.P., resulting in net proceeds of approximately $82.2&#160;million, after deducting underwriting discounts and commissions and estimated offering expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <lxrx:SharesSoldInJuly2022Offering
      contextRef="ie65c2031672c436c9ffb9020a455b7c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY184NzkvZnJhZzphZmY1ZDM2MjAwZWQ0ODRkOTM4YmZlM2ZlMTkwYzc3OC90ZXh0cmVnaW9uOmFmZjVkMzYyMDBlZDQ4NGQ5MzhiZmUzZmUxOTBjNzc4Xzg5_876e8c17-9a14-41a6-8487-a0c5426479c8"
      unitRef="shares">34000000</lxrx:SharesSoldInJuly2022Offering>
    <lxrx:SharePriceInJuly2022Offering
      contextRef="ie65c2031672c436c9ffb9020a455b7c6_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY184NzkvZnJhZzphZmY1ZDM2MjAwZWQ0ODRkOTM4YmZlM2ZlMTkwYzc3OC90ZXh0cmVnaW9uOmFmZjVkMzYyMDBlZDQ4NGQ5MzhiZmUzZmUxOTBjNzc4XzEzMw_25b7f01e-c3a9-4759-b23a-31fd76989f41"
      unitRef="usd">2.50</lxrx:SharePriceInJuly2022Offering>
    <lxrx:ProceedsFromJuly2022Offering
      contextRef="ie65c2031672c436c9ffb9020a455b7c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmOTVlYWJjNGNmMzRhYzFiMDM4M2MxYmE4ZDdkZWJjL3NlYzpiZjk1ZWFiYzRjZjM0YWMxYjAzODNjMWJhOGQ3ZGViY184NzkvZnJhZzphZmY1ZDM2MjAwZWQ0ODRkOTM4YmZlM2ZlMTkwYzc3OC90ZXh0cmVnaW9uOmFmZjVkMzYyMDBlZDQ4NGQ5MzhiZmUzZmUxOTBjNzc4XzI3Nw_7e766574-ee14-4915-a87a-9eead9319f16"
      unitRef="usd">82200000</lxrx:ProceedsFromJuly2022Offering>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>41
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( .N  U4'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #K@ -5XV)LN>T    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)O)TU!)71S43PI""XHWL)D=C?8M"$9:??M;>MN%]$'\)B9/]]\
M ]-@U-@G>DY]I,2>\M48VBYKC!MQ8(X:(..!@LWEE.BFYJY/P?+T3'N(%C_L
MGD!)>0V!V#K+%F9@$5>B,(U#C8DL]^F$=[CBXV=J%YA#H)8"=9RA*BL09IX8
MCV/;P 4PPYA2R-\%<BMQJ?Z)73H@3LDQ^S4U#$,YU$MNVJ&"MZ?'EV7=PG>9
M;8<T_<I>\S'21IPGO]9W]]L'8914JI"WA:RW2FIYHROY/KO^\+L(A][YG?_'
MQF=!T\"ONS!?4$L#!!0    ( .N  U697)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M-.?G!R>@YOCY+U8]B%*AG*_ !U]&0+]J3W3;&RTWS:'HO=1:%LWEFC/(%F,
MOZ^DU$\WYIRU.U=?_@=02P,$%     @ ZX #53M#]1$S P  O H  !@   !X
M;"]W;W)K<VAE971S+W-H965T,RYX;6RMEFUOTS 0Q[^*%1 ":2Q.^KC11MHZ
M(4!"JK8!+Q OO.3:6$OL8#OMMD_/V<E"TV8MFWC3^.'^Y]]=S\E-UE+=ZA3
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MF;FSPXU'_K)5^L9\=;VC+^R)J>^[AP(^S8]>$IZQ7'*1HX)M;F:W[E5$EGI
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M<$=*=/_&%5H/[>'L7D:'VP=#=]%+ H/54+@M.6([.9Z6%=BZ9U R937799X
M-MW#RJC>$2 XO#U\S]!#2G-YB?8Z/XRZ]#GO8QFU?Z.Q.[6IO'7U:_$3C^O
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MFC\P(K;I]UE>.=OT3A1U7\]$;)>'O]EQ^% 7#^V?C/A4U'6Q:[_=I(E8#!N
M^/U=4=1?/S1_A>+XEU.N_PM02P,$%     @ ZX #5>Y1!;L^$0  :3   !@
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MS'.U9I]SYI*X=R6GJI@A;@!X8O>X^W06J4RS/.0.PMGY"QT35;'O3/IH\+6
MP4K?1$@BK D?#KJ[W6>7Z_"UH7\]?+/!V+,D3JA4B:7HHB<C8<-WD'#AS9J_
M/2R,!UGPSY628#MZ <]+@RS%"U+0?8RZ^B]02P,$%     @ ZX #542P-<5_
M!0  >PP  !D   !X;"]W;W)K<VAE971S+W-H965T,3,N>&ULI5?;;ALW$/V5
M@6H$"2!+JY4OBF,;L)T639 T1B[-0]$':G=6(L(E-R37LOZ^9[C26G9CHY<7
MBTL.S\R9&1[2IROGOX4E<Z3;VMAP-EC&V)R,QZ%8<JW"R#5LL5(Y7ZN(3[\8
MA\:S*M.FVHSS+#L:UTK;P?EIFKOVYZ>NC49;OO84VKI6?GW)QJW.!I/!=N*C
M7BRC3(S/3QNUX$\<OS37'E_C'J74-=N@G27/U=G@8G)R>2#VR>!WS:NP,R9A
M,G?NFWR\*<\&F03$AHLH" H_-WS%Q@@0POB^P1ST+F7C[GB+_DOB#BYS%?C*
MF:^ZC,NSP6Q )5>J-?&C6_W*&SZ'@E<X$])?6G6VA_F BC9$5V\V(X):V^Y7
MW6[RL+-AECVR(=]LR%/<G:,4Y6L5U?FI=ROR8@TT&22J:3>"TU:*\BEZK&KL
MB^=7KJYU1)9C(&5+NG(V:KM@6V@.I^,(%V(X+C9PEQU<_@C<$;T'P#+0S[;D
M\O[^,4+KX\NW\5WF3P*^;>V(IMF0\BS/G\";]GRG"6_Z7_C2:QT*XT+KF?ZX
MF(?HT31__B@+G9.#'SN1@W02&E7PV0 G);"_X<'YLY\F1]FK)R@<]!0.GD+_
MQQ1^%/?_0?[0L%?R3>\8YX ^S(U>*#E;@4XP=ZL+9Y_]-,LGQZ\"N=[:B'4@
M;0O3EDRNJG3!E/*#2?J\9/KJ7&G@,0SI,]^JSONE"M]D_T==+GA(O^&$OV4?
M>)U65]H8XMM&^X1RT2YP6*1+#M/R:RZXGK-/?3.$?(2&DP"8]8B^H#D]:;!,
ML9%:>.9$>[CE01H4.H)<4G34J#4U7EC%-45UR[#5%GE6MD!TXE,T,+*5"2I<
M@%C2&TMO6[/>1!%!%3ENE%T3O+$'-+8X4@\#(<@M9K$IRS)(5:L\[U?.Q;^E
M[])+>E8(T]_+$5!72UTL09,:Y#;(C(<(%S!-D>P8=Z"(5XH!I!HSR:8+"[E
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MAT<@JMN)J]U85?NA9:$L1B"_7&%()>T$<%\H99\VSD W]D[_ U!+ P04
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M@_&T -\OG8O# S$8?]QU]7]02P,$%     @ ZX #56#*")J6!   R@L  !D
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MA"7FQFI@]%KC!RQ+JXC<^+;5V6E,6L']]4[[1Q<[Q3)E&C_(\BLOS.*LT^]
M@3.V*LVUW/R&VW@2JR^7I79/V&SO!AW(5]K(:BM,'E1<U&_VL,W#:P2BK4#D
M_*X-.2\OF&&CH9(;4/8V:;,+%ZJ3)N>XL*#<&$5?.<F9T4T-!L@9W/"YX#.>
M,V%@G.=R)0P7<YC(DN<<-5Q^6W'S")]$CL*F$L8;I@H-1[=L6J(^'G8-.635
M=O.M\?/:>/2"\10^2V$6I%H46#R7[U(@3331+IKSJ%7A[ROA0QQX$ 51U*(O
M;K(3.WWQ2]FA&BA6);KT+)C"$\N  B;LD8AIZ@QX<&-D?@]72\LS[<$=*U?,
M<6ZLB>SU,?PUGFJCB(5_'TI4[4?OL!^V,D_UDN5XUJ'2TZC6V!F]>Q.FP?N6
M*'M-E+TV[<^B).#5BB+\@[,I+[DAX ^YVZKPL+L[S>63YE,X< @Y98MK0Z?D
MCUD@S&1)O8.X2/>U/228T<%<;R\PQVJ*"N*P1MX^0CCB@L3E2C-1Z./&E'6(
MJ7P!=$SUNZ:^M'1@6C]Y3@Z\A=@;1(%[I^F@D<QE1;U0U]!:Z2D*G'&CH>?%
MT0 2+PM#XHE4!@RJ"DHDMC2Q/4+6'T#H!?2\HK@4]+(,(B\)8KB5AI74HG[,
MQEL8>$F8T#N,O$$600O@20-X\FK _S>M7?7#+3X8."])X""]6_TYS!>X?%A2
MZR:W[F1)=ET&K[F^/YDI1&I#E&+4!JZ9P:>[MS;O%WS-"R2 &J)85IS"9;4L
MY2-25L,@A5\@\D-Z]N#=FWX41N]I?36C!HA*.WB%%">X%8&"*[(@Z=/ "H7^
M@)[9GNB^K?"Y+2L0^.E_L14X6^%S6RT42!L*I.T4. 2[4DS,T:Z]+>Q48O:W
M:5/_.J!;K;X ])9A\-7]0LFA\1H5302$*JJ<4PE-%&7J^X*^6AEM:&E_4LS\
MT 5"Z'MQFE'AI'X_@%\I-JN[YT5)!K%/!"#24*(+. K3^)C*RT\"H%_]#+F]
M>!0G=#KPJ1%\9^D9JVQ9AD$?$C_N[1QVB?KA8N+UHIC<R?PX::OBK($P>W45
M_RG%&EW/O*879<LNZ_K](FR'^DD86RV_ *.CU $47>;API;ISR(8>OVD1RE+
M_#!M$*1\]Q.JW2B!NSKF(VJJ870,/;^?[B-(N!P3U+U_09#Z:CBPW=X/LX/
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M970R,"YX;6S-EU]OXC@0P+_**"N=;J66_(%"Z0$2T%;;U787E;O>P^H>3#*
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M=>8^$(5Z/DECOD64=6 S;[O66U,OUP._X;5[[KH,K%;(+X0J("X*$!>G O%
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M$\3W'!0MIM,=X- _KYOMY9Q,#R.(&J5=Q(,6!"UQOM<2F'1F>2*#?LV@W\W
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MFJ3L;;UFV^R!N^:;8$DF/?E$<<*VI#?]_3?HNW\T";/DK"83ES*QR;OLMH4
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ML<#E"MH%X/U**;LS7()V7:=_ %!+ P04    " #K@ -5OW[ XPX$  !!%@
M&0   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6RU6&N/FS@4_2L66ZU::6;
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MZ*DE\2*5*2J2929]6#*IDA%3C%7Z!UP/4/TKQN1+16<D94(9_ 502P,$%
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M2LZ(RJN%FSQ0,)5:I)_D\K[O.15G$Z'C_B<> T5;7"0<IVASH@#BKG*&W@3
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ME TP^X64>#1L@N&52O\"4$L#!!0    ( .N  U6+MIHD30,   X5   -
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MC6-D=6+XNO<'NTNB*$W="&!N!U&$(7 WX@CF #Q@2!29]^#.^RA8O:>"]7]
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M=+9HI3P/>=?ZRK!F\R]L\Q_O]"=02P,$%     @ ZX #5=JP!6U2 0  _A$
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M%53(*JB055 AJZ!"5O&?9'UW;OG7OU7:M3!2V8,_Z_Y=S3X!4$L! A0#%
M  @ ZX #50=!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    " #K@ -5XV)LN>T    K @  $0
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M=#(N>&UL4$L! A0#%     @ ZX #53M#]1$S P  O H  !@
M ("!110  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( .N
M U6=_7RR!08  * :   8              " @:X7  !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6Q02P$"% ,4    " #K@ -5#2T_T @#  !@"0  &
M        @('I'0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%
M  @ ZX #5;O4GSD\"   &BT  !@              ("!)R$  'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( .N  U7(!B31L@L  $5E   8
M              " @9DI  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"
M% ,4    " #K@ -5[E$%NSX1  !I,   &               @(&!-0  >&PO
M=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ ZX #57!<P+NX!
M?PH  !@              ("!]48  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;%!+ 0(4 Q0    ( .N  U72+3MGNP,  -$)   9              " @>-+
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ ZX #54-K
M2AM.!0  80T  !D              ("!U4\  'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6Q02P$"% ,4    " #K@ -5>GPS@RD*  "8&@  &0
M    @(%:50  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (
M .N  U5$L#7%?P4  'L,   9              " @;I?  !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL4$L! A0#%     @ ZX #5>T;>GI( P  *P<  !D
M             ("!<&4  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"
M% ,4    " #K@ -52HKW9/L#   ""P  &0              @('O:   >&PO
M=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( .N  U6/;:J,/@T
M .@E   9              " @2%M  !X;"]W;W)K<VAE971S+W-H965T,38N
M>&UL4$L! A0#%     @ ZX #56#*")J6!   R@L  !D              ("!
MEGH  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " #K@ -5
M!*;>)%H#  #%"   &0              @(%C?P  >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;%!+ 0(4 Q0    ( .N  U6EF.7A\@(  $T'   9
M      " @?2"  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%
M  @ ZX #5<PPS_.% P  80X  !D              ("!'88  'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #K@ -58=_\@1(%  ##'0
M&0              @('9B0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+
M 0(4 Q0    ( .N  U6Y99R\+0,  &T+   9              " @2*/  !X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ ZX #51=MS&>A
M!0  WR8  !D              ("!AI(  'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"% ,4    " #K@ -5SP:^Q%L"  "Z!0  &0
M@(%>F   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( .N
M U6_?L#C#@0  $$6   9              " @?":  !X;"]W;W)K<VAE971S
M+W-H965T,C4N>&UL4$L! A0#%     @ ZX #50<S^#Y]"0  @F8  !D
M         ("!-9\  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
M    " #K@ -50.V#&QT#  !<"@  &0              @('IJ   >&PO=V]R
M:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( .N  U78S6D(;@,  !</
M   9              " @3VL  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
M4$L! A0#%     @ ZX #5<#3WF8T @  L00  !D              ("!XJ\
M 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #K@ -5B[::
M)$T#   .%0  #0              @ %-L@  >&PO<W1Y;&5S+GAM;%!+ 0(4
M Q0    ( .N  U67BKL<P    !,"   +              "  <6U  !?<F5L
M<R\N<F5L<U!+ 0(4 Q0    ( .N  U41K+QW!@,  $L4   /
M  "  :ZV  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #K@ -5VK %;5(!
M  #^$0  &@              @ 'AN0  >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    " #K@ -55@Q15'\!  ##$@  $P
M@ %KNP  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     )0 E /H)   ;O0
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>96</ContextCount>
  <ElementCount>222</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>16</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="lxrx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lxrx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets-Unaudited</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Consolidated Balance Sheets-Unaudited</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lxrx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets Parentheticals</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>Consolidated Balance Sheets Parentheticals</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lxrx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Comprehensive Loss-Unaudited</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss-Unaudited</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lxrx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Comprehensive Loss Parentheticals</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss Parentheticals</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lxrx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lxrx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Statements of Stockholders' Equity/Deficit-Unaudited</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity/Deficit-Unaudited</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lxrx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Summary of Significant Accounting Policies (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes</Role>
      <ShortName>Summary of Significant Accounting Policies (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lxrx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2109102 - Disclosure - Recent Accounting Pronouncements Level 1 (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes</Role>
      <ShortName>Recent Accounting Pronouncements Level 1 (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lxrx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2110103 - Disclosure - Cash and Cash Equivalents and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments</Role>
      <ShortName>Cash and Cash Equivalents and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lxrx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2114104 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lxrx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2117105 - Disclosure - Debt Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DebtObligations</Role>
      <ShortName>Debt Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lxrx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2120106 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lxrx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2122107 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CollaborationandLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lxrx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2125108 - Disclosure - Other Capital Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/OtherCapitalAgreements</Role>
      <ShortName>Other Capital Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lxrx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="lxrx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Summary of Significant Accounting Policies Equity Incentive Awards (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables</Role>
      <ShortName>Summary of Significant Accounting Policies Equity Incentive Awards (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lxrx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Cash and Cash Equivalents and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables</Role>
      <ShortName>Cash and Cash Equivalents and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="lxrx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/FairValueMeasurements</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="lxrx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="lxrx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1</Role>
      <ShortName>Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="lxrx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Summary of Significant Accounting Policies Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="lxrx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Cash and Cash Equivalents and Investments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1</Role>
      <ShortName>Cash and Cash Equivalents and Investments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="lxrx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Cash and Cash Equivalents and Investments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2</Role>
      <ShortName>Cash and Cash Equivalents and Investments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="lxrx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="lxrx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Debt Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DebtObligationsDetails</Role>
      <ShortName>Debt Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/DebtObligations</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="lxrx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CommitmentsandContingencies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="lxrx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2426412 - Disclosure - Other Capital Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/OtherCapitalAgreementsDetails</Role>
      <ShortName>Other Capital Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/OtherCapitalAgreements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="lxrx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Other Capital Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/OtherCapitalAgreementsDetails_1</Role>
      <ShortName>Other Capital Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/OtherCapitalAgreements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="lxrx-20220630.htm">lxrx-20220630.htm</File>
    <File>exh311certificationofprinc.htm</File>
    <File>exh312certificationofprinc.htm</File>
    <File>exh321certificationofprinc.htm</File>
    <File>lxrx-20220630.xsd</File>
    <File>lxrx-20220630_cal.xml</File>
    <File>lxrx-20220630_def.xml</File>
    <File>lxrx-20220630_lab.xml</File>
    <File>lxrx-20220630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="470">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>47
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lxrx-20220630.htm": {
   "axisCustom": 0,
   "axisStandard": 4,
   "contextCount": 96,
   "dts": {
    "calculationLink": {
     "local": [
      "lxrx-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lxrx-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "lxrx-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lxrx-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lxrx-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lxrx-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 355,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 48,
   "keyStandard": 174,
   "memberCustom": 0,
   "memberStandard": 16,
   "nsprefix": "lxrx",
   "nsuri": "http://www.lexpharma.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information",
     "role": "http://www.lexpharma.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110103 - Disclosure - Cash and Cash Equivalents and Investments",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments",
     "shortName": "Cash and Cash Equivalents and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114104 - Disclosure - Fair Value Measurements",
     "role": "http://www.lexpharma.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117105 - Disclosure - Debt Obligations",
     "role": "http://www.lexpharma.com/role/DebtObligations",
     "shortName": "Debt Obligations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120106 - Disclosure - Commitments and Contingencies",
     "role": "http://www.lexpharma.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122107 - Disclosure - Collaboration and License Agreements",
     "role": "http://www.lexpharma.com/role/CollaborationandLicenseAgreements",
     "shortName": "Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lxrx:OtherCapitalAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125108 - Disclosure - Other Capital Agreements",
     "role": "http://www.lexpharma.com/role/OtherCapitalAgreements",
     "shortName": "Other Capital Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lxrx:OtherCapitalAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Summary of Significant Accounting Policies Equity Incentive Awards (Tables)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables",
     "shortName": "Summary of Significant Accounting Policies Equity Incentive Awards (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Cash and Cash Equivalents and Investments (Tables)",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables",
     "shortName": "Cash and Cash Equivalents and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.lexpharma.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "i8f9d4917340c4a8a8775c9336387b2a9_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets-Unaudited",
     "role": "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
     "shortName": "Consolidated Balance Sheets-Unaudited",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "i8f9d4917340c4a8a8775c9336387b2a9_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "if8c71021eb1240e190c19cb072abf3f6_D20220101-20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails",
     "shortName": "Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "if8c71021eb1240e190c19cb072abf3f6_D20220101-20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "i32d0edfce10547eaa9f6a4a37c3c0e9e_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
     "shortName": "Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "i32d0edfce10547eaa9f6a4a37c3c0e9e_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "i8f9d4917340c4a8a8775c9336387b2a9_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:AccruedResearchAndDevelopmentServicesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407404 - Disclosure - Summary of Significant Accounting Policies Accrued Liabilities (Details)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails",
     "shortName": "Summary of Significant Accounting Policies Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "i8f9d4917340c4a8a8775c9336387b2a9_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:AccruedResearchAndDevelopmentServicesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "i8f9d4917340c4a8a8775c9336387b2a9_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Cash and Cash Equivalents and Investments (Details 1)",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1",
     "shortName": "Cash and Cash Equivalents and Investments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "i537aa7da0127497a9ab35f8f1601120c_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RealizedInvestmentGainsLosses",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RealizedInvestmentGainsLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Cash and Cash Equivalents and Investments (Details 2)",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2",
     "shortName": "Cash and Cash Equivalents and Investments (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RealizedInvestmentGainsLosses",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RealizedInvestmentGainsLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "i8f9d4917340c4a8a8775c9336387b2a9_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Fair Value Measurements (Details 1)",
     "role": "http://www.lexpharma.com/role/FairValueMeasurementsDetails1",
     "shortName": "Fair Value Measurements (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "i8f9d4917340c4a8a8775c9336387b2a9_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "i71a46b4fd0da412cbd90061ff289cf49_D20141101-20141130",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Debt Obligations (Details)",
     "role": "http://www.lexpharma.com/role/DebtObligationsDetails",
     "shortName": "Debt Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "i71a46b4fd0da412cbd90061ff289cf49_D20141101-20141130",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "i8f9d4917340c4a8a8775c9336387b2a9_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtAndCapitalLeaseObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "i8f9d4917340c4a8a8775c9336387b2a9_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtAndCapitalLeaseObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:SharesSoldInJanuary2021ATMOffering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426412 - Disclosure - Other Capital Agreements (Details)",
     "role": "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails",
     "shortName": "Other Capital Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "idedf7d4d550b40a6bb706bcb45a785da_D20210401-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:SharesSoldInJanuary2021ATMOffering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ie65c2031672c436c9ffb9020a455b7c6_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:SharesSoldInJuly2022Offering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Other Capital Agreements (Details)",
     "role": "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails_1",
     "shortName": "Other Capital Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ie65c2031672c436c9ffb9020a455b7c6_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:SharesSoldInJuly2022Offering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "i8f9d4917340c4a8a8775c9336387b2a9_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets Parentheticals",
     "role": "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals",
     "shortName": "Consolidated Balance Sheets Parentheticals",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "i8f9d4917340c4a8a8775c9336387b2a9_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "id7499383fea84c358f938bdc6560e4ce_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RoyaltyIncomeNonoperating",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Comprehensive Loss-Unaudited",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
     "shortName": "Consolidated Statements of Comprehensive Loss-Unaudited",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "id7499383fea84c358f938bdc6560e4ce_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RoyaltyIncomeNonoperating",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "id7499383fea84c358f938bdc6560e4ce_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Comprehensive Loss Parentheticals",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals",
     "shortName": "Consolidated Statements of Comprehensive Loss Parentheticals",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "id7499383fea84c358f938bdc6560e4ce_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ie8a7ca19bc1a4556a6e59951312a250b_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Statements of Stockholders' Equity/Deficit-Unaudited",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
     "shortName": "Consolidated Statements of Stockholders' Equity/Deficit-Unaudited",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ib6cf877d5e034cbe9a21bc4654ebb5f6_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Summary of Significant Accounting Policies (Notes)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes",
     "shortName": "Summary of Significant Accounting Policies (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109102 - Disclosure - Recent Accounting Pronouncements Level 1 (Notes)",
     "role": "http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes",
     "shortName": "Recent Accounting Pronouncements Level 1 (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220630.htm",
      "contextRef": "ia496c9fee9ce42b8a11e460b94d3e9ae_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 16,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "lxrx_A2025OxfordPrincipalPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2025 Oxford Principal Payments",
        "label": "2025 Oxford Principal Payments",
        "terseLabel": "2026 Oxford Principal Payments"
       }
      }
     },
     "localname": "A2025OxfordPrincipalPayments",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_A2026OxfordPrincipalPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2026 Oxford Principal Payments",
        "label": "2026 Oxford Principal Payments",
        "terseLabel": "2027 Oxford Principal Payments"
       }
      }
     },
     "localname": "A2026OxfordPrincipalPayments",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_A2027OxfordPrincipalPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2027 Oxford Principal Payments",
        "label": "2027 Oxford Principal Payments",
        "terseLabel": "2027 Oxford Principal Payments2"
       }
      }
     },
     "localname": "A2027OxfordPrincipalPayments",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ATMOfferingTotal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Offering Total",
        "label": "ATM Offering Total",
        "terseLabel": "ATM Offering Total"
       }
      }
     },
     "localname": "ATMOfferingTotal",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_AccruedCompensationAndBenefitsCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued compensation and benefits current - due within 1 year",
        "label": "Accrued compensation and benefits current",
        "terseLabel": "Accrued compensation and benefits current"
       }
      }
     },
     "localname": "AccruedCompensationAndBenefitsCurrent",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_AccruedInterestOnConvertible": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "accrued interest on convertible",
        "label": "accrued interest on convertible",
        "terseLabel": "accrued interest on convertible"
       }
      }
     },
     "localname": "AccruedInterestOnConvertible",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_AccruedLiabilitiesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "accrued liabilities",
        "label": "accrued liabilities [Axis]",
        "terseLabel": "Accrued Liabilities [Axis]"
       }
      }
     },
     "localname": "AccruedLiabilitiesAxis",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lxrx_AccruedLiabilitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities",
        "label": "Accrued Liabilities [Domain]",
        "terseLabel": "Accrued Liabilities [Domain]"
       }
      }
     },
     "localname": "AccruedLiabilitiesDomain",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lxrx_AccruedLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities",
        "label": "Accrued Liabilities [Line Items]",
        "terseLabel": "Accrued Liabilities [Line Items]"
       }
      }
     },
     "localname": "AccruedLiabilitiesLineItems",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lxrx_AccruedLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "accrued liabilities [Table]",
        "label": "accrued liabilities [Table]",
        "terseLabel": "Accrued Liabilities [Table]"
       }
      }
     },
     "localname": "AccruedLiabilitiesTable",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lxrx_AccruedResearchAndDevelopmentServicesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development services current",
        "label": "Accrued research and development services current",
        "terseLabel": "Accrued research and development services current"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentServicesCurrent",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_CashAndCashEquivalentsAndInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and Cash Equivalents and Investments [Abstract]",
        "label": "Cash and Cash Equivalents and Investments [Abstract]",
        "terseLabel": "Cash and Cash Equivalents and Investments [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndInvestmentsAbstract",
     "nsuri": "http://www.lexpharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "lxrx_CollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and License Agreements [Abstract]",
        "label": "Collaboration and License Agreements [Abstract]",
        "terseLabel": "Collaboration and License Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://www.lexpharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedBalanceSheetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Balance Sheets [Abstract]",
        "label": "Consolidated Balance Sheets [Abstract]",
        "terseLabel": "Consolidated Balance Sheets [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedBalanceSheetsAbstract",
     "nsuri": "http://www.lexpharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedStatementsOfOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Statements of Operations [Abstract]",
        "label": "Consolidated Statements of Operations [Abstract]",
        "terseLabel": "Consolidated Statements of Operations [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfOperationsAbstract",
     "nsuri": "http://www.lexpharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Statements of Stockholders\u2019 Equity [Abstract]",
        "label": "Consolidated Statements of Stockholders\u2019 Equity [Abstract]",
        "terseLabel": "Consolidated Statements of Stockholders\u2019 Equity [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfStockholdersEquityAbstract",
     "nsuri": "http://www.lexpharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConvDebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conv Debt Instrument Interest Rate Stated Percentage - contractual interest rate for convertible debt bonds under the debt agreement",
        "label": "Conv Debt Instrument Interest Rate Stated Percentage",
        "terseLabel": "Conv Debt Instrument Interest Rate Stated Percentage"
       }
      }
     },
     "localname": "ConvDebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ConvertibleDebtExchange": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible debt exchange",
        "label": "Convertible debt exchange",
        "terseLabel": "Convertible debt exchange"
       }
      }
     },
     "localname": "ConvertibleDebtExchange",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ConvertibleDebtExchangeRemainingNotes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible debt exchange Remaining Notes",
        "label": "Convertible debt exchange Remaining Notes",
        "terseLabel": "Convertible debt exchange Remaining Notes"
       }
      }
     },
     "localname": "ConvertibleDebtExchangeRemainingNotes",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ConvertibleDebtExchangeSeptemberCashPortion": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible debt exchange- September cash portion",
        "label": "Convertible debt exchange- September cash portion",
        "terseLabel": "Convertible debt exchange- September cash portion"
       }
      }
     },
     "localname": "ConvertibleDebtExchangeSeptemberCashPortion",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ConvertibleDebtExchangeSeptemberSharePayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible debt exchange - September share payment",
        "label": "Convertible debt exchange - September share payment",
        "terseLabel": "Convertible debt exchange - September share payment"
       }
      }
     },
     "localname": "ConvertibleDebtExchangeSeptemberSharePayment",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_ConvertibleDebtExchangeTotalPrincipalAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible debt exchange - Total Principal Amount",
        "label": "Convertible debt exchange - Total Principal Amount",
        "terseLabel": "Convertible debt exchange - Total Principal Amount"
       }
      }
     },
     "localname": "ConvertibleDebtExchangeTotalPrincipalAmount",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_DebtObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Obligations [Abstract]",
        "label": "Debt Obligations [Abstract]",
        "terseLabel": "Debt Obligations [Abstract]"
       }
      }
     },
     "localname": "DebtObligationsAbstract",
     "nsuri": "http://www.lexpharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "lxrx_FairValueMeasurementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Measurements [Abstract]",
        "label": "Fair Value Measurements [Abstract]",
        "terseLabel": "Fair Value Measurements [Abstract]"
       }
      }
     },
     "localname": "FairValueMeasurementsAbstract",
     "nsuri": "http://www.lexpharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "lxrx_FinalPaymentWithExtention": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Final Payment % with extention",
        "label": "Final Payment % with extention",
        "terseLabel": "Final Payment % with extention"
       }
      }
     },
     "localname": "FinalPaymentWithExtention",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_FinalPaymentWithNoExtention": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Final Payment % with no extention",
        "label": "Final Payment % with no extention",
        "terseLabel": "Final Payment % with no extention"
       }
      }
     },
     "localname": "FinalPaymentWithNoExtention",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_FutureConvertibleDebtExchange": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "future convertible debt exchange",
        "label": "future convertible debt exchange",
        "terseLabel": "future convertible debt exchange"
       }
      }
     },
     "localname": "FutureConvertibleDebtExchange",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_FutureConvertibleDebtExchangeShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future Convertible debt exchange shares",
        "label": "Future Convertible debt exchange shares",
        "terseLabel": "Future Convertible debt exchange shares"
       }
      }
     },
     "localname": "FutureConvertibleDebtExchangeShares",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_GainOnSaleOfNonFinancialAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain on sale of non-financial assets",
        "label": "Gain on sale of non-financial assets",
        "negatedTerseLabel": "Gain on sale of non-financial assets",
        "terseLabel": "Gain on sale of non-financial assets"
       }
      }
     },
     "localname": "GainOnSaleOfNonFinancialAssets",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_InitialRecognitionOfRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial recognition of right of use asset",
        "label": "Initial recognition of right of use asset",
        "terseLabel": "Initial recognition of right of use asset"
       }
      }
     },
     "localname": "InitialRecognitionOfRightOfUseAsset",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenMaximumSalesMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum sales milestones payments.",
        "label": "Ipsen Maximum Sales Milestones",
        "terseLabel": "Ipsen Maximum Sales Milestones"
       }
      }
     },
     "localname": "IpsenMaximumSalesMilestones",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the milestone payments received under the agreement.",
        "label": "Ipsen Milestone Payment",
        "terseLabel": "Ipsen Milestone Payment"
       }
      }
     },
     "localname": "IpsenMilestonePayment",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenMilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of milestone payments earned during the period.",
        "label": "Ipsen Milestone Payment Received",
        "terseLabel": "Ipsen Milestone Payment Received"
       }
      }
     },
     "localname": "IpsenMilestonePaymentReceived",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the development services deliverable.",
        "label": "Ipsen Revenue Allocated to Development Deliverable",
        "terseLabel": "Ipsen Revenue Allocated to Development Deliverable"
       }
      }
     },
     "localname": "IpsenRevenueAllocatedtoDevelopmentDeliverable",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period.",
        "label": "Ipsen Revenue Recognized",
        "terseLabel": "Ipsen Revenue Recognized"
       }
      }
     },
     "localname": "IpsenRevenueRecognized",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenTotalPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the total payments received to date under the agreement.",
        "label": "Ipsen Total Payments",
        "terseLabel": "Ipsen Total Payments"
       }
      }
     },
     "localname": "IpsenTotalPayments",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_LexiconIncrementalBorrowingRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lexicon incremental borrowing rate",
        "label": "Lexicon incremental borrowing rate",
        "terseLabel": "Lexicon incremental borrowing rate"
       }
      }
     },
     "localname": "LexiconIncrementalBorrowingRate",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_LiabilitiesAssumedByTerSera": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities assumed by TerSera",
        "label": "Liabilities assumed by TerSera",
        "terseLabel": "Liabilities assumed by TerSera"
       }
      }
     },
     "localname": "LiabilitiesAssumedByTerSera",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_Lxrx_Sanofiterminationcashpayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "lxrx_Sanofi termination cash payment - represents the cash payment from Sanofi to terminate the collaboration alliance",
        "label": "lxrx_Sanofi termination cash payment",
        "terseLabel": "Sanofi termination cash payment"
       }
      }
     },
     "localname": "Lxrx_Sanofiterminationcashpayment",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails",
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_Lxrx_sanofiInitialCashPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "lxrx_sanofi initial cash payment",
        "label": "lxrx_sanofi initial cash payment",
        "terseLabel": "lxrx_sanofi initial cash payment"
       }
      }
     },
     "localname": "Lxrx_sanofiInitialCashPayment",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_Netproductrevenue": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net product revenue - amount of revenue recognized from product sales, net of discounts. Sales process constitutes an earnings process.",
        "label": "Net product revenue",
        "terseLabel": "Net product revenue"
       }
      }
     },
     "localname": "Netproductrevenue",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_OtherCapitalAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Capital Agreements",
        "label": "Other Capital Agreements [Text Block]",
        "terseLabel": "Other Capital Agreements"
       }
      }
     },
     "localname": "OtherCapitalAgreementsTextBlock",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lxrx_OxfordFacilityFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford Facility Fee",
        "label": "Oxford Facility Fee",
        "terseLabel": "Oxford Facility Fee"
       }
      }
     },
     "localname": "OxfordFacilityFee",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_OxfordLoanFacility": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford Loan Facility",
        "label": "Oxford Loan Facility",
        "terseLabel": "Oxford Loan Facility"
       }
      }
     },
     "localname": "OxfordLoanFacility",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_PrincipalAmountOfConvertibleNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "principal amount of convertible notes",
        "label": "principal amount of convertible notes",
        "terseLabel": "principal amount of convertible notes"
       }
      }
     },
     "localname": "PrincipalAmountOfConvertibleNotes",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ProceedsFromJanuary2021ATMOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from January 2021 ATM Offering",
        "label": "Proceeds from January 2021 ATM Offering",
        "terseLabel": "Proceeds from January 2021 ATM Offering"
       }
      }
     },
     "localname": "ProceedsFromJanuary2021ATMOffering",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ProceedsFromJuly2022Offering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from July 2022 Offering",
        "label": "Proceeds from July 2022 Offering",
        "terseLabel": "Proceeds from July 2022 Offering"
       }
      }
     },
     "localname": "ProceedsFromJuly2022Offering",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ProceedsFromNov2020ATMOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Nov 2020 ATM Offering",
        "label": "Proceeds from Nov 2020 ATM Offering",
        "terseLabel": "Proceeds from Nov 2020 ATM Offering"
       }
      }
     },
     "localname": "ProceedsFromNov2020ATMOffering",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ProceedsFromSeptember2021ATMOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from September 2021 ATM Offering",
        "label": "Proceeds from September 2021 ATM Offering",
        "terseLabel": "Proceeds from September 2021 ATM Offering"
       }
      }
     },
     "localname": "ProceedsFromSeptember2021ATMOffering",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_RecentAccountingPronouncementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recent Accounting Pronouncements [Abstract]",
        "label": "Recent Accounting Pronouncements [Abstract]",
        "terseLabel": "Recent Accounting Pronouncements [Abstract]"
       }
      }
     },
     "localname": "RecentAccountingPronouncementsAbstract",
     "nsuri": "http://www.lexpharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "lxrx_SanofiDisputedCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi Disputed Costs",
        "label": "Sanofi Disputed Costs",
        "terseLabel": "Sanofi Disputed Costs"
       }
      }
     },
     "localname": "SanofiDisputedCosts",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the revenue recognized in the period.",
        "label": "Sanofi Revenue Recognized",
        "terseLabel": "Sanofi Revenue Recognized"
       }
      }
     },
     "localname": "SanofiRevenueRecognized",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]",
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]"
       }
      }
     },
     "localname": "ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract",
     "nsuri": "http://www.lexpharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "lxrx_Sellinggeneralandadministrativeexpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selling, general and administrative expenses - the expenses related to selling Lexicon's product as well as general and administrative costs.",
        "label": "Selling, general and administrative expenses",
        "terseLabel": "Selling, general and administrative, including stock-based compensation of $1,734, $1,602, $3,474 and $3,167 respectively"
       }
      }
     },
     "localname": "Sellinggeneralandadministrativeexpenses",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SettlementPaymentFromTermination": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement Payment from Termination",
        "label": "Settlement Payment from Termination",
        "terseLabel": "Settlement Payment from Termination"
       }
      }
     },
     "localname": "SettlementPaymentFromTermination",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expected term assumption that is used in valuing an option on its own shares for employees.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_SharePriceInJanuary2021ATMOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share price in January 2021 ATM Offering",
        "label": "Share price in January 2021 ATM Offering",
        "terseLabel": "Share price in January 2021 ATM Offering"
       }
      }
     },
     "localname": "SharePriceInJanuary2021ATMOffering",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharePriceInJuly2022Offering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Price in July 2022 Offering",
        "label": "Share Price in July 2022 Offering",
        "terseLabel": "Share Price in July 2022 Offering"
       }
      }
     },
     "localname": "SharePriceInJuly2022Offering",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SharePriceInNovember20ATMOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share price in November 20 ATM Offering",
        "label": "Share price in November 20 ATM Offering",
        "terseLabel": "Share price in November 20 ATM Offering"
       }
      }
     },
     "localname": "SharePriceInNovember20ATMOffering",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SharePriceInSeptember2021ATMOfferring": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Price in September 2021 ATM Offerring",
        "label": "Share Price in September 2021 ATM Offerring",
        "terseLabel": "Share Price in September 2021 ATM Offerring"
       }
      }
     },
     "localname": "SharePriceInSeptember2021ATMOfferring",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SharesSoldInJanuary2021ATMOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares sold in January 2021 ATM offering",
        "label": "Shares sold in January 2021 ATM offering",
        "terseLabel": "Shares sold in January 2021 ATM offering"
       }
      }
     },
     "localname": "SharesSoldInJanuary2021ATMOffering",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharesSoldInJuly2022Offering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares sold in July 2022 Offering",
        "label": "Shares sold in July 2022 Offering",
        "terseLabel": "Shares sold in July 2022 Offering"
       }
      }
     },
     "localname": "SharesSoldInJuly2022Offering",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails_1"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharesSoldInNov2020ATMOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares sold in Nov 2020 ATM Offering",
        "label": "Shares sold in Nov 2020 ATM Offering",
        "terseLabel": "Shares sold in Nov 2020 ATM Offering"
       }
      }
     },
     "localname": "SharesSoldInNov2020ATMOffering",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharesSoldInSeptember2021ATMOfferring": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares sold in September 2021 ATM Offerring",
        "label": "Shares sold in September 2021 ATM Offerring",
        "terseLabel": "Shares sold in September 2021 ATM Offerring"
       }
      }
     },
     "localname": "SharesSoldInSeptember2021ATMOfferring",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation expense included in research and development expense.",
        "label": "Stock-based compensation expense associated with research and development expense",
        "terseLabel": "Stock-based compensation expense associated with research and development expense"
       }
      }
     },
     "localname": "StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation expense associated with selling, general and administrative expense",
        "label": "Stock-based compensation expense associated with selling, general and administrative expense",
        "terseLabel": "Stock-based compensation expense associated with selling, general and administrative expense"
       }
      }
     },
     "localname": "Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SummaryOfSignificantAccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of Significant Accounting Policies [Abstract]",
        "label": "Summary of Significant Accounting Policies [Abstract]",
        "terseLabel": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesAbstract",
     "nsuri": "http://www.lexpharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "lxrx_TermLoanA": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A",
        "label": "Term Loan A",
        "terseLabel": "Term Loan A"
       }
      }
     },
     "localname": "TermLoanA",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanABWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A&amp;B Warrant %",
        "label": "Term Loan A&amp;B Warrant %",
        "terseLabel": "Term Loan A&amp;B Warrant %"
       }
      }
     },
     "localname": "TermLoanABWarrant",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_TermLoanADebtDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A Debt Discount",
        "label": "Term Loan A Debt Discount",
        "terseLabel": "Term Loan A Debt Discount"
       }
      }
     },
     "localname": "TermLoanADebtDiscount",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanADebtIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A Debt Issuance Costs",
        "label": "Term Loan A Debt Issuance Costs",
        "terseLabel": "Term Loan A Debt Issuance Costs"
       }
      }
     },
     "localname": "TermLoanADebtIssuanceCosts",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanAFinalPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A Final Payment",
        "label": "Term Loan A Final Payment",
        "terseLabel": "Term Loan A Final Payment"
       }
      }
     },
     "localname": "TermLoanAFinalPayment",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanAInterestExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A Interest Expense",
        "label": "Term Loan A Interest Expense",
        "terseLabel": "Term Loan A Interest Expense"
       }
      }
     },
     "localname": "TermLoanAInterestExpense",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanANetCashReceipt": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A Net Cash Receipt",
        "label": "Term Loan A Net Cash Receipt",
        "terseLabel": "Term Loan A Net Cash Receipt"
       }
      }
     },
     "localname": "TermLoanANetCashReceipt",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanAWarrantExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A Warrant Exercise Price",
        "label": "Term Loan A Warrant Exercise Price",
        "terseLabel": "Term Loan A Warrant Exercise Price"
       }
      }
     },
     "localname": "TermLoanAWarrantExercisePrice",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lxrx_TermLoanAWarrantsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A Warrants Number",
        "label": "Term Loan A Warrants Number",
        "terseLabel": "Term Loan A Warrants Number"
       }
      }
     },
     "localname": "TermLoanAWarrantsNumber",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_TermLoanB": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B",
        "label": "Term Loan B",
        "terseLabel": "Term Loan B"
       }
      }
     },
     "localname": "TermLoanB",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanC": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan C",
        "label": "Term Loan C",
        "terseLabel": "Term Loan C"
       }
      }
     },
     "localname": "TermLoanC",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanCWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan C Warrant %",
        "label": "Term Loan C Warrant %",
        "terseLabel": "Term Loan C Warrant %"
       }
      }
     },
     "localname": "TermLoanCWarrant",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_TermLoanD": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan D",
        "label": "Term Loan D",
        "terseLabel": "Term Loan D"
       }
      }
     },
     "localname": "TermLoanD",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanDWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan D Warrant %",
        "label": "Term Loan D Warrant %",
        "terseLabel": "Term Loan D Warrant %"
       }
      }
     },
     "localname": "TermLoanDWarrant",
     "nsuri": "http://www.lexpharma.com/20220630",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r161",
      "r166",
      "r167",
      "r168",
      "r169",
      "r186",
      "r222",
      "r237",
      "r246",
      "r248",
      "r281",
      "r282",
      "r283",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r385",
      "r386",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r161",
      "r166",
      "r167",
      "r168",
      "r169",
      "r186",
      "r222",
      "r237",
      "r246",
      "r248",
      "r281",
      "r282",
      "r283",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r385",
      "r386",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r96",
      "r101",
      "r165",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r96",
      "r101",
      "r165",
      "r247",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Statement, Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r23",
      "r340"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r144",
      "r145"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r362",
      "r380"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.",
        "label": "Accrued Liabilities",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r7",
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation and amortization, property and equipment"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r17",
      "r40",
      "r41",
      "r42",
      "r375",
      "r391",
      "r392"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r39",
      "r42",
      "r48",
      "r49",
      "r50",
      "r88",
      "r89",
      "r90",
      "r304",
      "r337",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Gain (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r15",
      "r340"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r285",
      "r286",
      "r287",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r250",
      "r289",
      "r290"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r225",
      "r231"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "negatedTerseLabel": "Payments of Stock Issuance Costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r182",
      "r225",
      "r231"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Adjustments to Additional Paid in Capital, Warrant Issued"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r72",
      "r206",
      "r215",
      "r216",
      "r330"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r72",
      "r158"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset Impairment Charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r10",
      "r84",
      "r130",
      "r133",
      "r139",
      "r151",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r301",
      "r305",
      "r319",
      "r338",
      "r340",
      "r357",
      "r373"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r22",
      "r84",
      "r151",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r301",
      "r305",
      "r319",
      "r338",
      "r340"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r149"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "terseLabel": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Available-for-Sale Securities",
        "terseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "AvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r149"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-Sale Securities, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-Sale Securities, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.",
        "label": "Available-for-Sale Securities, Current",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r147",
      "r153"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Debt Securities, Available-for-Sale, Current"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1",
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r273",
      "r274",
      "r276",
      "r277",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]",
        "terseLabel": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r273",
      "r274",
      "r276",
      "r277",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Domain]",
        "terseLabel": "Award Date [Domain]"
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r273",
      "r274",
      "r276",
      "r277",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessExitCosts1": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Business Exit Costs",
        "terseLabel": "Business Exit Costs"
       }
      }
     },
     "localname": "BusinessExitCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r6",
      "r74"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.",
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "terseLabel": "Cash and Cash Equivalents Disclosure"
       }
      }
     },
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease) (Deprecated 2022)",
        "terseLabel": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r68",
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r82",
      "r84",
      "r104",
      "r105",
      "r106",
      "r108",
      "r110",
      "r116",
      "r117",
      "r118",
      "r151",
      "r171",
      "r175",
      "r176",
      "r177",
      "r180",
      "r181",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r319",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r296",
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Arrangement Disclosure"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r33",
      "r363",
      "r379"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r170",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies Disclosure"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r88",
      "r89",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value per share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14",
      "r340"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 300,000 shares authorized; 150,114 and 150,082 shares issued, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r44",
      "r46",
      "r47",
      "r54",
      "r365",
      "r382"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r78",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r238",
      "r245",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r56",
      "r355"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales (including finite-lived intangible asset amortization)"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Goods and Service [Policy Text Block]"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r81",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r200",
      "r207",
      "r208",
      "r210",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt Disclosure"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r185",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt Instrument, Convertible, Conversion Price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r30",
      "r185",
      "r226",
      "r227",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Debt Instrument, Convertible, Conversion Ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r198",
      "r213",
      "r214",
      "r316"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Debt Instrument, Fair Value Disclosure"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r29",
      "r203",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Debt Instrument, Interest Rate During Period"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r29",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r31",
      "r83",
      "r86",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r190",
      "r196",
      "r197",
      "r198",
      "r199",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r209",
      "r213",
      "r214",
      "r215",
      "r216",
      "r226",
      "r228",
      "r229",
      "r230",
      "r328",
      "r329",
      "r331",
      "r332",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "auth_ref": [
      "r148",
      "r153"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current",
        "terseLabel": "Debt Securities, Available-for-Sale, Amortized Cost, Current"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r72",
      "r129"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r55",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r102",
      "r104",
      "r108",
      "r109",
      "r110",
      "r113",
      "r114",
      "r310",
      "r311",
      "r366",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income (loss) per common share, Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r55",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r104",
      "r108",
      "r109",
      "r110",
      "r113",
      "r114",
      "r310",
      "r311",
      "r366",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Earnings Per Share, Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r111",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings Per Share, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Share-based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity:"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r48",
      "r49",
      "r50",
      "r88",
      "r89",
      "r90",
      "r92",
      "r98",
      "r100",
      "r115",
      "r152",
      "r225",
      "r231",
      "r285",
      "r286",
      "r287",
      "r293",
      "r294",
      "r309",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r337",
      "r387",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1",
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r312",
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r312",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table Text Block]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r198",
      "r213",
      "r214",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r313",
      "r344",
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r198",
      "r238",
      "r239",
      "r244",
      "r245",
      "r313",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r198",
      "r213",
      "r214",
      "r238",
      "r239",
      "r244",
      "r245",
      "r313",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r198",
      "r213",
      "r214",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r313",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.",
        "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]",
        "terseLabel": "Fair Value, Measurement Inputs, Disclosure"
       }
      }
     },
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r198",
      "r213",
      "r214",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r344",
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r72",
      "r217",
      "r218"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Gain (Loss) on Extinguishment of Debt",
        "terseLabel": "Gain (Loss) on Extinguishment of Debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r8",
      "r154",
      "r155",
      "r156",
      "r157",
      "r340",
      "r356"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Decrease in accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "(Increase) decrease in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "(Increase) decrease in inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Decrease in other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "(Increase) decrease in prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r51",
      "r128",
      "r327",
      "r330",
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r67",
      "r69",
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investment [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Total Cash and Cash Equivalents and Investments"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets held for their financial return, rather than for the entity's operations.",
        "label": "Investments [Member]",
        "terseLabel": "Total Cash and Cash Equivalents and Investments"
       }
      }
     },
     "localname": "InvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "terseLabel": "Issuance of Stock and Warrants for Services or Claims"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due after Year Five"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Four"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Three"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Two"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r26",
      "r84",
      "r134",
      "r151",
      "r171",
      "r172",
      "r173",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r302",
      "r305",
      "r306",
      "r319",
      "r338",
      "r339"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r20",
      "r84",
      "r151",
      "r319",
      "r340",
      "r359",
      "r377"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r28",
      "r84",
      "r151",
      "r171",
      "r172",
      "r173",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r302",
      "r305",
      "r306",
      "r319",
      "r338",
      "r339",
      "r340"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding": {
     "auth_ref": [
      "r316"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of the amount outstanding under the credit facility.",
        "label": "Line of Credit Facility, Fair Value of Amount Outstanding",
        "terseLabel": "Line of Credit Facility, Fair Value of Amount Outstanding"
       }
      }
     },
     "localname": "LineOfCreditFacilityFairValueOfAmountOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r11",
      "r197",
      "r211",
      "r213",
      "r214",
      "r358",
      "r374"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Long-Term Debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r11"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-Term Debt and Lease Obligation",
        "terseLabel": "Long-term Debt and Lease Obligation"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt, net of deferred issuance costs"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "negatedTerseLabel": "Long-term debt, net of deferred issuance costs",
        "terseLabel": "Long-term debt, net of deferred issuance costs"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.",
        "label": "Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate",
        "terseLabel": "Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate"
       }
      }
     },
     "localname": "LongTermDebtPercentageBearingFixedInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongTermDebtTerm": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Long-Term Debt, Term",
        "terseLabel": "Long-Term Debt, Term"
       }
      }
     },
     "localname": "LongTermDebtTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r68",
      "r70",
      "r73"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r43",
      "r45",
      "r50",
      "r53",
      "r73",
      "r84",
      "r91",
      "r93",
      "r94",
      "r95",
      "r96",
      "r99",
      "r100",
      "r107",
      "r130",
      "r132",
      "r135",
      "r138",
      "r140",
      "r151",
      "r171",
      "r172",
      "r173",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r311",
      "r319",
      "r364",
      "r381"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Pronouncements, Policy"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r130",
      "r132",
      "r135",
      "r138",
      "r140"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating Lease, Liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedTerseLabel": "Operating Lease, Liability, Current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r333"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating Lease, Right-of-Use Asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other Accrued Liabilities, Current"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r21",
      "r340"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r37",
      "r38",
      "r40"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r37",
      "r40"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r273",
      "r274",
      "r276",
      "r277",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r273",
      "r274",
      "r276",
      "r277",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value per share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r13",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r13",
      "r340"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.01 par value; 5,000 shares authorized; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from Convertible Debt"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from debt borrowings, net of fees"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "terseLabel": "Proceeds from Sale of Productive Assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r160",
      "r340",
      "r370",
      "r378"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation and amortization of $5,070 and $4,853, respectively"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment.",
        "label": "Realized Investment Gains (Losses)",
        "terseLabel": "Realized Investment Gains (Losses)"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy election not to recognize asset and liability at acquisition for lease with remaining lease term of one year or less.",
        "label": "Recognition of Asset and Liability for Lease of Acquiree [Policy Text Block]",
        "terseLabel": "Recognition of Asset and Liability for Lease of Acquiree"
       }
      }
     },
     "localname": "RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Repayment of debt borrowings, net of fees"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r292",
      "r354",
      "r414"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development, including stock-based compensation of $1,098, $1,184, $2,130 and $2,470 respectively"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r16",
      "r231",
      "r340",
      "r376",
      "r390",
      "r392"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r88",
      "r89",
      "r90",
      "r92",
      "r98",
      "r100",
      "r152",
      "r285",
      "r286",
      "r287",
      "r293",
      "r294",
      "r309",
      "r387",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r126",
      "r127",
      "r131",
      "r136",
      "r137",
      "r141",
      "r142",
      "r143",
      "r234",
      "r235",
      "r355"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaborative agreements"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r79",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue [Policy Text Block]"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r52",
      "r84",
      "r126",
      "r127",
      "r131",
      "r136",
      "r137",
      "r141",
      "r142",
      "r143",
      "r151",
      "r171",
      "r172",
      "r173",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r319",
      "r368"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyIncomeNonoperating": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.",
        "label": "Royalty Income, Nonoperating",
        "terseLabel": "Royalties and other revenue"
       }
      }
     },
     "localname": "RoyaltyIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of Cash, Cash Equivalents and Short-term Investments [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Investments [Line Items]",
        "terseLabel": "Schedule of Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A container table for all schedule of investment items. It ties in the \"Legal Entity [Axis]\" to all of its contained line items.",
        "label": "Schedule of Investments [Table]",
        "terseLabel": "Schedule of cash and cash equivalents and investments",
        "verboseLabel": "Schedule of Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1",
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r249",
      "r251",
      "r252",
      "r253",
      "r254",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r273",
      "r274",
      "r276",
      "r277",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r256",
      "r272",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Share-based Payment Arrangement, Option, Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredLongTermDebt": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.",
        "label": "Secured Long-Term Debt, Noncurrent",
        "terseLabel": "Secured Long-Term Debt, Noncurrent"
       }
      }
     },
     "localname": "SecuredLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r266",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r266",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r257",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r257",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r273",
      "r274",
      "r276",
      "r277",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r255",
      "r278",
      "r279",
      "r280",
      "r281",
      "r284",
      "r288",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based Payment Arrangement [Policy Text Block]"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r21",
      "r360",
      "r361",
      "r372"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-Term Investments [Member]",
        "terseLabel": "Total Short-term Investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermLeaseCommitmentAmount": {
     "auth_ref": [
      "r336"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease commitment.",
        "label": "Short-Term Lease Commitment, Amount",
        "terseLabel": "Short-term Lease Commitment, Amount"
       }
      }
     },
     "localname": "ShortTermLeaseCommitmentAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r77",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies [Text Block]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r82",
      "r84",
      "r104",
      "r105",
      "r106",
      "r108",
      "r110",
      "r116",
      "r117",
      "r118",
      "r151",
      "r171",
      "r175",
      "r176",
      "r177",
      "r180",
      "r181",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r319",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r35",
      "r48",
      "r49",
      "r50",
      "r88",
      "r89",
      "r90",
      "r92",
      "r98",
      "r100",
      "r115",
      "r152",
      "r225",
      "r231",
      "r285",
      "r286",
      "r287",
      "r293",
      "r294",
      "r309",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r337",
      "r387",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r115",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r225",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock under Equity Incentive Plans, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r13",
      "r14",
      "r225",
      "r231",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": {
     "auth_ref": [
      "r14",
      "r225",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Shares, Treasury Stock Reissued",
        "terseLabel": "Stock Issued During Period, Shares, Treasury Stock Reissued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r225",
      "r231"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "negatedTerseLabel": "Issuance of common stock under Equity Incentive Plans, value",
        "terseLabel": "Issuance of common stock under Equity Incentive Plans, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r13",
      "r14",
      "r231",
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "auth_ref": [
      "r13",
      "r14",
      "r225",
      "r231",
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "negatedTerseLabel": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "terseLabel": "Stock Issued During Period, Value, Treasury Stock Reissued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r18",
      "r19",
      "r84",
      "r146",
      "r151",
      "r319",
      "r340"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholder's equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r49",
      "r84",
      "r88",
      "r89",
      "r90",
      "r92",
      "r98",
      "r151",
      "r152",
      "r231",
      "r285",
      "r286",
      "r287",
      "r293",
      "r294",
      "r299",
      "r300",
      "r307",
      "r309",
      "r319",
      "r321",
      "r322",
      "r326",
      "r337",
      "r388",
      "r389"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance, value",
        "periodStartLabel": "Balance, value"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubordinatedBorrowingInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stated interest rate of the subordinated debt.",
        "label": "Subordinated Borrowing, Interest Rate",
        "terseLabel": "Subordinated Borrowing, Interest Rate"
       }
      }
     },
     "localname": "SubordinatedBorrowingInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r341",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalIncomeStatementElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Income Statement Elements [Abstract]",
        "terseLabel": "Supplemental Income Statement Elements [Abstract]"
       }
      }
     },
     "localname": "SupplementalIncomeStatementElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradingActivityByTypeAxis": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of trading activity.",
        "label": "Trading Activity [Axis]",
        "terseLabel": "Trading Activity, by Type [Axis]"
       }
      }
     },
     "localname": "TradingActivityByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradingActivityByTypeDomain": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gains and losses on trading activities (including both derivative and nonderivative instruments) recognized in the statement of financial performance, separately by major types of items (such as fixed income/interest rates, foreign exchange, equity, commodity, and credit).",
        "label": "Trading Activity, by Type [Domain]",
        "terseLabel": "Trading Activity, by Type [Domain]"
       }
      }
     },
     "localname": "TradingActivityByTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r34",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r34",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock, shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r34",
      "r232",
      "r233"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost, 488 and 1,165 shares, respectively"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r225",
      "r231",
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r85",
      "r238",
      "r245",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury Securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r273",
      "r274",
      "r276",
      "r277",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r273",
      "r274",
      "r276",
      "r277",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r103",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r102",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Shares used in computing net loss per common share, Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "https://asc.fasb.org/topic&trid=2122478"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28B",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128091968&loc=SL77931625-128468"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "https://asc.fasb.org/topic&trid=2155941"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918705-209980"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r415": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r416": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r417": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r418": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r419": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r420": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r421": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>48
<FILENAME>0001062822-22-000035-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001062822-22-000035-xbrl.zip
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MYCR1E5<)UZ[)KHJDC7 =/X]P]7<N7#]SAR!AYO,9NRW,5$LQQFH)4;,Q5L+
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MP ?BK49:4AR9!"A'6KF,Y$DL!T$22=*]4"[1QE7H1]1IC8ZJ2FL2*?#8L=?
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M3FB-B",\44D(S'4K&X0,&I57K6Y>2"GUZ$8]>@F_[O;JW:_+Z0K<1XNJGRE
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M=\9"G%[SO74]P)\0K)M.PORE!STV4]LLUK VAX?0K)&6L]$!-1>5HUX561G
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M$A<>'!?,,R8S]\"%>TYX"X0+WSC *)#>/NG%!MR7JWB\[?;[5Y !5>J@6K%
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MX)=\U#()F#(LDF K&Y2O8CZK?)[;F<P29?H\6PR8=:9N:?H/:?K7 PTQQ6!
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MG58KG3BX3W; $H+-/#WJW3SVEX_O&\7^2NCY%>C9GG*PK1,XZ"A08C(A0!Z
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M/4BJ!.'1HEU1R1%POLSK9,X%*K*H&3_K =^VHS$5OO< W_FP"TL\*Y>!:,N
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MXGB2I.2WFQ!=-)%M;)E-Q1:''U6BJ43S V<P,8LH0@A&6>DH!;P#E4Q,:1O
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M8/Q!8X55I]\_T/M7@9ZLM2 ,$,N,)U(+29PM$VS+" :A@Q)EHL[U0KW"_,G
M_$&CA=64WR?"]^9,N09$M5".N,Q8J4&DQ'&9B$^&07(J"MW)8_5UJ$)\DTY.
MQ^$()DTH,303Y>X02*S)$5T-).)7;!Z:5)IK@^86)P,F+7VP@9)$J262V40@
M&$N"5]I')2P7J>8]/3EH/W+PL,*Z95C/%Q%JDT0$YPDUR99)0:%,"I($]]<;
MEP6P"NNU@/6#Q@LKK%N&]7P](2]3?"E','L1B4Q2XV]@2%))<"F "JBUP>L
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M^(-+#TXYIU$U;FR)NYRK5BYX8EP R0MI4^84N)0J6"N$03*@-B6!,J)*AZ=
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M!6^Z?%^]3"=X+_6;@;@]&,8>')? _>?F#[5?]7TF8;2@YZ_:R\M[B;\/4I.
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M:Q!R&#+,M) 0VKWQ/E8;VB$V'T:P=G0/>KO.7(C@SQKFEDG%_IX80H"ZM]4
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MJN>\"?3:39TSY#=:5VAKG<?.<*#!P).-CQ@7PN,HN%^;R!&OQI+%M71]TP:
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MQ:.ET9BUS79G#GWG?M$8U6%LY?YN^%)8-S3[X/&IMBS\W>@U?S5.P0:.>XT
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MZ/#<_VB5U'5ZMS]+MUQCR&F>JCU_I^;4]G"%/9#=3]^)%Q8;99&)!<SS3CA
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MF/_WK#?US)V&'$O-_79E)W&@G!$L=_.;*GG8:D($-\H4CM?XVWF!=9C\KW1
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M.+)6T5] :X95>-3(.IG+R#H6R3EH=*>H4QA">Y"9]UN]#:9>HPB@X[#9:=6
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M<>'%A+4$*G%*)IXA'WPWZSYH+./FXPQA1"7?5KG7$V%2.HY O/]* !&VR\L
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MH^N>VYBFVM;.[_*/&S>IO_'BK^T]O[U5@['7K9?Z][9\_/0FV[ GX#T!WX"
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MQA3$@L8LJ6I%"L?50*T8! <J#>:YJ98J'I6\ZFHX-?G-^CU56%'+LD[5%!K
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MEV?G&?D!L8Y598YNQU2 8=9W=+9@B:!=D4X;]"?Y2H")2LWFTFF<9$W85Q0
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M58(&AY5V->AX:'54J^GFA#8+;K$WG.7WAHRW06[?@)5V^K3 $ZZ$TX'.I2!
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MJG/TSED(B>H&P9*V)OD09.O&T6T4J_#"_,4+^)*(L:;.-]$^NFQC88A2,UL
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MC69K<:"1[C<2QZY@T;YD%YP$=,A V9+)OZ*'8%A"QBQJVSJ]O1O)ED:S]?S
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M@99"1].2DM5J$_?6-+: ARA.@?>.NGW(MFKJ" Y$$-P86G5LU!:4HZ4G<B>
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MWXF82%^,K#"?G??['@-[?6+XMBR#W(OY;![&M<K)@ GO!(\!O(J. *.&J#&
M$DDIX7+$V+HFQ;883]>,FC&SPI2Z[2/6N?#U)(Q_'JB@C0Z.@2B10EY6$ *6
M"(A1!HTBJ_MU.=8$#]>//&X^.ZAG1>).M[W *Q@O!Z@)+J>))HFH07F=(+ L
MP'H?(\4?Q;/-]GZN'WE"+&VGGA4L==O#NX+QBH9TXL77>A6<[$1Q:PE&BB!5
M-%XXI[S:[(SM^I$GQ-)VZEG!4K?=M;=?"CVH KF:G0?<>:>2$B RA7;*.0KI
MDR6WO["<N466T6Y$U\-GGP!O'16V@L!N6V)7=O1B(#.:@L) =<7(CDH!EY*&
M9*6)JB;C;G@ <OW($Z!K-_6L8&GGG:J[,'[^1YA.PV)/'8UEAH$6KN8QB0S>
MTX+*?3+.:R5RWFQW\L&C3XFUG=2U@KUN>5_7*^HU&ANUY#Q#4KHFNQ<!/N8
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M<@J EA-A\Z7%YDL_-@5_ILG2N 1%^=+Z@MM8OWO+*JUX8[JB%6MTW]S^H_'
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M2=1.\+@1XBGS>VGOX*;IR.V4OL\H[.1%PPN4MV5'3>ZLYL<Z7]W*%<]EM6O
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MN^0Q,FP(CKXVDUU$3[N[/ "4@^WF(6,,C"C;]#DQK0=C%B?"E.Z/46"*^.,
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M@N_E5\MOYD=)JZK@N9'[>U[?57*I1[F]E2M94OT@"2KN\U5N:M'5^:/<W+/
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M_BS7CZ 9QH^/?/65@\_WGVNR=A?GO\?E7+<BEU^_ZI4L^;RM%NQ<X;;WOU1
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MM0/!.["E]$%VJ!C <,#ZB@(,Z'G<.,!P2$XB 2.:&)DYNB6/?/M=KV19N<"
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M=#-?_MER%2\WH@.^E3VP)'C$N/@=6PZ+]@B7_#78&_'=(>-/3@-K>GX&6R7
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M^4/K-^5*2_M)5#-MA$8%3Z# PC$04 8%TCE$.G5,!$4J1.Y/3//"VDS-V/7
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M5VK;[*C.T;$RQ^[.R>\O3;=]?-_;G_[;?]K\B_V/"^CY;__I?P%02P,$%
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M\AQ<(=7K$=W''3@9I\'A=[O1AL+0=]E9X/R_/2^BYS=Y';ZQP.WEQ^\K\*A
M1F@KH#E+F(T'%C.G<T%P<-9G8%88XYG@R93MK-QS;2O@BO12<<A6T<&8<@$7
M)%*<%X,4BJG _M%68'YH6X%=8#9@6X$==-U!5LN-XN?LA"S)43PD380Z30V"
M,1H\0QLMQ4?A]M2K?[05.!0"C[45V$4?'6'I/+_+)Y.4HB @:]2@(B.7RD4'
MM957,+5_KVS=C;.G\K?]-?EX6X%=Q-H!*&[6/9.'[40=@8!6D+/JN(' N "-
MSDHFM=*A-2:^S[8"!YB8_372$YPNFFQ@+DX: 5S4GO*N3G,O1D$2P4H;/1;1
M.J6RX[8".RGSB;8"NTBV%V!<5AL'DWWT+ )36%M,!00GI24C2=NFF.A*\Z$X
MWV=;@4/MS%X:Z0!.@Y06QR"4Q1C!LE3'!PA+&S7X>G-#3D 0/F%K5'[O;05V
M@M4QV@KLHN,.<'YQGWBW<EVHH*K3"E84VOH1B9'H&$3%!,8LT:G8&*P/$M-Y
MNO7@.+D]:*>)TCI WWT-=-^]__V<&=JZW'$9@2(E7TL/&82L)# CR*LI)B3;
MN@?9HP1UGL5\;!2V4UX'2'RXWMX*PXKA#B+YO+5N*($WWH 7)3'O-4;1?*C(
M=]_XX@"WLHVF.H#</<T8LBS<1D7[Q>=8!Y_(.MQ;@"P>H\WTT^:C/YY/XXN=
MU/MTXXM=9-U#)X.-#%A)+C@=Z'SWB620,M2$)1 ZL*BCR(%O58?\IVM\L8?!
MV5_R/<#ETB%T15MB%R,J4-9D<,+QVGJ;15K7Z\1; ::?QA<[*>N!QA>[2*Z#
MT^1ZC;[/J425'<7#-8F?)0FA>$7L2Q.\L2'JUH[S]]CXX@ G95]M] .D\U,2
M=196UEG S-(I6?M.H;,*&$E T3;*WK>^!>BT\<5.:GRT\<4N,NT $ VRZW()
MD3LT@,0C<9P#.%;(M")*@=)J%IHW#_Q'XXL6P=9Q=?^<T7X^?^K-Z7JUQGFB
M[?[Z=.-(*,U-+LQ!";4"U2L+6*=@<V[(JT!.CD3KSN?-F>C\ K8Q"EMM@B:0
M^+[VQ-_R]..G=4XOON0E?LR_?,W+.%WEM\MIS!-A#"I#1JKXVJ4N!7*Y&>>
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M!QDA&_QZ,8_G7"E>YT!H!SHJ3;P8BC*$$, %^BPLFJA;-[+:CK)Q[J8'!=@
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MK8GKQ.L["F:VZAY^J ([0.;NJ=75]?#$#V99Q])D<#(ID$Z1;'T(UC:?!31
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M[9$%R.394SAI$[AB/-A,[A;7=0@&'F(R;BZW%5;\L\%*>Q&/#9I?3]>GR_P
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M"48JQ;7F*? V0+J^ZG9(>A:WNL-*O(-[WM\6M1O6\J0R]GHQCQ=SSUPTW*
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M2Y' >_(WN(_&>:U$2MM=G-_YZ.TT_BQN-!O(KA?-O[PDW@8M.4\0E:Y%3$6
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MA[D_*G:,'*?7$=O_47]B6./?_O)?4$L! A0#%     @ ZX #5>O 54C6!P
M.B4  !X              ( !     &5X:#,Q,6-E<G1I9FEC871I;VYO9G!R
M:6YC+FAT;5!+ 0(4 Q0    ( .N  U7$UENMN@<  ((D   >
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M<G@M,C R,C V,S N>'-D4$L! A0#%     @ ZX #57\X>Y""#P  YH,  !4
M             ( !1DT! &QX<G@M,C R,C V,S!?8V%L+GAM;%!+ 0(4 Q0
M   ( .N  U5! W\\6SL  ,B5 @ 5              "  ?M< 0!L>')X+3(P
M,C(P-C,P7V1E9BYX;6Q02P$"% ,4    " #K@ -517*N]Y*F  #(]P8 %0
M            @ &)F $ ;'AR>"TR,#(R,#8S,%]L86(N>&UL4$L! A0#%
M  @ ZX #54 W"M2K6P  &!L$ !4              ( !3C\" &QX<G@M,C R
C,C V,S!?<')E+GAM;%!+!08     "0 ) &X"   LFP(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
